Split (1)

train · 2.51M rows

text stringlengths 10 159k	url stringlengths 19 865	crawl_date timestamp[s]date 2022-02-01 01:02:23 2024-12-02 05:16:38	lang stringclasses 1 value	lang_conf float64 0.65 1
You need to enable JavaScript to run this app.	https://sportspyder.com/mlb/st-louis-cardinals/articles/39658264	2022-05-31T12:42:12	en	0.738227
Partnership Reflects Growing Adoption of the Tetra Data Platform to Create Data Liquidity for Customers BOSTON, May 31, 2022 /PRNewswire/ -- TetraScience, the R&D Data Cloud company, announced today that Biorep Technologies, Inc., the leading provider of scientific instruments that help pharmaceutical companies and leading universities research cures for Type 1 and Type 2 diabetes, has joined the Tetra Partner Network. The partnership builds on a joint deployment of Biorep's Islet Counter and the Tetra Data Platform at a global pharmaceutical company, which is now utilizing the implementation as its worldwide standard for stem cell counting. "We are thrilled to formalize our partnership with Biorep Technologies, whose premier products are used globally to advance research into diabetes," said Simon Meffan-Main, Ph.D., Vice President, Tetra Partner Network. "By integrating Biorep's instruments with the Tetra Data Platform, together we are helping researchers maximize the value of scientific data to increase understanding of the underlying causes of diabetes which affects more than 422 million people globally and is the 9th leading cause of death." Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Biorep's product suite, installed at more than 440 customer sites globally, pioneers industry-wide research to gain insights into stem cells as a source of producing insulin. The company's instruments streamline and automate the process of isolating islet cells from a donor pancreas, which is an essential part of diabetes research. "By joining the Tetra Partner Network, Biorep will be able to help unlock the full value of scientific data across multiple sites where our products are used," said Felipe Echeverri, CEO, Biorep. "Our core company philosophy centers in collaboration with researchers around the world. With TetraScience, our customers will be able to share scientific data that is accessible, engineered, actionable, and compliant, which is the core of efficient collaboration across labs to accomplish greater success for those living with diabetes." "Every partner added to the Tetra Partner Network creates value for customers," explained Patrick Grady, TetraScience Chairman and CEO. "As partners and customers continue to accelerate adoption of our open platform, the entire life sciences industry works in lockstep, eliminating data silos and delivering unrestricted scientific data innovation." TetraScience is the R&D Data Cloud company with a mission to transform life sciences R&D, accelerate discovery, and improve and extend human life. The Tetra R&D Data Cloud provides life sciences companies with the flexibility, scalability, and data-centric capabilities to enable easy access to centralized, harmonized, and actionable scientific data and is actively deployed across enterprise pharma and biotech organizations. As an open platform, TetraScience has built the largest integration network of lab instruments, informatics applications, CRO/CDMOs, analytics, and data science partners, creating seamless interoperability and an innovation feedback loop that will drive the future of life sciences R&D. For more information, please visit tetrascience.com. Biorep Technologies, Inc., was founded in 1994 as a privately owned family business with the mission to help the Diabetes Research Institute (DRI) with their research efforts to find the biological cure for type I diabetes. As a full-service development firm, Biorep has an exclusive focus on medical products and over 25 years of experience developing medical devices. Biorep is ISO 13485 certified and FDA registered. For more information, visit Biorep.com. SOURCE TETRASCIENCE	https://www.prnewswire.com/news-releases/biorep-technologies-inc-joins-the-tetra-partner-network-to-accelerate-research-into-stem-cell-derived-insulin-to-cure-diabetes-301557389.html	2022-05-31T12:42:15	en	0.910794
MISSISSAUGA, ON, May 31, 2022 /PRNewswire/ - Integran is pleased to announce that on May 16, 2022 it entered into a research license agreement with the National Research Council of Canada (NRC), Canada's largest federal research and development organization. The agreement relates to the NRC's patents and know-how of the carbon nanotubes (CNT) and boron nitride nanotubes (BNNT) technology. NRC and Integran, with funding from the Innovative Solutions Canada Program (Contract 31103-212430/001/SI), have been collaborating on developing scalable production methods for thermoplastic fabrics containing high loadings of nanotubes. "This licence agreement with NRC is a natural progression of a multi-year mutually beneficial relationship between our two organizations and recognizes the value of the NRC's technology which is protected by numerous U.S. and international patents. Integran intends to develop and manufacture novel nanocomposite fabrics and composite prepreg utilizing the NRC's technologies and Integran's nano- metallurgical (NanovateTM) technology. These multifunctional fabrics can then be used to manufacture numerous aero and defence components requiring impact & wear resistance, as well as other functional benefits such as flame resistance and EMI shielding", said Dr. Gino Palumbo, Integran's President and CEO. About Integran Technologies, Inc. Integran is a world leader in advanced metallurgical nano-technologies, providing a broad international base of customers with advanced process & product design solutions through R&D, material sales, contract manufacturing and technology licensing. Integran has been at the forefront of metallurgical nano-technology development for over twenty years and has established an international reputation for excellence in materials technology development and commercialization. Integran owns the intellectual property rights for the cost-effective production of metallurgical nano-structures with over 250 filed patents dealing with the structure, composition, processing and application of its revolutionary materials. View original content to download multimedia: SOURCE Integran Technologies Inc.	https://www.wlbt.com/prnewswire/2022/05/31/integran-technologies-inc-integran-enters-into-research-license-agreement-with-national-research-council-canada-nrc-nrcs-carbon-nanotube-cnt-boron-nitride-nanotube-bnnt-technology/	2022-05-31T12:42:16	en	0.913168
- Extraordinary General Meeting of BAC's shareholders postponed until June 3, 2022, at 10:00 a.m., Eastern Time NEW YORK and SOUTH SAN FRANCISCO, May 31, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company based in South San Francisco, Calif., today announced the postponement of BAC's extraordinary general meeting of shareholders (the "Extraordinary Meeting") originally scheduled to be held on June 1, 2022. The Extraordinary Meeting has been postponed until June 3, 2022, at 10:00 a.m. Eastern Time. As previously announced, the Extraordinary Meeting will occur at the offices of Ellenoff Grossman and Schole LLP located at 1345 Avenue of the Americas, 11th Floor, New York, New York, 10105 and virtually via live webcast at https://www.cstproxy.com/biotechacquisition/2022. The Extraordinary Meeting is being held to vote on the proposals described in BAC's definitive proxy statement, filed with the Securities and Exchange Commission (the "SEC") on May 9, 2022, as supplemented by a Prospectus Supplement dated May 23, 2022 relating to the previously announced proposed business combination with Blade. The record date for the determination of shareholders entitled to vote at the Extraordinary Meeting, including all adjournments thereof, remains March 28, 2022. The BAC Board of Directors continues to recommend that shareholders vote in favor of the proposals. As of the date of this press release, a sufficient number of BAC's shareholders have voted to approve the proposed business combination. The postponement of the Extraordinary Meeting is intended to permit more time to satisfy all conditions necessary to effect the closing of the proposed Business Combination. BAC shareholders who have any questions or who need assistance voting their shares may contact BAC's proxy solicitor, Morrow Sodali LLC, by calling (800) 662-5200 (or banks and brokers can call collect at (203) 658-9400) or by emailing [email protected]. Biotech Acquisition Company raised $230 million in its initial public offering in January 2021. The Class A ordinary shares and warrants of BAC trade on the Nasdaq Capital Market under the symbols "BIOT" and "BIOTW," respectively. BAC is a blank check company, incorporated as a Cayman Islands exempted company, formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or other similar business combination with one or more businesses. BAC believes that a business combination with a company focused on the healthcare sector will complement the background and expertise of SPRIM Global Investments, a global investment firm in the life sciences and healthcare industries, which is an affiliate of BAC and of several members of the management team behind BAC. BAC is led by Dr. Michael Shleifer, its CEO and chairman. Blade Therapeutics, Inc. is a biopharmaceutical company focused on developing cutting-edge treatments for debilitating, incurable fibrotic and neurodegenerative diseases that impact millions of people worldwide. The company has deep expertise in novel biological pathways – including autotaxin / LPA and calpain biology – that are foundational to cell- and tissue-damage responses resulting from protein deposition or aggregation associated with fibrotic and neurodegenerative diseases. Blade expects to advance a differentiated pipeline of oral, small-molecule therapies that include a non-competitive autotaxin inhibitor and inhibitors of dimeric calpains designed for potential treatment of lung, liver and cardiac fibrosis or neurodegenerative diseases. The company's focused approach offers the potential to produce disease-modifying, life-saving therapies. Visit www.blademed.com for more information and follow Blade on LinkedIn. This press release relates to a proposed business combination between BAC and Blade (the "Transaction"). This press release does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In connection with the Transaction, BAC has publicly filed a registration statement on Form S-4 with the U.S. Securities and Exchange Commission (the "SEC"), which includes a preliminary proxy statement/prospectus. The registration statement has been declared effective by the SEC on May 9, 2022, and BAC has mailed the definitive proxy statement/prospectus, dated May 9, 2022 and a proxy card to each shareholder of BAC as of the March 28, 2022 record date for the meeting of BAC shareholders. On May 23, 2022, BAC issued a Prospectus Supplement. Investors are urged to read these materials (including any amendments or supplements thereto), and any other relevant documents that BAC has filed or will file with the SEC, when they become available, because they do or will contain important information about BAC, Blade and the Transaction. The preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, as supplemented, and other relevant materials in connection with the Transaction, and any other documents filed by BAC with the SEC, may be obtained free of charge on the SEC's website (www.sec.gov). The documents filed by BAC with the SEC may also be obtained free of charge upon written request to Biotech Acquisition Company, 545 West 25th Street, 20th Floor, New York, NY 10001. BAC and its directors and executive officers may be deemed participants in the solicitation of proxies from BAC's shareholders with respect to the Transaction and related matters. Information about BAC's directors and executive officers and a description of their interests in BAC and the Transaction is included in the proxy statement/prospectus for the Transaction which is available free of charge at the SEC's website (www.sec.gov). Blade and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of BAC in connection with the Transaction. Information about Blade's directors and executive officers and information regarding their interests in the Transaction is included in the proxy statement/prospectus for the Transaction which can be obtained free of charge as described in the preceding paragraph. This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Transaction and does not constitute an offer to sell or a solicitation of an offer to buy, or a recommendation to purchase, any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation, purchase or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities will be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom. Certain statements included in this press release that are not historical facts but rather are forward-looking statements. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other performance metrics and projections of market opportunity. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of BAC's and Target's respective management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of BAC and the Target. Some important factors that could cause actual results to differ materially from those in any forward-looking statements could include changes in domestic and foreign business, market, financial, political and legal conditions. These forward-looking statements are subject to a number of risks and uncertainties, including, the inability of the parties to successfully or timely consummate the Transaction, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined entity or the expected benefits of the Transaction, if not obtained; the failure to realize the anticipated benefits of the Transaction; matters discovered by the parties as they complete their respective due diligence investigation of the other parties; the ability of BAC prior to the Transaction, and the combined entity following the Transaction, to maintain the listing of the Company's shares on Nasdaq; costs related to the Transaction; future financial performance of the Company following the Transaction; the ability of the Company to forecast and maintain an adequate rate of revenue growth and appropriately plan its expenses; expectations regarding future expenditures of the Company following the Transaction; the future mix of revenue and effect on gross margins of the Company following the Transaction; the Company's ability to execute its business plans and strategy; the failure to satisfy the conditions to the consummation of the Transaction, including the approval of the definitive merger agreement by the shareholders of BAC, the satisfaction of the minimum cash requirements of the definitive merger agreement following any redemptions by BAC's public shareholders; the risk that the Transaction may not be completed by the stated deadline and the potential failure to obtain an extension of the stated deadline; the inability to complete a PIPE transaction; the outcome of any legal proceedings that may be instituted against BAC or the Target related to the Transaction; the attraction and retention of qualified directors, officers, employees and key personnel of BAC and the Target prior to the Transaction, and the Company following the Transaction; the ability of the Company to compete effectively in a highly competitive market; neither BAC nor the Target are currently generating revenues and there can be no assurance that following the Transaction, the Company will ever achieve revenues or profitability; the ability to protect and enhance the Target's respective corporate reputation and brand; the impact from future regulatory, judicial, and legislative changes in the Target's or the Company's industry; the timing, costs, conduct, and outcome of clinical trials and future preclinical studies and clinical trials, including the timing of the initiation and availability of data from such trials; the timing and likelihood of regulatory filings and approvals for product candidates; whether regulatory authorities determine that additional trials or data are necessary in order to obtain approval; the potential market size and the size of the patient populations for product candidates, if approved for commercial use, and the market opportunities for product candidates; the ability to locate and acquire complementary products or product candidates and integrate those into the Company's business; and, the uncertain effects of the COVID-19 pandemic; and those factors set forth in documents of BAC filed, or to be filed, with SEC. The foregoing list of risks is not exhaustive. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither BAC nor the Target presently know or that BAC and the Target currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect BAC's and the Target's current expectations, plans and forecasts of future events and views as of the date of this press release. BAC and the Target anticipate that subsequent events and developments will cause BAC's and the Target's assessments to change. However, while BAC and the Target may elect to update these forward-looking statements at some point in the future, BAC and the Target specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing BAC's or the Target's assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. SOURCE Biotech Acquisition Company	https://www.prnewswire.com/news-releases/biotech-acquisition-company-and-blade-therapeutics-announce-postponement-of-extraordinary-meeting-of-shareholders-to-approve-proposed-business-combination-301557554.html	2022-05-31T12:42:21	en	0.947031
iRobot OS offers more pet features, understands more voice commands and has recognized more objects than any other robot iRobot OS marks the evolution of company's Genius Home Intelligence platform BEDFORD, Mass., May 31, 2022 /PRNewswire/ -- iRobot Corp. (NASDAQ: IRBT), a leader in consumer robots, today introduced iRobot OS, an evolution of the company's Genius Home Intelligence platform. iRobot OS delivers a new level of customer experience for a cleaner, healthier and smarter home. Leveraging iRobot's growing base of over 20 million connected devices sold, a unique understanding of the home environment and an advanced computer vision platform, iRobot OS is already enabling over 2.7 million cleaning missions each and every day around the world. "As iRobot expands its ecosystem of connected robots and smart home devices, we are placing a strategic emphasis on superior software intelligence delivered on high-performance, beautifully designed hardware," said Colin Angle, chairman and CEO of iRobot. "iRobot OS brings it all to life, enabling products that understand the home environment, respect customer preferences and intuitively connect with the smart home ecosystem to get the job done. iRobot OS lets our robots get smarter and clean even more effectively over time, delivering valuable new features and functionality that benefits all customers, including pet owners, busy families and those looking to get the most out of their voice assistants. This is just the beginning, and we look forward to continuously building upon iRobot OS, providing customers with even more thoughtful ways to clean in the months and years ahead." Built With More Pet Features Than Any Other Robot The #1 choice for pet owners, and the only robot that guarantees it identifies and avoids solid pet waste, the iRobot OS powered Roomba® j7 and j7+ robot vacuums are built with more pet features than any other robot. With pet-centric features like Pet Lock and Keep Out Zones, which can be set to prevent a robot from cleaning areas like around a water dish, along with thoughtfully intelligent suggestions like recommended cleaning schedules during pet shedding season, iRobot's products are designed with the pet owner in mind. Has Recognized and Avoided More Objects Than Any Other Robot1 Able to avoid shoes, socks, cords, headphones, clothing, towels and solid pet waste, the iRobot OS powered Roomba j7 and j7+ robot vacuums have detected more than 43 million objects in people's homes. With a computer vision platform that is currently able to recognize over 80 common objects,2 iRobot OS will continue enabling the Roomba j7 Series to identify and avoid even more objects in the future, letting customers not worry about cleaning up before the cleaning begins. This game-changing functionality has enabled the Roomba j7 Series to become the top-selling robot in both the United States and Japan since it was launched in September 2021. Understands More Voice Commands Than Any Other Robot With approximately 600 supported Alexa®, Google Assistant and Siri commands, iRobot OS delivers the most flexible voice-activated cleaning options and understands more voice commands than any other robot.3 iRobot OS powered robots can clean specific rooms using voice and are the only robots that can be told to clean targeted areas like "around the couch." For more information: Roomba robot vacuum and Braava jet robot mop photos, videos and information can be found at: http://media.irobot.com/media-kits. Please join iRobot on Facebook, Instagram, TikTok, Twitter, and YouTube. Follow iRobot CEO Colin Angle on Twitter and LinkedIn. 1US market only. Estimated objects based on US robotic vacuum sales volume from September 2021 through April 2022. 2Robot behavior varies by object. 3Works with Alexa and Google Assistant enabled devices. Alexa and all related logos are trademarks of Amazon.com or its affiliates. Google is a trademark of Google LLC. Siri is a registered trademark of Apple Inc., registered in the U.S. and other countries and regions. About iRobot Corp. iRobot, the leading global consumer robot company, designs and builds the world's most thoughtful robots and intelligent home innovations that make life better. iRobot created the home robot cleaning category with the introduction of its Roomba® robot vacuum in 2002. Today, iRobot is a global enterprise that has sold more than 40 million robots worldwide. iRobot's product portfolio features proprietary technologies and advanced concepts in cleaning, mapping and navigation. Leveraging this portfolio, iRobot engineers are working to build an ecosystem of robots and smart home devices to help consumers make their homes easier to maintain and healthier places to live. For more information about iRobot, please visit www.irobot.com. For iRobot Investors Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to iRobot Corporation's expectations concerning new product features, including features that expand product performance over time. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. iRobot undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by iRobot, see the disclosure contained in our public filings with the Securities and Exchange Commission including, without limitation, our most recent Annual Report on Form 10-K. View original content to download multimedia: SOURCE iRobot Corporation	https://www.wlbt.com/prnewswire/2022/05/31/irobot-unveils-irobot-os-most-thoughtfully-intelligent-operating-system-home/	2022-05-31T12:42:23	en	0.916939
FREMONT, Calif., May 31, 2022 /PRNewswire/ -- The global carbon capture utilization and storage market is projected to reach $12.16 billion in terms of revenue by 2031 at a CAGR of 19.2%, reveals the premium market intelligence study by BIS Research. Carbon Capture Utilization and Storage (CCUS) involves the capture of CO2 from huge point sources, including power generation, cement industries, or other industrial facilities that use fossil fuels or biomass for fuel. In the report, three types of carbon capture technologies, namely, pre-combustion capture, oxy-fuel combustion, and post-combustion capture, have been considered. Post-combustion capture is one of the proven technologies for CO2 capture from flue gases. The majority of the carbon capture plant utilizes this technology for reasons such as easy availability and lower cost of installation. Growth in the CCUS market is being driven by the increasing focus on reducing carbon dioxide (CO2) emissions, supportive government initiatives, and increasing demand for CO2 for enhanced oil recovery (EOR). The detailed study is a compilation of 80 Market Data Tables and 23 Figures spread through 153 Pages and in-depth TOC on "Global Carbon Capture Utilization and Storage Market – Analysis and Forecast, 2022-2031" USP of the Report This extensive report can help in the following ways: - Market ranking analysis based on product portfolio, recent developments, and regional spread. - Investment landscape including product adoption scenario, funding, and patent analysis. - The study provides the reader a detailed understanding of the different carbon capture utilization and storage application in industries such as the oil and gas industry, power industry, and others (cement and chemical industry). Analyst's Take on the Market: According to Pooja Tanna, Principal Analyst, BIS Research, "The carbon capture utilization and storage is expected to be the best option for reducing carbon footprints. With the increasing investments globally and the rising government support through incentives, the growth of the CCUS industry is expected to be exponential." View the report from BIS Research on Global Carbon Capture Utilization and Storage Market Key Companies Operating in the Market and Competition Landscape The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration. Some prominent names established in this market are: - Fluor Corporation - Exxon Mobil - Mitsubishi Heavy Industries - Linde Plc - Aker Carbon Capture - Royal Dutch Shell - Climeworks Who Should Buy This Report? The report is suitable for carbon capture technology providers and companies involved in capturing and storing CO2. Key Questions Answered in the Report: - What are some of the major factors and trends that are impacting the carbon capture utilization and storage market? - How has COVID-19 impacted the carbon capture utilization and storage market across the globe? Which are the leading end-use industries that are rapidly adopting the CCUS technology? - Which CCUS technology (post-combustion, pre-combustion, and oxy-fuel combustion) is majorly preferred by the key end-use industries? - What are the latest developments in various countries for the development of the carbon capture utilization and storage industry? - What are the various latest governmental regulations/initiatives toward the deployment of CCUS technology globally? - For a new company looking to enter the carbon capture utilization and storage market, which areas could it focus upon to stay ahead of the competition? - What kind of new strategies is being adopted by the existing market players to strengthen their market position in the industry? About BIS Research: BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends which can disrupt the market dynamics in the near future. We publish more than 200 market intelligence studies annually that focus on several deep technology verticals. Our strategic market analysis emphasizes on market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management. BIS Research offers syndicate as well as custom studies and expert consultations to firms, providing them specific and actionable insights on novel technology markets, business models, and competitive landscape. BIS Healthcare vertical offers intelligence in the healthcare technology market for Medical Devices, Digital Health, Life Sciences, Robotics and Imaging, Information Technology, Precision Medicine, and other emerging healthcare technologies, covering the entire industry spectrum. In the past 5 years, BIS Healthcare has published more than 50 reports under the precision medicine banner. Additionally, BIS Research has been nominating Top 25 Voices in Precision Medicine on its Insight Monk platform for the past two years successfully. Contact: Head of Marketing Email: [email protected] BIS Research Inc. 39111 PASEO PADRE PKWY STE 313, FREMONT CA 94538-1686 Visit our Blog @ https://bisresearch.com/news Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research Connect with us on [email protected] https://twitter.com/BISResearch SOURCE BIS Research	https://www.prnewswire.com/news-releases/bis-research-study-highlights-the-global-carbon-capture-utilization-and-storage-market-to-reach-12-16-billion-by-2031--301557725.html	2022-05-31T12:42:27	en	0.92107
Studies spanning industry-leading hematologic malignancies portfolio and pipeline with new research in solid tumor therapies to highlight precision medicine and targeted therapy strategies RARITAN, N.J., May 31, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigational therapies that are being studied for the treatment of multiple blood cancers and solid tumors. "The science and data that we will present at ASCO and EHA highlight the breadth and depth of our oncology portfolio and pipeline, and our team's commitment to advance and deliver innovative treatments for patients," said Peter Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology, Janssen Research & Development, LLC. "Our research and collaborations underscore a focused scientific strategy to deeply understand disease biology in working towards our ultimate goal of preventing, intercepting and one day curing cancer." Consistent with ASCO's theme of Advancing Equitable Cancer Care Through Innovation, Janssen recognizes the importance of eliminating health inequities – from research and clinical trials to access and quality of care – to address the diverse needs of patients and ensure access to cancer therapies. "We are committed to improving representation of real-world patient populations in our clinical development programs and providing access to clinical trials, especially for those in underserved communities," said Craig Tendler, M.D., Vice President, Late Development and Global Medical Affairs, Janssen Research & Development, LLC. "We also look to support investigators, communities and sites to overcome obstacles in oncology clinical trial participation among racial and ethnic minorities so that everyone can benefit from the advances in oncology drug development, which may have a profound impact on the lives of all patients in the future." With nearly six million patients diagnosed annually across hematologic malignancies and prostate, lung and bladder cancers, there remains significant unmet need in the treatment of these complex cancers.1 The latest research and data at ASCO and EHA will demonstrate Janssen's commitment to exploring new vital science for patients in these areas through precision medicine, targeted therapies and novel platforms. "At Janssen, part of our mission to reimagine cancer care includes working to drive better outcomes for patients," said Tyrone Brewer, U.S. President, Oncology, Janssen Biotech, Inc. "The research presented at ASCO underscores our commitment to advancing science, treatment options and patient care across hematologic malignancies, lung cancer, prostate cancer and bladder cancer, and our continued focus on helping patients navigate their treatment journeys." Key ASCO and EHA data presentations include: Leukemia & lymphoma Janssen continues to study IMBRUVICA® (ibrutinib) with the goal of addressing unmet clinical needs and helping to improve outcomes for patients living with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). Data from the Phase 3 SHINE study evaluating IMBRUVICA® in combination with bendamustine and rituximab (BR) in older patients with previously untreated MCL will be featured as an oral presentation (ASCO Oral Abstract: #7502). Additionally, three-year follow-up data from the Phase 2 CAPTIVATE Fixed Duration cohort evaluating IMBRUVICA® plus venetoclax fixed duration treatment for previously untreated patients with CLL or small lymphocytic lymphoma (SLL) will be highlighted in a poster presentation (ASCO Poster Abstract: #7519). At EHA, additional data from the CAPTIVATE study will focus on synergistic activity and immune restoration with this combination regimen. In acute lymphoblastic leukemia or lymphoblastic lymphoma, data from the Phase 2 DELPHINUS study will be featured in an oral presentation, reporting safety and efficacy results for the investigational use of DARZALEX® (daratumumab) in the treatment of pediatric and young adult patients with relapsed or refractory disease (ASCO Oral Abstract: #10001; EHA Poster Session: #P360). Multiple myeloma With a portfolio of four therapies with distinct target antigens and different mechanisms of action, Janssen continues to focus on developing and delivering tailored immunotherapy regimens to treat patients with multiple myeloma. Data at ASCO and EHA will span frontline and relapsed or refractory settings with the latest updates from two investigational therapies and two approved treatments. Two presentations will highlight treatment with DARZALEX® in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma, including updated results from the Phase 3 MAIA study in transplant-ineligible patients (ASCO Poster Abstract: #8044; EHA Poster Session: #P936), and the Phase 2 GRIFFIN study evaluating the investigational use of DARZALEX® in combination with bortezomib, lenalidomide and dexamethasone in transplant-eligible patients (ASCO Poster Abstract: #8011; EHA Poster Session: #P934). In relapsed or refractory disease, results from the POLLUX and CASTOR studies will report on treatment with DARZALEX® in combination with lenalidomide and dexamethasone and in combination with bortezomib and dexamethasone in patients who experienced early or late relapse following at least one prior therapy (ASCO Poster Abstract: #8052; EHA Poster Session: #P933). The latest data to be presented at ASCO and EHA for CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), Janssen's first approved cell therapy, will include longer-term efficacy and safety results from the CARTITUDE-1 study and cohorts A and B of the CARTITUDE-2 study. Both studies include patients with relapsed or refractory multiple myeloma (ASCO Poster Abstracts: #8020, #8029, #8028; EHA Oral Abstract: #S185). Data at ASCO and EHA for the investigational bispecific antibody teclistamab (BCMAxCD3 bispecific antibody) will include an updated analysis from the Phase 1/2 MajesTEC-1 study evaluating monotherapy treatment for patients with relapsed or refractory multiple myeloma (ASCO Oral Abstract: #8007; EHA Poster Abstract: #P921) and results from an analysis of patients who were previously treated with a BCMA-targeted agent (ASCO Poster Abstract: #8013; EHA Oral Abstract: #S184). Additionally, updated results from the TRIMM-2 study of teclistamab in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma will be presented in an oral session at ASCO and EHA (ASCO Poster Abstract: #8032; EHA Oral Abstract: #S188). Updated results from the Phase 1 MonumenTAL-1 study of the investigational bispecific antibody talquetamab (GPRC5DxCD3 bispecific antibody) as a monotherapy treatment for highly refractory multiple myeloma will be reported (ASCO Poster Abstract: #8015; EHA Oral Abstract: #S182). In addition, updated Phase 1b results from the TRIMM-2 study evaluating talquetamab in combination with DARZALEX FASPRO® for the treatment of relapsed or refractory patients with multiple myeloma will be highlighted (EHA Oral Abstract: #S183). Biomarker-driven solid tumors Janssen's first presentation of tumor-agnostic data will share interim analysis results from the Phase 2 RAGNAR study evaluating the investigational use of BALVERSA® (erdafitinib) in patients with advanced or metastatic solid tumors with fibroblast growth factor receptor (FGFR) alterations (ASCO Oral Abstract: #3007). The interim analysis comprises a patient population with 32 distinct solid tumor histologies. Lung cancer Updated data will be presented for the bispecific antibody RYBREVANT® (amivantamab-vmjw) that highlights Janssen's commitment to precision medicine strategies, with an oral presentation of updated results for RYBREVANT® as a monotherapy in patients with non-small cell lung cancer (NSCLC) characterized by MET exon 14 skipping mutations (ASCO Oral Abstract: #9008). A second oral presentation of the CHRYSALIS-2 study of the investigational combination of RYBREVANT® and lazertinib in patients with exon 19 deletion or L858R EGFR-mutated NSCLC (ASCO Oral Abstract: #9006) will also be reported. Prostate cancer A gene-by-gene analysis will provide new insights from the prospectively designed Phase 3 MAGNITUDE study, which is evaluating the safety and efficacy of the combination of niraparib and abiraterone acetate plus prednisone in patients with homologous recombination repair (HRR)-gene mutated metastatic castration-resistant prostate cancer (mCRPC). The data evaluated HRR gene alterations beyond BRCA1/2, including PALB 2, CHEK2 and other mutations (ASCO Poster Abstract: #5020). Janssen will present baseline patient characteristics and the application of different radiation therapy regimens from the Phase 3 ATLAS study investigating if the addition of ERLEADA® (apalutamide) to a gonadotropin-releasing hormone agonist (GnRH) in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy results in an improvement of metastasis-free survival (ASCO Poster Abstract: #5084). A complete list of Janssen-sponsored abstracts at ASCO and EHA is available at: Janssen.com/ASCO2022. About IMBRUVICA® IMBRUVICA® (ibrutinib) is a once-daily oral medication that is jointly developed and commercialized by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. IMBRUVICA® blocks the Bruton's tyrosine kinase (BTK) protein, which is needed by normal and abnormal B cells, including specific cancer cells, to multiply and spread. By blocking BTK, IMBRUVICA® may help move abnormal B cells out of their nourishing environments and inhibits their proliferation.2,3,4 IMBRUVICA® is approved in more than 100 countries for at least one indication and has been used to treat more than 250,000 patients worldwide. There are more than 50 company-sponsored clinical trials, including 18 Phase 3 studies, over 11 years evaluating the efficacy and safety of IMBRUVICA®. IMBRUVICA® was first approved by the U.S. Food and Drug Administration (FDA) in November 2013, and today is indicated for adult patients in six disease areas, including five hematologic cancers. These include indications to treat adults with CLL/SLL with or without 17p deletion (del17p), and adults with Waldenström's macroglobulinemia (WM), and adult patients with previously treated mantle cell lymphoma (MCL), as well as to treat adult patients with previously treated marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy, and adult patients with previously treated chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy.5 Accelerated approval was granted for MCL and MZL based on overall response rate. Continued approval for MCL and MZL may be contingent upon verification and description of clinical benefit in confirmatory trials. The National Comprehensive Cancer Network® (NCCN®), recommends ibrutinib (IMBRUVICA®) as a preferred regimen for the initial treatment of CLL/SLL and has Category 1 treatment status for treatment-naïve patients without deletion 17p/TP53 mutation and as a preferred treatment for treatment-naïve patients with deletion 17p/TP53 mutation. The NCCN Guidelines also recommend IMBRUVICA®, with or without rituximab, as a preferred regimen for the treatment of relapsed/refractory MCL, as a Category 1 preferred regimen for both untreated and previously treated WM patients, and as a preferred regimen for relapsed/refractory MZL.6 For more information, visit www.IMBRUVICA.com. About DARZALEX FASPRO® and DARZALEX® DARZALEX FASPRO® received U.S. FDA approval in May 2020 and is approved for eight indications in multiple myeloma (MM), three of which are for frontline treatment in newly diagnosed patients who are transplant eligible or ineligible.7 DARZALEX FASPRO® is the only subcutaneous CD38-directed antibody globally approved to treat patients with MM. DARZALEX FASPRO® is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE® drug delivery technology. In January 2021, DARZALEX FASPRO® became the first FDA-approved therapy for light chain amyloidosis. In August 2012, Janssen Biotech, Inc. entered into an exclusive global license and development agreement with Genmab A/S to develop, manufacture, and commercialize DARZALEX®.8 DARZALEX® has been approved in eight indications, three of which are in the frontline setting, including for newly diagnosed patients who are transplant eligible as well as those who are ineligible.9 For more information, visit www.DARZALEX.com. About CARVYKTI™ CARVYKTI™ (cilta-cel) received approval by the U.S. FDA in February 2022 for the treatment of adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.10 CARVYKTI™ is a BCMA-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient's own T cells with a transgene encoding a chimeric antigen receptor (CAR) that directs the CAR positive T cells to eliminate cells that express BCMA. BCMA is primarily expressed on the surface of malignant multiple myeloma B-lineage cells, as well as late-stage B cells and plasma cells. The CARVYKTI™ CAR protein features two BCMA-targeting single domain designed to confer high avidity against human BCMA. Upon binding to BCMA-expressing cells, the CAR promotes T-cell activation, expansion, and elimination of target cells. In December 2017, Janssen Biotech, Inc. entered into an exclusive worldwide license and collaboration agreement with Legend Biotech USA, Inc. to develop and commercialize CARVYKTI™. Cilta-cel received a PRIority MEdicines (PRIME) designation from the European Commission in April 2019, and the Orphan Drug Designation for cilta-cel from the European Commission in February 2020. In May 2022, Janssen announced that the European Commission (EC) granted conditional marketing authorisation of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. In March 2022, Janssen announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization of cilta-cel for the treatment of adults with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an IMiD, a PI and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. There are several ongoing Phase 3 clinical trials investigating CARVYKTI™ in earlier treatment settings, including first-line. For more information, visit www.CARVYKTI.com. About Teclistamab Teclistamab is an off-the-shelf, T-cell redirecting, bispecific antibody targeting both BCMA (B-cell maturation antigen) and CD3, the T-cell receptor. BCMA is expressed at high levels on multiple myeloma cells.11,12,13,14,15 Teclistamab redirects CD3-positive T-cells to BCMA-expressing myeloma cells to induce killing of tumor cells.14 Teclistamab is currently being evaluated in several monotherapy and combination studies. In 2020, the European Commission and the U.S. FDA each granted teclistamab Orphan Drug Designation for the treatment of multiple myeloma. In January 2021 and May 2021, teclistamab received a PRIority MEdicines (PRIME) designation by the European Medicines Agency (EMA) and Breakthrough Therapy Designation (BTD) by the U.S. FDA, respectively. PRIME offers enhanced interaction and early dialogue to optimize drug development plans and speed up evaluation of cutting-edge, scientific advances that target a high unmet medical need.16 The U.S. FDA granted teclistamab Priority Review Designation in December 2021. About Talquetamab Talquetamab is a first-in-class, off-the-shelf, investigational T-cell redirecting bispecific antibody targeting both GPRC5D and CD3, a primary component of the T-cell receptor. GPRC5D is a novel target which is highly expressed on multiple myeloma cells. Talquetamab is currently being evaluated in a Phase 1/2 clinical study for the treatment of relapsed or refractory multiple myeloma (NCT03399799) and is also being explored in combination studies (NCT04586426). In January 2021, talquetamab was granted PRIME designation by the European Commission. In 2021, the European Commission and the U.S. FDA each granted talquetamab Orphan Drug Designation for the treatment of multiple myeloma. About BALVERSA® BALVERSA® (erdafitinib) is a once-daily, oral FGFR kinase inhibitor that is approved by the U.S. FDA for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC) that has susceptible FGFR3 or FGFR2 genetic alterations and has progressed during or following at least one line of platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Patients are selected for therapy based on an FDA-approved companion diagnostic for BALVERSA®. Information on FDA-approved tests for the detection of FGFR genetic alterations in urothelial cancer is available at: http://www.fda.gov/CompanionDiagnostics. This indication is approved under accelerated approval based on tumor response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.7,15 In addition to RAGNAR, BALVERSA® is being studied in multiple clinical trials including the Phase 3 THOR (NCT03390504) study evaluating BALVERSA® versus standard of care, consisting of chemotherapy (docetaxel or vinflunine) or anti-PD-1 agent pembrolizumab, in participants with advanced urothelial cancer and selected FGFR aberrations with disease progression following one prior line of therapy; and the Phase 2 THOR-2/BLC2003 study (NCT04172675) study examining BALVERSA® versus investigator choice of intravesical chemotherapy in participants who received Bacillus Calmette-Guérin and recurred with high risk non-muscle-invasive bladder cancer.16,17,18 In 2008, Janssen entered into an exclusive worldwide license and collaboration agreement with Astex Pharmaceuticals to develop and commercialize BALVERSA®. For more information, visit https://www.BALVERSA.com. About RYBREVANT® RYBREVANT® (amivantamab-vmjw) received accelerated approval by the U.S. FDA in May 2021 for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.17 This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer prefer NGS-based strategies over PCR-based approaches for the detection of EGFR exon 20 insertion variants and include amivantamab-vmjw (RYBREVANT®) as a subsequent therapy option with a Category 2A recommendation for patients that have progressed on or after platinum-based chemotherapy with or without immunotherapy and have EGFR exon 20 insertion mutation-positive advanced NSCLC.18†‡ RYBREVANT® has also received approval from health authorities in Europe, as well as other markets around the world. RYBREVANT® is being studied in multiple clinical trials, including the Phase 1/1b CHRYSALIS-2 (NCT04077463) study assessing the combination of RYBREVANT® and lazertinib in patients who have progressed after treatment with osimertinib and chemotherapy; as first-line therapy in untreated advanced EGFR-mutated NSCLC in the Phase 3 MARIPOSA (NCT04487080NCT04487080) study assessing amivantamab in combination with lazertinib; the planned Phase 3 MARIPOSA-2 (NCT04988295) study assessing the efficacy of lazertinib, RYBREVANT® and carboplatin-pemetrexed versus carboplatin-pemetrexed in patients with locally advanced or metastatic EGFR exon 19 deletion or exon 21 L858R substitution NSCLC after osimertinib failure; the Phase 3 PAPILLON (NCT04538664) study assessing RYBREVANT® in combination with carboplatin-pemetrexed versus chemotherapy alone in patients with advanced or metastatic EGFR-mutated NSCLC and exon 20 insertion mutations; and the Phase 1 PALOMA (NCT04606381) study assessing the feasibility of subcutaneous (SC) administration of RYBREVANT® based on safety and pharmacokinetics and to determine a dose, dose regimen and formulation for RYBREVANT® SC delivery.19,20,21,22,23,24 * NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. †See the NCCN Guidelines for detailed recommendations, including other treatment options.20 ‡The NCCN Guidelines for NSCLC provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays or commercial laboratories. For more information, visit: https://www.RYBREVANT.com. About Lazertinib Lazertinib is an oral, third-generation, brain-penetrant, EGFR tyrosine kinase inhibitor (TKI) that targets both the T790M mutation and activating EGFR mutations while sparing wild type-EGFR.25 Interim safety and efficacy results from the lazertinib Phase 1-2 study were published in The Lancet Oncology in 2019. In 2018, Janssen Biotech, Inc. entered into a license and collaboration agreement with Yuhan Corporation for the development of lazertinib. About Niraparib Niraparib is an orally administered, poly-ADP ribose polymerase (PARP) inhibitor that is currently being studied by Janssen for the treatment of patients with prostate cancer. Ongoing studies include the Phase 3 AMPLITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisone in a biomarker-selected patient population with mCSPC; the Phase 3 MAGNITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisone as a first-line treatment option compared to abiraterone acetate and prednisone plus placebo in adults with mCRPC; and QUEST, a Phase 1b/2 study of niraparib combination therapies for the treatment of mCRPC. In April 2022, Janssen announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of niraparib in combination with abiraterone acetate, in the form of a dual action tablet plus prednisone, based on the results of the Phase 3 MAGNITUDE study for the treatment of patients with prostate cancer who have progressed to metastatic castration-resistant prostate cancer (mCRPC) and are positive for homologous recombination repair (HRR) gene alterations. In April 2016, Janssen Biotech, Inc. entered a worldwide (except Japan) collaboration and license agreement with TESARO, Inc. (acquired by GSK in 2018), for exclusive rights to niraparib in prostate cancer. In the U.S., niraparib is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy; for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy; for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either: a deleterious or suspected deleterious BRCA mutation, or genomic instability and who have progressed more than six months after response to the last platinum-based chemotherapy. In the EU, niraparib is indicated as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response following platinum-based chemotherapy. Niraparib is currently marketed by GSK as ZEJULA®.26 About ERLEADA® ERLEADA® (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with mCSPC.27 ERLEADA® received U.S. FDA approval for nmCRPC in February 2018, and was approved for mCSPC in September 2019.22 To date, more than 50,000 patients worldwide have been treated with ERLEADA®. For more information, visit www.ERLEADA.com. IMBRUVICA® IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Hemorrhage: Fatal bleeding events have occurred in patients who received IMBRUVICA®. Major hemorrhage (≥ Grade 3, serious, or any central nervous system events; e.g., intracranial hemorrhage [including subdural hematoma], gastrointestinal bleeding, hematuria, and post procedural hemorrhage) occurred in 4.2% of patients, with fatalities occurring in 0.4% of 2,838 patients who received IMBRUVICA® in 27 clinical trials. Bleeding events of any grade including bruising and petechiae occurred in 39%, and excluding bruising and petechiae occurred in 23% of patients who received IMBRUVICA®, respectively. The mechanism for the bleeding events is not well understood. Use of either anticoagulant or antiplatelet agents concomitantly with IMBRUVICA® increases the risk of major hemorrhage. Across clinical trials, 3.1% of 2,838 patients who received IMBRUVICA® without antiplatelet or anticoagulant therapy experienced major hemorrhage. The addition of antiplatelet therapy with or without anticoagulant therapy increased this percentage to 4.4%, and the addition of anticoagulant therapy with or without antiplatelet therapy increased this percentage to 6.1%. Consider the risks and benefits of anticoagulant or antiplatelet therapy when co-administered with IMBRUVICA®. Monitor for signs and symptoms of bleeding. Consider the benefit-risk of withholding IMBRUVICA® for at least 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding. Infections: Fatal and non-fatal infections (including bacterial, viral, or fungal) have occurred with IMBRUVICA® therapy. Grade 3 or greater infections occurred in 21% of 1,476 patients who received IMBRUVICA® in clinical trials. Cases of progressive multifocal leukoencephalopathy (PML) and Pneumocystis jirovecii pneumonia (PJP) have occurred in patients treated with IMBRUVICA®. Consider prophylaxis according to standard of care in patients who are at increased risk for opportunistic infections. Monitor and evaluate patients for fever and infections and treat appropriately. Cardiac Arrhythmias, Cardiac Failure and Sudden Death: Fatal and serious cardiac arrhythmias and cardiac failure have occurred with IMBRUVICA®. Deaths due to cardiac causes or sudden deaths occurred in 1% of 4,896 patients who received IMBRUVICA® in clinical trials, including in patients who received IMBRUVICA® in unapproved monotherapy or combination regimens. These adverse reactions occurred in patients with and without preexisting hypertension or cardiac comorbidities. Patients with cardiac comorbidities may be at greater risk of these events. Grade 3 or greater ventricular tachyarrhythmias were reported in 0.2%, Grade 3 or greater atrial fibrillation and atrial flutter were reported in 3.7%, and Grade 3 or greater cardiac failure was reported in 1.3% of 4,896 patients who received IMBRUVICA® in clinical trials, including in patients who received IMBRUVICA® in unapproved monotherapy or combination regimens. These events have occurred particularly in patients with cardiac risk factors including hypertension and diabetes mellitus, a previous history of cardiac arrhythmias, and in patients with acute infections. Evaluate cardiac history and function at baseline, and monitor patients for cardiac arrhythmias and cardiac function. Obtain further evaluation (e.g., ECG, echocardiogram) as indicated for patients who develop symptoms of arrhythmia (e.g., palpitations, lightheadedness, syncope, chest pain), new onset dyspnea, or other cardiovascular concerns. Manage cardiac arrhythmias and cardiac failure appropriately, follow dose modification guidelines, and consider the risks and benefits of continued IMBRUVICA® treatment. Hypertension: Hypertension occurred in 19% of 1,476 patients who received IMBRUVICA® in clinical trials. Grade 3 or greater hypertension occurred in 8% of patients. Based on data from 1,124 of these patients, the median time to onset was 5.9 months (range, 0.03 to 24 months). Monitor blood pressure in patients treated with IMBRUVICA®, initiate or adjust anti-hypertensive medication throughout treatment with IMBRUVICA® as appropriate, and follow dosage modification guidelines for Grade 3 or higher hypertension. Cytopenias: In 645 patients with B-cell malignancies who received IMBRUVICA® as a single agent, grade 3 or 4 neutropenia occurred in 23% of patients, grade 3 or 4 thrombocytopenia in 8% and grade 3 or 4 anemia in 2.8%, based on laboratory measurements. Monitor complete blood counts monthly. Second Primary Malignancies: Other malignancies (10%), including non-skin carcinomas (3.9%), occurred among the 1,476 patients who received IMBRUVICA® in clinical trials. The most frequent second primary malignancy was non-melanoma skin cancer (6%). Tumor Lysis Syndrome: Tumor lysis syndrome has been infrequently reported with IMBRUVICA®. Assess the baseline risk (e.g., high tumor burden) and take appropriate precautions. Monitor patients closely and treat as appropriate. Embryo-Fetal Toxicity: Based on findings in animals, IMBRUVICA® can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with IMBRUVICA® and for 1 month after the last dose. Advise males with female partners of reproductive potential to use effective contraception during the same time period. ADVERSE REACTIONS B-cell malignancies: The most common adverse reactions (≥30%) in patients with B-cell malignancies (MCL, CLL/SLL, WM and MZL) were thrombocytopenia (54.5%), diarrhea (43.8%), fatigue (39.1%), musculoskeletal pain (38.8%), neutropenia (38.6%), rash (35.8%), anemia (35.0%), and bruising (32.0%). The most common Grade ≥ 3 adverse reactions (≥5%) in patients with B-cell malignancies (MCL, CLL/SLL, WM and MZL) were neutropenia (20.7%), thrombocytopenia (13.6%), pneumonia (8.2%), and hypertension (8.0%). Approximately 9% (CLL/SLL), 14% (MCL), 14% (WM) and 10% (MZL) of patients had a dose reduction due to adverse reactions. Approximately 4-10% (CLL/SLL), 9% (MCL), and 7% (WM [5%] and MZL [13%]) of patients discontinued due to adverse reactions. cGVHD: The most common adverse reactions (≥20%) in patients with cGVHD were fatigue (57%), bruising (40%), diarrhea (36%), thrombocytopenia (33%), muscle spasms (29%), stomatitis (29%), nausea (26%), hemorrhage (26%), anemia (24%), and pneumonia (21%). The most common Grade 3 or higher adverse reactions (≥5%) reported in patients with cGVHD were pneumonia (14%), fatigue (12%), diarrhea (10%), neutropenia (10%), sepsis (10%), hypokalemia (7%), headache (5%), musculoskeletal pain (5%), and pyrexia (5%). Twenty-four percent of patients receiving IMBRUVICA® in the cGVHD trial discontinued treatment due to adverse reactions. Adverse reactions leading to dose reduction occurred in 26% of patients. Treatment-emergent decreases (all grades) were based on laboratory measurements. DRUG INTERACTIONS CYP3A Inhibitors: Co-administration of IMBRUVICA® with strong or moderate CYP3A inhibitors may increase ibrutinib plasma concentrations. Increased ibrutinib concentrations may increase the risk of drug-related toxicity. Dose modifications of IMBRUVICA® are recommended when used concomitantly with posaconazole, voriconazole, and moderate CYP3A inhibitors. Avoid concomitant use of other strong CYP3A inhibitors. Interrupt IMBRUVICA® if strong inhibitors are used short-term (e.g., for ≤ 7 days). Avoid grapefruit and Seville oranges during IMBRUVICA® treatment, as these contain strong or moderate inhibitors of CYP3A. See dose modification guidelines in USPI sections 2.3 and 7.1. CYP3A Inducers: Avoid coadministration with strong CYP3A inducers. SPECIFIC POPULATIONS Hepatic Impairment (based on Child-Pugh criteria): Avoid use of IMBRUVICA® in patients with severe hepatic impairment. In patients with mild or moderate impairment, reduce recommended IMBRUVICA® dose and monitor more frequently for adverse reactions of IMBRUVICA®. Please click here to see the full Prescribing Information. DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) INDICATIONS AND IMPORTANT SAFETY INFORMATION INDICATIONS DARZALEX® (daratumumab) is indicated for the treatment of adult patients with multiple myeloma: - In combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy - In combination with bortezomib, melphalan, and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant - In combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant - In combination with bortezomib and dexamethasone in patients who have received at least one prior therapy - In combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy - In combination with pomalidomide and dexamethasone in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (PI) - As monotherapy in patients who have received at least three prior lines of therapy including a PI and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) is indicated for the treatment of adult patients with multiple myeloma: - In combination with bortezomib, melphalan, and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant - In combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy - In combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant - In combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor (PI) - In combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy - In combination with bortezomib and dexamethasone in patients who have received at least one prior therapy - As monotherapy in patients who have received at least three prior lines of therapy including a PI and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent DARZALEX® AND DARZALEX FASPRO®: CONTRAINDICATIONS DARZALEX® and DARZALEX FASPRO® are contraindicated in patients with a history of severe hypersensitivity to daratumumab, hyaluronidase (for DARZALEX FASPRO®), or any of the components of the formulations. DARZALEX®: Infusion-Related Reactions DARZALEX® can cause severe and/or serious infusion-related reactions including anaphylactic reactions. These reactions can be life-threatening, and fatal outcomes have been reported. In clinical trials (monotherapy and combination: N=2066), infusion-related reactions occurred in 37% of patients with the Week 1 (16 mg/kg) infusion, 2% with the Week 2 infusion, and cumulatively 6% with subsequent infusions. Less than 1% of patients had a Grade 3/4 infusion-related reaction at Week 2 or subsequent infusions. The median time to onset was 1.5 hours (range: 0 to 73 hours). Nearly all reactions occurred during infusion or within 4 hours of completing DARZALEX®. Severe reactions have occurred, including bronchospasm, hypoxia, dyspnea, hypertension, tachycardia, headache, laryngeal edema, pulmonary edema, and ocular adverse reactions, including choroidal effusion, acute myopia, and acute angle closure glaucoma. Signs and symptoms may include respiratory symptoms, such as nasal congestion, cough, throat irritation, as well as chills, vomiting, and nausea. Less common signs and symptoms were wheezing, allergic rhinitis, pyrexia, chest discomfort, pruritus, hypotension, and blurred vision. When DARZALEX® dosing was interrupted in the setting of ASCT (CASSIOPEIA) for a median of 3.75 months (range: 2.4 to 6.9 months), upon re-initiation of DARZALEX®, the incidence of infusion-related reactions was 11% for the first infusion following ASCT. Infusion-related reactions occurring at re-initiation of DARZALEX® following ASCT were consistent in terms of symptoms and severity (Grade 3 or 4: <1%) with those reported in previous studies at Week 2 or subsequent infusions. In EQUULEUS, patients receiving combination treatment (n=97) were administered the first 16 mg/kg dose at Week 1 split over two days, i.e., 8 mg/kg on Day 1 and Day 2, respectively. The incidence of any grade infusion-related reactions was 42%, with 36% of patients experiencing infusion-related reactions on Day 1 of Week 1, 4% on Day 2 of Week 1, and 8% with subsequent infusions. Pre-medicate patients with antihistamines, antipyretics, and corticosteroids. Frequently monitor patients during the entire infusion. Interrupt DARZALEX® infusion for reactions of any severity and institute medical management as needed. Permanently discontinue DARZALEX® therapy if an anaphylactic reaction or life-threatening (Grade 4) reaction occurs and institute appropriate emergency care. For patients with Grade 1, 2, or 3 reactions, reduce the infusion rate when re-starting the infusion. To reduce the risk of delayed infusion-related reactions, administer oral corticosteroids to all patients following DARZALEX® infusions. Patients with a history of chronic obstructive pulmonary disease may require additional post-infusion medications to manage respiratory complications. Consider prescribing short and long-acting bronchodilators and inhaled corticosteroids for patients with chronic obstructive pulmonary disease. Ocular adverse reactions, including acute myopia and narrowing of the anterior chamber angle due to ciliochoroidal effusions with potential for increased intraocular pressure or glaucoma, have occurred with DARZALEX® infusion. If ocular symptoms occur, interrupt DARZALEX® infusion and seek immediate ophthalmologic evaluation prior to restarting DARZALEX®. DARZALEX FASPRO®: Hypersensitivity and Other Administration Reactions Both systemic administration-related reactions, including severe or life-threatening reactions, and local injection-site reactions can occur with DARZALEX FASPRO®. Fatal reactions have been reported with daratumumab-containing products, including DARZALEX FASPRO®. Systemic Reactions In a pooled safety population of 898 patients with multiple myeloma (N=705) or light chain (AL) amyloidosis (N=193) who received DARZALEX FASPRO® as monotherapy or in combination, 9% of patients experienced a systemic administration-related reaction (Grade 2: 3.2%, Grade 3: 1%). Systemic administration-related reactions occurred in 8% of patients with the first injection, 0.3% with the second injection, and cumulatively 1% with subsequent injections. The median time to onset was 3.2 hours (range: 4 minutes to 3.5 days). Of the 140 systemic administration-related reactions that occurred in 77 patients, 121 (86%) occurred on the day of DARZALEX FASPRO® administration. Delayed systemic administration-related reactions have occurred in 1% of the patients. Severe reactions included hypoxia, dyspnea, hypertension, tachycardia, and ocular adverse reactions, including choroidal effusion, acute myopia, and acute angle closure glaucoma. Other signs and symptoms of systemic administration-related reactions may include respiratory symptoms, such as bronchospasm, nasal congestion, cough, throat irritation, allergic rhinitis, and wheezing, as well as anaphylactic reaction, pyrexia, chest pain, pruritus, chills, vomiting, nausea, hypotension, and blurred vision. Pre-medicate patients with histamine-1 receptor antagonist, acetaminophen, and corticosteroids. Monitor patients for systemic administration-related reactions, especially following the first and second injections. For anaphylactic reaction or life-threatening (Grade 4) administration-related reactions, immediately and permanently discontinue DARZALEX FASPRO®. Consider administering corticosteroids and other medications after the administration of DARZALEX FASPRO® depending on dosing regimen and medical history to minimize the risk of delayed (defined as occurring the day after administration) systemic administration-related reactions. Ocular adverse reactions, including acute myopia and narrowing of the anterior chamber angle due to ciliochoroidal effusions with potential for increased intraocular pressure or glaucoma, have occurred with daratumumab-containing products. If ocular symptoms occur, interrupt DARZALEX FASPRO® and seek immediate ophthalmologic evaluation prior to restarting DARZALEX FASPRO®. Local Reactions In this pooled safety population, injection-site reactions occurred in 8% of patients, including Grade 2 reactions in 0.7%. The most frequent (>1%) injection-site reaction was injection-site erythema. These local reactions occurred a median of 5 minutes (range: 0 minutes to 6.5 days) after starting administration of DARZALEX FASPRO®. Monitor for local reactions and consider symptomatic management. DARZALEX® and DARZALEX FASPRO®: Neutropenia and Thrombocytopenia DARZALEX® and DARZALEX FASPRO® may increase neutropenia and thrombocytopenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. Consider withholding DARZALEX® or DARZALEX FASPRO® until recovery of neutrophils or for recovery of platelets. In lower body weight patients receiving DARZALEX FASPRO®, higher rates of Grade 3-4 neutropenia were observed. DARZALEX® and DARZALEX FASPRO®: Interference With Serological Testing Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive indirect antiglobulin test (indirect Coombs test). Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab administration. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient's serum. The determination of a patient's ABO and Rh blood type are not impacted. Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX® and DARZALEX FASPRO®. Type and screen patients prior to starting DARZALEX® and DARZALEX FASPRO®. DARZALEX® and DARZALEX FASPRO®: Interference With Determination of Complete Response Daratumumab is a human immunoglobulin G (IgG) kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and of disease progression in some patients with IgG kappa myeloma protein. DARZALEX® and DARZALEX FASPRO®: Embryo-Fetal Toxicity Based on the mechanism of action, DARZALEX® and DARZALEX FASPRO® can cause fetal harm when administered to a pregnant woman. DARZALEX® and DARZALEX FASPRO® may cause depletion of fetal immune cells and decreased bone density. Advise pregnant women of the potential risk to a fetus. Advise females with reproductive potential to use effective contraception during treatment with DARZALEX® or DARZALEX FASPRO® and for 3 months after the last dose. The combination of DARZALEX® or DARZALEX FASPRO® with lenalidomide, pomalidomide, or thalidomide is contraindicated in pregnant women because lenalidomide, pomalidomide, and thalidomide may cause birth defects and death of the unborn child. Refer to the lenalidomide, pomalidomide, or thalidomide prescribing information on use during pregnancy. DARZALEX®: ADVERSE REACTIONS The most frequently reported adverse reactions (incidence ≥20%) were upper respiratory infection, neutropenia, infusion-related reactions, thrombocytopenia, diarrhea, constipation, anemia, peripheral sensory neuropathy, fatigue, peripheral edema, nausea, cough, pyrexia, dyspnea, and asthenia. The most common hematologic laboratory abnormalities (≥40%) with DARZALEX® are neutropenia, lymphopenia, thrombocytopenia, leukopenia, and anemia. DARZALEX FASPRO®: ADVERSE REACTIONS In multiple myeloma, the most common adverse reaction (≥20%) with DARZALEX FASPRO® monotherapy is upper respiratory tract infection. The most common adverse reactions with combination therapy (≥20% for any combination) include fatigue, nausea, diarrhea, dyspnea, insomnia, headache, pyrexia, cough, muscle spasms, back pain, vomiting, hypertension, upper respiratory tract infection, peripheral sensory neuropathy, constipation, pneumonia, and peripheral edema. The most common hematologic laboratory abnormalities (≥40%) with DARZALEX FASPRO® are decreased leukocytes, decreased lymphocytes, decreased neutrophils, decreased platelets, and decreased hemoglobin. Please read full Prescribing Information for DARZALEX®. Please read full Prescribing Information for DARZALEX FASPRO®. CARVYKTI™ IMPORTANT SAFETY INFORMATION INDICATIONS AND USAGE CARVYKTI™ (ciltacabtagene autoleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma, after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. WARNINGS AND PRECAUTIONS Cytokine Release Syndrome (CRS) including fatal or life-threatening reactions, occurred following treatment with CARVYKTI™ in 95% (92/97) of patients receiving ciltacabtagene autoleucel. Grade 3 or higher CRS (2019 ASTCT grade) occurred in 5% (5/97) of patients, with Grade 5 CRS reported in 1 patient. The median time to onset of CRS was 7 days (range: 1-12 days). The most common manifestations of CRS included pyrexia (100%), hypotension (43%), increased aspartate aminotransferase (AST) (22%), chills (15%), increased alanine aminotransferase (14%) and sinus tachycardia (11%). Grade 3 or higher events associated with CRS included increased AST and ALT, hyperbilirubinemia, hypotension, pyrexia, hypoxia, respiratory failure, acute kidney injury, disseminated intravascular coagulation, HLH/MAS, angina pectoris, supraventricular and ventricular tachycardia, malaise, myalgias, increased C-reactive protein, ferritin, blood alkaline phosphatase and gamma-glutamyl transferase. Identify CRS based on clinical presentation. Evaluate for and treat other causes of fever, hypoxia, and hypotension. CRS has been reported to be associated with findings of HLH/MAS, and the physiology of the syndromes may overlap. HLH/MAS is a potentially life-threatening condition. In patients with progressive symptoms of CRS or refractory CRS despite treatment, evaluate for evidence of HLH/MAS. Sixty-nine of 97 (71%) patients received tocilizumab and/or a corticosteroid for CRS after infusion of ciltacabtagene autoleucel. Forty-four (45%) patients received only tocilizumab, of whom 33 (34%) received a single dose and 11 (11%) received more than one dose; 24 patients (25%) received tocilizumab and a corticosteroid, and one patient (1%) received only corticosteroids. Ensure that a minimum of two doses of tocilizumab are available prior to infusion of CARVYKTI™. Monitor patients at least daily for 10 days following CARVYKTI™ infusion at a REMS-certified healthcare facility for signs and symptoms of CRS. Monitor patients for signs or symptoms of CRS for at least 4 weeks after infusion. At the first sign of CRS, immediately institute treatment with supportive care, tocilizumab, or tocilizumab and corticosteroids. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time. Neurologic toxicities, which may be severe, life-threatening or fatal, occurred following treatment with CARVYKTI™. Neurologic toxicities included ICANS, neurologic toxicity with signs and symptoms of parkinsonism, Guillain-Barré Syndrome, peripheral neuropathies, and cranial nerve palsies. Counsel patients on the signs and symptoms of these neurologic toxicities, and on the delayed nature of onset of some of these toxicities. Instruct patients to seek immediate medical attention for further assessment and management if signs or symptoms of any of these neurologic toxicities occur at any time. Overall, one or more subtypes of neurologic toxicity described below occurred following ciltacabtagene autoleucel in 26% (25/97) of patients, of which 11% (11/97) of patients experienced Grade 3 or higher events. These subtypes of neurologic toxicities were also observed in two ongoing studies. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): Patients may experience fatal or life-threatening ICANS following treatment with CARVYKTI™, including before CRS onset, concurrently with CRS, after CRS resolution, or in the absence of CRS. ICANS occurred in 23% (22/97) of patients receiving ciltacabtagene autoleucel including Grade 3 or 4 events in 3% (3/97) and Grade 5 (fatal) events in 2% (2/97). The median time to onset of ICANS was 8 days (range 1-28 days). All 22 patients with ICANS had CRS. The most frequent (≥5%) manifestation of ICANS included encephalopathy (23%), aphasia (8%) and headache (6%). Monitor patients at least daily for 10 days following CARVYKTI™ infusion at the REMS-certified healthcare facility for signs and symptoms of ICANS. Rule out other causes of ICANS symptoms. Monitor patients for signs or symptoms of ICANS for at least 4 weeks after infusion and treat promptly. Neurologic toxicity should be managed with supportive care and/or corticosteroids as needed. Parkinsonism: Of the 25 patients in the CARTITUDE-1 study experiencing any neurotoxicity, five male patients had neurologic toxicity with several signs and symptoms of parkinsonism, distinct from immune effector cell-associated neurotoxicity syndrome (ICANS). Neurologic toxicity with parkinsonism has been reported in other ongoing trials of ciltacabtagene autoleucel. Patients had parkinsonian and non-parkinsonian symptoms that included tremor, bradykinesia, involuntary movements, stereotypy, loss of spontaneous movements, masked facies, apathy, flat affect, fatigue, rigidity, psychomotor retardation, micrographia, dysgraphia, apraxia, lethargy, confusion, somnolence, loss of consciousness, delayed reflexes, hyperreflexia, memory loss, difficulty swallowing, bowel incontinence, falls, stooped posture, shuffling gait, muscle weakness and wasting, motor dysfunction, motor and sensory loss, akinetic mutism, and frontal lobe release signs. The median onset of parkinsonism in the 5 patients in CARTITUDE-1 was 43 days (range 15-108) from infusion of ciltacabtagene autoleucel. Monitor patients for signs and symptoms of parkinsonism that may be delayed in onset and managed with supportive care measures. There is limited efficacy information with medications used for the treatment of Parkinson's disease, for the improvement or resolution of parkinsonism symptoms following CARVYKTI™ treatment. Guillain-Barré Syndrome: A fatal outcome following Guillain-Barré Syndrome (GBS) has occurred in another ongoing study of ciltacabtagene autoleucel despite treatment with intravenous immunoglobulins. Symptoms reported include those consistent with Miller-Fisher variant of GBS, encephalopathy, motor weakness, speech disturbances and polyradiculoneuritis. Monitor for GBS. Evaluate patients presenting with peripheral neuropathy for GBS. Consider treatment of GBS with supportive care measures and in conjunction with immunoglobulins and plasma exchange, depending on severity of GBS. Peripheral Neuropathy: Six patients in CARTITUDE-1 developed peripheral neuropathy. These neuropathies presented as sensory, motor or sensorimotor neuropathies. Median time of onset of symptoms was 62 days (range 4-136 days), median duration of peripheral neuropathies was 256 days (range 2-465 days) including those with ongoing neuropathy. Patients who experienced peripheral neuropathy also experienced cranial nerve palsies or GBS in other ongoing trials of ciltacabtagene autoleucel. Cranial Nerve Palsies: Three patients (3.1%) experienced cranial nerve palsies in CARTITUDE-1. All three patients had 7th cranial nerve palsy; one patient had 5th cranial nerve palsy as well. Median time to onset was 26 days (range 21-101 days) following infusion of ciltacabtagene autoleucel. Occurrence of 3rd and 6th cranial nerve palsy, bilateral 7th cranial nerve palsy, worsening of cranial nerve palsy after improvement, and occurrence of peripheral neuropathy in patients with cranial nerve palsy have also been reported in ongoing trials of ciltacabtagene autoleucel. Monitor patients for signs and symptoms of cranial nerve palsies. Consider management with systemic corticosteroids, depending on the severity and progression of signs and symptoms. Hemophagocytic Lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS): Fatal HLH occurred in one patient (1%), 99 days after ciltacabtagene autoleucel. The HLH event was preceded by prolonged CRS lasting 97 days. The manifestations of HLH/MAS include hypotension, hypoxia with diffuse alveolar damage, coagulopathy, cytopenia, and multi-organ dysfunction, including renal dysfunction. HLH is a life-threatening condition with a high mortality rate if not recognized and treated early. Treatment of HLH/MAS should be administered per institutional standards. CARVYKTI™ REMS: Because of the risk of CRS and neurologic toxicities, CARVYKTI™ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the CARVYKTI™ REMS. Further information is available at www.CARVYKTIrems.com or 1-844-672-0067. Prolonged and Recurrent Cytopenias: Patients may exhibit prolonged and recurrent cytopenias following lymphodepleting chemotherapy and CARVYKTI™ infusion. One patient underwent autologous stem cell therapy for hematopoietic reconstitution due to prolonged thrombocytopenia. In CARTITUDE-1, 30% (29/97) of patients experienced prolonged Grade 3 or 4 neutropenia and 41% (40/97) of patients experienced prolonged Grade 3 or 4 thrombocytopenia that had not resolved by Day 30 following ciltacabtagene autoleucel infusion. Recurrent Grade 3 or 4 neutropenia, thrombocytopenia, lymphopenia and anemia were seen in 63% (61/97), 18% (17/97), 60% (58/97), and 37% (36/97) after recovery from initial Grade 3 or 4 cytopenia following infusion. After Day 60 following ciltacabtagene autoleucel infusion, 31%, 12% and 6% of patients had a recurrence of Grade 3 or higher lymphopenia, neutropenia and thrombocytopenia, respectively, after initial recovery of their Grade 3 or 4 cytopenia. Eighty-seven percent (84/97) of patients had one, two, or three or more recurrences of Grade 3 or 4 cytopenias after initial recovery of Grade 3 or 4 cytopenia. Six and 11 patients had Grade 3 or 4 neutropenia and thrombocytopenia, respectively, at the time of death. Monitor blood counts prior to and after CARVYKTI™ infusion. Manage cytopenias with growth factors and blood product transfusion support according to local institutional guidelines. Infections: CARVYKTI™ should not be administered to patients with active infection or inflammatory disorders. Severe, life-threatening or fatal infections occurred in patients after CARVYKTI™ infusion. Infections (all grades) occurred in 57 (59%) patients. Grade 3 or 4 infections occurred in 23% (22/97) of patients; Grade 3 or 4 infections with an unspecified pathogen occurred in 17%, viral infections in 7%, bacterial infections in 1%, and fungal infections in 1% of patients. Overall, four patients had Grade 5 infections: lung abscess (n=1), sepsis (n=2) and pneumonia (n=1). Monitor patients for signs and symptoms of infection before and after CARVYKTI™ infusion and treat patients appropriately. Administer prophylactic, pre-emptive and/or therapeutic antimicrobials according to the standard institutional guidelines. Febrile neutropenia was observed in 10% of patients after ciltacabtagene autoleucel infusion, and may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad-spectrum antibiotics, fluids and other supportive care, as medically indicated. Viral Reactivation: Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death, can occur in patients with hypogammaglobulinemia. Perform screening for Cytomegalovirus (CMV), HBV, hepatitis C virus (HCV), and human immunodeficiency virus (HIV), or any other infectious agents if clinically indicated in accordance with clinical guidelines before collection of cells for manufacturing. Consider antiviral therapy to prevent viral reactivation per local institutional guidelines/clinical practice. Hypogammaglobulinemia was reported as an adverse event in 12% (12/97) of patients; laboratory IgG levels fell below 500 mg/dL after infusion in 92% (89/97) of patients. Monitor immunoglobulin levels after treatment with CARVYKTI™ and administer IVIG for IgG <400 mg/dL. Manage per local institutional guidelines, including infection precautions and antibiotic or antiviral prophylaxis. Use of Live Vaccines: The safety of immunization with live viral vaccines during or following CARVYKTI™ treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during CARVYKTI™ treatment, and until immune recovery following treatment with CARVYKTI™. Hypersensitivity Reactions have occurred in 5% (5/97) of patients following ciltacabtagene autoleucel infusion. Serious hypersensitivity reactions, including anaphylaxis, may be due to the dimethyl sulfoxide (DMSO) in CARVYKTI™. Patients should be carefully monitored for 2 hours after infusion for signs and symptoms of severe reaction. Treat promptly and manage appropriately according to the severity of the hypersensitivity reaction. Secondary Malignancies: Patients may develop secondary malignancies. Monitor life-long for secondary malignancies. In the event that a secondary malignancy occurs, contact Janssen Biotech, Inc., at 1-800-526-7736 for reporting and to obtain instructions on collection of patient samples for testing of secondary malignancy of T cell origin. Effects on Ability to Drive and Use Machines: Due to the potential for neurologic events, including altered mental status, seizures, neurocognitive decline, or neuropathy, patients are at risk for altered or decreased consciousness or coordination in the 8 weeks following CARVYKTI™ infusion. Advise patients to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery during this initial period, and in the event of new onset of any neurologic toxicities. ADVERSE REACTIONS The most common non-laboratory adverse reactions (incidence greater than 20%) are pyrexia, cytokine release syndrome, hypogammaglobulinemia, hypotension, musculoskeletal pain, fatigue, infections of unspecified pathogen, cough, chills, diarrhea, nausea, encephalopathy, decreased appetite, upper respiratory tract infection, headache, tachycardia, dizziness, dyspnea, edema, viral infections, coagulopathy, constipation, and vomiting. The most common laboratory adverse reactions (incidence greater than or equal to 50%) include thrombocytopenia, neutropenia, anemia, aminotransferase elevation, and hypoalbuminemia. Please read full Prescribing Information including Boxed Warning for CARVYKTI™. BALVERSA® IMPORTANT SAFETY INFORMATION Warnings and Precautions Ocular Disorders – BALVERSA® can cause ocular disorders, including central serous retinopathy/retinal pigment epithelial detachment (CSR/RPED) resulting in visual field defect. CSR/RPED was reported in 25% of patients treated with BALVERSA®, with a median time to first onset of 50 days. Grade 3 CSR/RPED, involving central field of vision, was reported in 3% of patients. CSR/RPED resolved in 13% of patients and was ongoing in 13% of patients at the study cutoff. CSR/RPED led to dose interruptions and reductions in 9% and 14% of patients, respectively, and 3% of patients discontinued BALVERSA®. Dry eye symptoms occurred in 28% of patients during treatment with BALVERSA® and were Grade 3 in 6% of patients. All patients should receive dry eye prophylaxis with ocular demulcents as needed. Perform monthly ophthalmological examinations during the first 4 months of treatment and every 3 months afterwards, and urgently at any time for visual symptoms. Ophthalmological examination should include assessment of visual acuity, slit lamp examination, fundoscopy, and optical coherence tomography. Withhold BALVERSA® when CSR occurs and permanently discontinue if it does not resolve within 4 weeks or if Grade 4 in severity. For ocular adverse reactions, follow the dose modification guidelines [see Dosage and Administration (2.3)]. Hyperphosphatemia and Soft Tissue Mineralization – BALVERSA® can cause hyperphosphatemia leading to soft tissue mineralization, cutaneous calcinosis, non-uremic calciphylaxis and vascular calcification. Increases in phosphate levels are a pharmacodynamic effect of BALVERSA® [see Pharmacodynamics (12.2)]. Hyperphosphatemia was reported as adverse reaction in 76% of patients treated with BALVERSA®. The median onset time for any grade event of hyperphosphatemia was 20 days (range: 8–116) after initiating BALVERSA®. Thirty-two percent of patients received phosphate binders during treatment with BALVERSA®. Cutaneous calcinosis, non-uremic calciphylaxis and vascular calcification have been observed in 0.3% of patients treated with BALVERSA®. Monitor for hyperphosphatemia throughout treatment. In all patients, restrict phosphate intake to 600-800 mg daily. If serum phosphate is above 7.0 mg/dL, consider adding an oral phosphate binder until serum phosphate level returns to <5.5 mg/dL. Withhold, dose reduce, or permanently discontinue BALVERSA® based on duration and severity of hyperphosphatemia [see Dosage and Administration (2.3), Table 2: Dose Modifications for Adverse Reactions]. Embryo-fetal Toxicity – Based on the mechanism of action and findings in animal reproduction studies, BALVERSA® can cause fetal harm when administered to a pregnant woman. In a rat embryo-fetal toxicity study, erdafitinib was embryotoxic and teratogenic at exposures less than the human exposures at all doses studied. Advise pregnant women of the potential risk to the fetus. Advise female patients of reproductive potential to use effective contraception during treatment with BALVERSA® and for one month after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with BALVERSA® and for one month after the last dose [see Use in Specific Populations (8.1, 8.3) and Clinical Pharmacology (12.1)]. Most common adverse reactions including laboratory abnormalities ≥20%: Phosphate increased (76%), stomatitis (56%), fatigue (54%), creatinine increased (52%), diarrhea (47%), dry mouth (45%), onycholysis (41%), alanine aminotransferase increased (41%), alkaline phosphatase increased (41%), sodium decreased (40%), decreased appetite (38%), albumin decreased (37%), dysgeusia (37%), hemoglobin decreased (35%), dry skin (34%), aspartate aminotransferase increased (30%), magnesium decreased (30%), dry eye (28%), alopecia (26%), palmar-plantar erythrodysesthesia syndrome (26%), constipation (28%), phosphate decreased (24%), abdominal pain (23%), calcium increased (22%), nausea (21%), and musculoskeletal pain (20%). The most common Grade 3 or greater adverse reactions (>1%) were stomatitis (9%), nail dystrophy, palmar-plantar erythrodysesthesia syndrome (6%), paronychia (3%), nail disorder, keratitis†, onycholysis (10%), and hyperphosphatemia. *Included within onycholysis. †Included within dry eye. - An adverse reaction with a fatal outcome in 1% of patients was acute myocardial infarction. - Serious adverse reactions occurred in 41% of patients, including eye disorders (10%). - Permanent discontinuation due to an adverse reaction occurred in 13% of patients. The most frequent reasons for permanent discontinuation included eye disorders (6%). - Dosage interruptions occurred in 68% of patients. The most frequent adverse reactions requiring dosage interruption included hyperphosphatemia (24%), stomatitis (17%), eye disorders (17%), and palmar-plantar erythrodysesthesia syndrome (8%). - Dose reductions occurred in 53% of patients. The most frequent adverse reactions for dose reductions included eye disorders (23%), stomatitis (15%), hyperphosphatemia (7%), palmar-plantar erythrodysesthesia syndrome (7%), paronychia (7%), and nail dystrophy (6%). Drug Interactions - Moderate CYP2C9 or strong CYP3A4 Inhibitors: Consider alternative agents or monitor closely for adverse reactions. (7.1) - Strong CYP2C9 or CYP3A4 inducers: Avoid concomitant use with BALVERSA®. (7.1) - Moderate CYP2C9 or CYP3A4 inducers: Increase BALVERSA® dose up to 9 mg. (7.1) - Serum phosphate level-altering agents: Avoid concomitant use with agents that can alter serum phosphate levels before the initial dose modification period. (2.3, 7.1) - CYP3A4 substrates: Avoid concomitant use with sensitive CYP3A4 substrates with narrow therapeutic indices. (7.2) - OCT2 substrates: Consider alternative agents or consider reducing the dose of OCT2 substrates based on tolerability. (7.2) - P-gp substrates: Separate BALVERSA® administration by at least 6 hours before or after administration of P-gp substrates with narrow therapeutic indices. (7.2) Use in Specific Populations Lactation – Because of the potential for serious adverse reactions from erdafitinib in a breastfed child, advise lactating women not to breastfeed during treatment with BALVERSA® and for one month following the last dose. Please see the full Prescribing Information for BALVERSA®. RYBREVANT® IMPORTANT SAFETY INFORMATION19 WARNINGS AND PRECAUTIONS Infusion Related Reactions19 RYBREVANT® can cause infusion related reactions (IRR); signs and symptoms of IRR include dyspnea, flushing, fever, chills, nausea, chest discomfort, hypotension, and vomiting. Based on the safety population, IRR occurred in 66% of patients treated with RYBREVANT®. Among patients receiving treatment on Week 1 Day 1, 65% experienced an IRR, while the incidence of IRR was 3.4% with the Day 2 infusion, 0.4% with the Week 2 infusion, and cumulatively 1.1% with subsequent infusions. Of the reported IRRs, 97% were Grade 1-2, 2.2% were Grade 3, and 0.4% were Grade 4. The median time to onset was 1 hour (range 0.1 to 18 hours) after start of infusion. The incidence of infusion modifications due to IRR was 62% and 1.3% of patients permanently discontinued RYBREVANT® due to IRR. Premedicate with antihistamines, antipyretics, and glucocorticoids and infuse RYBREVANT® as recommended. Administer RYBREVANT® via a peripheral line on Week 1 and Week 2. Monitor patients for any signs and symptoms of infusion reactions during RYBREVANT® infusion in a setting where cardiopulmonary resuscitation medication and equipment are available. Interrupt infusion if IRR is suspected. Reduce the infusion rate or permanently discontinue RYBREVANT® based on severity. Interstitial Lung Disease/Pneumonitis19 RYBREVANT® can cause interstitial lung disease (ILD)/pneumonitis. Based on the safety population, ILD/pneumonitis occurred in 3.3% of patients treated with RYBREVANT®, with 0.7% of patients experiencing Grade 3 ILD/pneumonitis. Three patients (1%) discontinued RYBREVANT® due to ILD/pneumonitis. Monitor patients for new or worsening symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Immediately withhold RYBREVANT® in patients with suspected ILD/pneumonitis and permanently discontinue if ILD/pneumonitis is confirmed. Dermatologic Adverse Reactions19 RYBREVANT® can cause rash (including dermatitis acneiform), pruritus and dry skin. Based on the safety population, rash occurred in 74% of patients treated with RYBREVANT®, including Grade 3 rash in 3.3% of patients. The median time to onset of rash was 14 days (range: 1 to 276 days). Rash leading to dose reduction occurred in 5% of patients, and RYBREVANT® was permanently discontinued due to rash in 0.7% of patients. Toxic epidermal necrolysis occurred in one patient (0.3%) treated with RYBREVANT®. Instruct patients to limit sun exposure during and for 2 months after treatment with RYBREVANT®. Advise patients to wear protective clothing and use broad spectrum UVA/UVB sunscreen. Alcohol free emollient cream is recommended for dry skin. If skin reactions develop, start topical corticosteroids and topical and/or oral antibiotics. For Grade 3 reactions, add oral steroids and consider dermatologic consultation. Promptly refer patients presenting with severe rash, atypical appearance or distribution, or lack of improvement within 2 weeks to a dermatologist. Withhold, dose reduce or permanently discontinue RYBREVANT® based on severity. Ocular Toxicity19 RYBREVANT® can cause ocular toxicity including keratitis, dry eye symptoms, conjunctival redness, blurred vision, visual impairment, ocular itching, and uveitis. Based on the safety population, keratitis occurred in 0.7% and uveitis occurred in 0.3% of patients treated with RYBREVANT®. All events were Grade 1-2. Promptly refer patients presenting with eye symptoms to an ophthalmologist. Withhold, dose reduce or permanently discontinue RYBREVANT® based on severity. Embryo Fetal Toxicity19 Based on its mechanism of action and findings from animal models, RYBREVANT® can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to the fetus. Advise female patients of reproductive potential to use effective contraception during treatment and for 3 months after the final dose of RYBREVANT®. Adverse Reactions19 The most common adverse reactions (≥20%) were rash (84%), IRR (64%), paronychia (50%), musculoskeletal pain (47%), dyspnea (37%), nausea (36%), fatigue (33%), edema (27%), stomatitis (26%), cough (25%), constipation (23%), and vomiting (22%). The most common Grade3 to 4 laboratory abnormalities (≥2%) were decreased lymphocytes (8%), decreased albumin (8%), decreased phosphate (8%), decreased potassium (6%), increased alkaline phosphatase (4.8%), increased glucose (4%), increased gamma-glutamyl transferase (4%), and decreased sodium (4%). Please read full Prescribing Information for RYBREVANT®. ERLEADA® IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Cerebrovascular and Ischemic Cardiovascular Events — In a randomized study (SPARTAN) of patients with nmCRPC, ischemic cardiovascular events occurred in 3.7% of patients treated with ERLEADA® and 2% of patients treated with placebo. In a randomized study (TITAN) in patients with mCSPC, ischemic cardiovascular events occurred in 4.4% of patients treated with ERLEADA® and 1.5% of patients treated with placebo. Across the SPARTAN and TITAN studies, 4 patients (0.3%) treated with ERLEADA® and 2 patients (0.2%) treated with placebo died from an ischemic cardiovascular event. Patients with history of unstable angina, myocardial infarction, congestive heart failure, stroke, or transient ischemic attack within 6 months of randomization were excluded from the SPARTAN and TITAN studies. In the SPARTAN study, cerebrovascular events occurred in 2.5% of patients treated with ERLEADA® and 1% of patients treated with placebo. In the TITAN study, cerebrovascular events occurred in 1.9% of patients treated with ERLEADA® and 2.1% of patients treated with placebo. Across the SPARTAN and TITAN studies, 3 patients (0.2%) treated with ERLEADA®, and 2 patients (0.2%) treated with placebo died from a cerebrovascular event. Cerebrovascular and ischemic cardiovascular events, including events leading to death, occurred in patients receiving ERLEADA®. Monitor for signs and symptoms of ischemic heart disease and cerebrovascular disorders. Optimize management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidemia. Consider discontinuation of ERLEADA® for Grade 3 and 4 events. Fractures — In a randomized study (SPARTAN) of patients with nmCRPC, fractures occurred in 12% of patients treated with ERLEADA® and in 7% of patients treated with placebo. In a randomized study (TITAN) of patients with mCSPC, fractures occurred in 9% of patients treated with ERLEADA® and in 6% of patients treated with placebo. Evaluate patients for fracture risk. Monitor and manage patients at risk for fractures according to established treatment guidelines and consider use of bone-targeted agents. Falls — In a randomized study (SPARTAN), falls occurred in 16% of patients treated with ERLEADA® compared with 9% of patients treated with placebo. Falls were not associated with loss of consciousness or seizure. Falls occurred in patients receiving ERLEADA® with increased frequency in the elderly. Evaluate patients for fall risk. Seizure — In two randomized studies (SPARTAN and TITAN), 5 patients (0.4%) treated with ERLEADA® and 1 patient treated with placebo (0.1%) experienced a seizure. Permanently discontinue ERLEADA® in patients who develop a seizure during treatment. It is unknown whether anti-epileptic medications will prevent seizures with ERLEADA®. Advise patients of the risk of developing a seizure while receiving ERLEADA® and of engaging in any activity where sudden loss of consciousness could cause harm to themselves or others. Embryo-Fetal Toxicity — The safety and efficacy of ERLEADA® have not been established in females. Based on findings from animals and its mechanism of action, ERLEADA® can cause fetal harm and loss of pregnancy when administered to a pregnant female. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of ERLEADA® [see Use in Specific Populations (8.1, 8.3)]. ADVERSE REACTIONS The most common adverse reactions (≥10%) that occurred more frequently in the ERLEADA®-treated patients (≥2% over placebo) from the randomized placebo-controlled clinical trials (TITAN and SPARTAN) were fatigue, arthralgia, rash, decreased appetite, fall, weight decreased, hypertension, hot flush, diarrhea, and fracture. Laboratory Abnormalities — All Grades (Grade 3-4) - Hematology — In the TITAN study: white blood cell decreased ERLEADA® 27% (0.4%), placebo 19% (0.6%). In the SPARTAN study: anemia ERLEADA® 70% (0.4%), placebo 64% (0.5%); leukopenia ERLEADA® 47% (0.3%), placebo 29% (0%); lymphopenia ERLEADA® 41% (1.8%), placebo 21% (1.6%) - Chemistry — In the TITAN study: hypertriglyceridemia ERLEADA® 17% (2.5%), placebo 12% (2.3%). In the SPARTAN study: hypercholesterolemia ERLEADA® 76% (0.1%), placebo 46% (0%); hyperglycemia ERLEADA® 70% (2%), placebo 59% (1.0%); hypertriglyceridemia ERLEADA® 67% (1.6%), placebo 49% (0.8%); hyperkalemia ERLEADA® 32% (1.9%), placebo 22% (0.5%) - Rash — In 2 randomized studies (SPARTAN and TITAN), rash was most commonly described as macular or maculopapular. Adverse reactions of rash were 26% with ERLEADA® vs 8% with placebo. Grade 3 rashes (defined as covering >30% body surface area [BSA]) were reported with ERLEADA® treatment (6%) vs placebo (0.5%) The onset of rash occurred at a median of 83 days. Rash resolved in 78% of patients within a median of 78 days from onset of rash. Rash was commonly managed with oral antihistamines, topical corticosteroids, and 19% of patients received systemic corticosteroids. Dose reduction or dose interruption occurred in 14% and 28% of patients, respectively. Of the patients who had dose interruption, 59% experienced recurrence of rash upon reintroduction of ERLEADA®. Hypothyroidism — In 2 randomized studies (SPARTAN and TITAN), hypothyroidism was reported for 8% of patients treated with ERLEADA® and 1.5% of patients treated with placebo based on assessments of thyroid-stimulating hormone (TSH) every 4 months. Elevated TSH occurred in 25% of patients treated with ERLEADA® and 7% of patients treated with placebo. The median onset was at the first scheduled assessment. There were no Grade 3 or 4 adverse reactions. Thyroid replacement therapy, when clinically indicated, should be initiated or dose-adjusted. DRUG INTERACTIONS Effect of Other Drugs on ERLEADA® — Co-administration of a strong CYP2C8 or CYP3A4 inhibitor is predicted to increase the steady-state exposure of the active moieties. No initial dose adjustment is necessary; however, reduce the ERLEADA® dose based on tolerability [see Dosage and Administration (2.2)]. Effect of ERLEADA® on Other Drugs CYP3A4, CYP2C9, CYP2C19, and UGT Substrates — ERLEADA® is a strong inducer of CYP3A4 and CYP2C19, and a weak inducer of CYP2C9 in humans. Concomitant use of ERLEADA® with medications that are primarily metabolized by CYP3A4, CYP2C19, or CYP2C9 can result in lower exposure to these medications. Substitution for these medications is recommended when possible or evaluate for loss of activity if medication is continued. Concomitant administration of ERLEADA® with medications that are substrates of UDP-glucuronosyl transferase (UGT) can result in decreased exposure. Use caution if substrates of UGT must be co-administered with ERLEADA® and evaluate for loss of activity. P-gp, BCRP, or OATP1B1 Substrates — Apalutamide is a weak inducer of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and organic anion transporting polypeptide 1B1 (OATP1B1) clinically. Concomitant use of ERLEADA® with medications that are substrates of P-gp, BCRP, or OATP1B1 can result in lower exposure of these medications. Use caution if substrates of P-gp, BCRP, or OATP1B1 must be co-administered with ERLEADA® and evaluate for loss of activity if medication is continued. Please see the full Prescribing Information for ERLEADA®. About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. Learn more at www.janssen.com. Follow us at @JanssenUS and @JanssenGlobal. Janssen Research & Development, LLC and Janssen Biotech, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of IMBRUVICA® (ibrutinib), DARZALEX® (daratumumab), DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), CARVYKTITM (ciltacabtagene autoleucel), teclistamab, talquetamab, BALVERSA® (erdafitinib), RYBREVANT® (amivantamab-vmjw), niraparib and ERLEADA® (apalutamide). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC or any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Reports on Form 10-Q, and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments. Media Contacts: Brian Kenney +1 215-620-0111 Caroline Pavis +1 610-357-3121 Investor Relations: Raychel Kruper +1 732-524-6164 U.S. Medical Inquiries: +1 800-526-7736 View original content: SOURCE The Janssen Pharmaceutical Companies of Johnson & Johnson	https://www.wlbt.com/prnewswire/2022/05/31/janssen-highlight-science-innovation-advances-robust-oncology-portfolio-pipeline-through-more-than-60-data-presentations-asco-eha/	2022-05-31T12:42:29	en	0.896548
Blackford Capital Hires Ken Wagner as Chief Financial Officer - Blackford continues wave of executive leadership team growth - Expansion of the leadership team enhances firm's ability to pursue new strategies and manage its rapidly growing portfolio companies to create value GRAND RAPIDS, Mich., May 31, 2022 /PRNewswire/ -- Blackford Capital, a leading middle market private equity firm, today announced the appointment of Ken Wagner as Chief Financial Officer effective April 11, 2022, where he will lead the firm's finance, accounting, regulatory, compliance, reporting and controls functions. He will oversee portfolio company due diligence and provide deals team support. Wagner will report to Blackford Managing Partner and Chief Operating Officer Paul Doyle. Mr. Wagner previously worked for ten years with Mr. Doyle at other companies. He joins Blackford from Coastal Group, where he served as Chief Financial Officer with Coastal's then-CEO Paul Doyle to create nearly $80M of equity value in four years. Prior to that, Wagner and Doyle worked together at GHSP, a Tier 1 automotive supplier of advanced shift systems and smart pump systems, where Wagner was CFO and they created $400M of equity value over seven years. Prior to these positions, Mr. Wagner held a number of progressively responsible executive level positions in operations and finance with Magna and Donnelly Corporation companies Magna Mirrors Corporation, Magna Electronics, Inc and Magna E-Car Systems. The Wagner appointment comes as part of a strategic plan for organizational change within the Blackford Capital executive leadership team. In addition to several internal promotions and organizational restructuring, Blackford recently announced the appointment of Paul Doyle to Managing Partner after more than seven years as an Operating Partner. "We continue to make significant investment in our executive leadership team," said Blackford Capital founder and Managing Director Martin Stein. "As part of our commitment to delivering maximum growth and value creation for our investors we are laser-focused on leveraging our talents when and where they can be most effective. Ken's proven experience will help accelerate our ability to deliver the executive financial oversight, operational expertise and process excellence necessary to drive maximum returns." Mr. Wagner has extensive experience in asset restructuring, financial management and operations. "I'm delighted to join Martin and the dynamic Blackford Capital team at this time in the firm's growth cycle," said Ken Wagner. "This is a terrific opportunity for me to work with Paul again. We are already developing plans to implement new processes and procedures to improve the firm's efficiency and effectiveness, and to provide portfolio company oversight and standardization of reporting and controls, as well as guide CFO talent enhancement." Mr. Wagner earned a Bachelor of Arts in Accounting and Business Administration from Hope College in Holland, Michigan. He previously served in both committee and board chairman positions with Fleetwood Group, Inc., and is a past member of Geneva Camp and Retreat Center Board of Directors. About Blackford Capital Founded in 2010, Blackford Capital is a private equity investment firm headquartered in Grand Rapids, Michigan. Blackford acquires, manages, and builds founder and family-owned, lower middle-market companies, with a focus on the manufacturing, industrial and distribution industries. With a reputation for a relentless approach to value creation and a focus on operational excellent, Blackford was named the Private Equity Firm of the Year by M&A Advisor in 2021 and 2018. The firm has also received Deal of the Year honors from M&A Advisor in multiple categories, and its portfolio companies have also been included on the Inc. 5000. For more information, visit blackfordcapital.com. Media Contact: Amy Romano Lambert (480) 577-9989 [email protected] SOURCE Blackford Capital	https://www.prnewswire.com/news-releases/blackford-capital-hires-ken-wagner-as-chief-financial-officer-301557015.html	2022-05-31T12:42:33	en	0.951772
HANGZHOU, China, May 31, 2022 /PRNewswire/ -- Jiuzi Holdings, Inc. (NASDAQ: JZXN; the "Company"), a leading new energy vehicles (NEVs) franchisor and retailer under the brand name "Jiuzi" in China, today announced that its subsidiary, Hangzhou Jiuyao New Energy Automobile Technology Co. Ltd. ("Jiuyao"), an NEV procurement platform servicing business customers, has officially launched its operations. Set up as a joint venture with the Company and Hubei Yaonin Chuxing Automobile Service Co, Ltd. ("Yaonin Chuxing"), Jiuyao integrates the strengths, resources, and skills of both Jiuzi and Yaonin Chuxing to help car rental and ride-hailing corporate customers procure qualified NEVs to operate cost-effectively. Jiuyao also provides its customers with financial solutions via partnerships with licensed third-party financial institutions. Jiuyao will serve a quintessential role in furthering the value of the joint venture and implementing the Company's "ToB" strategy. "We are delighted to celebrate the official launch of our Jiuyao platform, which demonstrates our determination to manifest the Company's ambition to spearhead in the implementation of green travel in the EV industry," said by Mr. Shuibo Zhang, CEO of Jiuzi Holdings, Inc. "Since Jiuyao has strong customer resources and operational capacity in the online car rental sector, its launch represents a milestone in perfecting a one-stop service system in the EV industry, and renders us well positioned to meet the growing demand for EVs as a result of China's plan to achieve carbon neutrality by 2060. Jiuyao's launch will also help us optimize the resources from our strategic partners in the sectors of car services, dealership and EV charging facilities that allow us to both offer full-range of operational and commercial services to our customers and foresee the needs of tomorrow." About Jiuzi Holdings, Inc. Jiuzi Holdings, Inc., headquartered in Hangzhou, China, and established in 2017, franchises and operates retail stores under the brand name "Jiuzi" to sell New Energy Vehicles ("NEVs") in third-fourth tier cities in China. The Company mainly sells battery-operated electric vehicles, and sources NEVs through more than twenty NEV manufacturers. It has 31 operating franchise stores and one company-owned store. For more information, visit the Company's website at http://www.zjjzxny.cn/. Forward-Looking Statements All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the Offering will be successfully completed. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the SEC. For more information, please contact: Janice Wang EverGreen Consulting Inc. Email: IR@changqingconsulting.com Phone: +1 571-464-9470 (from U.S.) +86 13811768559 (from China) View original content: SOURCE Jiuzi Holdings, Inc.	https://www.wlbt.com/prnewswire/2022/05/31/jiuzi-holdings-inc-expands-tob-business-launches-new-subsidiary-jiuyao/	2022-05-31T12:42:36	en	0.944579
RICHMOND, Va., May 31, 2022 /PRNewswire/ -- Capital Square, one of the nation's leading sponsors of tax-advantaged real estate investments and an active developer of mixed-use multifamily communities, announced today that their inaugural development project, an 80-unit Class A multifamily property in Richmond, Virginia, has achieved 97% occupancy just over four months after opening its doors to residents. Dubbed "INK," the 80,000-square-foot property, which includes 1,939 square feet of ground-level retail space, was built in a qualified opportunity zone in the emerging neighborhood of Scott's Addition. INK is the first of three development projects of Scott's Collection, a group of boutique multifamily communities within the Scott's Addition neighborhood. Construction on the property began in the second quarter of 2020 and was completed in February 2022. "The quick lease-up of this property has exceeded our expectations but is not surprising given the exceptional quality we've delivered with INK to the increasingly popular Scott's Addition neighborhood," said Whit Huffman, chief strategy and investment officer. "Demand for quality housing in this emerging part of Richmond is very high, and Capital Square is working hard to help satisfy that demand with this project, as well as the four other multifamily properties we have in various stages of development throughout the neighborhood." Development of INK at Scott's Collection was primarily funded with proceeds from Capital Square's first qualified opportunity zone fund, CSRA Opportunity Zone Fund I, LLC. Capital Square has subsequently launched a total of seven qualified opportunity zone funds, including CSRA Opportunity Zone Fund VII, LLC, which seeks to raise $41.4 million from accredited investors to fund the development of an additional luxury multifamily development in the Scott's Addition neighborhood. Capital Square's successfully raised opportunity zone funds to date have initiated over $300 million in development value. Located at 3000 – 3008 Clay Street, the five-story INK features a number of one- and two-bedroom floorplans ranging in size from 585 square feet to 1,130 square feet, private balconies and attractive community amenities, including a pool courtyard and outdoor lounge with fire pit and grill stations. As the market leader, INK's current in-place and asking rents equal $1,718, or $2.46 per square foot. The property is managed by Greystar Property Management. In total, Capital Square currently has four multifamily developments under construction in the Scott's Addition neighborhood that have delivered or will deliver 559 luxury apartment homes by 2023, with another 350 units planned for the neighborhood. These projects include VIV and GEM, the remaining two Scott's Collection multifamily projects, which are currently pre-leasing and will welcome residents in the coming weeks. Also included is The Otis, a 350-unit joint development with Greystar that is expected to complete its first phase of construction during the fourth quarter of 2022. Once a hub for industrial buildings and businesses, Scott's Addition is one of Richmond's fastest growing and vibrant neighborhoods, with a plethora of entertainment and dining options in the walkable neighborhood. The area includes over 13 breweries, cideries, meaderies and distilleries, is home to nationally recognized cinema, a shuffleboard bar, retail shops, and more. Convenient access to Interstates 64, 95, 195 and the Powhite Parkway have also led to a growing number of employers choosing to relocate or open new offices in the neighborhood. Scott's Addition is considered the number one "millennial hot-spot" in Virginia, with a 43% increase in millennials in just five years, according to RENTCafe. Scott's Addition's apartment rental rates are projected to increase 3% to 4% per year for five years and is the second-highest performing market in Richmond, according to Yardi Matrix. Opportunity zones were created to stimulate long-term private investments in low-income urban and rural communities nationwide. Conceived as part of the Tax Cuts and Jobs Act of 2017, opportunity zone funds are intended to help foster economic growth by providing tax benefits to incentivize private investments in designated opportunity zones. About Capital Square Capital Square is a national real estate firm specializing in tax-advantaged real estate investments, including Delaware statutory trusts for Section 1031 exchanges, qualified opportunity zone funds for tax deferral and exclusion and a real estate investment trust (REIT). In recent years the company has become an active developer of multifamily properties in the southeastern US, with eight current projects totaling approximately 2,000 apartment units with a total development cost in excess of $600 million. Since 2012, Capital Square has completed more than $5.6 billion in transaction volume. Capital Square's related entities provide a range of services, including due diligence, acquisition, loan sourcing, property/asset management, and disposition, for a growing number of high-net-worth investors, private equity firms, family offices and institutional investors. Since 2017, Capital Square has been recognized by Inc. 5000 as one of the fastest growing companies in the nation for four consecutive years. In 2017, 2018 and 2020, the company was also ranked on Richmond BizSense's list of fastest growing companies. Additionally, Capital Square was listed by Virginia Business on their "Best Places to Work in Virginia" report in 2019 and their "Fantastic 50" reports in 2019 and 2020. To learn more, visit www.CapitalSquare1031.com. Disclaimer: Securities offered through WealthForge Securities, LLC, Member FINRA/SIPC. Capital Square and WealthForge Securities, LLC are separate entities. There are material risks associated with investing in DST properties and real estate securities including illiquidity, tenant vacancies, general market conditions and competition, lack of operating history, interest rate risks, the risk of new supply coming to market and softening rental rates, general risks of owning/operating commercial and multifamily properties, short term leases associated with multi-family properties, financing risks, potential adverse tax consequences, general economic risks, development risks, long hold periods, and potential loss of the entire investment principal. Past performance is not a guarantee of future results. Potential cash flow, returns and appreciation are not guaranteed. IRC Section 1031 is a complex tax concept; consult your legal or tax professional regarding the specifics of your particular situation. This is not a solicitation or an offer to see any securities. Please read the Private Placement Memorandum (PPM) in its entirety, paying careful attention to the risk section prior to investing. Diversification does not guarantee profits or protect against losses. Private placements are speculative. Contact: Jill Swartz Spotlight Marketing Communications 949.427.1389 [email protected] SOURCE Capital Square	https://www.prnewswire.com/news-releases/capital-squares-first-opportunity-zone-development-achieves-97-occupancy-just-months-after-completion-301557191.html	2022-05-31T12:42:39	en	0.95823
- The Corporation recorded revenues of $4.6 million in Q1 2022, a 65% increase from Q1 2021, and a 28% increase from Q4 2021 - Record revenue in medical cannabis of over $2.6 million in Q1 2022, a 470% increase from the prior year and 32% increase from Q4 2021 - Gross profit before fair value adjustments grew to $2.1 million, up 96% from Q1 2021, driven primarily by its 75% gross margin medical cannabis business, compared to 49% in Q4 2021. - In Q1 2022, Europe (the UK and Germany) represented 53% of all medical cannabis revenue, compared to 10% in Q1 2021. - The net change in cash and cash equivalents of -$3.3 million, compared to -$8.6 million in Q1 2022, ending Q1 2022 with $5.1 million in cash TORONTO, May 31, 2022 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Corporation") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a global leader in medical cannabis throughout Latin America and Europe, announced today its financial results for the quarter ended March 31, 2022, reporting record revenue in the medical cannabis business. These filings are available for review on the Corporation's SEDAR profile at www.sedar.com. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. Summary of Key Financial Results: Q1 2022 operating highlights and subsequent events: - Khiron's unique patient-focused medical cannabis segment posted 7th quarter of consecutive revenue growth in Q1 2022, and now represents 57% of the Corporation´s revenue and 92% of its total gross profits. In the month of March 2022, Khiron had surpassed $1 million in monthly revenues in medical cannabis alone. - Khiron's unique business model is already beginning to yield positive financial results during Q1 2022. ILANS SAS (Khiron's health service business in Colombia) has been instrumental in driving higher gross margin medical cannabis and clinical services. - Both Khiron's European expansion and continued growth in Colombia, is driving the medical cannabis segment growth in Q1 2022. In Q1 2022, Khiron surpassed $1 million in medical cannabis revenues in the United Kingdom. - In Colombia, Khiron continues to be a market leader in medical cannabis with its unique vertically integrated approach and leverage of insurance coverage on its clinics. Over 82% of sales were sold through insurance coverage, and over 84% of the sales were sold to returning patients, who are now purchasing up to 1.8 bottles per month. - At the end of Q1 2022, the Corporation had $37.6 million in total assets (excluding goodwill), with more than $9.4 million in land and buildings, high-quality medical cannabis inventory of $8.1 million, healthy Accounts Receivables with credit-worthy clients in Colombia and Europe of $4.4 million and $0.8 million in financial debt. - The Corporation's cash used in operating activities for Q1 2022 was $2.8 million, compared to -$8.2 million in Q1 2021 and approximately -$5.4 million in Q4 2021, resulting in net cash of $5.1 million at the end of Q1 2022. This is a result of actively managing the working capital cycle, improving collection times for the Corporation´s Accounts Receivable, and extending payment terms on its Accounts Payables while reducing overall general and administrative costs and increasing its high gross margin medical cannabis business. Management commentary: Alvaro Torres, Khiron CEO and Director, comments, "Khiron is the top-selling medical cannabis brand in Latin America and one of the top-selling brands in the United Kingdom. Our unique approach will continue to generate double-digit revenue and gross profits quarter over quarter in markets poised to become significant in the coming years. Our focus is to leverage the infrastructure we have built to continue driving sales in our target markets while maintaining discipline in our expenses so we can achieve profitability in the near future, and then continue to look for more growth opportunities in Latin America and Europe." Mr. Torres added, "The results of Q1 2022 continue to showcase the success of Khiron's global expansion and the Corporation's unique "patient-first" strategy. Webcast Details: Khiron invites individual and institutional investors, as well as advisors and analysts, to attend the Corporation's First Quarter 2022 Conference Call, followed by a Q&A session. DATE: Tuesday, May 31th, 2022 TIME: 10:00am ET PRESENTERS: Alvaro Torres, Khiron Chief Executive Officer and Director, Swapan Kakumanu, Khiron Chief Financial Officer, and Franziska Katterbach, President of Khiron Europe. FORMAT: Live 45 minute presentation & Q&A session REGISTER LINK: https://us02web.zoom.us/webinar/register/WN_VVgAryILSl-W9at7iftkCQ About Khiron Life Sciences Corp. Khiron is a leading vertically integrated international medical cannabis corporation with core operations in Latin America and Europe. Leveraging medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific, product innovation, and cannabis operations expertise to drive prescriptions and brand loyalty with patients worldwide. The Corporation has a sales presence in Colombia, Peru, Germany, United Kingdom, and Brazil and is positioned to commence sales in Mexico. The Corporation is led by co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and board of directors. Visit Khiron online at https://investors.khiron.ca. Linkedin https://www.linkedin.com/company/khiron-life-sciences-corp/ Non-IFRS Financial Measures This press release includes references to Adjusted EBITDA, which is a financial measure that does not have a standardized meaning prescribed by IFRS. Adjusted EBITDA is calculated as net loss before tax as reported under IFRS and adding back share-based compensation expense, transaction fees, unrealized gain on changes in fair value of biological assets, depreciation and non-recurring items. Adjusted EBITDA provides an indication of the results generated by the Corporation's principal business activities prior to how these activities and assets are financed (including mark-to-market movements of the warrant value), depreciated and amortized or how the results are taxed in various jurisdictions, impairment of property, plant, and equipment, impairment of intangible assets, changes in fair value of inventory, unrealized changes in fair value of biological assets, prior to the effect of foreign exchange, other income and expenses, and non-cash share-based payment expense. The term Adjusted EBITDA does not have any standardized meaning and therefore may not be comparable to similar measures presented by other issuers. The Corporation believes Adjusted EBITDA not only provides management with comparable financial data for internal financial analysis but also provides meaningful supplemental information to investors. In particular, management believes that this financial measure can provide information useful to its shareholders in understanding the performance of the Corporation and may assist in the evaluation of its business relative to that of its peers. Investors are cautioned that this non-IFRS measure should not be considered in isolation or construed as an alternative to the measurements of performance calculated in accordance with IFRS as, given the non-standardized meaning, it may not be comparable to similar measures presented by other issuers. Existing Adjusted EBITDA is not necessarily predictive of the Corporation's future performance or the Adjusted EBITDA of the Corporation as at any future date. Calculation and Reconciliation of Adjusted EBITDA The following table provides a reconciliation of net loss to Adjusted EBITDA. Cautionary Statement Regarding Forward-Looking Statements This press release may contain "forward-looking information" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature constitutes forward-looking information. Forward-looking information contained in this news release include, without limitation, statements pertaining to the Corporation's business plans and goals, including its goal of achieving profitability in the near future and improving revenue collections, reducing cash outflows, and leveraging the Corporation's assets to generate more working capital. Forward-looking information and statements contained in this news release reflect management's current beliefs and is based on information currently available and on assumptions that management believes to be reasonable. These assumptions include, but are not limited to, assumptions regarding the future regulatory developments and economic conditions, the Corporation's ability to continue its growth and reduce costs. Although management believes that its expectations and assumptions to be reasonable, forward-looking information is always subject to known and unknown risks, uncertainties and other factors, many of which are beyond the control of management, that may cause actual results to differ materially from those expressed or implied in such forward-looking information. Such risks and uncertainties include but are not limited to the following: risks relating to general economic conditions and capital markets; risks relating to the availability of financing on satisfactory terms; risks relating to the COVID-19 pandemic or other health crises; risks relating to regulatory, legislative, competitive and political conditions; as well as those other risk factors discussed in Khiron's most recent annual information form which is available on Khiron's SEDAR profile at www.sedar.com. As a result of the foregoing and other risks and uncertainties, readers are cautioned not to place undue reliance on forward-looking information contained in this press release. Readers are further cautioned that the foregoing risks and uncertainties is not exhaustive, and there may be other risks and uncertainties, presently unknown to management of the Corporation, that may cause actual results to differ materially from those expressed or implied in forward-looking statements contained in this press release. The forward-looking information contained in this press release is expressly qualified by this cautionary statement. Khiron disclaims any intention to update or revise any forward-looking information disclosed herein, whether as a result of new information, future events or otherwise, except as required by law. View original content to download multimedia: SOURCE Khiron Life Sciences Corp.	https://www.wlbt.com/prnewswire/2022/05/31/khiron-life-sciences-reports-first-quarter-2022-financial-results-with-record-revenue-medical-cannabis/	2022-05-31T12:42:42	en	0.933797
SAN JOSE, Calif., May 31, 2022 /PRNewswire/ -- Cisco today announced that it will participate in the following conferences with the financial community during the month of June. These sessions will be webcast. Interested parties can view these events on Cisco's Investor Relations website at investor.cisco.com. Bank of America Securities 2022 Global Technology Conference June 8, 2022 2:20 p.m. PT / 5:20 p.m. ET Liz Centoni, EVP, Chief Strategy Officer and General Manager, Applications Nasdaq Investor Conference June 14, 2022 1:00 a.m. PT/ 4:00 a.m. ET / 9:00 a.m. BST Scott Herren, EVP and Chief Financial Officer About Cisco Cisco (NASDAQ: CSCO) is the worldwide leader in technology that powers the Internet. Cisco inspires new possibilities by reimagining your applications, securing your data, transforming your infrastructure, and empowering your teams for a global and inclusive future. Discover more on The Newsroom and follow us on Twitter. Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco's trademarks can be found at www.cisco.com/go/trademarks. Third-party trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company. SOURCE Cisco Systems, Inc.	https://www.prnewswire.com/news-releases/cisco-announces-june-2022-events-with-the-financial-community-301556867.html	2022-05-31T12:42:45	en	0.919888
NASHVILLE, Tenn., May 31, 2022 /PRNewswire/ -- Kirkland's, Inc. (Nasdaq: KIRK) ("Kirkland's Home" or the "Company"), a specialty retailer of home décor and furnishings, announced financial results for the 13-week period ended April 30, 2022. - Net sales were $103.3 million, with comparable sales decreasing 15.8%. - Gross profit margin of 27.4%. - GAAP loss per diluted share of $0.63 and adjusted loss per diluted share of $0.62. - Adjusted EBITDA of negative $5.8 million. - Ended the period with a cash balance of $5.4 million, $35.0 million in outstanding debt and total liquidity of $45.4 million. - Repurchased $6.3 million of shares in the quarter, or 3.8% of the Company's outstanding shares. - Closed one store to end the quarter with 360 stores. "Our first quarter 2022 results reflect continued macroeconomic headwinds hampering consumer demand for home décor and furnishings," said Steve "Woody" Woodward, president and CEO of Kirkland's Home. "We were impacted by the shift in consumer spending stemming from rising interest rates, inflationary pressures and geopolitical conflicts that adversely affected our customer traffic and sales. We also continued to deal with constraints across the supply chain, particularly heightened freight and transportation costs, which pressured our margins. While we are disappointed with our results, we are still executing upon our long-term transformation strategy and making progress in areas that are within our control. "We are in the early innings of our initial test marketing campaigns, and we intend to use the curated data to further engage with new and existing customers at the appropriate time. Our in-home delivery is set to launch in the second quarter, boosting our omni-channel capabilities and improving our ability to support customers looking to purchase larger items, such as furniture. Given our strong inventory position, we aim to be opportunistic with promotional activities to spur consumer activity and highlight the progress we've made with our improved merchandise assortment. "While we believe the challenging near-term outlook on consumer demand for home furnishings will continue to pressure our results, we remain steadfast in our commitment to deliver upon the key strategic initiatives laid out within our transformation strategy. However, given the constraints the current macroenvironment presents for consumers, we are suspending the timelines in which we hope to achieve our long-term financial targets. We plan to be disciplined with our operational expenses and prudently manage our balance sheet and cash position in this environment. We are confident that our team is capable of adapting to these challenges and executing on our core principles to continue transforming Kirkland's Home into a premier specialty home furnishing retailer." Net sales in the first quarter of 2022 were $103.3 million, compared to $123.6 million in the prior year quarter. Comparable same-store sales decreased 15.8%, including a 23.6% decline in e-commerce sales. The decrease was primarily driven by a decline in traffic and conversion in stores and online due to macroeconomic conditions impacting the home furnishing industry. Gross profit in the first quarter of 2022 was $28.3 million, or 27.4% of net sales, compared to $40.3 million, or 32.6% of net sales, in the prior year quarter. The decline was primarily a result of the cost impact from global supply chain constraints, including an increase in freight costs, along with the aforementioned decline in net sales. Operating loss in the first quarter of 2022 was $11.1 million compared to operating income of $2.1 million in the prior year quarter. The decrease was primarily a result of the aforementioned decline in net sales and increase in freight and supply chain costs, along with higher store payroll related expenses. EBITDA in the first quarter of 2022 was a loss of $6.6 million compared to income of $7.3 million in the prior year quarter. Adjusted EBITDA in the first quarter of 2022 was a loss of $5.8 million compared to income of $7.7 million in the prior year quarter. Net loss in the first quarter of 2022 was $7.9 million, or $0.63 loss per diluted share, compared to income of $1.7 million, or $0.11 earnings per diluted share, in the prior year quarter. Adjusted net loss in the first quarter of 2022 was $7.7 million, or $0.62 loss per diluted share, compared to adjusted net income of $1.8 million, or $0.12 earnings per diluted share, in the prior year quarter. During the first quarter of 2022, the Company repurchased approximately 480,000 shares for $6.3 million at an average cost of $13.03 per share. At April 30, 2022, the Company had a cash balance of $5.4 million and total liquidity of $45.4 million, with $35.0 million of outstanding debt under its $75 million senior secured revolving credit facility. As Kirkland's Home continues to slow the pace of its merchandise-driven transformation strategy due to current macroenvironment conditions affecting consumer sentiment, the Company is suspending its timelines to achieve the long-term financial targets for gross profit margin, EBITDA as a percentage of sales and operating income as a percentage of sales. Kirkland's Home key strategic initiatives continue to include: - Accelerating product development to reinforce quality and relevancy as the Company continues its transformation into a specialty retailer where customers are able to furnish their entire home on a budget; - Bolstering its omni-channel strategy via website enhancements, more focused marketing spend, an expanded online assortment, and an improved in-store experience; - Improving the customer experience with the Company's re-launched loyalty program, extended credit options and broadened delivery options; and - Utilizing its leaner infrastructure to be nimbler to changes in consumer preference and buying behaviors. The key strategic initiatives are based on current information as of May 31, 2022, and are dependent on, among other things, consumer preferences, economic conditions and Kirkland's Home own successful execution of these initiatives. The information on which these initiatives is based is subject to change, and investors are cautioned that the Company may update the initiatives and targets, or any portion thereof, at any time for any reason. Kirkland's Home management will host a conference call to discuss its financial results for the first quarter ended April 30, 2022, followed by a question-and-answer period with Steve Woodward, President and CEO, and Nicole Strain, EVP, CFO and COO. Date: Tuesday, May 31, 2022 Time: 9:00 a.m. Eastern Time Toll-free dial-in number: (855) 560-2577 International dial-in number: (412) 542-4163 Conference ID: 10166327 Please call the conference telephone number 10-15 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Group at (949) 574-3860. The conference call will be broadcast live and available for replay here and via the investor relations section of the Company's website at www.kirklands.com. The online replay will follow shortly after the call and continue for one year. A telephonic replay of the conference call will be available after the conference call through June 7, 2022. Toll-free replay number: (877) 344-7529 International replay number: (412) 317-0088 Replay ID: 10166327 Kirkland's, Inc. is a specialty retailer of home furnishings in the United States, currently operating 359 stores in 35 states as well as an e-commerce website, www.kirklands.com, under the Kirkland's Home brand. The Company provides its customers an engaging shopping experience characterized by a curated, affordable selection of home furnishings along with inspirational design ideas. This combination of quality and stylish merchandise, value pricing and a stimulating online and store experience allows the Company's customers to furnish their home at a great value. More information can be found at www.kirklands.com. Except for historical information contained herein, the statements in this release, including all statements related to future initiatives, financial goals and expectations or beliefs regarding any future period, are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are subject to the finalization of the Company's quarterly financial and accounting procedures. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Kirkland's Home actual results to differ materially from forecasted results. Those risks and uncertainties include, among other things, risks associated with the Company's progress and anticipated progress towards its short-term and long-term objectives including its brand transformation, the timing of normalized macroeconomic conditions from the impacts of global geopolitical unrest and the COVID-19 pandemic on the Company's revenues, inventory and supply chain, the effectiveness of the Company's marketing campaigns, risks related to changes in U.S. policy related to imported merchandise, particularly with regard to the impact of tariffs on goods imported from China and strategies undertaken to mitigate such impact, the Company's ability to retain its senior management team, continued volatility in the price of the Company's common stock, the competitive environment in the home décor industry in general and in Kirkland's Home specific market areas, inflation, fluctuations in cost and availability of inventory, interruptions in supply chain and distribution systems, including our e-commerce systems and channels, the ability to control employment and other operating costs, availability of suitable retail locations and other growth opportunities, disruptions in information technology systems including the potential for security breaches of Kirkland's Home or its customers' information, seasonal fluctuations in consumer spending, and economic conditions in general. Those and other risks are more fully described in Kirkland's Home filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K filed on March 25, 2022 and subsequent reports. Forward-looking statements included in this release are made as of the date of this release. Any changes in assumptions or factors on which such statements are based could produce materially different results. Except as required by law, Kirkland's Home disclaims any obligation to update any such factors or to publicly announce results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments. Non-GAAP Financial Measures To supplement our unaudited consolidated condensed financial statements presented in accordance with generally accepted accounting principles ("GAAP"), this earnings release and the related earnings conference call contain certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted operating (loss) income, adjusted net (loss) income and adjusted diluted (loss) earnings per share. These measures are not in accordance with, and are not intended as alternatives to, GAAP financial measures. The Company uses these non-GAAP financial measures internally in analyzing our financial results and believes that they provide useful information to analysts and investors, as a supplement to GAAP financial measures, in evaluating the Company's operational performance. The Company defines EBITDA as net income or loss before interest, provision for income tax, and depreciation and amortization, adjusted EBITDA as EBITDA with non-GAAP adjustments and adjusted operating (loss) income as operating (loss) income with non-GAAP adjustments. The Company defines adjusted net (loss) income and adjusted diluted (loss) earnings per share by adjusting the applicable GAAP financial measures for non-GAAP adjustments. Non-GAAP financial measures are intended to provide additional information only and do not have any standard meanings prescribed by GAAP. Use of these terms may differ from similar measures reported by other companies. Each non-GAAP financial measure has its limitations as an analytical tool, and you should not consider them in isolation or as a substitute for analysis of the Company's results as reported under GAAP. The following table shows a reconciliation of operating (loss) income to EBITDA, adjusted EBITDA and adjusted operating (loss) income for the 13-week periods ended April 30, 2022 and May 1, 2021 and a reconciliation of net (loss) income and diluted (loss) earnings per share to adjusted net (loss) income and adjusted diluted (loss) earnings per share for the 13-week periods ended April 30, 2022 and May 1, 2021: View original content to download multimedia: SOURCE Kirkland's, Inc.	https://www.wlbt.com/prnewswire/2022/05/31/kirklands-reports-first-quarter-2022-results/	2022-05-31T12:42:49	en	0.946451
ORANGE COUNTY, Calif., May 31, 2022 /PRNewswire/ -- On Friday, June 3rd, 2022, Coastline College's 46th commencement ceremony, will be held for the first time on campus at their new Student Services Center, a building that is scheduled to open this summer. The ceremony will also be held virtually live at 6:00 pm, on the Coastline YouTube Channel for the 80% of Coastline students that are remote graduates. Coastline will recognize the accomplishments of 1,048 graduates receiving 2,012 degrees and certificate for the 2021-2022 academic year. A total of 238 will be graduating with honors and 39 students will be graduating as valedictorians. Coastline College is deeply committed to achieving the highest level of academic excellence and student success. The breadth of programs offered at Coastline College range from traditional credit degrees leading to transfer, associate degrees, and credit career education certificates and noncredit short term vocational certificates of completion. In addition, Coastline acknowledges program completion and accomplishments of students with disabilities and English as a second language learners. Coastline provides educational and career pathways to the military community (active duty, reserves, national guard, veterans, and family members), corporations and students who are currently incarcerated. Coastline College serves a special diverse student population. The graduating class of 2022 represents students of all ages, all ethnicities, all abilities from different backgrounds and circumstance, and socio-economic status. Some of these graduating students have had to overcome tremendous obstacles or adversities to reach this day of graduation. Some have been homeless, some have been in the military and seen combat, and some have had traumatic brain injury. Many of Coastline's students are trailblazers and the first in their families to go to college. Despite life's complications, these students are achieving, prevailing, and making a success of themselves in the process. "We are proud of our graduates and congratulate the many students reaching this significant milestone in their lives. Commencement means the beginning, the first step on a journey of who you want to become and what you want to do. We wish all our graduates continued success in their future endeavors." Dr. Vince Rodriguez, President of Coastline College. Community colleges are a first step for university graduates, community leaders and successful professionals and community colleges like Coastline are fundamental to making dreams come true for millions of Americans every year. Please click on the link below for the ceremony: https://www.coastline.edu/student-life/graduation.php Coastline College is accredited by the Western Association of Schools and Colleges. For eight consecutive years, Coastline College was selected as one of the top 150 colleges by The Aspen Institute for Community College Excellence which is considered the most prestigious designation for community colleges. Coastline delivers flexible courses and services that cultivate and guide diverse student populations across the globe to complete pathways leading to the attainment of associate degrees, certificates, career readiness, and transfer to four-year colleges/universities. Coastline currently offers more than 250 online and other distance education courses. CONTACT: Dawn Willson, [email protected], 714-241-6186 SOURCE Coastline College	https://www.prnewswire.com/news-releases/coastline-college-congratulates-and-graduates-the-class-of-2022-with-hybrid-commencement-301557077.html	2022-05-31T12:42:51	en	0.957035
Generates Over 8 km of Strike Length at Five Drill Target Areas VANCOUVER, BC, May 31, 2022 /PRNewswire/ - KORE Mining Ltd. (TSXV: KORE) (OTCQX: KOREF) ("KORE" or the "Company") is pleased to announce completion of a highly productive 2021-2022 winter exploration field season and provides a summary of the western drill targets of the Imperial Gold Project ("Imperial"). This release summarizes the geologic context for the five western targets: Ogilby, Powerline Discovery Outcrop, Ironwood, Smoketree, and East Mesquite (Figure 1), which are in the western exploration target area between the Imperial deposit and the Mesquite gold mine (operated by Equinox Gold (TSX: EQX)). The western target areas include five targets covering over 2,400 acres across 8.3 kilometers of strike length. ss = stream sediment sample rc = rock chip sample g/t = grams per tonne There are a total of nine drill target areas identified in the overall Mesquite-Imperial-Picacho District ("District") that captures a 28 kilometers ("km") trend. Refer to KORE's April 26, 2022 news release for exploration targets identified on the eastern portion of the District. KORE's Executive Chairman, James Hynes, commented, "KORE had a great field season on the Mesquite-Imperial-Picacho trend. While the area is still not fully covered with field mapping and sampling, KORE field tested all satellite alteration and historic known gold anomalies and outcrops aligned with the regional geophysical trend from the Mesquite mine through Imperial towards the closed Picacho mine. We have a large number of drill targets in inventory and must now prioritize for additional drill permit applications ." Over 100 additional rock chip and stream sediment assays are pending from the winter exploration program and any significant results will be released. Refer to KORE's May 17, 2022 news release for assays released on the Powerline and Ogilby target areas. KORE is committed to operating within the stringent environmental and labour standards of California. Exploration drilling is designed to avoid any sensitive areas and all land disturbances will be rehabilitated. Figure 2 shows the georeferenced ground resistivity sections intersecting the western area targets and mentioned subsurface anomalies. Figures 3-5 shows three photo compilations of the western area prospects Ogilby, Powerline/Smoketree/Ironwood, and East Mesquite. Ground resistivity and induced polarization ("IP") surveys provide strong evidence that the primary mineralizing structure at the Imperial deposit is continuous across the 3 km of strike length to the Ogilby target area. This data indicates two anomalous trends (Figure 2) which completed reconnaissance scale mapping and sampling in February 2022. Assay results have confirmed the presence of gold near the surface trace of these anomalies, including highlights of 1.4 g/t gold ("Au") and 0.8 g/t Au stream sediment samples (Figure 1). To date, a total of 19 strongly anomalous samples have been collected along the 2 km strike length of this WNW-ESE structural corridor. The Ogilby target area is covered by a thin veneer of young volcanic flows, which are steeply incised by seasonal stream channels ("arroyos") that expose the underlying Bear Canyon conglomerate. This unit is a significant alluvial sandstone conglomerate that covers the majority of the property. Proximal to known gold occurrences, the Bear Canyon often displays iron oxide alteration and quartz + calcite veining (Figure 3). Over nine acres of this type of altered bear canyon has been documented in the Ogilby target area, which yielded strongly anomalous assays and suggests that the mineralizing system is strong and near surface. The Powerline target area contains the largest and highest-grade surface expression of gold mineralization west of the Imperial Deposit. The Powerline area spans over 1300 acres and contains the highest-grade assay on the property at 9.98 g/t Au. Powerline also contains all known gneiss exposures west of the Imperial deposit (Figure 1). The mineralized trend of Powerline remains open and untested along strike for 3 km to the east, towards the Ogilby target area. Ground IP and resistivity survey data indicate two distinct anomalous structural trends that persist across the strike length of the Powerline target area (Figure 2). Along these trends, ground observations have confirmed the presence of these structural corridors which have assayed strongly anomalous for gold. Powerline currently contains three named prospect areas: the Powerline Discovery Outcrop, the Ironwood Prospect, and the Smoketree Prospect. The Powerline Discovery outcrop consists of two distinct, strongly brecciated and altered gneiss exposures that are interpreted as stacked thrust sheets. These regional scale faults bring crystalline basement host rock closer to surface. In 2021, KORE commissioned a multispectral satellite alteration survey, which highlighted the Powerline discovery area as being strongly anomalous for chlorite alteration. Other types of alteration observed at the outcrop include sericite, local silicification and quartz veining, and strong iron oxide staining (Figure 4). This is consistent with the alteration assemblage of the Imperial deposit, which was used to "tune" or fingerprint the signature associated with gold mineralization. Similar to the Powerline Discovery Outcrop, the Ironwood Prospect contains two structurally dismembered gneiss outcrops which are strongly folded, brecciated, and altered (Figure 4). Ironwood was first identified as an area of interest by the multispectral satellite data. The Ironwood outcrop is the largest gneiss exposure west of the Imperial deposit and forms a cliff approximately 25 feet tall. Ironwood is interpreted to have been formed via the same thrust fault architecture which causes the exposure of the Powerline discovery outcrops 2.5 km to the northwest. The Smoketree Prospect is a low grade subcrop of gneiss with an associated anomalous gold trend detected downstream. Smoketree is overlain by a thin veneer of Bear Canyon conglomerate that appears to be moderately altered and veined. The poor exposure of Smoketree makes it a priority target for the fully permitted person-portable drilling system, which produces BQ sized core at depths up to 30 feet. The East Mesquite segment boundary is located only 2 km to the southeast from the operating Mesquite Mine's Vista pit. Geophysical survey data indicates a strong anomaly that is directly on strike with the mineralized trend of the Vista pit. A small gneiss exposure referred to as the "Predator Hill outcrop" has been observed along this trend and provides strong evidence of structural continuity (Figure 5). Adjacent to the segment boundary in the southeast is a turtleback feature similar in character to the Powerline target area, which contains the highest-grade gold assays on site. Follow up reconnaissance sampling is ongoing in this area. KORE owns 100% of the Mesquite-Imperial-Picacho District which consists approximately 31,000 acres of claims capturing the entire 28-km trend from the operating Mesquite mine (Equinox Gold - TSX:EQX) to the closed Picacho mine and including KORE's Imperial project. In the District, gold is hosted in local fault structures related to a series of regional faults connecting the known District deposits. Those three District deposits (Mesquite, Imperial and Picacho) were discovered in exposed outcrops and from placer workings. The rest of the District is covered by alluvium and has never been systematically explored. The Mesquite-Imperial-Picacho District centers on KORE's Imperial project. Imperial is a structurally controlled orogenic gold deposit. The 100% oxide gold deposit is currently defined at 2.44 km long and up to 0.75 km wide and is open both along strike and down dip. It is hosted in a shallowly southwest dipping, amphibolite grade metamorphic rock suite along a west- northwest trending low-angle regional thrust fault system which controls the regional geometry of mineralization. East-west striking, post-mineralization normal faults control the property scale geometry of mineralization. Geophysical characterization of the deposit and regional controlling structures is an essential component of exploration for additional resources. Imperial has a mineral resource estimate and a positive preliminary economic assessment effective April 6, 2020 with the following highlights: - Robust economics: US$ 343 million NPV5% post-tax with 44% IRR at US$ 1,450 per ounce gold - Low capital intensity project with only US$ 143 million pre-production capital cost - Average 146,000 ounces gold per year over 8 years for 1.2 million ounces total production - Technically simple project: shallow open pit, run-of-mine heap leach with existing infrastructure - Value enhancement through Mesquite-Imperial-Picacho District exploration and resource expansion The Company's NI 43-101 compliant resource and preliminary economic assessment is titled "Preliminary Economic Assessment – Technical Report Imperial Gold Project" effective as of April 6, 2020 and revised and amended on June 10, 2021, prepared by Terre Lane and Todd Harvey of Global Resource Engineering and Glen Cole of SRK Consulting (Canada) Inc. can be found under the Company's profile on SEDAR (www.sedar.com) and on the Company's website. KORE Mining is focused on responsibly creating value from its portfolio of gold assets in California, USA. The Company is advancing the Imperial project towards development while continuing to explore across both district-scale gold assets. Management and Board, along with strategic investor, Eric Sprott (26% owner), are aligned with all KORE shareholders with the goal of creating per share value. Further information on Imperial and KORE can be found on the Company's website at http://www.koremining.com/ or by contacting us as info@koremining.com or by telephone at (888) 407-5450. On behalf of KORE Mining Ltd "Scott Trebilcock" Chief Executive Officer (888) 407-5450 Technical information with respect to the District and Imperial Gold Project contained in this news release has been reviewed and approved by Marc Leduc, P.Eng, who is KORE's Senior Technical Consultant and former COO, and is the qualified person under National Instrument 43-101 responsible for the technical matters of this news release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement Regarding Forward-Looking Information This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects", "intends", "indicates" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward- looking statements. Forward‐looking statements in this news release include, but are not limited to, statements with respect to: the nature and implication of sample assay results, the potential of target areas, the highly prospective nature of the project; the strategy, process, timing and grant of a permit for regional exploration drilling in the 28-kilometer Mesquite-Imperial-Picacho District ("Regional Exploration Drilling"); potential actions, behavior or position of the Bureau of Land Management (the "BLM"); the underexplored and prospective nature of the Imperial Regional Exploration Drilling area; the results of the preliminary economic assessments for the Imperial Project, including future project opportunities, the projected NPV, permit timelines, the current mineral resource estimate, and the ability to obtain the requisite permits; the market and future price of and demand for gold; the opportunities of expansion at the Imperial Project; and the ability to work cooperatively with stakeholders, including all levels of government. Such forward‐looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business. In connection with the forward‐looking information contained in this presentation, the Company has made numerous assumptions, including, among others: there being no significant change to current geotechnical, metallurgical, hydrological and other physical conditions at the Imperial Project; exploration, permitting, and development of the Imperial Project being consistent with current expectations and planning; the geological, permitting and economic advice that the Company has received is reliable and is based upon practices and methodologies which are consistent with industry standards; and other planning assumptions. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies. Forward looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward‐looking information. Known risk factors include, among others: the outcome of BLM's review processes for permitting, including the final outcome(s) of BLM's mineral claim validity examination(s) and administrative review process(es) with respect to the Imperial Zone, including a change to the findings from the mineral claim validity examination conducted in 2002 for the mill sites at the Imperial Zone, resulting in the Company having to move its future Imperial Zone project support facilities to areas that are not within the Indian Pass mineral withdrawal area; the possibility that BLM may require and/or conduct further mineral claim validity examinations with respect to the Imperial project, and the outcome and final determination of such examination could, among other things, invalidate one or more mining claims; the possibility that BLM or other governmental authority review of the Regional Exploration Drilling program, delays or changes the Company's plan for Regional Exploration Drilling permitting, which could result, among other things, in delays, additional project requirements, additional costs and uncertainty of meeting anticipated program milestones; the exploration drill program may not be completed as planned; the need to obtain additional financing; uncertainty as to the availability and terms of future financing; the possibility of delay in exploration or development programs and uncertainty of meeting anticipated program milestones; uncertainty as to timely availability of permits and other government approvals. Additional risks and uncertainties are described in the "Risks" sections of (i) the Company's Annual Information Form for the year ended December 31, 2020 prepared as of April 29, 2021, and (ii) the Company's Management's Discussion and Analysis for the nine months ended September 30, 2021, both available under the Company's issuer profile on www.sedar.com. Forward-looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results, except as may be required by applicable securities laws. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. There is no certainty that all or any part of the mineral resource will be converted into mineral reserve. Itis uncertain if further exploration will allow improving the classification of the Indicated or Inferred mineral resource. Mineral resources are not mineral reserves and do not have demonstrated economic viability. View original content to download multimedia: SOURCE Kore Mining	https://www.wlbt.com/prnewswire/2022/05/31/kore-mining-continues-exploration-success-western-portion-imperial-gold-project-regional-exploration/	2022-05-31T12:42:56	en	0.920815
DENVER, May 31, 2022 /PRNewswire/ -- CryoMass Technologies Inc. ("CryoMass" or the "Company") (OTC: CRYM) is pleased to announce that the Canadian Intellectual Property Office has granted CryoMass a patent (#3064896) for its novel plant material separation process technology. The patent relates in general to separating plant particulates and, in particular, to a system and method for cryogenic separation of plant material. The patent will remain valid until 2039. The Canadian patent follows the precedent set by the United States Patent and Trademark Office and the State Intellectual Property Office of the P. R. of China, both of which granted process patents to CryoMass that are valid until 2038. Christian Noël, CryoMass CEO, stated, "After years of planning, engineering and technical validation, it is exciting to receive patent protection in another key target market for our highly-disruptive technology. Canada was the first G7 nation to legalize cannabis and as such spawned some of the biggest names in the global cannabis industry. It's definitely an important commercialization opportunity for CryoMass." CryoMass remains committed to expanding its global patent protection portfolio and is pursuing patents in other important jurisdictions, including the European Union. "Although we talk a lot about the burgeoning, $50 billion dollar cannabis/hemp industry, we believe that our technology can dramatically reduce costs and improve product quality in other multi-billion dollar industries as well. Canada, China and the United States all have large and diverse agricultural sectors and having secured long-term patent protection should enable us to effectively capitalize on multiple agriculture opportunities," added Noël. The common stock of CryoMass Technologies Inc. trades on the OTC QB market under the symbol CRYM. For further information, please contact the Company by email at [email protected] or by telephone at +1 833 256 2382. The Company will welcome your inquiry. This press release is not an offer of securities, or a solicitation for purchase, subscription or sale of securities in the United States of America or in any other jurisdiction in which it would be unlawful to do so. Forward-looking Statements This press release may contain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 that involve known and unknown risks, uncertainties and other factors, including risk factors identified in the Company's SEC filings, and which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Risks and uncertainties include, without limitation, changes in the regulatory environment affecting the sale and use of cannabis or hemp products and of other, potential lines of businesses that the Company will consider entering at a given time, demand for the Company's products, internal funding and the financial condition of the Company, product roll-out, competition, our dependence upon our commercial partners, variations in the global commodities markets and other commercial matters involving the Company, its products and the markets in which the Company operates or seeks to enter, as well as general economic conditions. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Caution Regarding Cannabis Operations in the United States Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Marijuana, as defined in the U.S. Controlled Substances Act, remains a Schedule I drug under the respective act, making it illegal under federal law in the U.S. to, among other things, cultivate, distribute or possess cannabis. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the U.S. may form the basis for prosecution under applicable U.S. federal money laundering legislation. Please carefully review the Company's SEC filings with respect to related risk factors. Related Links cryomass.com SOURCE CryoMass Technologies Inc	https://www.prnewswire.com/news-releases/cryomass-technologies-receives-canadian-patent-for-its-proprietary-cryogenic-process-for-separating-plant-material-patent-protection-good-until-2039-301557019.html	2022-05-31T12:42:57	en	0.923335
Quantexa continues its leadership of growing Decision Intelligence category by quickening expansion in North America and APAC and further establishing Fortune 1000 customer base Quantexa 2, the Company's Contextual Decision Intelligence Platform, delivered technical innovation with new Data Fusion and Contextual Analytics tools and enhanced Visualization capabilities The company continues to invest in expanding its UK presence with 133 employees hired in FY2022 and another 150 plus projected hires in FY 2023 LONDON and NEW YORK, May 31, 2022 /PRNewswire/ -- Quantexa, a global leader in Decision Intelligence (DI) solutions for banking, government, insurance, technology, telecom, and media industries, today announced strong growth across its business and its overall industry expansion in the last financial year, dating from April 1, 2021 to March 31, 2022. Quantexa also announced several new global partnerships, customer wins, and recently hired its 500th global employee. The company projects to end FY2023 with 700 employees. Vishal Marria, CEO of Quantexa, said: "Quantexa continues full sail on its journey as a leading player in the fast-growing Decision Intelligence category. We're proud to retain sustained support from our loyal customers like HSBC and Standard Chartered Bank, and world-leading partners who include Moody's, Google, and Deloitte. Beyond strengthening our presence in North America and Europe, it is also exciting to see Quantexa attract customers across the APAC region. We look forward to breaking more new ground as a leading Decision Intelligence solution provider with our innovative technology, which is helping to make data meaningful for organizations all over the world, so they can make better, trusted decisions." Quantexa goes global, growing across regions London-headquartered Quantexa serves companies in over 70 countries and four continents. The company achieved a 144% Net Retention Rate and more than 70% increase in Committed ARR in FY2022. Last year also witnessed a growing foothold across North America and APAC. - North America had a breakout fiscal year and now contributes 30% of total revenue. - After opening a new presence in Luxembourg, Quantexa continued growth in EMEA, which now represents over 50% of its revenue. - Opening offices in Melbourne and Singapore helped to drive growth in the APAC region, making up almost 20% of total revenue. Industry & Solution diversification highlights Quantexa is used by some of the world's largest banks while diversifying its customer portfolio with major additions from other industries. - While Banking, Quantexa's flagship industry vertical, continued to see major growth, nearly 30% of Quantexa's total revenue now comes from, Insurance, Government, and Telecom industries. - Quantexa saw global sales growth across its core solution suites; Contextual Data Management, Fraud Detection, Customer Intelligence (CI), and Know Your Customer (KYC), reflecting strong demand for new offerings with existing customers and growth in new industries. IDC's recent report with Quantexa confirms this momentum across all global sectors, predicting that by 2024, AI-based investment in AML and fraud technologies will exceed $6 billion globally. Delivering innovation through its leading Contextual Decision Intelligence Platform Throughout the past Financial Year, Quantexa continued to invest in the development and evolution of its Decision Intelligence Platform. - In October 2021, Quantexa launched Quantexa 2, the latest version of the company's Decision Intelligence Platform, responding to a growing global demand for trusted, actionable intelligence from fast-increasing and fragmented data volumes. Helping enterprises face the data explosion, the new platform version introduced powerful capabilities that boost control and functionality, reduce friction, and easily add new data sources to the analytics capability. Expanding customer and partnership portfolio - Quantexa announced its new customer, Govia Thameslink Railway (GTR) in June 2021, now using Quantexa's solutions to detect and tackle multifaceted transport fraud. - In July 2021, Quantexa's momentum was recognized with the Google Cloud 2021 Industry Solution Partner of the Year Award in the Financial Services category, for its achievements in the Google Cloud ecosystem. - Quantexa announced Bank of New York Mellon (BNYM) as its latest customer, as well as Series D investor, in September 2021. The leading bank now benefits from Quantexa's strengths in Master Data Management, Entity Resolution, Graph Network Intelligence, and AI, continuing to deliver innovative solutions for its clients. - Quantexa announced a new partnership with KPMG UK to optimize organizations' defences against fraud, money laundering, and illicit finance. - The UK Government's Cabinet Office signed to use Quantexa's solutions, to detect fraud stemming from the COVID-19 loan schemes. - Rounding off the financial year in March 2022, Quantexa's client, major Netherland's bank ABN AMRO, was awarded the Celent Model Risk Manager Award for use of Quantexa's technology. Quantexa's AI-powered analytics solution significantly improved ABN AMRO's data quality and enhanced the efficiency and intelligence for complex KYC investigations. Quantexa announced its Series D funding round of $153 million in July 2021, providing further growth funding and confirming its lead in the Decision Intelligence category. Alongside its existing world class investors, the round was led by leading private equity investor Warburg Pincus. ABOUT QUANTEXA Quantexa is a data and analytics software company pioneering Contextual Decision Intelligence that empowers organizations to make trusted operational decisions by making data meaningful. Using the latest advancements in big data and AI, Quantexa's platform uncovers hidden risk and new opportunities by providing a contextual, connected view of internal and external data in a single place. It solves major challenges across data management, financial crime, customer intelligence, credit risk, fraud, and throughout the customer lifecycle. The Quantexa platform enhances operational performance with over 90% faster accuracy and 60 times faster analytical model resolution than traditional approaches. Founded in 2016, Quantexa now has over 500 employees and thousands of users working with billions of transactions and data points across the world. The company has offices in London, New York, Boston, Brussels, Toronto, Singapore, Melbourne, and Sydney. For more information, contact Quantexa here or follow us on LinkedIn. SOURCE Quantexa	https://www.prnewswire.com/news-releases/decision-intelligence-leader-quantexa-accelerates-growth-by-achieving-a-144-net-retention-rate-in-fy2022-301556812.html	2022-05-31T12:43:03	en	0.927292
First kids digital brand ambassador - Rainy SHANGHAI, May 31, 2022 /PRNewswire/ -- Balabala announced its entry into the metaverse, creating a hyper-realistic digital brand ambassador named 'Rainy'. Rainy is the first digital kid's brand ambassador of balabala, highlighting the leading position of balabala brand in the children's wear industry. The name Rainy takes its inspiration from rain, the water of life, an essential requirement for nourishment and growth. Balabala is the brand that truly understands how children grow up. With an insight into the metaverse, balabala creates a new communication window with the Z-generation, at the same time enhancing it's multi-channel brand strategy. The new collection designs illustrate the beauty of growth in girls by merging a European culture with Chinese design concepts, encouraging kids to express themselves and become a part of their own fairy tale. Balabala continues to drive its ambition of providing its global customers with diversified, high-quality products in a vibrant, exciting shopping environment, encouraging children around the world to have a wonderful childhood and aiming to "Become the first-choice children's fashion brand" More information can be found at www.balabala.com.hk/pages/business-opportunities View original content to download multimedia: SOURCE balabala	https://www.wlbt.com/prnewswire/2022/05/31/leading-kids-brand-balabala-enters-metaverse-with-announcement-its-first-kids-digital-brand-ambassador/	2022-05-31T12:43:02	en	0.919712
ECRID/ResMac Mortgage Strikes Deal That Can Change the Entire Credit Industry PALM BEACH, FL , May 31, 2022 /PRNewswire/ -- ECRID, Inc. (Stock Symbol: ECDD) and ResMac Mortgage have teamed up to help millions of Americans become home owners who have difficulty obtaining mortgages or refinancing existing mortgages in this current economic climate. ECRID, the new Credit Bureau offers the tools and resources to assist Americans in taking control of their financial destinies to become financially stable and build wealth. Through the ECRID platform www.ecrid.com customers can sign up and create their own ECRID Credit Report and Apply for a Mortgage through ECRID Lending Corp. and begin their journey to financial health. About ECRID ECRID came to market to transform the financial lives of every American who needs a second chance of becoming credit worthy. The company has created an innovative fintech platform providing opportunity for individuals and families to regain their financial footing and build wealth in spite of a past bankruptcy, judgement, collections or lien. Second chances have been created to get each ECRID Member financially healthy through this new Innovative fintech platform. ECDD: Stock Symbol Contact: [email protected] Information for ECRID: [email protected] www.ecrid.com SOURCE ECRID, Inc.	https://www.prnewswire.com/news-releases/ecridresmac-mortgage-strikes-deal-that-can-change-the-entire-credit-industry-301557205.html	2022-05-31T12:43:09	en	0.923515
NEW YORK, May 31, 2022 /PRNewswire/ -- Lindblad Expeditions Holdings, Inc. (NASDAQ: LIND) a global leader of expedition cruises and adventure travel experiences, announced today it has named Noah Brodsky as its Chief Commercial Officer, effective today. Mr. Brodsky has built a 20+ year career focused on inspirational travel experiences and premium guest service through a succession of sales, marketing and operating roles at leading global hospitality companies. He is a demonstrated leader in innovative marketing strategies, revenue growth and digital transformation. Most recently, Mr. Brodsky served as the President of the Travel + Leisure Group and Chief Brand Officer for Travel + Leisure Co., the world's leading membership and leisure travel company. During his tenure, he led the rebranding of the Company, substantially grew the rental division, and created and launched multiple branded products, including a full-service travel agency, a subscription travel club, and a licensed goods business. Previously, Mr. Brodsky served as Chief Brand Officer for Wyndham Destinations, the world's largest vacation ownership and exchange business with more than $4B in annual revenue. While there, he led the enterprise level digital, brand, CRM, Partnership and PR departments. Earlier roles included SVP of Worldwide Loyalty and Engagement for Wyndham Hotels & Resorts, Chief Experience Officer at WeWork, and various marketing and operations roles at Starwood Hotels and Four Seasons Resorts. In his role with Lindblad Expeditions, Mr. Brodsky will be responsible for all revenue production and will lead marketing, sales, digital product development and strategic partnerships for the Company. "Lindblad Expeditions is poised for continued growth, as we expand our reach to provide our guests with more ways to discover the world. Noah's proven leadership skills in marketing, digital transformation and team building will be vital as we further build out a world class sales and marketing platform to support our growing fleet and inspiring new experiences for guests across the globe," shared Dolf Berle, CEO of Lindblad Expeditions. "Travelers today are seeking out extraordinary experiences that offer a sense of exploration and discovery and Lindblad Expeditions leads the category in sought-after, remote destinations. I am excited and honored to join the team that is building upon the Company's rich legacy of adventure, excellence and life-changing travel experiences for the next generation of Lindblad Expeditions' guests," said Brodsky. Lindblad Expeditions Holdings, Inc. is a global provider of small ship expeditions and adventure travel experiences recognized as the category leader for its pioneering, cutting edge programming and conservation commitment. Lindblad focuses on ship-based voyages through its Lindblad Expeditions brand and on land-based travel through its subsidiaries, Natural Habitat, Inc., Off the Beaten Path LLC, DuVine Cycling + Adventure Co. and Classic Journeys, LLC. Lindblad works in partnership with National Geographic to inspire people to explore and care about the planet. The organizations work in tandem to produce innovative marine expedition programs and to promote conservation and sustainable tourism around the world. Guests interact with and learn from leading scientists, naturalists and researchers while discovering stunning natural environments, above and below the sea, through state-of-the-art exploration tools. Photo of Noah Brodsky: here View original content: SOURCE Lindblad Expeditions Holdings, Inc.	https://www.wlbt.com/prnewswire/2022/05/31/lindblad-expeditions-holdings-inc-appoints-noah-brodsky-chief-commercial-officer/	2022-05-31T12:43:11	en	0.940088
EffectiV HVAC's Innovative UV Diffusers Receive Major Accreditation Amid 99.949% Effectiveness Against SARS-CoV-2 Virus EffectiV HVAC, a world leader in UV diffusers that help kill and contain airborne viruses, has revealed its devices now come officially backed by the California Air Resources Board (CARB). MONTREAL, May 31, 2022 /PRNewswire/ -- As all air cleaning devices installed in California must be CARB-certified, achieving this latest major milestone for the Canadian-based company means its innovative diffuser solutions can play an effective part in protecting Californians from the effects of COVID-19 and other pathogens. Their PLAY-UV Diffuser was third-party tested by an independent lab in California with live samples of SARS-CoV-2. It achieved an average single-pass reduction rate of 99.949% for 458 cfm of air passing through the diffuser. "We're thrilled that our UV diffuser is recognized by third party experts and is now CARB-certified," said Frank Godbout, President of EffectiV HVAC. "It confirms data previously provided by experts in UV-C irradiation and who analyzed our product that they are an effective solution in preventing the spread of COVID-19 through ventilation systems." EffectiV HVAC's UV Diffusers act as a shield that treats the recycled air coming from the ventilation system before entering the room and with no risk of recontamination. Their innovative solutions simultaneously treat the air using UV-C light, catch dust and mold spores with a MERV-9 filter, and improve air mixing in the room. UVC radiation is a well-known disinfectant for air, with the radiation being used effectively to reduce bacteria and virus spread. The diffusers are the visible part of the ventilation system installed in the ceiling. Air coming from the ducts pass through diffusers in order to be distributed more evenly in the room. EffectiV HVAC's high performance architectural diffusers improve air mixing in the room, and have a significant impact on thermal comfort, energy efficiency and indoor air quality.The diffusers are ideal for both retrofits in commercial and public buildings, and new constructions. They effectively treat all of the air entering the room, including up to 90% of air that's recycled and recirculated everywhere in a building. They are also UL Certified for Safety and Zero Ozone Emissions. At the heart of the operation is their unique plenum which integrates ozone-free UV lamps and its design to increase air contact with UVC light - helping to neutralize COVID-19, Tuberculosis, Legionella and other pathogens. EffectiV HVAC's PLAY-UV diffuser is also the only diffuser in the world providing a 360-degree horizontal airflow adjustment. Each round sector can be manually rotated from the face to redirect the airflow exactly where needed to improve air mixing and thermal comfort. The PLAY-UV diffuser was a finalist in the 2021 AHR Expo Innovation Awards in the 'Indoor Air Quality' category. UV Diffusers were one of the first products to be tested against the actual SARS-CoV-2 virus. UV Diffusers, which can replace existing diffusers in a building or be installed in a single space, are also highly efficient, meaning they can reduce energy consumption compared to other ceiling diffusers and other UV-C air treatment technologies. For more information about EffectiV HVAC's UV Diffusers: www.uvdiffusers.com. More about EffectiV HVAC EffectiV HVAC manufactures and supplies high-performance and innovative architectural diffusers to improve ventilation in commercial and institutional buildings. Their products help improve thermal comfort, energy efficiency, indoor air quality and interior design. They can be found in office buildings, schools, hospitals, airports, retail stores, hotels, restaurants and factories across North America. For more information about EffectiV HVAC's UV Diffusers, check their website: www.effectiv-hvac.com. Media Contact: Frank Godbout 514-375-3885 ext. 1008 [email protected] SOURCE EffectiV HVAC Inc.	https://www.prnewswire.com/news-releases/effectiv-hvacs-innovative-uv-diffusers-receive-major-accreditation-amid-99-949-effectiveness-against-sars-cov-2-virus-301557750.html	2022-05-31T12:43:16	en	0.929251
TSX-V: MKO; OTCQX: MAKOF VANCOUVER, BC, May 31, 2022 /PRNewswire/ - Mako Mining Corp. (TSXV: MKO) (OTCQX: MAKOF) ("Mako" or the "Company") is pleased to provide financial results for the three months ended March 31, 2022 ("Q1 2022"), which is the third full quarter of financial results since declaring commercial production on July 1, 2021 at its San Albino gold mine ("San Albino") in northern Nicaragua. For detailed Q1 2022 operating results, please see the press release dated April 27, 2022. All dollar amounts referred to herein are expressed in United States dollars unless otherwise stated. - $17.3 million in Revenue - $8.3 million in Adjusted EBITDA(1) - $8.7 million in Mine Operating Cash Flow ("Mine OCF") (1) (3) - $1.0 million in Net Loss - $797 Cash Costs ($/oz sold) (1) (2) - $862 Total Cash Costs ($/oz sold) (1) (2) - $1,104 All-In Sustaining Costs ("AISC") ($/oz sold) (1) (2) - $4.6 million of principal repayments during Q1 2022 - $1.9 million in exploration and evaluation expenses ($1.4 million at San Albino and $0.4 million at Las Conchitas) - $2.1 million of surface rights for regional expansion added this quarter - 401,500 shares purchased under the normal course issuer bid for total consideration of $94,340 (C$121,770) - Two monthly repayment installments totaling $0.8 million were made on the Sailfish Loan - Principal repayments of $0.5 million were made on the Wexford Loan - Total principal repayment of approximately $9.0 million since the beginning of Q4 2021 to Wexford and Sailfish Akiba Leisman, Chief Executive Officer, states that, "Q1 2022 was the third full quarter of financial results since declaring commercial production at San Albino at our initial 500 tonnes per day mine and processing plant, where 9,580 ounces were sold at $797/oz Cash Costs and $1,104/oz AISC. Costs are higher than Q4 due to an increase in diesel and other key reagents as well as an increase in waste development tonnage. The processing plant was operating at 596 tonnes per day at 87% availability (104% of nameplate capacity), as the plant has now been fully debottlenecked. The Company generated $8.3 million in Adjusted EBITDA, which excludes $1.9 million in exploration expenditures incurred in the quarter. As a result, approximately $9 million of principal has been repaid since the beginning of Q4 2021, including $4.6 million repaid in Q1 2022, and $1.3 million repaid on outstanding loans subsequent to quarter end. In addition, the $17.2 million exploration program announced in March 2022 is being funded out of cash flow, with the focus on discovering new veins and mineralization elsewhere on our property. The first results from this program are expected to be announced later this week. These extraordinary cash flows from our relatively small scale mine are expected to allow us to fund our growth with the ultimate objective of doubling capacity to 1,000 tonnes per day by next year." Table 1 – Revenue Table 2 – Operating and Financial Data Table 3 – EBITDA Reconciliation Q1 2022 - Mine OCF Calculation and Cash Reconciliation (in $ millions) For complete details, please refer to the Consolidated Financial Statements and the associated Management Discussion and Analysis for the three months ended March 31, 2022, available on SEDAR (www.sedar.com) or on the Company's website (www.makominingcorp.com). The Company has included certain non-GAAP financial measures and non-GAAP ratios in this press release such as EBITDA, Adjusted EBITDA, Mine Operating Cash Flow cash cost per ounce sold, total cash cost per ounce sold, AISC per ounce sold. These non-GAAP measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. In the gold mining industry, these are commonly used performance measures and ratios, but do not have any standardized meaning prescribed under IFRS and therefore may not be comparable to other issuers. The Company believes that, in addition to conventional measures prepared in accordance with IFRS, certain investors use this information to evaluate the Company's underlying performance of its core operations and its ability to generate cash flow. "EBITDA" represents earnings before interest (including non-cash accretion of financial obligation and lease obligations), income taxes and depreciation, depletion and amortization. "Adjusted EBITDA" represents EBITDA, adjusted to exclude exploration activities, share-based compensation and change in provision for reclamation and rehabilitation. "Cash costs per ounce sold" is calculated by deducting revenues from silver sales and dividing the sum of mining, milling and mine site administration cost. "Total cash costs per ounce sold" is calculated by deducting revenues from silver sales from production cash costs and production taxes and royalties and dividing the sum by the number of gold ounces sold. Production cash costs include mining, milling, mine site security and mine site administration costs. "AISC per ounce sold" includes total cash costs (as defined above) and adds the sum of G&A, sustaining capital and certain exploration and evaluation ("E&E") costs, sustaining lease payments, provision for environmental fees, if applicable, and rehabilitation costs paid, all divided by the number of ounces sold. As this measure seeks to reflect the full cost of gold production from current operations, capital and E&E costs related to expansion or growth projects are not included in the calculation of AISC per ounce. Additionally, certain other cash expenditures, including income and other tax payments, financing costs and debt repayments, are not included in AISC per ounce. "Mine OCF" represents operating cash flow, excluding Nicaraguan taxes and royalties, changes in non-cash working capital and exploration expenses. On behalf of the Board, Akiba Leisman Chief Executive Officer Mako Mining Corp. is a publicly listed gold mining, development and exploration company. The Company operates the high-grade San Albino gold mine in Nueva Segovia, Nicaragua, which ranks as one of the highest-grade open pit gold mines globally. Mako's primary objective is to operate San Albino profitably and fund exploration of prospective targets on its district-scale land package. Forward-Looking Information: Some of the statements contained herein may be considered "forward-looking information" within the meaning of applicable securities laws. Forward-looking information can be identified by words such as, without limitation, "estimate", "project", "believe", "anticipate", "intend", "expect", "plan", "predict", "may" or "should" or variations thereon or comparable terminology. The forward-looking information contained herein reflects the Company's current beliefs and expectations, based on management's reasonable assumptions, and includes, without limitation, that, based on the financial results, the Company intends to announce the first results from its previously announced exploration results later this week; the Company expects to fund its growth with the ultimate objective of doubling capacity to 1,000 tonnes per day by next year and Mako's primary objective to operate San Albino profitably and fund exploration of prospective targets on its district-scale land package. Such forward-looking information is subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking information, including, without limitation, changes in the Company's exploration and development plans and growth parameters and its ability to fund its growth to reach its stated target capacity; unanticipated costs; and other risks and uncertainties as disclosed in the Company's public disclosure filings on SEDAR at www.sedar.com. Such information contained herein represents management's best judgment as of the date hereof, based on information currently available and is included for the purposes of providing investors with information regarding the Company's Q1 2022 financial results and may not be appropriate for other purposes. Mako does not undertake to update any forward-looking information, except in accordance with applicable securities laws. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. View original content to download multimedia: SOURCE Mako Mining Corp.	https://www.wlbt.com/prnewswire/2022/05/31/mako-mining-provides-q1-2022-financial-results/	2022-05-31T12:43:18	en	0.941219
Effective Growth Strategy To Counter Raw Material Price Hikes Challenges With Supply Chain Integration Supported By Strong Market Demands & Increased Production Capacity NEW YORK, May 31, 2022 /PRNewswire/ -- On May 19, 2022, CBAK Energy Technology, Inc. (Nasdaq: CBAT), a leading China-based lithium-ion battery manufacturer and electric energy solution provider released its first quarter earnings ended March 31, 2022. Momentous Revenue Growth CBAT kicked off 2022 with net revenues in 1Q-2022 surging more than eight-fold year-over-year to reach $80.2 million; of which, $65 million was from lithium battery cells materials business acquired from Hitran's merger completed in 4Q-2022. Nevertheless, demand for CBAT's high power lithium batteries has continued to prove robust. Sales of the Company's high-power lithium-ion batteries increased ~70% year-over-year in the fourth quarter of 2022, especially driven by the Light Electric Vehicle end-product application, as well as by the continued momentum in its Uninterruptible Supplies products, achieved even when CBAT was still ramping up production capacity at its Nanjing battery manufacturing facility. CBAK Energy's production facilities, both in Dalian and Nanjing, currently have a total battery production capacity of 2GWh, and its Nanjing facility is ramping towards a maximum capacity of 18GWh. Based on the strong lithium batteries sales registered in 1Q-2022, CBAT has tremendous potential to multiply its battery sales once the facility has reached its maximum production capacity, supported by strong market demand from the EV and LEV battery ecosystem. Owing to the positive market feedback on the Company's products, CBAT has an order backlog of approximately $69 million as of May 9, 2022, including the order for lithium-ion batteries supply worth of ~$29.3 million from a leading European provider of heating, cooling and renewable energy systems company, to be met by the full capacity at its main factory in Dalian, together with increased production at its Nanjing plant. CBAT also expects to receive more orders in the coming quarters, and some in bigger orders starting in the 3rd quarter of 2022. CBAT continued to develop Large Cylindrical batteries targeting at the LEV and passenger-grade EV markets. The design and R&D for model 42140 battery were completed, and its model prototype production is being worked on catered to the robust market demand. The Company's main focus in the second quarter is to maintain stable revenues from its uninterruptible supplies and raw material businesses, and will also continue to expand its large-cylindrical batteries through signing new contracts with the LEV and EV manufacturer customers. Particularly benefiting from the rapidly rising global commodity prices, the new raw material business resulting from Hitran's acquisition has now accounted for a major stream of the Company's total revenues. With reliable product quality, Hitran is able to develop and accumulate a number of strategic customers, and is now in full production and expected to further make high nickel, cathode materials used for EV safety and driving range improvement. 3-Step Strategic Plan to Counter Material Price Hikes and Improve Margins In order to combat the impact of rising raw material costs which decreased the profitability of its downstream battery production, CBAT management is proactively taking measures in three main aspects: Step 1. Sign long-term supply agreements with major suppliers to secure major materials supplies. Step 2. Expand into the upstream raw material business and use material price inflation to offset the decrease in gross margins of battery plants. Step 3. Renegotiate prices with downstream customers to successfully raise product prices for the Company's key customers. Management expects the gross margin to improve once its raw-material production capacity and downstream price increases are implemented through the 3-step strategic plan, and subsequently becomes a leading lithium-ion battery and electric energy solutions provider, with secured raw materials and augmented downstream battery production capacity, despite the short-term pressure on the Company's cash flow by the rising material prices. The Company also plans to actively search for quality assets for value-add acquisitions, aiming at stabilized supply chain and enhanced investment returns. Net revenues were $80.2 million, representing a year-over-year increase of 752%, and a quarter-over-quarter increase of 188%. The increases were mainly driven by incremental revenues from integrating lithium battery materials business post Hitran acquisition, as well as by ~70% year-over-year growth in high power lithium batteries sales. Additionally in terms of net revenues by end-product applications, revenues from high power lithium batteries used in LEV grew 329% YoY in the quarter. 1Q-2022 gross profit margin was 6.6%, down from 19.5% in 1Q-2021 while up from 3.7% in 4Q-2021, primarily due to the increase in raw material costs, which are expected to abate when new capacity is being added by the overall industry. Total operating expenses increased 256% YoY, primarily due to growing headcount and consolidation of Hitran; among which, R&D expense in particular increased 585% YoY, coupled with 290% YoY increase in Sales & Marketing expenses. Despite the increases, operating expenses was limited to 8.3% of revenues in the quarter, down significantly from 19.8% from a year ago. Net income attributable to CBAT shareholders was $0.4 million, compared to $29.6 million in 1Q-2021 when the fair value of its warrant's liability decreased significantly due to lower stock prices, which in turn led to higher GAAP earnings. Change in CBAT warrant's fair value was merely $1.6 million in 1Q-2022, compared to $28.4 million in the same period of 2021. Basic and fully-diluted net income per share were both $0.01 in the quarter, compared to a net income per share of $0.35 in 1Q-2021. Cash and cash equivalents were $5.6 million as of March 31, 2022, compared to $7.4 million as of December 31, 2021. Stone Street Group LLC ("Stone Street") publishes research reports on publicly-traded companies. Stone Street has been retained by the Company discussed in this report (the "Company") to provide ongoing digital investor relations services, including the creation and dissemination of this report. All research published by Stone Street is based on public information, or on information from the Company that the Company is required to promptly make public. Stone Street is not a broker-dealer or a "covered person" under SEC Regulation AC, and does not distribute its research through a registered broker-dealer or any associated person of a registered broker-dealer. Accordingly, Stone Street is exempt from the provisions of Regulation AC. Nevertheless, Stone Street makes the following voluntary disclosures and disclaimers in connection with its research reports: NO GUARANTEE: This research report is not a substitute for the exercise of an investor's independent due diligence and independent investment determinations. Information contained herein is based on sources we believe to be reliable but we do not guarantee their accuracy. It should be presumed that the analyst who authored this report has had discussions with the Company to endeavor to ensure factual accuracy prior to publication, however, no independent due diligence or verification has been undertaken by the analyst. No endorsements are made in respect of information provided or published by the subject Company and relied upon by the analyst for purposes of this research report. Recipients of this report should consider this report as only one factor in making any investment decision. This report is for information purposes only and is not intended as an offer to sell or a solicitation to buy securities. Any and all information provided by the Company which has been publicly disclosed as "forward looking information" remains subject to all uncertainties in such regard and Stone Street makes no assurances or guaranties of actual outcomes. NO CONFLICTS OF INTEREST: Stone Street does NOT own securities of the issuers described herein, and Stone Street does not make a market in any securities. Stone Street does not engage in, or receive compensation from, any investment banking or corporate finance-related activities with the Company discussed in the report. Stone Street's contracts with issuers protect Stone Street's full editorial control of all research, timing of release of reports, and release from liability for negative reports. ANALYST INDEPENDENCE: Each Stone Street analyst has full discretion on the analysis and revenue targets contained in the report, based on his or her own due diligence. Analysts are paid in part based on overall profitability of Stone Street. No part of analyst compensation was, or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or article. Stone Street policy does not allow an analyst or a member of their household (i) to own, trade, or have any beneficial interest in any securities of any Company that analyst covers, or (ii) serve as an officer or director of a covered Company. RISK FACTORS: Earnings targets and opinions concerning the composition of market sectors included in this report reflect analyst judgments as of this date and are subject to change without notice. A risk to our earnings targets is that the analyst's estimates or forecasts may not be met. This report contains forward-looking statements, which involve risks and uncertainties. Actual results may differ significantly from such forward-looking statements. Factors that may cause such differences include, but are not limited to, those discussed in the "Risk Factors" section in the issuer's SEC filings available in electronic format through SEC Edgar filings at www.sec.gov. COMPENSATION: Stone Street received a flat fee from or on behalf of the Company for the creation and dissemination of the report. Stone Street has not received investment banking income from the Company in the past 12 months, and does not expect to receive investment banking income from the Company in the next 12 months. ANALYST CERTIFICATION: The research analyst certifies that this report accurately reflects his/her personal views about the Company's securities that none of the research analyst's compensation was, is or will be, directly or indirectly, related to the analyst's specific recommendations or views contained in this research report. SOURCE CBAK Energy	https://www.prnewswire.com/news-releases/effective-growth-strategy-to-counter-raw-material-price-hikes-challenges-with-supply-chain-integration-supported-by-strong-market-demands--increased-production-capacity-301557578.html	2022-05-31T12:43:22	en	0.959091
Melio Continues To Expand Its Product Offering, Enabling Users To Pay Suppliers Internationally NEW YORK, May 31, 2022 /PRNewswire/ -- Melio, a leading B2B payments platform for small businesses, today announced the launch of international payments, enabling U.S. small businesses to make payments abroad with ease and build resiliency in their supply chains. By July 1, Melio customers will be able to pay suppliers in over 70 countries, including main import markets. Small businesses are withstanding the brunt of supply chain disruptions with 63% saying they have had to alter their supply chains in the past six months. Cross-border payments made by small businesses have been growing sharply but many small businesses lack the infrastructure to process complex international payments. Melio's international payments solution widens the number of vendors that its customers can conduct business with, enabling them to better compete in the global marketplace. "As Melio continues to scale rapidly we are growing our product and R&D team in order to expand our product offering for small businesses," said Ilan Atias, Melio's co-founder and CTO. "I am pleased that Melio has reached this milestone of enabling payments to over 70 countries, which will provide small businesses with more flexibility to expand their pool of suppliers abroad and with room to innovate." Melio provides a single, integrated payments solution that allows small businesses to quickly and seamlessly transfer and receive payments – helping with cash flow needs, eliminating late payment costs, and giving businesses back valuable time. About Melio: Melio's mission is to keep small business in business, helping them improve their cash flow and workflow, gain more control over their finances, and optimize their business's financial health. Melio was founded by CEO Matan Bar, CTO Ilan Atias, and Ziv Paz in 2018, with headquarters in New York, an R&D center in Tel Aviv, and western U.S. headquarters in Colorado. The company has raised $506 million to date. Melio's smart B2B online payment solution is tailor-made for small businesses' needs. It is a free, simple, and secure solution that allows small businesses and their suppliers to transfer and receive payments quickly and easily. View original content to download multimedia: SOURCE Melio	https://www.wlbt.com/prnewswire/2022/05/31/melio-launches-international-payments-over-70-countries/	2022-05-31T12:43:24	en	0.971006
Customers will be able to transact faster and cheaper with USDC on the Stellar network SAN FRANCISCO, May 31, 2022 /PRNewswire/ -- As of today, customers of Mercado Bitcoin, the largest platform for digital assets in Latin America, will have access to USDC issued on the Stellar network, which offers fast and affordable transactions. It is the first time that the Mercado Bitcoin platform has offered the same asset issued by different networks. Now, with the possibility of transacting using USDC with lower fees, a fraction of one cent per transaction, the customer will be able to choose the network most suitable for their needs. Since 2014, the Stellar network has been offering safe and cheap transactions. In the first quarter of 2022, it processed an average of $8.6 million a day in payments. Currently, it has also been one of the most chosen networks for payments, tokenization, and issuance of real assets. "USDC on Stellar provides Mercado Bitcoin customers both valuable interoperability and a truly borderless digital dollar," said Denelle Dixon, CEO of Stellar Development Foundation. "As we continue our mission of creating equitable access to the global financial system, this integration is a mutually beneficial step forward. MB is one of the largest digital assets exchanges in the southern hemisphere, with the potential to bring significant volume and liquidity to the Stellar network." By the end of 2022, the network plans to launch native smart contracts that will unlock the creation of numerous applications, which will further increase the utility of USDC on Stellar. Stellar is a decentralized, fast, scalable, and uniquely sustainable network for financial products and services. It is both a cross-currency transaction system and a platform for digital asset issuance, designed to connect the world's financial infrastructure. Dozens of financial institutions worldwide issue assets and settle payments on the Stellar network, which has grown to over 6 million accounts. For more information, visit stellar.org. The Stellar Development Foundation (SDF) is a non-profit organization that supports the development and growth of Stellar, an open-source network that connects the world's financial infrastructure. Founded in 2014, the Foundation helps maintain Stellar's codebase, supports the technical and business communities building on the network, and serves as a voice to regulators and institutions. The Foundation seeks to create equitable access to the global financial system, using the Stellar network to unlock the world's economic potential through blockchain technology. For more information, visit stellar.org/foundation. About Mercado Bitcoin - Mercado Bitcoin is the largest cryptocurrency and alternative asset trading platform in Latin America. The company, which offers freedom, security, and liquidity in trading, is among the 25 most trusted exchanges in the world to trade cryptoassets, according to a study conducted by the Blockchain Transparency Institute (BTI). With more than 3.5 million customers and more than R$40 billion traded since its creation in 2013, the company is transforming people's relationships with their own money and democratizing access to alternative assets with liquidity and security. View original content to download multimedia: SOURCE The Stellar Development Foundation	https://www.wlbt.com/prnewswire/2022/05/31/mercado-bitcoin-integrates-usdc-stellar/	2022-05-31T12:43:31	en	0.929595
ENEL AMÉRICAS ANNOUNCES VOLUNTARY DELISTING OF ITS AMERICAN DEPOSITARY SHARES FROM THE NEW YORK STOCK EXCHANGE SANTIAGO, Chile, May 31, 2022 /PRNewswire/ -- ENEL AMÉRICAS S.A. (NYSE: ENIA) today announced that its Board of Directors has unanimously approved the voluntary delisting of its American Depositary Shares ("ADSs") from The New York Stock Exchange (the "NYSE"), termination of its American Depositary Receipt ("ADR") facility and deregistration with the U.S. Securities and Exchange Commission (the "SEC") upon satisfaction of the requirements for deregistration. In connection with its intended delisting, Enel Américas notified the NYSE today that it will apply for voluntary delisting of its ADSs and has requested that the ADSs be suspended from trading on June 20, 2022. As a result, the last day of trading for the ADSs on the NYSE is expected to be on June 19, 2022. 1. Reasons for the Application for Voluntary Delisting of ADSs from the NYSE Following the merger transaction and related tender offer that occurred in April 2021, its parent company, Enel S.p.A., now owns 82.3% of the total outstanding shares of Enel Américas' common stock and Enel Américas ADSs as of April 30, 2022 comprise only approximately 2.49% of the total outstanding shares of common stock. Enel Américas believes that the costs associated with continuing the listing of its ADSs on the NYSE exceed the benefits received by the company, as the primary market for the shares of Enel Américas not owned by Enel S.p.A. is now the Santiago Stock Exchange. As a result, Enel Américas has decided to file an application for voluntary delisting from the NYSE as part of its effort to reduce operational expenses. 2. Stock Exchanges on Which Enel Américas will Maintain its Listings Enel Américas will maintain its listings on the Santiago Stock Exchange and the Chile Electronic Stock Exchange in Chile. Enel Américas has not otherwise arranged for the listing of the ADSs, ADRs or shares of its common stock on another national securities exchange in the United States or for quotation of such securities in any other quotation system. 3. Implementation Schedule of Application for Voluntary Delisting of ADSs from the NYSE* * The schedule provided above, including the anticipated effective dates, may be delayed if the SEC objects to the delisting or requests an extended review or for other reasons. 4. Additional Information for ADS Holders Enel Américas will direct Citibank, N.A., as depositary ("Citibank"), to terminate Enel Américas' ADR facility. Consequently, and in accordance with the deposit agreement, Citibank will provide at least 30 days' notice of termination to all ADS holders. Prior to termination of the deposit agreement, ADR holders are entitled to surrender their ADSs to Citibank for cancellation, and upon payment of the applicable fees, taxes and charges as provided in the deposit agreement, receive the underlying shares of common stock of Enel Américas. Following termination of the deposit agreement, Citibank will discontinue registration of transfers of the ADSs and suspend the distribution of dividends to ADS holders. Holders of ADSs should contact Citibank or, to the extent holding ADSs through a bank, broker or other nominee, should contact such bank, broker or nominee with any questions regarding the ADSs. For inquiries regarding Enel Américas' ADSs and ADR facility, please contact: Citibank, N.A. Shareholder Services Tel: USA +1-877-248-4237 (toll free) International: +1-781-575-4555 Website: www.citi.com/dr E-mail: [email protected] Shareholder Services representatives are available Monday through Friday from 8:30 a.m. to 6:00 p.m. Eastern time in the U.S. 5. Future Actions Enel Américas' reporting obligations under applicable U.S. federal securities laws are expected to continue after the delisting from the NYSE and termination of the ADR facility. Following satisfaction of the relevant deregistration conditions under the applicable U.S. federal securities laws, Enel Américas intends to terminate its reporting obligations under the applicable U.S. federal securities laws and to deregister all classes of its registered securities. Enel Américas intends to release further information on such deregistration and termination of reporting obligations at a later date. Enel Américas reserves the right, for any reason, to delay any of the filings described above, to withdraw them prior to effectiveness, and to otherwise change its plans in respect of delisting, termination of the ADR facility and deregistration and termination of its reporting obligations under applicable U.S. federal securities laws in any way. Forward-Looking Statements This announcement contains statements that could constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include statements regarding the intent, belief or current expectations of Enel Américas and its management with respect to, among other things: (1) any statements preceded by, followed by or that include the words "believes," "expects," "predicts," "anticipates," "intends," "estimates," "should," "may" or similar expressions; and (2) any statement that is not a historical fact. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of various factors. These factors include, but are not limited to, the following: the risk that the delisting from the NYSE, the termination of the ADR facility or the deregistration with the SEC may not occur or may be delayed; and the risk factors discussed in Enel Américas' Annual Report on Form 20-F for the year ended December 31, 2021 under the heading "Item 3.D. Risk Factors." These forward-looking statements are made only as of the date hereof and Enel Américas undertakes no obligation to update these forward-looking statements, except as required by law. SOURCE Enel Américas	https://www.prnewswire.com/news-releases/enel-americas-announces-voluntary-delisting-of-its-american-depositary-shares-from-the-new-york-stock-exchange-301557547.html	2022-05-31T12:43:34	en	0.939684
- ISS states that the proposed acquisition is in the best interest of Numinus shareholders - Shareholders are encouraged to vote their common shares prior to the proxy deadline of June 6, 2022 at 11:00 a.m. PT. - For any questions on voting, please contact Laurel Hill Advisory Group at 1-877-452-7184 (North American Toll Free) or by email at assistance@laurelhill.com VANCOUVER, BC, May 31, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF) is pleased to announce that Institutional Shareholder Services ("ISS"), a leading proxy advisory firm that provides independent voting recommendations to institutional investors, has recommended that Numinus shareholders vote "FOR" the Company's resolutions in connection with the proposed acquisition of Novamind Inc. ("Novamind"), which was announced on April 12, 2022. The Numinus Special Shareholder Meeting will be held on June 8, 2022 at 11:00 am PT in a virtual-only format conducted by live audio webcast. ISS recommends that Numinus shareholders vote "FOR" the share issuance associated with the acquisition of Novamind. In reaching its conclusion, ISS noted: "Based on a review of the terms of the transaction, the proposed amalgamation makes strategic sense as the target company operates in the same segment, and it is expected that there will be significant benefits associated with annual cost saving synergies." Numinus' board of directors, in consultation with its financial and legal advisors, has unanimously determined that the acquisition and associated issuance of up to 63,010,034 Common Shares is in the best interest of the Company and its Shareholders, and unanimously recommend that Shareholders vote in favour of the Share Issuance Resolution to facilitate the acquisition of Novamind. Shareholders are asked to consider, and if deemed advisable, to approve, with or without variation, an ordinary resolution (the "Share Issuance Resolution") authorizing and approving the issuance of up to 63,010,034 Common Shares of the Company to the securityholders of Novamind in connection with the proposed Transaction. The Meeting is scheduled to be held on June 8, 2022 at 11:00 a.m. PT. At the Meeting, Shareholders will be asked to consider the Share Issuance Resolution. The Circular, form of proxy and voting instruction form, as applicable, for the Meeting contain important information with respect to how registered and beneficial Shareholders may vote at the Meeting. The Circular is also available under the Company's profile on SEDAR at www.sedar.com and on Numinus' investor relations website at: https://www.investors.numinus.com/events-and-presentations/events/event-details/2022/Special-Meeting-of-Shareholders/default.aspx. Only shareholders of record as of the close of business (Eastern Time) on April 29, 2022 are eligible to vote at the meeting. The deadline for completed proxies to be received by the Company's transfer agent is June 6, 2022 at 11:00 a.m. PT. The Company will be holding the Meeting in a virtual-only format, which will be conducted via live audio webcast online at https://web.lumiagm.com/222613031. During the audio webcast, Shareholders will be able to hear the Meeting live, and registered Shareholders and duly appointed proxyholders will be able to submit questions and vote at the Meeting. The Circular provides important and detailed instructions about how to participate at the virtual Meeting. Shareholders who have questions regarding the special resolution or require assistance with voting may contact the Company's proxy solicitation agent and shareholder communications advisor, Laurel Hill Advisory Group, by telephone at 1-877-452-7184 (toll free North America) or 416-304-0211 (calls outside North America) or by email at assistance@laurelhill.com. Numinus Wellness (TSX: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model - including psychedelic production, research and clinic care - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society. Learn more at www.numinus.com and follow us on LinkedIn, Facebook, Twitter, and Instagram. This news release includes certain "forward‐looking information" and "forward‐looking statements" (collectively "forward‐looking statements") within the meaning of applicable Canadian securities legislation, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. All statements in this news release that address events or developments that the Company expects to occur in the future are forward‐looking statements. Forward‐looking statements are statements that are not historical facts and are often identified by words such as "expect", "plan", "anticipate", "project", "target", "potential", "schedule", "forecast", "budget", "estimate", "intend" or "believe" and similar expressions or their negative connotations, or that events or conditions "will", "would", "may", "could", "should" or "might" occur, and include information regarding: (i) expectations regarding whether the proposed Transaction will be consummated, including whether conditions to the consummation of the Transaction will be satisfied, or the timing for completing the Transaction and receiving the required securityholder, regulatory and court approvals, (ii) the anticipated timing of the securityholder meeting of the Company; (iii) expectations regarding the potential benefits of the Transaction and the ability of the combined company to successfully achieve business objectives; and (iv) expectations for other economic, business, and/or competitive factors. Forward‐looking statements necessarily involve assumptions, risks and uncertainties, certain of which are beyond the Company's control. These forward‐looking statements are qualified in their entirety by cautionary statements and risk factor disclosure contained in filings made by the Company with the Canadian securities regulators, including the Company's financial statements and related MD&A for the financial year ended August 31, 2021 and its interim financial statements and related MD&A for the three and six months ended February 28, 2022, all filed with the securities regulatory authorities in all provinces and territories of Canada, except Québec, and available under the Company's profile at www.sedar.com. The risk factors are not exhaustive of the factors that may affect the Company's forward‐looking statements. The Company's forward‐looking statements are based on the applicable assumptions and factors management considers reasonable as of the date hereof, based on the information available to management of the Company at such time. The Company does not assume any obligation to update forward‐looking statements if circumstances or management's beliefs, expectations or opinions should change other than as required by applicable securities laws. There can be no assurance that forward‐looking statements will prove to be accurate, and actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward‐looking statements. Accordingly, undue reliance should not be placed on forward‐looking statements. View original content: SOURCE Numinus Wellness Inc.	https://www.wlbt.com/prnewswire/2022/05/31/numinus-announces-iss-recommends-shareholders-vote-favor-share-issuance-acquire-novamind/	2022-05-31T12:43:38	en	0.933692
NEW YORK, May 31, 2022 /PRNewswire/ -- The worldwide epoxy adhesive market size was $8,217.9 million in 2021, and it is likely to reach $13,483.9 million by 2030, at a 5.7% CAGR from 2021 to 2030. This is credited to the surging requirement for these adhesives from the construction, cement, automotive, industrial, woodworking, plastic, and marine industries. The one-component category dominates the epoxy adhesive market because of the short remedial time and solvent-free character of this product. Furthermore, this kind of adhesive is perfect for assembly lines since, unlike two-component adhesives, it requires no mixing, which makes the process of usage easier and more efficient. Though, two component-based epoxy adhesives are expected to observe a high-volume requirement for building & construction applications in the coming years. Get the sample pages of this report at: https://www.psmarketresearch.com/market-analysis/epoxy-adhesives-market/report-sample Key Findings of Epoxy Adhesive Market Report - The building & construction industry is the largest user of epoxy adhesives, producing the highest revenue, of approximately $2.3 billion, in 2021. This is credited to the adaptability of these adhesives in construction applications. - The increasing demand for epoxy adhesives for structural bonding applications will drive the market growth in the automotive & transport category at a CAGR of approximately 6% in the coming years. - A lot of flexibility is offered by offline distribution channels in selecting products and assessing their quality. Additionally, the automotive and construction industries source their required capacity straight from suppliers and dealers in bulk. - Therefore, the offline category is expected to have more than 75% share of the revenue in the epoxy adhesive market in 2030. - APAC has the largest share in the market because of its huge automotive, construction, electronics, electrical, and semiconductor businesses. Furthermore, this kind of adhesive is widely used in construction and manufacturing activities, which will lead the regional industry to the top in the near future as well. - The revenue share of China was the largest in the APAC market in 2021. It is the largest country in purchasing power parity, the second-largest in terms of nominal GDP, and one of the major exporters of sealants and adhesives. Similarly, the U.S. holds the majority of the market share in North America, as the construction sector is a major contributor to the country's economy. The momentous development in the construction industry is credited for the rise in the demand for these adhesives in the country. Browse detailed report on Epoxy Adhesive Market Trends, Business Strategies, Regional Outlook, Challenges and Analysis Through 2030 The stalwarts of the epoxy adhesive market are actively taking part in mergers and partnerships to fortify their presence. For example, Huntsman Corporation publicized its partnership with Azelis Americas CASE LLC, its delivery partner in the U.S.; and Azelis Canada Inc., its delivery partner in Canada, in July 2020. Epoxy Adhesive Market Segmentation Analysis By Type - One-Component - Two-Component By End User - Building & Construction - Automotive & Transportation - Aerospace - Semiconductor - Electrical & Electronics - Wind Energy By Distribution Channel - Online - Offline By Region - North America - U.S. - Canada - Europe - Germany - U.K. - Italy - Spain - France - Asia-Pacific - China - India - Japan - Australia - South Korea - Latin America - Brazil - Mexico - Middle East and Africa - Saudi Arabia - South Africa - U.A.E. Browse More Related Reports Global Adhesive Tapes Market Growth Forecast Report Global Adhesives and Sealants Market Growth Forecast Report Global Structural Adhesives Market Growth Forecast Report Global Packaging Adhesives Market Growth Forecast Report About P&S Intelligence P&S Intelligence provides market research and consulting services to a vast array of industries across the world. As an enterprising research and consulting company, P&S believes in providing thorough insights on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness. P&S keeps the interest of its clients at heart, which is why the insights we provide are both honest and accurate. Our long list of satisfied clients includes entry-level firms as well as multi-million-dollar businesses and government agencies. Contact: Prajneesh Kumar P&S Intelligence Phone: +1-347-960-6455 Email: [email protected] Web: https://www.psmarketresearch.com Follow Us: LinkedIn Twitter SOURCE P&S Intelligence	https://www.prnewswire.com/news-releases/epoxy-adhesive-market-size-to-surpass-13-483-9-million-value-by-2030--says-ps-intelligence-301557627.html	2022-05-31T12:43:40	en	0.91441
OpenBCI's new platform 'Galea', will be combined with the cutting-edge Varjo Aero VR headset to provide developers and researchers a powerful new tool for understanding and augmenting the human mind. Pre-orders for Galea Beta devices open today. BROOKLYN, N.Y., May 31, 2022 /PRNewswire/ -- OpenBCI, a Brooklyn-based neurotechnology company, announced today that it has partnered with Varjo, the leader in professional-grade VR/XR, for the launch of Galea, OpenBCI's eagerly anticipated new product. Galea is a hardware and software platform that merges next-generation brain-computer interface technology with head-mounted displays. Galea beta systems will come integrated with the Varjo Aero headset and will be the world's first device that simultaneously measures the user's heart, skin, muscles, eyes, and brain. Pre-orders are now open for existing Galea Beta Program applicants via galea.co. The Galea Beta Program has already received significant interest from applicants spanning consumer technology, healthcare, research, training, and gaming & interactive media. Galea beta units will come fully-integrated with the industry-leading Varjo Aero and include robust SDKs with ready-to-use building blocks for accessing the sensor data inside of Unity, Python, and several other common development environments. The Aero is Varjo's newest VR headset that offers industry-leading visual fidelity, featuring true-to-life, edge-to-edge clarity across 115 degrees field of view designed for professionals and leading-edge VR users alike. By combining Galea's multi-modal sensor system, integrated software and Varjo VR hardware, users are equipped with powerful tools to help accelerate innovations within the neurotechnology industry. For nearly a decade, OpenBCI has been at the forefront of expanding consumer access to neurotechnology. What started as a movement among makers and early-adopters, has grown into a global community of scientists, developers, educators, and increasingly, innovation teams of major technology companies. Galea's unique multi-modal sensor network and complementary software dramatically simplifies the process of collecting tightly-synchronized data from the body and unlocks new techniques for anyone looking to objectively measure user experiences and cognitive states. "Ultimately, I see the combination of neurotechnology and mixed reality as the future of personal computers," says OpenBCI founder and CEO, Conor Russomanno. "We've been watching carefully as neuroscience, BCI, and consumer technology have converged over the past several years. Varjo's headsets are some of the best I've ever experienced and I can't wait to see what our Beta users will be able to create with Galea." "Varjo is proud to join forces with OpenBCI and expand access to the highest-fidelity VR to the research and developer community looking to pioneer new understandings of the human body and mind," said Urho Konttori, co-founder and Chief Technology Officer of Varjo. "The integration will allow Galea users to unlock the most immersive VR experience available on the market today and truly push the boundaries of innovation in a number of fields." Pre-orders for Galea will initially be open to the thousands of companies, developers, and researchers who have already applied to the Galea Beta Program. Remaining units will be available for pre-order by the general public on July 1, 2022. For more information on Galea visit https://galea.co/. Media assets available here: OpenBCI/Varjo Media Kit (2022) OpenBCI has been creating open-source tools for biosensing and neuroscience since 2014. OpenBCI's mission is to lower the barrier to entry for human-computer interface technologies, while ensuring that these technologies are adopted into the consumer landscape in an ethical way that protects user agency and mental health. Based in Brooklyn, NY, the company's hardware and software products enable a global community of scientists, designers, artists, and engineers to further our understanding of the human body and mind. https://openbci.com Varjo (pronounced var-yo) makes revolutionary VR/XR hardware and software that together allow you to see and experience virtual and augmented content just as clearly as you see the real world. Our virtual and mixed reality products take you to another level of performance and emotional immersion – recreating the exact feeling and conditions of real life, allowing you to perform better and learn faster. www.varjo.com Contact: Galea@openbci.com View original content to download multimedia: SOURCE OpenBCI	https://www.wlbt.com/prnewswire/2022/05/31/openbci-varjo-partner-bring-neurotechnology-spatial-computing/	2022-05-31T12:43:44	en	0.91929
Fintel Connect CEO Nominated for RBC Canadian Women Entrepreneur Awards The founder and CEO of Fintel Connect has been selected amongst Canada's Top Female Entrepreneurs, recognized as a Woman of Influence VANCOUVER,BC, May 31, 2022 /PRNewswire/ -- Fintel Connect is proud to announce its founder and CEO, Nicky Senyard, has been nominated for the 30th Annual RBC Canadian Women Entrepreneur Awards. The RBC Canadian Women Entrepreneur Awards, sponsored by the Royal Bank of Canada, is the premier national awards program celebrating the achievements of the most successful Canadian female entrepreneurs. Now in its 30th year, tens of thousands have been nominated and over 200 women have taken home the top awards for demonstrating excellence — from economic growth to social change, across multiple sectors. "It's an honour to be nominated," shares Senyard. "As a leader of a women-led technology company in financial services, I'm proud to be surrounded by talented, capable women that are shaping the future of technology and finance across Canada. It's an exciting role to be in as we help drive growth in a male-dominated industry." Senyard founded Fintel Connect, the leading specialist in performance marketing technology for financial services, in January 2020. The company provides marketing intelligence solutions for financial brands across North America and is led by an all-women C-suite team. RBC's awards showcase forward-thinking entrepreneurs who have recognized a new market, product, service, technological advancement, or opportunity and led the way. Nominees have demonstrated outstanding leadership within their company and market, and have set standards for originality, quality, and successful management. Award finalists will be announced in September 2022, and the winners will be announced at the November 2022 gala event. About Fintel Connect Fintel Connect is the leading specialist in performance marketing technology for the financial industry. As a marketing intelligence solution built specifically for financial services, Fintel Connect serves North American fintechs, banks, credit unions, and insurtechs. The company's suite of turn-key products drive scalable growth through its tracking and reporting platform, curated network of financial publishers and influencers, and AI-driven marketing compliance tools. As a proud partner of the Visa Fintech Partner Connect program, Fintel Connect is helping build the next generation of digital banking. Discover how Fintel Connect helps brands scale their growth: www.fintelconnect.com. Media inquiries: Gilian Ortillan, 604-783-1724, [email protected] For brands: Please visit https://www.fintelconnect.com/brands For publishers interested in joining our network, please visit http://www.fintelconnect.com/publishers SOURCE Fintel Connect	https://www.prnewswire.com/news-releases/fintel-connect-ceo-nominated-for-rbc-canadian-women-entrepreneur-awards-301557733.html	2022-05-31T12:43:46	en	0.94642
Companies operating in France will soon benefit from an integrated cloud payroll system that helps simplify payroll processes AUSTIN, Texas, May 31, 2022 /PRNewswire/ -- Oracle plans to deliver Oracle France Payroll, part of Oracle Fusion Cloud Human Capital Management (HCM). The new cloud payroll solution will help organizations manage compliance, automate workflows, and quickly process payroll for employees working in France. With the addition of Oracle France Payroll, Oracle Cloud HCM will provide built-in payroll support for 13 countries including Bahrain, Canada, China, Kuwait, Mexico, Qatar, Saudi Arabia, United Arab Emirates, United Kingdom, and the United States, with upcoming support for India and Oman. France has one of the most complex payroll processes in Europe, requiring employers to report and withhold income for a variety of taxes on behalf of the country's 30 million workers. Additionally, organizations operating in France experience rapid and continuous legislative and regulatory changes, meaning payroll processes will often vary from one year to the next. To manage this complexity, organizations with employees working in France need the support and flexibility of a cloud-based payroll system that automatically updates to match current payroll and reporting needs. "Payroll is one of the single most important functions for keeping a workforce running smoothly. Employees have zero tolerance for mistakes or delays when it comes to their compensation, no matter how complicated the local rules and regulations are," said Holger Muller, principal analyst, Constellation Research. "It's essential that organizations use a cloud-based payroll system that natively integrates with their core HR systems to automatically stay up to date with changes in regulations and their workforce. The upcoming launch of Oracle France Payroll is a huge opportunity for local and multinational companies operating in France to benefit from that integration in their HR and payroll operations." Oracle France Payroll will help organizations save time and reduce payroll errors by eliminating manual processes and automating complex rules and calculations so customers can easily comply with tax and reporting obligations. Adding France-specific capabilities to Oracle Payroll will allow French companies and multinational organizations operating in France to grow with one global payroll solution. Oracle France Payroll will provide the following benefits to organizations: - Built-in Compliance Rules: Will address regulatory and legislative requirements for processing payroll in France. As Oracle France Payroll is built in the cloud, it can adapt to France's frequently changing rules as needed. It will also give payroll administrators the flexibility to configure pay rules for different collective bargaining agreements, trade union activities, and complex regulations for minimum and variable wages. - Robotic Process Automation: Will help simplify payroll and data entry tasks for payroll administrators, enabling them to calculate payroll faster and more accurately. It will also help reduce errors in more complex work rules that are common in France. - Payroll Unified with Core HR: Will give Oracle France Payroll complete access to workforce data within Oracle Cloud HCM to help ensure that deductions for income, social, and other tax withholdings are managed correctly. This will also help organizations easily onboard new employees and get them paid quickly. "In France, the government and collective bargaining groups are constantly changing the laws and agreements regarding taxes and compensation in hopes of improving working conditions for employees. That can make it challenging for organizations to stay up to date on the latest processes they need to follow to pay their employees accurately and fairly," said Chris Leone, senior vice president of development, Oracle Cloud HCM. "With Oracle France Payroll, local and multinational organizations with employees in France will be able to automate payroll operations to pay their workers quickly and accurately. Frequent and automatic updates will help ensure payroll operations are always in compliance, even as laws and contracts change." See here for more information about Oracle Payroll: https://www.oracle.com/human-capital-management/payroll/ Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com. Oracle, Java, and MySQL are registered trademarks of Oracle Corporation. View original content to download multimedia: SOURCE Oracle	https://www.wlbt.com/prnewswire/2022/05/31/oracle-fusion-cloud-hcm-add-payroll-support-france/	2022-05-31T12:43:50	en	0.936941
- Plan of Operations approves drilling on 28 new pads off patented claims - Allows testing of 4 high priority exploration targets and 22 resource expansion and infill drill holes within the northwest, southwest and southern margins of the Lemhi Gold Deposit - 5 new holes (>700 m) completed at Beauty with rush assays pending - Completed 21 step out / resource expansion and 8 infill drill holes for a total of 7,926 metres on Phase 2 drilling at Lemhi. Samples from 14 drill holes are at the lab awaiting analysis. Toronto Venture Stock Exchange: FMAN VANCOUVER, BC, May 31, 2022 /PRNewswire/ - Freeman Gold Corp. (TSXV: FMAN) (OTCQX: FMANF) (FSE: 3WU) ("Freeman" or the "Company") is pleased to report it has received approval of a Plan of Operations ("Plan") application to the USDA-Forest Service ("USFS"), Salmon and Challis National Forests, North Fork Ranger District, submitted in September 2021. The Plan was approved May 23, 2022, as POO-2021-081646. "The approval allows us to drill test key extensions of the Lemhi Gold Deposit to maximize the near surface oxide ounce count. We are very much looking forward to drill testing exiting new targets in our underexplored land package. After our success at Beauty, we are very optimistic that additional gold mineralization can be discovered in the property package," commented Paul Matysek, Executive Chairman of the Company. "We are extremely pleased with the support and collaboration received from the USFS and its staff and hope we can build upon this positive relationship as we develop the Lemhi Deposit." The Plan includes the construction of 28 drill pads of which 22 are selected for resource infill and expansion at the Lemhi Gold Deposit. These drill pads are situated within Freeman's Bureau of Land Management ("BLM") claims in the northwest, southwest and southern margins of the Lemhi Gold Deposit. The remaining six drill pads are designed to test high priority targets 2, 3 and 7 as defined in the new release dated May 6, 2021, which contain rock grab samples up to 38.23 grams per tonne gold ("g/t Au"). An additional drill pad has been permitted in the northwest portion of the claim block to partially test a coincidental Induced Polarization ("IP") Target, also defined by Freeman as Target 11. All these targets have never been drill-tested, like the Beauty Zone discovery drilled in late 2021 (see press release dated March 22, 2022). - Target 2: Rock grab samples returned assays 2.55 g/t Au up to 32.8 g/t Au; - Target 3: Rock grab samples in historic trenches reported 2.88 g/t Au up to 38.23 g/t Au; - Target 7: Rock grab samples in historic trenches from 1.05 g/t Au up to 12.1 g/t Au; - Target 11: Priority NNW trending IP anomaly. The Company continues to drill at both the newly discovered Beauty Zone and the Lemhi Gold Deposit. To date, 37 drill holes have been completed, totalling 8,977 metres. Five new diamond drill holes totalling 721.5 metres have been completed at the Beauty Zone, following up on the discovery hole which intersected 68.23 g/t Au over 6 metres (March 22, 2022). Drilling has stepped out up to 90 metres along strike and about 75 metres down dip, testing the extent of the high-grade mineralized structures encountered in the discovery holes. All new drill holes have intercepted the structure with widths varying between 2 and 6 metres with the exception of hole FG22-023 which encountered a 6-metre void where the structure was projected. The void is interpreted as the remains of historical mining. Three holes have been logged, sampled, and delivered to the assay laboratory. A rush has been placed on these samples to ensure timely return of results in order to plan the subsequent round of drilling. As of May 30, 2022, a total of 29 new drill holes have been completed at Lemhi for a total of 7,926 metres. These holes have been primarily designed to test on strike extensions of the known resource (21 drill holes) as well as infill in certain parts of the gold deposit (8 drill holes). In particular, the drill program has focused on areas currently modelled as pit waste because of no or sparse drill data. All ounces added in these areas, even if low grade, will add value to the project as it will be converting in pit waste material to resources (Figure attached). An additional 19 holes approximately 4,800 m have been planned as part of the Phase 2 drilling program. See Figure 1. Fourteen drill holes from Lemhi have been logged, sampled and sent to the laboratory. Analytical results are pending. Two drills continue to operate at Lemhi. The Company also announces that, further to its news release of September 15, 2020, it has agreed to issue, subject to acceptance by the TSX Venture Exchange (the "Exchange"), a further cash payment in the amount of US$100,000 and issue an additional 375,000 common shares in its capital in connection with the acquisition of the Moon #100 and Moon #101 unpatented mining claims ("Moon Claims"), located within the historical resource area of Lemhi gold project. On September 4, 2020, the Company entered into a purchase and sale agreement to acquire 100% ownership of the Moon Claims for cash consideration of US$150,000 and share consideration of 375,000 Freeman common shares. Subsequent to the transaction and in order to overcome certain mineral title matters, the Company entered into a follow up purchase and sale agreement on June 23, 2021 (the "Execution Date"), pursuant to which the Company agreed to make payment of an additional US$100,000 and issue a further 375,000 common shares in its capital (the "Final Consideration Shares") within one year of the Execution Date in order to complete the Moon Claims acquisition. Closing of the acquisition and the issuance of the Final Considerations Shares remains subject to certain conditions, including receipt of all necessary approvals, including the approval of the Exchange. The deemed value per Final Consideration Share is $0.33 being the current Discounted Market Price (as defined in the policies of the Exchange) per common share of the Company. The Final Consideration Shares will be subject to a statutory hold period expiring four months and one day from the date of issuance of such securities. Freeman Gold Corp. is a mineral exploration company focused on the development of its 100% owned Lemhi Gold property (the "Project"). The Project comprises 30 square kilometres of highly prospective land, hosting a near-surface oxide gold resource. The pit constrained National Instrument 43-101 ("NI 43- 101") compliant mineral resource estimate is comprised of 749,800 oz gold ("Au") at 1.02 grams per tonne ("g/t") in 22.94 million tonnes (Indicated) and 250,300 oz Au at 1.01 g/t Au in 7.83 million tonnes (Inferred). See the NI 43-101 technical report titled "Maiden Resource Technical Report for the Lemhi Gold Project, Lemhi County, Idaho, USA" with an effective date of June 1, 2021, and signing date of July 30, 2021, as prepared by APEX Geoscience Ltd. and F. Wright Consulting Inc. available under the Company's profile on SEDAR (www.sedar.com). The Company is focused on growing and advancing the Project towards a production decision. The technical content of this news release has been reviewed and approved by Dean Besserer, P.Geo., VP Exploration of the Company and a Qualified Person as defined by NI 43- 101. On Behalf of the Company William Randall President and Chief Executive Officer Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements: This press release contains "forward‐looking information or statements" within the meaning of Canadian securities laws, which may include, but are not limited to statements relating to further exploration, including proposed drilling, of the Lemhi Gold Deposit, the issuance of the Final Consideration Shares and regulatory approvals thereto, and the Company's future business plans. All statements in this release, other than statements of historical facts that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ from those in the forward-looking statements. Such forward-looking information reflects the Company's views with respect to future events and is subject to risks, uncertainties, and assumptions. The reader is urged to refer to the Company's reports, publicly available through the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com for a more complete discussion of such risk factors and their potential effects. The Company does not undertake to update forward‐looking statements or forward‐looking information, except as required by law. SOURCE Freeman Gold Corp.	https://www.prnewswire.com/news-releases/freeman-gold-receives-approval-of-plan-of-operations-and-provides-lemhi-gold-project-update-301557713.html	2022-05-31T12:43:52	en	0.942901
Leigh Prather - stock.adobe.com Attack of the clones: the rise of identity theft on social media The proliferation of social media platforms has resulted in the rise of identity theft on these platforms, with accounts copied for fraudulent or malicious purposes. This affects both content creators and the platforms. So, what can be done to mitigate it? Earlier this year, Derbyshire-based freelance model Elle Jones was informed by acquaintances that they had been contacted by someone claiming to be her. Investigating, Jones discovered an Instagram account had been created mimicking her own profile, which offered pornographic content through a link. Jones reported the account, but two days later received an automated response saying the account had not been removed. She then emailed Instagram, contesting the inaction, and two days later the fraudulent account was removed. Jones’s experience is not unique. Author Joe Dunthorne had his identity exploited when an Instagram profile, which claimed to be him, attempted to convince people to buy cryptocurrencies. Of course, the problem is not restricted to Instagram. For example, artist and cosplayer Giulietta Zawadzki had her Twitter account cloned earlier this year, in an attempt to sell pornography. These impersonators are targeting businesses just as much as individuals – any account that has a significant following on social media can become a target for identity theft. In 2020, the Little Soap Company had its account cloned. Participants in its online competition were then privately contacted by the fraudulent account to be told they had won – and asked for their PayPal details. As we become an increasingly digital society, there has been an associated rise in the number of fraudulent social media profiles being created. These accounts are then used to distribute misinformation, share fraudulent links, sell goods or attempt to solicit bank details. “It’s fairly easy to create and clone the account of someone else, trying to steal their identity – of a person, company or institution – and using that account to force information from other people, force money, but also for spreading misinformation and so on,” says Piotr Bródka, a professor in the Department of Artificial Intelligence at Wroclaw University of Science and Technology. The impact of these social engineering attacks extends beyond any immediate losses due to malicious activities. The person whose profile is copied can become associated with the actions of the impersonator, causing reputational damage. “The bigger problem, which we possibly don’t see, is the damage to the people; how they are seen by their friends and how damaging the misinformation is,” says Bródka. “I’m seeing a lot of clients that will have a rival account set up on Twitter that looks very similar to them,” says reputation consultant Madelaine Hanson. “That person will then claim that the original account was hacked, or they can’t remember their password, and will then share recommendations on NFTs [non-fungible tokens] or cryptocurrencies to invest in.” A problem for platforms, not just for users There is also an impact on social media platforms, because as more of these incidents occur, there will be an associated loss of trust in that platform’s ability to protect its users. This will lead to user habits changing, such as limiting their use of platforms perceived as being vulnerable to identity theft, or switching to platforms that are seen as more secure. “Since it happened on Instagram, I have changed my profile to a private account,” says Jones. “I was previously a business account, but with a private account I can see who asks to be a follower.” One of the problems with social media identity theft is that the reporting mechanisms are limited. The support teams for social media platforms can often be swamped by demands, and reports of identity theft can be overlooked. When reporting cloned accounts, there is usually an option for blocking the account. Of course, the malicious account can also block the original account, thereby obfuscating the cloned account’s activities. It is often several days before any response is received, and even then, it is not guaranteed that any action will be taken. Jones had to wait more than four days before an account was taken down. To date, there has still been no action taken against the profile mimicking Zawadzki on Twitter. There are also limited legal avenues that victims can pursue. As identity theft is covered by fraud, it is only considered criminal if the victim has lost money through the perpetrator’s actions – irrespective of money made by the perpetrator through exploiting the victim’s identity. “A crime will only be recorded when the individual or company who has or may have suffered a financial loss through the use of a stolen identity reports it,” explains a government spokesperson for the Home Office. “We encourage all victims to report incidents to Action Fraud, as it provides important information to law enforcement.” However, equating reputational harm to financial loss can be challenging, as there needs to be evidence proving there has been a loss of earnings through the malicious activities by the cloned account. “Defamation law, in general, needs to be completely reformed,” says Hanson. “I’d like to see more focus on crime, such as impersonating others for information, being included under fraud.” Is being verified enough? The “blue tick” system, which is used by major social media platforms Facebook, Twitter and Instagram to indicate accounts that have had their identity verified, has had mixed success. Having verified status means it is easier and faster to have any bogus accounts taken down. However, only certain users are currently able to apply for the verified status, often depending upon the business they are associated with. “A lot of people are perhaps not noteworthy enough to get a blue tick, but they’re big enough to influence markets,” says Hanson. The application process for becoming verified is a delicate balancing act for social media platforms. If the prerequisites are too broad, the platforms can become swamped with applications, but if they are too narrow, their use becomes too limited to be beneficial. Likewise, the verification systems used on each platform are not uniform. While one platform may grant a verified status, another will not, even if a user is already verified on an existing platform. This can cause people to question the legitimacy of a genuine but non-verified profile. There has been some research into detecting cloned social media accounts. In 2014, Bródka published a paper titled Profile cloning detection in social networks. Profile cloning detection enables platforms to spot potentially fraudulent social media accounts, which are exploiting people’s trust for malicious purposes. “We created a simple app, which was collecting your friends and friends of friends,” says Bródka. “Based on that, we did some experiments on how effectively we can create a cloned profile and how effectively we can detect them.” In the paper, Bródka demonstrated two methods that could be used. The first method examines the similarity of attributes between profiles, the second evaluates the similarity between their social networks. Both techniques proved useful in detecting cloned profiles, but the volume of data on social media platforms means the initial outlined methodologies would be unsuitable for mass deployment. “You would need to simplify that because I don’t think there is a possibility to effectively run it online for every account in big social networking services like Facebook,” says Bródka. Unfortunately, in the wake of the Cambridge Analytica scandal, Facebook data has become harder to acquire for research purposes. As such, it has become challenging to research cloning detection. What can be done? The proliferation of social media and inadequate reporting mechanisms on the platforms has seen identity theft flourish online. This will continue until further action is taken to counter these malicious activities. “I hope it’ll be much faster to freeze an account that’s impersonating you, as it’s very easy to do at their end,” says Hanson. “We need to recognise that people who commit crimes online are harmful and impactful.” The Online Safety Bill has been introduced to the UK Parliament and is currently at the committee stage. It includes a duty to prevent fraudulent advertising on the largest social media platforms, but only time will tell how effective it will be in tackling identity theft on social media. “We are determined to crack down on fraudsters and are introducing legislation to make digital identities as trusted and secure as official documents such as passports and driving licences, including setting up a new Office for Digital Identities and Attributes,” says the Home Office. Until then, individuals and organisations with a social media presence need to maintain vigilance regarding account cloning to protect their brand and reputation. Having verified status will help in that regard, but this measure is not foolproof. Following his planned takeover of Twitter, Elon Musk tweeted “authenticate all real humans”, which implies a push for more Twitter profiles to be verified in the future. In the current digital climate, a proactive social media strategy should be followed, such as regularly checking for any cloned profiles. If any are found, the reporting mechanisms should be used for them to be taken down. Screenshots of all comments and posts by the fraudulent account will provide further evidence of their illegal activity. However, there is only so much that social media users can do to protect themselves from identity theft on social media. “The main responsibility lies on the authorities and social media platform owners to create mechanisms that will allow them to quickly identify such cases,” says Bródka.	https://www.computerweekly.com/feature/Attack-of-the-clones-the-rise-of-identity-theft-on-social-media	2022-05-31T12:43:54	en	0.968284
- With strong support from the Government of Djibouti, this program will pilot a new Friendly™ mosquito control technology to combat the growing threat to the region posed by the rapidly spreading malaria vector, Anopheles stephensi. - Oxitec will work hand-in-hand with the Djibouti Ministry of Health through the national malaria program and with civil society through Association Mutualis, a Djiboutian not-for-profit organisation dedicated to delivering public health impact in Djibouti. - The invasive Anopheles stephensi has caused massive increases in urban malaria in Djibouti's capital city since it was first reported in 2012. It is also rapidly spreading to other countries in the region. - This partnership marks the start of a long-term relationship to validate environmentally sustainable vector control tools, which are urgently needed against this difficult-to-control mosquito. OXFORD, England , May 31, 2022 /PRNewswire/ -- Oxitec Ltd, the leading developer of biological pest control solutions, today announced the launch of a new partnership with the Government of Djibouti and Association Mutualis, a leading not-for-profit organisation serving the public health needs of communities in Djibouti. This exciting partnership was formed in response to a request from the Government of Djibouti to explore how Oxitec's Friendly™ solutions can deliver impact in towns and cities threatened by vector-borne diseases. Recent years have seen unprecedented increases in malaria incidence in Djibouti's capital city and surrounding communities. Where national annual malaria cases previously numbered in their hundreds, public health authorities are now reporting many tens of thousands of cases. This explosion has been ascribed to the arrival, first reported in 2012, of a single invasive mosquito species, Anopheles stephensi. Native to Asia, this malaria vector is highly capable of colonising urban locations, unlike many other malaria-transmitting mosquitoes. In Djibouti, where 70% of people live in the capital city, this urban invasion has exposed most of the country's population to a very new and deadly threat. And it is spreading through the region: it has now been reported in Ethiopia, Sudan, Somalia, and is predicted to spread much further. Leading malaria experts have warned that "urgent action is needed to prevent urban malaria epidemics from emerging and causing a public health disaster". The government of Djibouti has expressed the need for, as part of an integrated approach, innovative solutions to complement existing tools such as mosquito nets, indoor residual spray or environmental management. From that perspective, the Government of Djibouti approached Oxitec in 2018 to explore how the Friendly™ mosquito technology, already proven against the dengue fever mosquito, Aedes aegypti, could serve as a new tool to combat this urban malaria vector. Oxitec recently launched its Friendly™ Aedes as a commercial product for households, communities and businesses in Brazil. Oxitec's malaria program is well under way, and this collaboration heralds a new pilot phase that will enable field validation of the Friendly™ Anopheles stephensi solution under development. Grey Frandsen, CEO of Oxitec, said, "We're excited and honored to be partnering with the Government of Djibouti and Association Mutualis as we work together to pilot Oxitec's newest Friendly™ mosquito technology. It is exactly this type of public-private partnership that unlocks real potential for public health impact to new and growing health challenges. Djibouti's leadership on this front will no doubt serve as an exemplar for how other countries in the region tackle emerging issues, especially in the face of a rapidly changing climate. We are thrilled with our partnership with the Government of Djibouti and Mutualis, as it represents yet another collaboration we undertake to move our technologies to impact." Djibouti's Ministry of Health commented that "As a government, we are focused on delivering safe, effective and sustainable vector control to protect our people from disease-spreading mosquitoes. This new partnership demonstrates our government's commitment to lead the way in changing how malaria-spreading mosquitoes are combated. We're excited about working with Oxitec to explore the impact that this new solution can deliver in our country's malaria-threatened communities. And we believe that this kind of public-private collaboration is the way forward to deliver impact in many fields." A spokesperson for Association Mutualis added, "Current vector management tools are inadequate against Anopheles stephensi and, despite our best efforts, malaria continues to blight people in and around our capital city. We have established a strong partnership with Oxitec, with a shared purpose: to improve management of this invasive mosquito for the benefit of malaria-threatened communities. Their Friendly™ solution represents a promising new tool which we look forward to assessing in Djibouti." About Oxitec Oxitec is the leading developer of biological solutions to control pests that transmit disease, destroy crops and harm livestock. Founded in 2002 at the University of Oxford, Oxitec is led by a passionate team comprised of 15 nationalities and is supported by world-class public, private and non-profit partners. Learn more at oxitec.com. View original content to download multimedia: SOURCE Oxitec Ltd	https://www.wlbt.com/prnewswire/2022/05/31/oxitec-government-djibouti-announce-new-multi-year-partnership-fight-invasive-malaria-transmitting-mosquitoes-threatening-horn-africa/	2022-05-31T12:43:57	en	0.935642
BRUSSELS, Belgium — In the most significant effort yet to punish Russia for its war in Ukraine, the European Union agreed to ban the overwhelming majority of Russian oil imports after tense negotiations that exposed the cracks in European unity. From the moment Russia invaded on Feb. 24, the West has sought to hit Moscow's lucrative energy sector to cut off funding for its war. But any such move is a double-edged sword, especially in Europe, which relies on the country for 25% of its oil and 40% of its natural gas. European countries that are even more heavily dependent on Russia have been especially reluctant to act. In a move unthinkable just months ago, EU leaders agreed late Monday to cut around 90% of all Russian oil imports over the next six months. In response to the EU’s decision, Mikhail Ulyanov, Russia’s permanent representative to international organizations in Vienna, took to Twitter, saying: “Russia will find other importers.” Russia has not shied away from withholding its energy supplies, despite the economic damage it could suffer as a result. And Russian energy giant Gazprom announced it would cut natural gas supplies to Dutch trader GasTerra on Tuesday and it is considering cutting off Denmark. It’s already turned the taps off in Bulgaria, Poland and Finland. Dutch trader GasTerra said the move was announced after it refused Gazprom’s “one-sided payment requirements.” That's a reference to Russian President Vladimir Putin’s demand that European nations pay for gas in rubles — an arrangement many have refused. GasTerra said homes would not be hit as it had bought gas elsewhere in anticipation of a shutoff. Talks at EU headquarters in Brussels were set Tuesday to focus on ways to end the trading bloc’s dependence on Russian energy, by diversifying supplies and speeding up the transition to renewable sources and away, as much as possible given recent price hikes, from fossil fuels. The oil embargo, tied up in a new package of sanctions that will also target Russia's biggest bank and state media outlets accused of spreading propaganda, covers crude oil and petroleum products but has an exception for oil delivered by pipeline. Hungarian Prime minister Viktor Orban made clear that he could only support the new sanctions if his country’s oil supply security was guaranteed. Hungary gets more than 60% of its oil from Russia and depends on crude that comes through the Soviet-era Druzhba pipeline. The EU estimated that could mean around 90% of Russian oil — the majority of it brought into Europe by sea — is banned by the end of the year. As part of the measure, Germany and Poland agreed to stop using oil from the northern branch of the Druzhba pipeline. The sanctions package must still be finalized in the coming days. The leaders reached their compromise after Ukrainian President Volodymyr Zelenskyy urged them to end “internal arguments that only prompt Russia to put more and more pressure on the whole of Europe.” ___ Mike Corder in The Hague, Netherlands, contributed to this report.	https://www.12newsnow.com/article/news/nation-world/eu-russian-oil-ban/507-843b706b-bbe0-46fc-9d40-a33d0362a2d2	2022-05-31T12:44:04	en	0.970286
SYDNEY, May 31, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the GBM AGILE study in glioblastoma (NCT03970447) has opened recruitment to the paxalisib arm in Europe. University Hospital Zurich in Zurich, Switzerland, under the leadership of principal investigator and regional principal investigator of Europe, Dr Michael Weller, will join over 40 sites in the US and Canada that are currently recruiting to the paxalisib arm. This represents the first time that paxalisib has been the subject of clinical trial activity in Switzerland. Additional sites are expected to open in Switzerland, and in several other European countries, in the near future. Key Points - GBM AGILE is a multi-drug platform study, designed to identify promising new therapies for glioblastoma. It is sponsored by the Global Coalition for Adaptive Research (GCAR) and three drug candidates are currently participating: Bayer's regorafenib, Kazia's paxalisib, VAL-083 from Kintara Therapeutics. Two additional drug candidates will be starting in 2Q CY2022; Troriluzole from Biohaven Pharmaceuticals, and VG1021 from Vigeo Therapeutics. - The first US site opened to the paxalisib arm in January 2021, and the first Canadian site in November 2021. At present, over 40 sites are recruiting to the paxalisib arm. - University Hospital Zurich in Zurich, Switzerland, is the first European site to commence recruitment to the paxalisib arm, with additional sites in Switzerland and in several other European countries expected to come online during 1H CY2022. - Expansion of GBM AGILE to China is anticipated in 2Q or 3Q CY2022. Dr Michael Weller, Director of the Department of Neurology at University Hospital Zurich, commented, "We are very pleased to see the ongoing expansion in Europe of this very innovative clinical trial. There is a profound need for new treatment options in glioblastoma, and GBM AGILE has been designed to evaluate new therapies in the most efficient way possible. We look forward to making a significant contribution to the study, and to seeing results in due course." GBM AGILE The paxalisib arm of GBM AGILE is recruiting two groups of patients: newly diagnosed patients with the unmethylated MGMT promotor, a genetic marker that denotes near-total resistance to temozolomide, the existing FDA-approved standard of care, and recurrent patients who have progressed despite treatment with temozolomide. The paxalisib arm commenced recruitment in the United States in January 2021 and in Canada in November 2021. The primary endpoint of GBM AGILE is overall survival, which is considered the gold standard for the evaluation of new cancer therapies, and which is the preferred approval endpoint for regulators such as the US FDA. Kazia expects GBM AGILE to serve as the pivotal study for registration in key markets, including in the European Union. Patients recruited to the paxalisib arm will be compared against a shared control group. The duration of paxalisib's enrolment is initially estimated to be approximately 30-36 months, and final data is provisionally anticipated by the end of CY2023. About Kazia Therapeutics Limited Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in January 2021. Seven additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020. Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A phase I study commenced recruitment in November 2021. For more information, please visit www.kaziatherapeutics.com or follow us on Twitter @KaziaTx. This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Managing Director. SOURCE Kazia Therapeutics Limited	https://www.prnewswire.com/news-releases/gbm-agile-opens-to-paxalisib-in-europe-301557275.html	2022-05-31T12:44:04	en	0.940307
BRENTWOOD, Tenn. (AP) _ Kirkland's Inc. (KIRK) on Tuesday reported a fiscal first-quarter loss of $7.9 million, after reporting a profit in the same period a year earlier. On a per-share basis, the Brentwood, Tennessee-based company said it had a loss of 63 cents. Losses, adjusted for non-recurring costs, came to 62 cents per share. The home decor retailer posted revenue of $103.3 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on KIRK at https://www.zacks.com/ap/KIRK	https://www.theheraldreview.com/business/article/Kirkland-s-Fiscal-Q1-Earnings-Snapshot-17209004.php	2022-05-31T12:44:04	en	0.923737
Deborah Gallegos and Carlos Reyes Promoted to Co-Heads of ESG & Sustainability NEW YORK, May 31, 2022 /PRNewswire/ -- Palladium Equity Partners, LLC (along with its affiliates, "Palladium"), the oldest minority-owned private equity buyout firm in the industry, announced today it has launched the next phase of the firm's sustainability framework to further its mission to be a trusted manager recognized for delivering outstanding returns to all stakeholders. Following Palladium's recent certification as a B-Corp, Palladium today announced the promotion of Deborah Gallegos and Carlos Reyes, both Managing Directors, to lead the Firm's ongoing ESG initiatives as Co-Heads of ESG & Sustainability. Ms. Gallegos and Mr. Reyes will lead Palladium's ESG and sustainability efforts and advance its commitments as a UNPRI signatory and a founding signatory to both ILPA's Diversity in Action Initiative and the Data Convergence Project. Palladium has a robust ESG infrastructure focused on implementing a fully-integrated process for the identification and analysis of ESG factors that seek to drive value creation, reduce costs, and mitigate enterprise risk across the firm. The team has been instrumental in building the program, and will seek to further identify and manage ESG risks throughout the life cycle of Palladium's investments. Ms. Gallegos and Mr. Reyes' deep prior experience in both investment and investor roles has already brought a differentiating factor to Palladium's ESG program, as they are both already embedded into Palladium's funds and work closely with the investment teams and portfolio companies. Ms. Gallegos and Mr. Reyes bring decades of experience investing institutional assets. Ms. Gallegos has more than 25 years of investment experience, including serving as Chief Investment Officer of the New York City Comptroller and as Deputy State Investment Officer for the New Mexico State Investment Council. Mr. Reyes has more than 20 years of experience in private equity, sustainability/ESG, and corporate M&A. Prior to joining Palladium, Mr. Reyes worked at IFC Asset Management Company, a division of IFC – itself a member of the World Bank Group – where he was a Principal in IFC's $1.0 billion African, Latin American and Caribbean Fund, as well as Head of IFC Asset Management Company's Direct Equity Impact Fund. Marcos A. Rodriguez, Palladium's Chairman and CEO, said, "Both Deborah and Carlos are well suited for success in their new roles as Co-Heads of ESG & Sustainability. They are strong leaders who will help us implement the next phase of Palladium's sustainability framework, which we believe will accrue to the benefit of all our investors, our portfolio companies as well as our employees." Eugenie Cesar-Fabian, who formerly held the role of Head of ESG & Sustainability, will be transitioning out of the firm to pursue a senior legal role at a sustainability-focused fintech firm. She noted that, "Deborah and Carlos are exceptionally strong ESG professionals who have achieved significant success already in designing, building and implementing Palladium's internal ESG program. I believe their understanding and passion for ESG will support the firm's position as one of the leading industry voices in this area." Mr. Rodriguez added that, "Genie made a major contribution to Palladium during her decade-plus tenure at the firm. We appreciate her efforts and wish her all the best." Palladium is the oldest minority-owned private equity buyout firm in the industry with over $3 billion of assets under management. The firm seeks to acquire and grow companies in partnership with founders and experienced management teams by providing capital, strategic guidance and operational oversight. Since its founding in 1997, Palladium has invested over $3 billion of capital in 38 platform investments and 153 add-on acquisitions, realizing 23 of these platform investments. The principals of the firm have meaningful experience in consumer, services, industrials, and healthcare businesses, with a special focus on companies they believe will benefit from the growth in the U.S. Hispanic population. Palladium, which is a Certified B Corp, is based in New York City. For more information, visit www.palladiumequity.com. Todd Fogarty or Jeffrey Taufield Kekst CNC todd.fogarty@kekstcnc.com or jeffrey.taufield@kekstcnc.com View original content: SOURCE Palladium Equity Partners	https://www.wlbt.com/prnewswire/2022/05/31/palladium-promotes-two-managing-directors-broaden-firms-sustainability-framework/	2022-05-31T12:44:04	en	0.953203
PARIS, France — French authorities defended police on Monday for indiscriminately firing tear gas and pepper spray at Liverpool supporters at the Champions League final, while blaming industrial levels of fraud that saw 30,000 to 40,000 people try to enter the Stade de France with fake tickets or none at all. After a meeting into Saturday’s chaos, the ministers of the sport and the interior shifted responsibility onto the Liverpool fans while not providing details on how they were sure so many fake tickets were in circulation. People with legitimate tickets bought through Liverpool and UEFA reported struggling to access the stadium. “There was massive fraud at an industrial level and an organization of fake tickets because of the pre-filtering by the Stade de France and the French Football Federation, 70% of the tickets were fake tickets coming into the Stade de France,” Interior minister Gérald Darmanin said. "Fifteen percent of fake tickets also were after the first filtering ... more than 2,600 tickets were confirmed by UEFA as non-validated tickets even though they’d gone through the first filtering. “A massive presence of these fake tickets of course was the issue why there were delays, three times the beginning of the match was delayed.” UEFA launched an independent investigation into what caused the chaotic scenes and said the "comprehensive review will examine decision making, responsibility and behaviors of all entities involved in the final.” The final, which Liverpool lost 1-0 to Real Madrid, kicked off 37 minutes late. Tear gas and pepper spray was targeted at Liverpool fans, impacting children — a tactic defended by Darmanin to prevent deaths. “I’d like to thank the forces of law and order, also those who worked in the stadium because they were very calm and they were able to avoid drama and so thank you for organizing the pre-filtering but lifting it when there was too much pressure to avoid a drama," Darmanin said. “That was a decision made by the prefecture to avoid any kind of deaths or seriously injured." French Sports minister Amélie Ouéda-Castéra blamed fans arriving at the stadium late for the crowd control issues, but did not say when they should have arrived at the stadium on the outskirts of Paris. “We have seen, we have to improve in risky matches certain aspects with regard to managing the flows, first filtering, second filtering, and we have to make sure we look at electronic ticketing as closely as possible so we can avoid fraud as far as ticketing is concerned,” Ouéda-Castéra said. “That is something which is absolutely essential.” There was no apology for the conduct by authorities. “We are extremely sorry for all the people whose experience was wasted all that evening," Ouéda-Castéra said. "For the people who had bought tickets and were unable to attend the match. That’s why we have asked UEFA to really work on a compensation system for those people — 2,700, including British people — so that they get compensation.” UEFA did not raise the issue of compensating fans in its statement about its own investigation. “Evidence will be gathered from all relevant parties and the findings of the independent report will be made public once completed,” UEFA said, without giving a timeline. ___ AP Sports Writer Graham Dunbar in Geneva contributed to this report	https://www.12newsnow.com/article/news/nation-world/france-blames-ticket-fraud-for-champion-league-chaos/507-9eba3c18-79eb-4af2-837d-fd88ce8d91b3	2022-05-31T12:44:10	en	0.98146
LAKEWOOD, Colo. (AP) _ Mesa Laboratories Inc. (MLAB) on Tuesday reported a fiscal fourth-quarter loss of $1.8 million, after reporting a profit in the same period a year earlier. The Lakewood, Colorado-based company said it had a loss of 34 cents per share. Earnings, adjusted for amortization costs and stock option expense, came to $2.22 per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of $1.88 per share. The quality control instruments and disposable products maker posted revenue of $58.9 million in the period, which also beat Street forecasts. Three analysts surveyed by Zacks expected $55.5 million. For the year, the company reported profit of $1.9 million, or 35 cents per share. Revenue was reported as $184.3 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MLAB at https://www.zacks.com/ap/MLAB	https://www.theheraldreview.com/business/article/Mesa-Labs-Fiscal-Q4-Earnings-Snapshot-17209081.php	2022-05-31T12:44:10	en	0.952005
DUBLIN, May 31, 2022 /PRNewswire/ -- The "Global Interactive Kiosk Market with COVID-19 Impact by Offering (Hardware and Software & Services), Type (Bank Kiosks, Self-service Kiosks and Vending Kiosks), Location (Indoor and Outdoor), Panel Size, Vertical and Region - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering. The interactive kiosk market is projected to grow from USD 28.8 billion in 2022 and is projected to reach USD 39.1 billion by 2027; it is expected to grow at a CAGR of 6.3 % from 2022 to 2027. The growth of this market is driven by factors such as enhanced shopping experience for customers, rising demand for self-service in banking & financial services, enhanced applications over conventional services and innovations in touch screen display and glass technology. Market for banking & financial services vertical segment to grow at the highest CAGR during the forecast period. The interactive kiosk market for banking & financial services is expected to witness the highest growth during the forecast period. The growth of the interactive kiosk market for the banking sector is attributed to the ability of these kiosks to be cost-effective solutions, reducing manual tasks, and minimizing human errors to ensure fast and seamless performance. They are remote banking channels providing extra convenience to customers and saving service costs for banks. The growth of the interactive kiosk market for the banking & financial services sector is attributed to the ability of interactive kiosks to be cost-effective solutions, reducing manual tasks, and minimizing human errors to ensure fast and seamless performance. The key reason behind the growth of the interactive kiosk market is the rapidly expanding banking and financial services sector in developing countries such as India and China. Vending kiosks held the largest share of the interactive kiosk market in 2021 The vending kiosks held the largest share in the interactive kiosk market in 2021. Vending kiosks are installed in sectors such as transportation, hospitality, retail, and entertainment, as an effective way to reduce costs and increase customer satisfaction. For consumers, vending kiosks offer convenience as they can get required services instantly without standing in long queues. The increasing demand for vending machines and automated devices, technological advancements, and remote management are the factors driving the market for vending kiosks. These factors have led to the widespread adoption of self-service technology among the customers in rural, as well as urban areas. Outdoor kiosks expected to register the higher CAGR in the interactive kiosk market during the forecast period The market for outdoor interactive kiosks is expected to grow at a higher CAGR during the forecast period. This can be attributed to the growing popularity of these kiosks in amusement and theme parks, sporting events, and institutional premises may create opportunities for such kiosks. However, putting up an outdoor kiosk is more challenging as it can be prone to theft and fraud. Also, it should have a protection system against dust, rain, temperature, and humidity. Because of exposed placement, outdoor kiosks do have a more limited configurability for peripherals. Europe to hold a significant share of the data center interconnect market during the forecast period Europe is expected to hold a significantly large share for interactive kiosk market during the forecast period. Factors such as technological advancements and the trend of implementing self-service or automated technologies are driving the interactive kiosk market in Europe. Healthy economic conditions in European countries such as Germany, France, and the UK lead to favorable conditions for the implementation of interactive kiosk technology. Competitive Analysis Some key companies operating in the market are KIOSK Information Systems (US); Olea Kiosks (US); Frank Mayer and Associates, Inc. (US); Source Technologies (US); NCR Corporation (US); Diebold Nixdorf (US); Embross (Canada); Meridian Kiosks (US); REDYREF Interactive Kiosks (US); and Lilitab, LLC (US). Premium Insights - Asia-Pacific to be Fastest-Growing Market for Interactive Kiosks During Forecast Period - Market for Bank Kiosks to Grow at Highest CAGR During Forecast Period - Retail Vertical and Japan to be Largest Shareholders in Interactive Kiosk Market in Asia-Pacific in 2022 - Banking & Financial Services to Witness Highest CAGR in Interactive Kiosk Market During Forecast Period - US to Account for Largest Share of Interactive Kiosk Market in 2022 Market Dynamics Drivers - Strong Focus of Retailers to Provide Enhanced Shopping Experience to Customers to Increase Sales and Achieve Quick Return on Investment - Increased Deployment of Kiosks in Newer Applications to Improve Business Efficiency - Novel Innovations in Touchscreen Display and Smart Glass Technologies - Elevated Demand for Self-Service Machines by Customers from Banking and Finance Sector - Sudden Outbreak of COVID-19 Pandemic Restraints - High Installation Cost and Constant Need for Regular Maintenance, Coupled with Increased Risk of Theft - Substantial Increase in Cybercrime Opportunities - Increasing Emphasis on Integrating Advanced Technologies, Such as Ipa and Gps, in Kiosks - Rising Number of Smart Cities and Smart Infrastructure - Ongoing Innovations in Self-Service Kiosks - Growing Need to Emplace Interactive Kiosks for Physically Challenged Individuals Challenges - Growing Preference for Tablets and Mobile Kiosks for Online Shopping - Developing Kiosks Suitable for All-Weather Conditions for Outdoor Applications Value Chain Analysis - Research & Development (R&D) - Assembly and Manufacturing - Software Integration - Marketing & Sales - End Use/Application - Post-Sales Services Porters Five Force Analysis Case Study Analysis - Nutmeg State Fcu Used Source Technologies Kiosks to Enhance Dmv Express Experience - Antuar Integrated Source Technologies Self-Service Kiosk to Enhance Productivity - Maryland Mva Used Self-Service Kiosk to Improve Service Experience - Leading Global Food & Beverage Company Deployed Employment Kiosk to Efficiently Serve Its Employees - Trillium Health Resources Leveraged Temperature-Screening Kiosks Offered by Meridian Kiosks to Ensure Safety of Their Staff and Patients During COVID-19 Pandemic - Ikea Leveraged Retail Kiosk Platform Offered by Meridian Kiosks to Develop Its Instant Credit Solution Trends Impacting Businesses of Customers - Revenue Shift and New Revenue Pockets for Interactive Kiosk Manufacturers Technology Analysis - Integration of Artificial Intelligence (Ai) with Interactive Kiosks - Combining Contactless Technology with Interactive Kiosks - Integration of Facial Recognition with Interactive Kiosks Company Profiles Key Players - NCR Corporation - Diebold Nixdorf - Glory Limited - Kiosk Information Systems - Olea Kiosks Inc. - Frank Mayer and Associates, Inc. - Source Technologies - Embross - Meridian Kiosks - Redyref Interactive Kiosks - Lilitab, LLC Other Players - Kal - Acante Solutions Limited - Zebra Technologies Corporation - Slabbkiosks - Advantech Co., Ltd. - Intuiface - Verifone - Aila Technologies - Advanced Kiosks - Dynatouch - Peerless-Av - Lamasatech - Iqmetrix - Sita Aero - Shenzhen Lean Kiosk Systems Co.Ltd (Lks) - Viewpoint Interactive Solutions - Aidio - Xiphias Software Technologies - Grgbanking For more information about this report visit https://www.researchandmarkets.com/r/oa77j3 Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets	https://www.prnewswire.com/news-releases/global-39-billion-interactive-kiosk-bank-self-service-vending-markets-to-2027-increased-deployment-of-kiosks-in-newer-applications-to-improve-business-efficiency-301557697.html	2022-05-31T12:44:10	en	0.861276
Agreement of Sale for 11 outparcels fully executed Purchase and Sale Agreement for the hotel at Springfield Town Center fully executed for $2.5 million PHILADELPHIA, May 31, 2022 /PRNewswire/ -- PREIT (NYSE: PEI) (the "Company") announced execution of a purchase and sale agreement for 11 outparcels that will generate gross proceeds in excess of $32 million. The Company also executed an agreement of sale for a vacant parcel at Springfield Town Center set to be developed into a hotel site for $2.5 million as the Company executes on its vision of delivering one-stop destinations for the communities it serves. These transactions represent a portion of the asset sale pipeline referenced in conjunction with the Company's first quarter 2022 earnings release dated May 5, 2022 with $275 million of transactions in process. The Company expects that the outparcels will close in multiple phases with a portion closing prior to June 30, 2022. Closing on the hotel parcel is anticipated to occur in the fourth quarter of 2022. "Our plan to raise capital is materializing as a result of a portfolio that is thriving due to our efforts to bring in dynamic and compelling uses and our optimally-located platform," said Joseph F. Coradino, Chairman and CEO of PREIT. "We have a clear mandate to raise capital and improve our balance sheet and we are unwavering in our commitment to generate results. As new opportunities continue to arise, we are confident we can strategically harvest value from our portfolio to reduce debt." As noted during the Company's Q1 2022 earnings call, the Company continues to anticipate it will close on asset sales totaling approximately $109 million in gross proceeds by June 30, 2022. About PREIT PREIT (NYSE:PEI) is a publicly traded real estate investment trust that owns and manages innovative properties developed to be thoughtful, community-centric hubs. PREIT's robust portfolio of carefully curated, ever-evolving properties generates success for its tenants and meaningful impact for the communities it serves by keenly focusing on five core areas of established and emerging opportunity: multi-family & hotel, health & tech, retail, essentials & grocery and experiential. Located primarily in densely-populated regions, PREIT is a top operator of high quality, purposeful places that serve as one-stop destinations for customers to shop, dine, play and stay. Additional information is available at www.preit.com or on Twitter, Instagram or LinkedIn. Forward Looking Statements This press release contains certain forward-looking statements that can be identified by the use of words such as "anticipate," "believe," "estimate," "expect," "project," "intend," "may" or similar expressions. Forward-looking statements relate to expectations, beliefs, projections, future plans, strategies, anticipated events, trends and other matters that are not historical facts. These forward-looking statements reflect our current expectations and assumptions regarding our business, the economy and other future events and conditions and are based on currently available financial, economic and competitive data and our current business plans. Actual results could vary materially depending on risks, uncertainties and changes in circumstances that may affect our operations, markets, services, prices and other factors as discussed in the Risk Factors section of our other filings with the Securities and Exchange Commission. While we believe our assumptions are reasonable, we caution you against relying on any forward-looking statements as it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, the effectiveness of strategies we may employ to address our liquidity and capital resources in the future, our ability to achieve our forecasted revenue and pro forma leverage ratio and generate free cash flow to further reduce our indebtedness; our ability to manage our business through the impacts of the COVID-19 pandemic, a weakening of global economic and financial conditions, changes in governmental regulations and related compliance and litigation costs and the other factors listed in our SEC filings. Additionally, our business might be materially and adversely affected by changes in the retail and real estate industries, including bankruptcies, consolidation and store closings, particularly among anchor tenants; current economic conditions, including consumer confidence and spending levels and supply chain challenges and the impact of the COVID-19 pandemic and the public health and governmental response as well as the corresponding effects on tenant business performance, prospects, solvency and leasing decisions; our inability to collect rent due to the bankruptcy or insolvency of tenants or otherwise; our ability to maintain and increase property occupancy, sales and rental rates; increases in operating costs that cannot be passed on to tenants; the effects of online shopping and other uses of technology on our retail tenants; risks related to our development and redevelopment activities, including delays, cost overruns and our inability to reach projected occupancy or rental rates; social unrest and acts of vandalism and violence at malls, including our properties, or at other similar spaces, and the potential effect on traffic and sales; the frequency, severity and impact of extreme weather events at or near our properties; our ability to sell properties that we seek to dispose of or our ability to obtain prices we seek; our substantial debt and the liquidation preference of our preferred shares and our high leverage ratio and our ability to remain in compliance with our financial covenants under our debt facilities; our ability to refinance our existing indebtedness when it matures, on favorable terms or at all; our ability to raise capital, including through sales of properties or interests in properties and through the issuance of equity or equity-related securities if market conditions are favorable; and potential dilution from any capital raising transactions or other equity issuances. Additional factors that might cause future events, achievements or results to differ materially from those expressed or implied by our forward-looking statements include those discussed herein, and in the sections entitled "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2020. We do not intend to update or revise any forward-looking statements to reflect new information, future events or otherwise. Contact: Heather Crowell heather@gregoryfca.com preit@gregoryfca.com View original content to download multimedia: SOURCE PREIT	https://www.wlbt.com/prnewswire/2022/05/31/preit-executes-purchase-sale-agreements-35-million/	2022-05-31T12:44:10	en	0.940391
WASHINGTON — As the U.S. mourns the victims of its latest mass shooting — 19 elementary school students and two teachers gunned down in Texas — Democratic governors are amplifying their calls for greater restrictions on guns. Many Republican governors are emphasizing a different solution: more security at schools. The divide among the nation's governors mirrors a partisan split that has stymied action in Congress and many state capitols over how best to respond to a record-high number of gun-related deaths in the U.S. The political differences tap deep into the country's roots, highlighting the tensions between life, liberty and the constitutional rights spelled out in the nation's founding documents. After the massacre Tuesday at Robb Elementary School in Uvalde, Texas, The Associated Press asked governors across the U.S. whether they believed their states have an obligation to reduce mass shootings and violence committed with guns and, if so, how to do that. About half the governor's offices responded to the AP. There was agreement that they had a responsibility to try to do something. Democrats and Republicans alike mentioned the need to invest in mental health services and training to try to help people potentially prone to a violent outburst. But the commonality generally ended after that. Should people younger than 21 be prohibited from buying semi-automatic guns? Should ammunition magazines be limited to no more than 10 bullets? Many Democratic governors said “yes.” “If you’re not serious about guns, you’re not serious about crime prevention. I think that’s more true today than ever before," said Democratic Gov. Ned Lamont of Connecticut, where 20 students and six adults were killed at Sandy Hook Elementary School a decade ago. Pennsylvania Gov. Tom Wolf said he supports limits on both bullet capacities and the purchase of semi-automatic weapons. He rallied Friday with gun-control advocates in Philadelphia while denouncing his state's Republican-led Legislature for not passing his gun proposals. “They would rather cave in cravenly to the gun manufacturing lobby than pass commonsense legislation that would keep children from dying,” Wolf said. Among Republican governors who responded to the AP, only Vermont Gov. Phil Scott expressed support for such gun control efforts. Scott signed a law in 2018 limiting the capacity of firearm magazines and raising the general age to buy guns to 21, with exceptions for 18- to 20-year-olds who undergo a firearms safety course. Other Republican governors either sidestepped the AP's questions about specific gun-control measures or said they opposed them. Alaska Gov. Mike Dunleavy was a firm “no” on setting bullet limits or age restrictions that could infringe on constitutional rights. “Stricter gun laws are not a solution to this problem – we must focus our attention on the status of mental health in our communities,” Dunleavy's office said in email. Ohio Gov. Mike DeWine said he would not endorse such gun-control proposals, because he believes they have no chance of passing in the state's GOP-led Legislature. DeWine, a Republican, instead proposed spending “a significant amount of money” on efforts to ensure schools are protected against potential attacks. He didn't outline exactly what that security would entail. Republican governors were more likely to support efforts to strengthen security at schools. The AP asked about proposals to arm teachers and staff with firearms, add security guards or secure schools with such things as metal detectors and fencing. During a speech Friday to the National Rifle Association convention in Houston, Republican Gov. Kristi Noem of South Dakota denounced calls for gun-control as “garbage” and embraced greater school security measures “Why do we protect our banks, our stores and celebrities with armed guards but not our children? Are they not truly our greatest treasure?” Noem said. Republican Gov. Kim Reynolds of Iowa also laid out a variety of potential school safety steps while talking to reporters Friday. “It’s looking for ways to harden schools, it’s talking about having conversations about state resource officers,” she said, later adding: "Maybe a single entrance into the school system and making sure educators are trained.” While dismissing proposals to restrict gun ownership, Indiana Gov. Eric Holcomb said the solution is to “focus on the individual problems” and to continue providing grants to schools for security upgrades. “You might call it hardening them when children are in their classroom,” said Holcomb, a Republican. Some Democrats also support funding for specially trained police known as school resources officers, or improving the security of buildings. But none of the Democratic governors who responded to the AP's questions supported arming teachers or staff to deter or stop attacks. Wisconsin Gov. Tony Evers — a Democrat who is a former teacher, school superintendent and state education chief — said he's concerned that arming teachers would make schools more dangerous. Placing additional security guards or police at every school building could be both impractical and counterproductive, he said. “There’s not enough people to do it,” Evers said, “and I’m not sure we want to turn our learning institutions into armed camps.” ___ Associated Press writers Scott Bauer in Madison, Wisconsin; Tom Davies in Indianapolis; Susan Haigh in Hartford, Connecticut; David Pitt in Des Moines, Iowa; Andrew Welsh-Huggins in Columbus, Ohio; and AP statehouse reporters from across the U.S. contributed to this report.	https://www.12newsnow.com/article/news/nation-world/governors-different-positions-on-gun-control-school-security/507-fc705e22-43dc-491e-9d6e-15faaa6e7b8b	2022-05-31T12:44:16	en	0.966009
DUBLIN, May 31, 2022 /PRNewswire/ -- The "Global Commercial Aircraft Interiors Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. This study analyses the global commercial aircraft cabin interiors market for the period 2021 to 2032, including the impact of the COVID-19 pandemic on market dynamics. The market forecasts are divided between revenue streams (linefit, retrofit, and aftermarket) and segments (seating, lavatory, galley, and other equipment) to provide insightful dimensions about how each factor contributes to total market revenue. Research on aircraft deliveries indicates that by 2032, the total number of aircraft delivered to lessors and airlines will total more than 22,000 units. Linefit market performance per year largely reflects the aircraft deliveries completed within that year. This is the highest contributing revenue stream at 58.3% of the total market; similarly, the seating segment contributes almost 56.2% of the total market. Both industry and stakeholder sustainability are important focus areas in this report. Commercial aircraft cabins have seen major innovations, especially focused on controlling the spread of COVID-19 within the shared aircraft interior. While the focus of innovations has largely been on this safety aspect, the industry's long-term sustainability goals and its multiple stakeholders (e.g., OEMs, suppliers, and aircraft operators [airlines and lessors]) are also considered when discussing innovations. The key technological growth opportunities seen for this market are discussed, such as a new method of additive manufacturing and the use Internet of Things (IoT) devices in the cabin. Industry trends including market consolidation are covered with a focus on growth perspective. Key Topics Covered: 1. Strategic Imperatives - Why is it Increasingly Difficult to Grow? - The Strategic Imperative - The Impact of the Top 3 Strategic Imperatives on the Commercial Aircraft Interiors Industry - Growth Opportunities Fuel the Growth Pipeline Engine 2. Growth Opportunity Analysis - Scope of Analysis - Segmentation - Market Structure - Key Competitors - Key Growth Metrics - Growth Drivers - Growth Driver Analysis - Growth Restraints - Growth Restraint Analysis - Forecast Assumptions - Aircraft Deliveries Forecast - Aircraft Deliveries Forecast by Platform Type - Aircraft Deliveries Forecast Analysis - Revenue Forecast - Revenue Forecast by Revenue Stream - Revenue Forecast by Segment - Revenue Forecast Analysis - Revenue Forecast by Revenue Stream Analysis - Revenue Forecast by Segments Analysis - Competitive Environment - Revenue Share - Revenue Share Analysis 3. Growth Opportunity Analysis - Seating Segment - Key Growth Metrics - Revenue Forecast - Revenue Forecast by Revenue Stream - Seating Segment Forecast by Revenue Stream Analysis 4. Growth Opportunity Analysis - Lavatory Segment - Key Growth Metrics - Revenue Forecast - Revenue Forecast by Revenue Stream - Lavatory Segment Forecast by Revenue Stream Analysis 5. Growth Opportunity Analysis - Galley Segment - Key Growth Metrics - Revenue Forecast - Revenue Forecast by Revenue Stream - Galley Segment Forecast by Revenue Stream Analysis 6. Growth Opportunity Analysis - Other Equipment Segment - Key Growth Metrics - Revenue Forecast - Revenue Forecast by Revenue Stream - OE Segment Forecast by Revenue Stream Analysis 7. Sustainability - The Role of Interiors Market Stakeholders in Reducing CO2 Emissions - CO2 Emissions by Seating Class - Stakeholder Sustainability Avenues - OEMs and Suppliers - Stakeholder Sustainability Avenues - Aircraft Operators and Airlines 8. Aircraft Cabin - New Lightweight Materials with Potential Uses in Aircraft Interiors - Innovations in Seating - Passenger Comfort - Innovations for Lavatories - Innovations for the Galley - Air Quality Monitoring and Purification Systems for the Cabin - Lighting Systems for the Cabin - Future Outlook 9. Growth Opportunity Universe - Commercial Aircraft Cabin Interiors - Growth Opportunity 1: Additive Manufacturing (Fused Filament Fabrication Process) for Incorporating Durable and Lighter Materials in the Cabin - Growth Opportunity 2: Implementing IoT Applications and Concepts to Improve Passenger Experience and Reduce Crew Workload - Growth Opportunity 3: M&As of Promising Start-ups for Business Growth, New Product Development, and Faster Integration - Growth Opportunity 4: Implementation and Promotion of Novel Cabin Cleaning and Hygiene Maintenance Solutions for Increasing Customer Attraction and Safety Assurance 10. Appendix - List of Additional Companies Involved in Interiors Market For more information about this report visit https://www.researchandmarkets.com/r/egk889 Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets	https://www.prnewswire.com/news-releases/global-commercial-aircraft-interiors-market-report-2022-2032-focus-on-sustainability-and-new-technologies-power-innovation-culture-301557741.html	2022-05-31T12:44:16	en	0.844377
HAMILTON HM 11, Bermuda (AP) _ Nordic American Tankers Ltd. (NAT) on Tuesday reported a loss of $27 million in its first quarter. The Hamilton Hm 11, Bermuda-based company said it had a loss of 14 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 11 cents per share. The tanker company posted revenue of $15.5 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NAT at https://www.zacks.com/ap/NAT	https://www.theheraldreview.com/business/article/Nordic-American-Tankers-Q1-Earnings-Snapshot-17209043.php	2022-05-31T12:44:16	en	0.948902
MELVILLE, N.Y., May 31, 2022 /PRNewswire/ -- Professional Physical Therapy, a leading provider of outpatient physical therapy and rehabilitation services throughout New York, New Jersey, Connecticut, Massachusetts, and New Hampshire, announces today the acquisition of Somerset Family PT in Somerset, NJ. The addition of this clinic elevates Professional's footprint in New Jersey to more than 60 locations and over 200 locations in the Northeast. Somerset Family Physical Therapy, a private orthopedic clinic was started in 2004 by Kevin Kurtz, MPT and Eileen Kurtz, PT. Patients at the Somerset location, located at 14 Worlds Fair Drive, will now be able to experience the expanded benefits of being Professional Physical Therapy clinic, including added convenience with access to more locations, telehealth certified clinicians, extended hours, and most notably, in-network status with most major insurances. Steve Schneider, CEO of Professional states, "It is critical to us that our partners share the same values as we have, and that is clearly the case with Kevin and his team. We are proud to welcome them to the Professional Physical Therapy family. We are excited to continue on an exciting year of growth." Kevin Kurtz will stay with the practice as Clinic Director. He has been practicing as a physical therapist for over 10 years and specializes in orthopedics, post-operative care, and work injuries. "Kevin and his team have earned an excellent reputation for clinical care, patient service, and professionalism in the Somerset market, and we are thrilled to partner with them," says Tom Doherty, VP Mergers & Acquisitions. As Professional Physical Therapy continues to be a top provider in the region, expansion and growth are still among the top priorities for its leadership. Professional's latest acquisition in Somerset reflects their ongoing commitment to providing world-class patient care. For more information and a list of all Professional Physical Therapy locations and services, please visit http://www.professionalpt.com. About Professional Physical Therapy Professional Physical Therapy was founded in 1999 and is an industry leader, providing private outpatient physical and hand therapy services throughout the Northeast. Our clinical team is comprised of multi-specialty Physical, Hand and Occupational Therapists who can treat a wide variety of orthopedic injuries and conditions with excellence. Today, Professional has grown to include over 190 facilities in New York, New Jersey, Connecticut, Massachusetts, and New Hampshire. View original content to download multimedia: SOURCE Professional Physical Therapy	https://www.wlbt.com/prnewswire/2022/05/31/professional-physical-therapy-acquires-somerset-family-pt/	2022-05-31T12:44:17	en	0.943741
LONDON, UK — The World Health Organization’s top monkeypox expert said she doesn’t expect the hundreds of cases reported to date to turn into another pandemic, but acknowledged there are still many unknowns about the disease, including how exactly it’s spreading and whether the suspension of mass smallpox immunization decades ago may somehow be speeding its transmission. In a public session on Monday, WHO's Dr. Rosamund Lewis said it was critical to emphasize that the vast majority of cases being seen in dozens of countries globally are in gay, bisexual or men who have sex with men, so that scientists can further study the issue. She urged those at risk to be careful. “It’s very important to describe this because it appears to be an increase in a mode of transmission that may have been under-recognized in the past,” said Lewis. “At the moment, we are not concerned about a global pandemic,” she said. “We are concerned that individuals may acquire this infection through high-risk exposure if they don’t have the information they need to protect themselves.” She warned that anyone is at potential risk for the disease, regardless of their sexual orientation. Other experts have pointed out that it may be accidental that the disease was first picked up in gay and bisexual men, saying it could quickly spill over into other groups if it is not curbed. Last week, WHO said 23 countries that haven't previously had monkeypox have now reported more than 250 cases. On Monday, the U.K. announced another 71 monkeypox cases. Lewis said it’s unknown whether monkeypox is being transmitted by sex or just the close contact between people engaging in sexual activity and described the threat to the general population as “low.” Monkeypox is known to spread when there is close physical contact with an infected person, their clothing or bedsheets. She also warned that among the current cases, there is a higher proportion of people with lesions that are more concentrated in the genital region and sometimes nearly impossible to see. “You may have these lesions for two to four weeks (and) they may not be visible to others, but you may still be infectious," she said. Last week, a top adviser to WHO said the monkeypox outbreak in Europe, U.S., Israel, Australia and beyond was likely linked to sex at two recent raves in Spain and Belgium. That marks a significant departure from the disease’s typical pattern of spread in central and western Africa, where people are mainly infected by animals like wild rodents and primates. Scientists haven't yet determined whether the monkeypox outbreak in rich countries can be traced to Africa, but the disease continues to sicken people on the continent. On Monday, Nigerian authorities confirmed the country's first monkeypox death this year, in addition to six more cases. WHO says thousands of cases are reported from Nigeria and Congo every year. Most monkeypox patients experience only fever, body aches, chills and fatigue. People with more serious illness may develop a rash and lesions on the face and hands that can spread to other parts of the body. No deaths have been reported in the current outbreak beyond Africa. WHO's Lewis also said while previous cases of monkeypox in central and western Africa have been relatively contained, it was not clear if people could spread monkeypox without symptoms or if the disease might be airborne, like measles or COVID-19. Monkeypox is related to smallpox, but has milder symptoms. After smallpox was declared eradicated in 1980, countries suspended their mass immunization programs, a move that some experts believe may be helping monkeypox spread now, since there is now little widespread immunity to related diseases. Smallpox vaccines are also protective against monkeypox. Lewis said it was also uncertain how much immunity people who were previously vaccinated against smallpox might still have, since that was at least more than four decades ago. She said WHO's priority was to stop the current spread of monkeypox before the disease became entrenched in new regions. “If we all react quickly and we all work together, we will be able to stop this," she predicted. "We will be able to stop it before it reaches more vulnerable people and before it establishes itself as a replacement for smallpox.” ___ Chinedu Asadu in Abuja, Nigeria, contributed to this report.	https://www.12newsnow.com/article/news/nation-world/monkeypox-and-unknowns/507-33fa511d-dd4e-46cc-b967-a89c3a767b1b	2022-05-31T12:44:22	en	0.972411
DUBLIN, May 31, 2022 /PRNewswire/ -- The "Diaphragm Pumps Market by Mechanism (Air Operated and Electrically Operated), Operation (Single Acting and Double Acting), Discharge Pressure (Up to 80 Bar, 81 to 200 Bar & above 200 Bar), End User and Region - Global Trends & Forecast to 2027" report has been added to ResearchAndMarkets.com's offering. The diaphragm pumps market is projected to reach USD 7.6 billion by 2027 from an estimated USD 6.1 billion in 2022, at a CAGR of 4.5% The global diaphragm pumps market has a promising growth potential driven primarily by factors such as the growth of the water and wastewater treatment industry, as well as the spurt in oil & gas activities globally. A diaphragm pump is a type of positive displacement pump which consists of one or more pumping chambers alternately filled and discharged by the movement of a flexible diaphragm. Hence, liquid flows inside a diaphragm pump with cyclic flow. This cyclic action of the pump creates pulses in the discharge, with the fluid accelerating during the compression/discharge phase and slowing during the suction phase. This pulsation is undesirable and can cause vibrations which may cause catastrophic components or entire pumping system failure. Pulsation dampeners are commonly employed to limit a diaphragm pump's pulsation but they cannot eliminate it. Diaphragm pumps can also be used in sequence to mitigate the pulsation problem to an extent. However, both these remedies result in an additional cost for pump users. The undesirable effect of pulsation, as a result, is expected to hamper the growth of the diaphragm pumps market. The double-acting segment, by operation, is expected to be the fastest-growing market from 2022 to 2027 The operation segment is categorized into single-acting, and double-acting diaphragm pumps. The double-acting diaphragm pumps segment held the largest share of the diaphragm pumps market and is expected to grow at the fastest CAGR. Double-acting diaphragm pumps utilize two flexible diaphragms and two sets of valves. Compressed air or electric motor is utilized to alternately drive the two diaphragms of the pump. These pumps have a good suction lift, as well viscous fluid handling capabilities. Compared to single-acting diaphragm pumps, these pumps provide a smoother flow with low pulsation making them more desirable. These advantages will fuel the fast growth of the double-acting segment shortly. The up to 80 Bar segment, by discharge pressure, is expected to be the largest market from 2022 to 2027 The up to 80 Bar segment held the largest market share of the diaphragm pumps market in 2021. The above 80 Bar diaphragm pumps find applications in a wide range of industries, including, water & wastewater, food & beverage, chemicals, pharmaceuticals, pulp, and paper industry, amongst others. The up to 80 Bar diaphragm pumps are also primarily used for metering and dosing applications in the chemicals and pharmaceuticals industry. The growth of this segment, hence, can be attributed to the high demand for diaphragm pumps in the water & wastewater, pharmaceuticals, chemicals, and food & beverage industries. Asia Pacific: The largest and the fastest-growing region in the diaphragm pumps market Asia Pacific is expected to dominate the global diaphragm pumps market and is expected to grow at the highest CAGR between 2022-and 2027 The growth of the regional market is driven by increasing investments and government incentives in the water and wastewater industry in countries like China and India. Also, the region is experiencing increased investments in the mining, pharmaceuticals, and chemicals sectors with the region accounting for the largest global chemicals sales in 2021, further driving the growth of the diaphragm pumps market in the region. Competitive Analysis The major manufacturers and service providers in the diaphragm pumps market are PSG (US), IDEX Corporation (US), Ingersoll Rand Inc. (US), Flowserve Corporation (US), Xylem, Inc. (US), Yamada Corporation (Japan), Lewa GmbH (Germany), SPX FLOW (US), Tapflo AB (Sweden), Wanner Engineering (US), and Grundfos Holding A/S (Denmark). Premium Insights - Growth of Water & Wastewater Treatment Industry and Increased in Oil & Gas Activities Expected to Drive Market - Market in Asia-Pacific Projected to Grow at Highest CAGR During Forecast Period - Water & Wastewater Segment and China Held Largest Share of Market in Asia-Pacific - Air Operated Diaphragm Pumps Expected to Account for Larger Share by 2027 - Double Acting Segment Projected to Dominate Market - Up to 80 Bar Segment Expected to Hold Largest Share of Market - Water & Wastewater Segment to Dominate Diaphragm Pumps Market Market Dynamics Drivers - Growth of Water & Wastewater Treatment Industry - Spurt in Oil & Gas Activities Restraints - Undesirable Effects of Pulsation - Poor Efficiency When Pumping Fluids with Particulates Opportunities - Growth of Pharmaceutical Industry Challenges - Decrease in Coal Mining Activity - COVID-19 Impact - Trends/Disruptions Impacting Customers' Businesses - Revenue Shift and New Revenue Pockets for Diaphragm Pump Providers Market Map - Value Chain Analysis - Raw Material Providers/Suppliers - Component Manufacturers - Diaphragm Pump Manufacturers/Assemblers - Distributors (Buyers)/End-Users - Post-Sales Services Technology Analysis - IoT-Connected Diaphragm Pumps - Smart Electric Diaphragm Pumps Case Study Analysis - A North American Food Company Producing Chocolates Improved Food Safety by Deploying Sandpiper Fda Compliant Pumps - Indochem, a Leader in Solvent Production, Optimizes Production Rates and Air Consumption in Solvent Manufacturing by Using Aodd Pump from Wilden - A Major Kraft Pulp Mill Producing Pulp and Paper Safely Empties Sump of Hazardous Wastewater with Sandpiper Aodd Pump - A Large Soda Bottling Syrup Plant Saved USD 26,806 and Resolved Multiple Challenges with the Help of Aro Sd20S Fda Compliant Diaphragm Pump Company Profiles Key Players - Ingersoll Rand Inc. - PSG - Idex Corporation - Flowserve Corporation - Xylem, Inc. - Yamada Corporation - Lewa Gmbh - Verder International B.V. - Grundfos Holding A/S - Tapflo AB - Uraca - Spx Flow - Kimray, Inc. - Sandpiper Pump - Wanner Engineering, Inc. Other Players - Dr. Jessberger Gmbh - Price Pump - Wenzhou Kaixin Pump Co. Ltd - Serfilco - Versamatic For more information about this report visit https://www.researchandmarkets.com/r/unkr3v About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets	https://www.prnewswire.com/news-releases/global-diaphragm-pumps-market-report-2022-2027-featuring-major-manufacturers---psg-idex-ingersoll-rand-flowserve-xylem-yamada-lewa-spx-flow-tapflo-wanner-engineering-and-grundfos-301557701.html	2022-05-31T12:44:22	en	0.887834
This is a carousel. Use Next and Previous buttons to navigate Celebrity birthdays for the week of June 5-11: June 5: Actor-singer Bill Hayes (“Days of Our Lives,” “Your Show of Shows”) is 97. News correspondent Bill Moyers is 88. Country singer Don Reid of the Statler Brothers is 77. Guitarist Fred Stone of Sly and the Family Stone is 75. Singer-performance artist Laurie Anderson is 75. Country singer Gail Davies is 74. Financial expert Suze Orman (“The Suze Orman Show”) is 71. Drummer Nicko McBrain of Iron Maiden is 70. Jazz drummer Peter Erskine (Steps Ahead, Weather Report) is 68. Saxophonist Kenny G is 66. Singer Richard Butler of Psychedelic Furs is 66. Actor Beth Hall (“Mom,” ″Mad Men”) is 64. Actor Jeff Garlin (“The Goldbergs,” ″Curb Your Enthusiasm”) is 60. Actor Ron Livingston (“Sex and the City,” ″The Practice”) is 55. Singer Brian McKnight is 53. Musician Claus Norreen (Aqua) is 52. Actor-singer Mark Wahlberg is 51. Actor Chad Allen (“Dr. Quinn, Medicine Woman”) is 48. Bassist P-Nut of 311 is 48. Actor Navi Rawat (“Numb3rs”) is 45. Actor Liza Weil (“How To Get Away With Murder,” ″Gilmore Girls”) is 45. Bassist Pete Wentz of Fall Out Boy is 43. Guitarist Seb Lefebvre of Simple Plan is 41. Actor Chelsey Crisp (“Fresh Off The Boat”) is 39. Actor Amanda Crew (“Silicon Valley”) is 36. Musician Harrison Mills of Odesza is 33. Musician DJ Mustard is 32. Actor Sophie Lowe (“Once Upon a Time in Wonderland”) is 32. Actor Hank Greenspan (“The Neighborhood”) is 12. June 6: Singer-songwriter Gary “U.S.” Bonds is 83. Country singer Joe Stampley is 79. Jazz pianist Monty Alexander is 78. Actor Robert Englund (Freddie Krueger) is 75. Singer Dwight Twilley is 71. Playwright-actor Harvey Fierstein is 70. Actor-comedian Sandra Bernhard is 67. Actor Amanda Pays is 63. Record producer and musician Jimmy Jam (The Time) is 63. Comedian Colin Quinn is 63. Guitarist Steve Vai is 62. Singer-bassist Tom Araya of Slayer is 61. Actor Jason Isaacs (“Harry Potter” films) is 59. Bassist Sean Ysealt (White Zombie) is 56. Actor Max Casella (“Analyze This,” ″Doogie Howser, M.D.”) is 55. Actor Paul Giamatti is 55. Singer Damion Hall of Guy is 54. Guitarist James “Munky” Shaffer of Korn is 53. Country singer Lisa Brokop is 49. Singer Uncle Kracker is 48. Actor Sonya Walger (“Lost”) is 48. Actor Staci Keanan (“Step By Step,” ″My Two Dads”) is 47. Jazz singer Somi is 46. Actor Aubrey Anderson-Emmons (“Modern Family”) is 15. June 7: Actor Virginia McKenna (“Born Free”) is 91. Singer Tom Jones is 82. Talk show host Jenny Jones is 76. Actor Liam Neeson is 70. Actor Colleen Camp (“Die Hard: With A Vengeance”) is 69. Actor William Forsythe is 67. Record producer L.A. Reid is 66. Latin pop singer Juan Luis Guerra is 65. Singer-guitarist Gordon Gano of Violent Femmes is 59. Drummer Eric Kretz of Stone Temple Pilots is 56. Guitarist Dave Navarro is 55. Actor Helen Baxendale (“Friends”) is 52. Actor Karl Urban (2009′s “Star Trek”) is 50. TV personality Bear Grylls (“Man Vs. Wild”) is 48. Guitarist-keyboardist Eric Johnson of The Shins is 46. Actor Adrienne Frantz (“The Bold and the Beautiful,” “The Young and the Restless”) is 44. Comedian Bill Hader (“The Mindy Project,” ″Saturday Night Live”) is 44. Actor Anna Torv (“Fringe”) is 43. Actor Larisa Oleynik (“3rd Rock From The Sun,” ″Boy Meets World) is 41. Actor Michael Cera (“Juno,” ″Arrested Development”) is 34. Actor Shelley Buckner (“Summerland”) is 33. Rapper Iggy Azalea is 32. Model-actor Emily Ratajkowski (“Gone Girl”) is 31. Rapper Fetty Wap is 31. June 8: Actor James Darren is 86. Singer Nancy Sinatra is 82. Singer Chuck Negron (Three Dog Night) is 80. Singer Boz Scaggs is 78. Actor Sonia Braga is 72. Actor Kathy Baker (“Picket Fences”) is 72. Singer Bonnie Tyler is 71. Actor Griffin Dunne is 67. “Dilbert” cartoonist Scott Adams is 65. Actor-director Keenan Ivory Wayans is 64. Singer Mick Hucknall of Simply Red is 62. Keyboardist Nick Rhodes of Duran Duran is 60. Singer Doris Pearson of Five Star is 56. Actor Julianna Margulies (“The Good Wife,” ″ER”) is 55. Actor Dan Futterman (“Judging Amy”) is 55. Actor David Sutcliffe (“Private Practice,” “Gilmore Girls”) is 53. Actor Kent Faulcon (“Tyler Perry’s For Better or Worse”) is 52. Singer Nicci Gilbert of Brownstone is 52. Actor Kelli Williams (“The Practice”) is 52. Actor Mark Feuerstein (“West Wing,” ″Good Morning, Miami”) is 51. Guitarist Mike Scheuchzer of MercyMe is 47. Actor Eion Bailey (“Once Upon a Time”) is 46. Rapper Ye (formerly Kanye West) is 45. Singer-songwriter Sturgill Simpson is 44. Guitarist Derek Trucks (Allman Brother Band, Tedeschi Trucks Band) is 43. Singer Alex Band of The Calling is 41. Fiddler Sara Watkins of Nickel Creek is 41. Actor Torrey DeVitto (“Pretty Little Liars”) is 38 June 9: Sports commentator Dick Vitale is 83. Guitarist Mick Box of Uriah Heep is 75. Film composer James Newton Howard is 71. Actor Michael J. Fox is 61. Actor Johnny Depp is 59. Actor Gloria Reuben (“The Agency,” ″ER”) is 58. Singer-actor Tamela Mann (“Meet The Browns,” ″Medea” films) is 56. Bassist Dean Felber of Hootie and the Blowfish is 55. Bassist Dean Dinning (Toad the Wet Sprocket) is 55. Musician Ed Simons of the Chemical Brothers is 52. Actor Keesha Sharp (“Lethal Weapon”) is 49. Singer Jamie Dailey of Dailey and Vincent is 47. Actor Michaela Conlin (“Bones”) is 44. Actor Natalie Portman is 41. Actor Mae Whitman (“Parenthood,” ″Arrested Development”) is 34. Actor Lucien Laviscount (“Scream Queens”) is 30. June 10: Actor Alexandra Stewart (“Under the Cherry Moon”) is 83. Singer Shirley Alston Reeves of The Shirelles is 81. Actor Jurgen Prochnow (“The English Patient,” “Das Boot”) is 81. Actor Frankie Faison (“The Village,” “The Wire”) is 73. Actor Andrew Stevens (“Dallas”) is 67. Bassist Kim Deal of The Pixies and The Breeders is 61. Singer Maxi Priest is 61. Actor Gina Gershon is 60. Actor Jeanne Tripplehorn is 59. Drummer Jimmy Chamberlin of Smashing Pumpkins is 58. Actor Kate Flannery (“The Office”) is 58. Model-actor Elizabeth Hurley is 57. Guitarist Joey Santiago of The Pixies is 57. Actor Doug McKeon (“On Golden Pond”) is 56. Guitarist Emma Anderson (Lush) is 55. Country guitarist Brian Hofeldt of The Derailers is 55. Rapper The D.O.C. is 54. Singer Mike Doughty (Soul Coughing) is 52. Singer JoJo of K-Ci and JoJo is 51. Singer Faith Evans is 49. Actor Hugh Dancy is 47. Singer Lemisha Grinstead of 702 is 44. Actor DJ Qualls (“Memphis Beat,” ″Hustle and Flow”) is 44. Actor Shane West (“ER,” ″Now and Again”) is 44. Country singer Lee Brice is 43. Singer Hoku is 41. Actor Leelee Sobieski is 40. Bassist Bridget Kearney of Lake Street Dive is 37. Actor Titus Makin (TV’s “The Rookie”) is 33. Actor Tristin Mays (2018′s “MacGyver,” ″The Vampire Diaries”) is 32. Actor Eden McCoy (“General Hospital”) is 19. June 11: Singer Joey Dee of Joey Dee and the Starliters is 82. Actor Roscoe Orman (“Sesame Street”) is 78. Actor Adrienne Barbeau (“Maude”) is 77. Drummer Frank Beard of ZZ Top is 73. Singer Graham Russell of Air Supply is 72. Singer Donnie Van Zant of .38 Special and of Van Zant is 70. Actor Peter Bergman (“The Young and the Restless”) is 69. Actor Hugh Laurie (“House”) is 63. Talk show host Dr. Mehmet Oz (“The Dr. Oz Show”) is 62. Singer Gioia Bruno of Exposé is 59. Bassist Dan Lavery of Tonic is 56. Country singer Bruce Robison is 56. Actor Peter Dinklage (“Game of Thrones”) is 53. Bassist Smilin’ Jay McDowell (BR5-49) is 53. Actor Lenny Jacobson (“Nurse Jackie”) is 48. Bassist Tai Anderson of Third Day is 46. Actor Joshua Jackson (“Fringe,” ″Dawson’s Creek”) is 44. Actor Shia LaBeouf is 36.	https://www.theheraldreview.com/entertainment/article/Celebrity-birthdays-for-the-week-of-June-5-11-17209058.php	2022-05-31T12:44:22	en	0.869023
WASHINGTON, May 31, 2022 /PRNewswire/ -- With more than 28,000 cases of multiple sclerosis reported to the Department of Veterans Affairs annually, Paralyzed Veterans of America – the nation's premier nonprofit of choice for disabled veterans, their families, and caregivers – is expanding its membership as medical technology advances early detection of MS, inviting all veterans with MS to join. According to Charles Brown, national president of Paralyzed Veterans of America, "PVA has long helped veterans with MS involving the spinal cord who needed quality health care and disability benefits due to their diagnosis. Our National Service Officers are experts in securing their benefits, navigating the VA system, and helping these veterans throughout their continuum of care. It's important we keep pace with the improvements in MRI technology, which provides more precise imaging resulting in the early detection of MS. We want to help even more veterans living with the disease and become their go-to resource." The membership expansion means all Veterans with MS are now eligible to become a PVA member and obtain the same vital benefits as their counterparts with spinal cord injuries and diseases, like ALS. Among the benefits now available are: access to educational materials specific to MS; support from on-staff licensed architects who can review plans and provide subject matter expertise for making their homes more accessible; admission to PVA's private, members-only Facebook Groups that keep members abreast of important news that impact them; engagement with over 33 chapters across the country that support advocacy efforts specific to the MS community; and opportunities to take part in important surveys and webinars, as well as participate in sports and recreation events both virtually and in-person around the country. "Every case of MS reported is a person… a mother, a father, a son, a daughter, a proud Veteran, who selflessly served our nation, and they deserve our care and support now," continued Brown. "By expanding PVA's membership, we are not only helping more veterans but also honoring our roots, recognizing veterans like Gilford Moss – PVA's first president, who also had MS. We want all veterans with MS, from those actively serving to those who already served, to know that PVA is here and they are not alone." In August 2021, PVA created its first-ever MS Committee – a permanent committee of the Board of Directors – made up of eight PVA members from across the country who represent the everyday interests of veterans with MS. The committee acts as a voice on legislative issues concerning veterans with MS; provides first-hand input from its members with MS; puts out a weekly podcast on issues specific to those with MS; and serves as an expert resource for all veterans living with the disease. In addition to its committee and advocacy efforts, PVA also partners with expert groups in the field of MS, including the National MS Society and the VA's Multiple Sclerosis Centers of Excellence. To learn more about MS and how PVA helps military personnel thrive after diagnosis, visit: PVA.org/MS. To become a PVA member today visit PVA.org/Membership. Paralyzed Veterans of America is a 501(c)(3) non-profit and the only congressionally chartered veterans service organization dedicated solely for the benefit and representation of veterans with spinal cord injury or disease like MS and ALS. For 75 years, the organization has ensured that veterans receive the benefits earned through service to our nation; monitored their care in VA spinal cord injury units; and funded research and education in the search for a cure and improved care for individuals with paralysis. As a life-long partner and advocate for veterans and all people with disabilities, Paralyzed Veterans of America also develops training and career services, works to ensure accessibility in public buildings and spaces, and provides health and rehabilitation opportunities through sports and recreation. With more than 70 offices and 33 chapters, Paralyzed Veterans of America serves veterans, their families, and their caregivers in all 50 states, the District of Columbia, and Puerto Rico. Learn more at PVA.org. Contact: Oname Thompson OnameT@pva.org (703) 864-5980 cell View original content to download multimedia: SOURCE Paralyzed Veterans of America	https://www.wlbt.com/prnewswire/2022/05/31/pva-expands-membership-invites-all-veterans-with-ms-join/	2022-05-31T12:44:23	en	0.962275
BEIJING, China — Shanghai authorities say they will take some major steps Wednesday toward reopening China's largest city after a two-month COVID-19 lockdown that has throttled the national economy and largely bottled up millions of people in their homes. Full bus and subway service will be restored as will basic rail connections with the rest of China, Vice Mayor Zong Ming said Tuesday at a daily news conference on the city's outbreak. "The epidemic has been effectively controlled,” she said, adding that the city will start the process of fully restoring work and life on Wednesday. Schools will partially reopen on a voluntary basis for students and shopping malls, supermarkets, convenience stores and drug stores will continue to reopen gradually with no more than 75% of their total capacity. Cinemas and gyms will remain closed. Officials, who set June 1 as the target date for reopening earlier in May, appear ready to accelerate what has been a gradual easing in recent days. A few malls and markets have reopened, and some residents have been given passes allowing them out for a few hours at a time. In online chat groups, some expressed excitement about the prospect of being able to move about freely in the city for the first time since the end of March, while others remained cautious given the slow pace and stop-and-go nature of opening up so far. Shanghai recorded 29 new cases on Monday, continuing a steady decline from more than 20,000 a day in April. Li Qiang, the top official from China's ruling Communist Party in Shanghai, at a meeting Monday was quoted as saying that the city had made major achievements in fighting the outbreak through continuous struggle. The success came at a price. Authorities imposed a suffocating citywide lockdown under China's “zero-COVID” strategy that aims to snuff out any outbreak with mass testing and isolation at centralized facilities of anyone who is infected. However, the latest economic data showed that Chinese manufacturing activity started to rebound in May as the government rolled back some containment measures. Schools will reopen for the final two years of high school and the third year of middle school, but students can decide whether to attend in person. Other grades and kindergarten remain closed. Outdoor tourist sites will start reopening Wednesday, with indoor sites set to follow in late June, the Shanghai tourism authority said. Group tours from other provinces will be allowed again when the city has eliminated all high- and medium-risk pandemic zones. Beijing, the nation's capital, further eased restrictions Tuesday in some districts. The city imposed limited lockdowns, but nothing near a citywide level, in a much smaller outbreak that appears to be on the wane. Beijing recorded 18 new cases on Monday.	https://www.12newsnow.com/article/news/nation-world/shanghai-lockdown-easing/507-a37b1605-c780-4dfc-9994-dcc4d42b803e	2022-05-31T12:44:28	en	0.967937
Global Greeting Cards Market Projected to Shrink to $13.6 Billion by 2026 SAN FRANCISCO, May 31, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Greeting Cards - Global Market Trajectory & Analytics". The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace. FACTS AT A GLANCE What's New for 2022? - Global competitiveness and key competitor percentage market shares - Market presence across multiple geographies - Strong/Active/Niche/Trivial - Online interactive peer-to-peer collaborative bespoke updates - Access to our digital archives and MarketGlass Research Platform - Complimentary updates for one year Edition: 3; Released: April 2022 Executive Pool: 6915 Companies: 294 - Players covered include American Greetings Corporation; Carlton Cards Ltd.; John Sands (Australia) Ltd.; UK Greetings Ltd.; Archies Limited; Avanti Press Inc.; Budget Greeting Cards Ltd.; Card Factory plc; Child Rights and You; Crane & Co.; Current Media Group LLC; Galison Publishing LLC; Hallmark Cards, Inc.; IG Design Group Plc; LovePop, Inc.; Party City Holdco Inc.; Simon Elvin Ltd.; UNICEF and Others. Coverage: All major geographies and key segments Segments: Occasion (Birthday, Christmas/New Year, Valentine's Day, Anniversary, Other Occasions) Geographies: World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Latin America; Middle East; Africa. Complimentary Project Preview - This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass™ Platform which offers thousands of data bytes without an obligation to purchase our report. Preview Registry ABSTRACT- Amid the COVID-19 crisis, the global market for Greeting Cards estimated at US$15.9 Billion in the year 2022, is projected to shrink to US$13.6 Billion by 2027, declining at a CAGR of -4.4% over the analysis period. Birthday, one of the segments analyzed in the report, is projected to decline at a -2.6% CAGR, while growth in the Christmas/new Year segment is readjusted to a revised -6.5% CAGR. The global market for greeting cards is significantly impacted by changing consumer values, ideas, shifting demographics, and changing technology. The earlier vibrant greeting cards industry is currently under pressure to sustain in the modern digital technology era. The radical changes in the economy, lifestyle and demographics are resulting in steady decline in demand for greeting cards. With the tech-savvy new generation favoring e-cards in place of physical greeting cards, the impact has been evident on the greeting cards industry. With the advent of digitalization, social media platforms and messaging apps such as WhatsApp, the greeting card business has been affected considerably. This coupled with rising awareness among people about the need to save trees has led to rising demand for e-cards. Despite the challenges posed by the growing social media and e-cards, there still exists a niche consumer base for physical greeting cards, and giving and receiving these cards continues to matter to a set of consumers, albeit a shrinking one. For this niche group of consumers a physical greeting card on special occasions means much more than a Facebook message or an e-card. And this niche group is also willing to spend more on the desired card. As long as people continue to value real greeting cards received from their loved ones, the market for them is expected to co-exist alongside the digital alternatives. Aging baby boomers are the first and the most lucrative greeting card generation. Baby boomers who are indoctrinated into the custom of giving cards are perceived as more likely to value cards received from friends, family and relatives. In the UK, for instance, greeting cards remain an important part of the social culture and people still prefer to celebrate special occasions by sending of a card. In general, despite other distracting digital alternatives, people still wish to receive greeting cards through postal mail. In addition, the growing postage cost appears to be affecting the future of greeting card. Paper cards are increasingly incorporating technological characteristics, which help customers to adapt the greeting, for instance procuring cards with multitude of whistles and bells affixed, which is more meaningful. However, the longstanding tradition of paper message that are handwritten remains the most emotional and gentle method of passing on meaningful messages and offers the conventional greeting card industry some optimism for at least next few years. High levels of innovation and product development characterize the market for greeting cards. Low entry barriers associated with cards industry has fostered product innovations over the years. The use of high-end technologies to increase appeal and reach of greeting cards among consumers is emerging as a common strategy of card manufacturers to safeguard their business in the digital era. Card manufacturers are increasingly integrating audio capabilities and LED lighting features into physical greeting cards in order to boost adoption. Musical greeting cards especially have been attracting significant interest among consumers, especially in the mass market. Efforts are also on to integrate technology with creative art work in a wide range of hand-made cards. Another interesting trend is the use of electrical circuits made by printed ink to design interactive paper-based greeting cards. The use of graphics software, electronic circuits/transistors, miniaturized printed circuit boards, batteries, conductive ink, touch sensitive technologies, and microphones for audio effects, among others, are poised to gain momentum in the upcoming years. Use of 3D design effects, which enhances humorous images, is also poised for gains in the coming years. Women constitute the largest consumer group accounting for 80% of all card purchases, one of the few factors that have remained unchanged. The proliferation of everyday-general friendship cards is perhaps the most noteworthy trend. Today, the market is flooded with cards for every type of relationship, every ethnic group, and gender. This has resulted in the Everyday cards chewing into the dollar value of the more traditional occasion-specific seasonal cards. Of the total spending on greeting cards, 20% comes from the Millennials and the share is expected to grow further. Millennials, obsessed with digital communication, look for personalized form of wishes on special occasions. Greeting cards are back in trend as they are an essential part of culture in several countries such as the United States and United Kingdom. More MarketGlass™ Platform Our MarketGlass™ Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide. Our platform is free for qualified executives and is accessible from our website www.StrategyR.com or via our just released mobile application on iOS or Android About Global Industry Analysts, Inc. & StrategyR™ Global Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years. CONTACTS: Zak Ali Director, Corporate Communications Global Industry Analysts, Inc. Phone: 1-408-528-9966 www.StrategyR.com Email: [email protected] LINKS Join Our Expert Panel https://www.strategyr.com/Panelist.asp Connect With Us on LinkedIn https://www.linkedin.com/company/global-industry-analysts-inc./ Follow Us on Twitter https://twitter.com/marketbytes Journalists & Media [email protected] SOURCE Global Industry Analysts, Inc.	https://www.prnewswire.com/news-releases/global-greeting-cards-market-projected-to-shrink-to-13-6-billion-by-2026--301557155.html	2022-05-31T12:44:28	en	0.92534
This is a carousel. Use Next and Previous buttons to navigate WASHINGTON (AP) — When President Joe Biden and first lady Jill Biden disagree, they don't hash it out in front of other people. Instead, she says, they argue by text — “fexting” as they call it. Jill Biden also told Harper's Bazaar magazine in an interview that her divorce from her first husband taught her to be independent and that she has drilled that lesson into her daughter and granddaughters. She says she could soon be sharing White House living quarters with a teenage granddaughter. When Joe Biden was vice president, the couple decided to settle disagreements by text to avoid fighting in the presence of their Secret Service agents — and dubbed it fexting. After she recently texted him in a fit of pique, he told her, "'You realize that’s going to go down in history. There will be a record of that,’” she said. Presidential communications are preserved for the historical record. She told her interviewer, “I won’t tell you what I called him that time.” The first lady appears on the cover of the publication's June-July issue, available on newsstands June 7. Harper's Bazaar said it’s the first time in its 155-year history that a U.S. first lady has been so prominently featured. Jill Biden was 18 when she married her first husband. But by her mid-20s, she was divorced, alone and on her own for the first time in her life. The breakup dealt her an emotional blow as she had idolized her parents' union and thought she'd have a marriage as long-lasting as theirs. She finished college and became a teacher. “I knew I would never, ever put myself in that position again, where I didn’t feel like I had the finances to be on my own, that I had to get the money through a divorce settlement,” she said. “I drummed that into (my daughter), Ashley, ‘Be independent, be independent.’ And my granddaughters," she said. “You have to be able to stand on your own two feet.” Jill Biden met then-Sen. Joe Biden in 1975, and they were married two years later. She kept teaching throughout his rise in national politics, eventually becoming the first first lady to hold a paying job outside the White House. She fits her responsibilities as first lady around her twice-a-week teaching schedule at Northern Virginia Community College. Granddaughter Naomi is engaged to be married and is planning a White House wedding reception in November. Another granddaughter recently told the first lady that she landed an internship in Washington and would like to move into the executive mansion for the summer. “I'm going to be raising a teenager?” Jill Biden exclaimed.	https://www.theheraldreview.com/living/article/Jill-Biden-says-she-president-settle-arguments-17209061.php	2022-05-31T12:44:28	en	0.989384
Last week's U.S. Rocky Mountain and Canadian B.C. regional events attracted 17,500+ online bidders VANCOUVER, BC, May 31, 2022 /PRNewswire/ - Ritchie Bros. is building bigger and better events with its regional auction format, bringing together more consignors and buyers to provide more selection and increased competition. Last week, the company held regional auctions on both sides of the border, with US$65+ million of equipment sold in its U.S. Rocky Mountain Event and US$27+ million (CA$35+ million) sold in the Canadian B.C. Regional Event—both of which were new regional records. "Consignors love these big events because they attract more bidders and the increased competition results in more money in their pockets at the end of the auction," said Chad Apland, Regional Sales Manager (Denver), Ritchie Bros. "Our Rocky Mountain event last week featured 5,700+ items from 800+ consignors stored across eight locations, with all items selling to online bidders around the world. Low-hour construction equipment was in especially high demand, resulting in some phenomenal prices, including a 2011 Cat 988H wheel loader that sold for US$515,000!" The May 25 – 26 Rocky Mountain Event attracted 11,000+ bidders from 54 countries, with approximately 94% of the equipment sold to U.S. buyers, including 20% sold to Colorado, 11% to Utah, and 7% to Texas. The remaining 6% was sold to international buyers from as far away as Honduras, India, and Taiwan. Meanwhile, up north, Ritchie Bros. was selling 2,100+ items for approximately 500 consignors in its B.C. Regional Event, with equipment stored at three locations across the province. The May 24 – 25 auction was B.C.'s biggest ever in terms of gross transaction value and attracted 6,500+ bidders from 34 countries. "Our Chilliwack yard usually fills up quick, so it's great that we could add hundreds of additional items from elsewhere in B.C. and store them at yards in Prince George and Kamloops," said Pat Elliott, Regional Sales Manager (Chilliwack), Ritchie Bros. "We built the auction around a great package of forestry equipment and achieved excellent results on the late-model gear. Good quality, low-hour equipment continues to bring big money, so I encourage interested sellers to contact us to take advantage today." Approximately 94% of the equipment sold in the B.C. Regional Event was sold to Canadians, including 71% sold to B.C. buyers. The remaining 6% was sold to international buyers from as far away as Guatemala, Egypt, and Thailand. - 2011 Caterpillar 988H wheel loader – US$515,000 - 2018 Volvo A45 articulated dump truck – US$500,000 - 2013 Grove TMS9000E 90-ton 8x4x4 hydraulic truck crane – US$345,000 - 2011 Komatsu PC490LCI-11 hydraulic excavator – US$300,000 - 2019 John Deere 850K LGP dozer – US$295,000 - 2016 Caterpillar 3252D FM roadbuilder – CA$770,000 (US$602,294) - 2021 John Deere 959ML leveling heel boom log loader – CA$610,000 (US$477,142) - 2019 John Deere 872GP AWD motor grader – CA$410,000 (US$320,702) - 2019 John Deere 850L dozer – CA$350,000 (US$273,770) - 2019 Kenworth T880 6x4 twin-axle dump truck – CA$255,000 (US$199,461) Ritchie Bros. has more than 50,000 equipment items and trucks set to be sold in its upcoming auctions and online events, including a Phoenix, AZ auction on June 3 with 3,100+ items; 1,600-item auction in Saskatoon, SK on June 7 – 8; and a June 8 – 10 auction in Grande Prairie with 2,800+ items. The company also sells items weekly through IronPlanet.com, Marketplace-E, Ritchie List, and GovPlanet.com. Established in 1958, Ritchie Bros. (NYSE and TSX: RBA) is a global asset management and disposition company, offering customers end-to-end solutions for buying and selling used heavy equipment, trucks and other assets. Operating in a number of sectors, including construction, transportation, agriculture, energy, mining, and forestry, the company's selling channels include: Ritchie Bros. Auctioneers, the world's largest industrial auctioneer offering live auction events with online bidding; IronPlanet, an online marketplace with weekly featured auctions and providing the exclusive IronClad Assurance® equipment condition certification; Marketplace-E, a controlled marketplace offering multiple price and timing options; Ritchie List, a self-serve listing service for North America; Mascus, a leading European online equipment listing service; Ritchie Bros. Private Treaty, offering privately negotiated sales; and sector-specific solutions GovPlanet, TruckPlanet, and Kruse Energy. The Company's suite of solutions also includes Ritchie Bros. Asset Solutions and Rouse Services LLC, which together provides a complete end-to-end asset management, data-driven intelligence and performance benchmarking system; SmartEquip, an innovative technology platform that supports customers' management of the equipment lifecycle and integrates parts procurement with both OEMs and dealers; plus equipment financing and leasing through Ritchie Bros. Financial Services. For more information about Ritchie Bros., visit RitchieBros.com. Photos and video for embedding in media stories are available at rbauction.com/media. View original content: SOURCE Ritchie Bros.	https://www.wlbt.com/prnewswire/2022/05/31/ritchie-bros-regional-events-pay-off-big-with-us92-million-equipment-sold-11-locations/	2022-05-31T12:44:30	en	0.935512
BRUSSELS, Belgium — European Union leaders agreed Monday to embargo most Russian oil imports into the bloc by year-end as part of new sanctions on Moscow worked out at a summit focused on helping Ukraine with a long-delayed package of new financial support. The embargo covers Russian oil brought in by sea, allowing a temporary exemption for imports delivered by pipeline, a move that was crucial to bring landlocked Hungary on board a decision that required consensus. EU Council President Charles Michel said the agreement covers more than two-thirds of oil imports from Russia. Ursula Von der Leyen, the head of the EU's executive branch, said the punitive move will “effectively cut around 90% of oil imports from Russia to the EU by the end of the year.” Michel said leaders also agreed to provide Ukraine with a 9 billion-euro ($9.7 billion) tranche of assistance to support the war-torn country's economy. It was unclear whether the money would come in grants or loans. Mikhail Ulyanov, Russia’s permanent representative to international organizations in Vienna, responded to the EU’s decision on Twitter, saying: “As she rightly said yesterday, Russia will find other importers.” The new package of sanctions will also include an asset freeze and travel ban on individuals, while Russia’s biggest bank, Sberbank, will be excluded from SWIFT, the major global system for financial transfers from which the EU previously banned several smaller Russian banks. Three big Russian state-owned broadcasters will be prevented from distributing their content in the EU. “We want to stop Russia's war machine," Michel said, lauding what he called a “remarkable achievement." “More than ever it’s important to show that we are able to be strong, that we are able to be firm, that we are able to be tough,” he added. Michel said the new sanctions, which needed the support of all 27 member countries, will be legally endorsed by Wednesday. The EU had already imposed five previous rounds of sanctions on Russia over its war. It has targeted more than 1,000 people individually, including Russian President Vladimir Putin and top government officials as well as pro-Kremlin oligarchs, banks, the coal sector and more. But the sixth package of measures announced May 4 had been held up by concerns over oil supplies. The impasse embarrassed the bloc, which was forced to scale down its ambitions to break Hungary's resistance. When European Commission President Ursula von der Leyen proposed the package, the initial aim was to phase out imports of crude oil within six months and refined products by the end of the year. Both Michel and von der Leyen said leaders will soon return to the issue, seeking to guarantee that Russia’s pipeline oil exports to the EU are banned at a later date. Hungarian Prime minister Viktor Orban had made clear he could support the new sanctions only if his country’s oil supply security was guaranteed. Hungary gets more than 60% of its oil from Russia and depends on crude that comes through the Soviet-era Druzhba pipeline. Von der Leyen had played down the chances of a breakthrough at the summit. But leaders reached a compromise after Ukrainian President Volodymyr Zelenskyy urged them to end “internal arguments that only prompt Russia to put more and more pressure on the whole of Europe.” The EU gets about 40% of its natural gas and 25% of its oil from Russia, and divisions over the issue exposed the limits of the 27-nation trading bloc’s ambitions. In his 10-minute video address, Zelenskyy told leaders to end “internal arguments that only prompt Russia to put more and more pressure on the whole of Europe.” He said the sanctions package must “be agreed on, it needs to be effective, including (on) oil,” so that Moscow “feels the price for what it is doing against Ukraine" and the rest of Europe. Only then, Zelenskyy said, will Russia be forced to “start seeking peace.” It was not the first time he had demanded that the EU target Russia’s lucrative energy sector and deprive Moscow of billions of dollars each day in supply payments. But Hungary led a group of EU countries worried over the impact of the oil ban on their economy, including Slovakia, the Czech Republic and Bulgaria. Hungary relies heavily on Russia for energy and can't afford to turn off the pumps. In addition to its need for Russian oil, Hungary gets 85% of its natural gas from Russia. Orban had been adamant on arriving at the summit in Brussels that a deal was not in sight, stressing that Hungary needed its energy supply secured. Von der Leyen and Michel said the commitment by Germany and Poland to phase out Russian oil by the end of the year and to forgo oil from the northern part of the Druzhba pipeline will help cut 90% of Russian oil imports. The issue of food security will be on the table Tuesday, with the leaders set to encourage their governments to speed up work on “solidarity lanes” to help Ukraine export grain and other produce. ___ Karel Janicek contributed to this story from Prague.	https://www.12newsnow.com/article/news/nation-world/ukraine/eu-leaders-agree-on-russian-oil-embargo/507-8c8b07d8-79b6-47c9-9df1-357957d23ff1	2022-05-31T12:44:34	en	0.970786
Global Industry Analysts Predicts the World Metal Powders Market to Reach $5.5 Billion by 2026 SAN FRANCISCO , May 31, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Metal Powders - Global Market Trajectory & Analytics". The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace. FACTS AT A GLANCE What's New for 2022? - Global competitiveness and key competitor percentage market shares - Market presence across multiple geographies - Strong/Active/Niche/Trivial - Online interactive peer-to-peer collaborative bespoke updates - Access to our digital archives and MarketGlass Research Platform - Complimentary updates for one year Edition: 22; Released: May 2022 Executive Pool: 6121 Companies: 178 - Players covered include Allegheny Technologies Incorporated; American Chemet Corp.; AMETEK Specialty Metal Products Inc.; Burgess-Norton Manufacturing Company; Carpenter Technology Corporation; Daido Steel Co., Ltd.; Diamet Corporation; Dowa Holdings Co., Ltd.; Erasteel SAS; F. W. Winter Inc. & Co.; Federal-Mogul Corporation; Fine Sinter Co., Ltd.; Hoeganaes Corp.; H.C. Starck GmbH; JFE Steel Corp.; Kennametal, Inc.; Kobe Steel, Ltd.; Kymera International; Miba AG; Norilsk Nickel; PMG Holding GmbH; Pometon SpA; Rio Tinto Metal Powders; Showa Denko Materials Co., Ltd.; Sumitomo Electric Industries, Ltd. and Others. Coverage: All major geographies and key segments Segments: Type (Ferrous, Non-Ferrous, Other Types); Production Method (Physical, Chemical, Mechanical); Application (Automotive, Aerospace & Defense, Construction, Electrical & Electronics, Healthcare, Other Applications) Geographies: World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World. Complimentary Project Preview - This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass™ Platform which offers thousands of data bytes without an obligation to purchase our report. Preview Registry ABSTRACT- Amid the COVID-19 crisis, the global market for Metal Powders estimated at US$4.3 Billion in the year 2022, is projected to reach a revised size of US$5.5 Billion by 2026, growing at a CAGR of 5.9% over the analysis period. Ferrous, one of the segments analyzed in the report, is projected to grow at a 5.5% CAGR, while growth in the Non-Ferrous segment is readjusted to a revised 7.5% CAGR. The rising application of metal powders in the renewable energy segment along with the increase in demand for vehicles especially electric vehicles is pushing demand for different metal powders. The modern breed of vehicles possesses optimized performance and efficiency parameters. This factor along with the increased adoption of hybrid and electric vehicles that satisfy burgeoning environmental concerns has encouraged the growth of the world market. The inception of incentive-linked schemes for electric vehicle purchases along with strict government protocol regarding carbon emissions has encouraged the need for low carbon-emitting vehicles ultimately encouraging market growth. Metal powders are widely used for manufacturing structural components. Increase in demand for such structural components from various applications including home appliances, motorcycles, agriculture equipment and automotive parts among others is creating demand for metal powders. Iron & steel constitute the major ingredients in structural component manufacturing. Also, metal powders are expensive compared to billets, steel bars and such other raw materials in certain applications. Furthermore, when metal powder is used it requires specific equipment for processing, which are expensive. However, technological advancements are expected to help overcome such limitations over the coming years. Development of improved production techniques and better understanding of processes used in powder manufacture will continue to be critical to growth. These powders provide the foundation for numerous strategically significant net-shape processing operations such as injection molding, sintering, direct laser fabrication, and hot and cold isostatic pressing. Technological advancements in Powder Metal (PM) forging, spray forming, hot isostatic pressing, direct powder rolling, high temperature vacuum sintering, and metal injection molding are expanding the metal powder market. The rising adoption of three-dimensional printing has further encouraged market growth. A unique process adopted for processing metal powders is additive manufacturing, which is also known as 3D printing, freeform fabrication or rapid prototyping. Additive manufacturing is a process of combining various materials to form objects that are placed layer upon layer from 3D model data as against machining, which follows subtractive manufacturing methodologies. 3D printing involves process in which materials are deposited with the help of either a print nozzle or head or a different printer technology. Three-dimensional printing implements three-dimensional data for creating layered components that minimize material wastage and negates the usage of complicated and expensive tools. The process of three-dimensional printing needs an extensive array of products that allow mass production. some of these products encompass nickel, aluminum, cobalt, and copper. Conventional printing machines can use just a single variant of material but three-dimensional printers can use many metal powders at the same time for printing minimizing the overhead expense needed for manufacturing. The product demand has risen in object manufacturing domains commanding optimum stability and strength along with the capacity of tolerating difficult environments, high exposure to chemicals, and high temperatures. The metallic powders can be either ferrous or nonferrous types. The ferrous powders have been the traditional market leaders as they have diverse applications in different domains like automotive and aerospace. The enhanced use of machinery along with the rise in industrialization and automation around the world has encouraged the growth of the market. Surface coating, stains and dyes, magnetics, and friction products are some goods that make heavy use of ferrous metal powders. The chemical domain is poised to grow at a high rate in the near future due to enhanced adoption by different industries like automotive, aerospace, and healthcare due to greater versatility. The increasing rise of usage of Metal granules/ powders in different paints for enhancing reflectivity, robustness, and cost-effectiveness is also propelling market growth. The use of metal granules offers a metallic finish to all items creating a visual effect of solid casting. Metal powders have a lot of versatility and they lead to the reduction of waste in the manufacturing processes of coatings and other metal parts. Some easily accessible products in thar market are nickel, zinc iron, aluminum, cadmium oxide, manganese, and tin powders. There has been an increasing demand for aluminum because of its inflammable features and versatility. Aluminum powder is used to make solar cells. The growing cognizance about the usage of renewable energy sources along with increased investment for the creation of solar energy has encouraged higher demand for aluminum across the world. Fireworks and pyrotechnics use aluminum powder extensively due to the latter's flammable features. Zinc is another material commanding wide usage in metal plating, paints and precision die casting. The creation of brass production and galvanized steel also rely heavily on zinc powder. Nickel's demand has increased considerably as it has corrosion resistance that is useful to the marine industries. More MarketGlass™ Platform Our MarketGlass™ Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide. Our platform is free for qualified executives and is accessible from our website www.StrategyR.com or via our just released mobile application on iOS or Android About Global Industry Analysts, Inc. & StrategyR™ Global Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years. CONTACTS: Zak Ali Director, Corporate Communications Global Industry Analysts, Inc. Phone: 1-408-528-9966 www.StrategyR.com Email: [email protected] LINKS Join Our Expert Panel https://www.strategyr.com/Panelist.asp Connect With Us on LinkedIn https://www.linkedin.com/company/global-industry-analysts-inc./ Follow Us on Twitter https://twitter.com/marketbytes Journalists & Media [email protected] SOURCE Global Industry Analysts, Inc.	https://www.prnewswire.com/news-releases/global-industry-analysts-predicts-the-world-metal-powders-market-to-reach-5-5-billion-by-2026--301557101.html	2022-05-31T12:44:34	en	0.898548
FRUITLAND, Wash. (AP) — FRUITLAND, Wash. — A 9-year-old girl survived a cougar attack after wandering up a trail with two friends while camping in northwest Washington state. It happened Saturday morning near Fruitland, Washington. The girl fought back while her friends ran for their lives. Adults rushed to help and found the girl covered in blood. She was soon airlifted to a hospital, where she's recovering after surgery for multiple wounds to her head and upper body. Others found the young male cougar and killed it. Fish and Wildlife spokeswoman Staci Lehman says cougar attacks are rare, with only two fatalities in the last century in Washington state. “In this instance, this little girl did nothing wrong,” she said. “It happened so quickly, and there’s nothing she could have done to prevent it.” Anyone confronted by a cougar should yell at the animal and try to make yourself look bigger than it is, she said. If it attacks, “fight back as hard as you can and try to stay on your feet.” “Do not turn around. Don’t take your eyes off the animal,” Lehman added. “Don’t run.”	https://www.theheraldreview.com/news/article/9-year-old-girl-survives-rare-cougar-attack-in-17209003.php	2022-05-31T12:44:35	en	0.976093
Global Industry Analysts Predicts the World Tungsten Market to Reach 141.4 Thousand Metric Tons by 2026 SAN FRANCISCO, May 31, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Tungsten - Global Market Trajectory & Analytics". The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace. FACTS AT A GLANCE What's New for 2022? - Global competitiveness and key competitor percentage market shares - Market presence across multiple geographies - Strong/Active/Niche/Trivial - Online interactive peer-to-peer collaborative bespoke updates - Access to our digital archives and MarketGlass Research Platform - Complimentary updates for one year Edition: 17; Released: May 2022 Executive Pool: 454 Companies: 152 - Players covered include A.L.M.T. Corp.; Allegheny Technologies Inc.; Almonty Industries Inc.; Betek GmbH & Co. KG; Buffalo Tungsten Inc.; China Molybdenum Co., Ltd.; Chongyi Zhangyuan Tungsten Co., Ltd.; Guangdong XiangLu Tungsten Co. Ltd.; H.C. Starck GmbH; IMC Group; Kennametal, Inc.; Nippon Tungsten Co., Ltd.; Plansee Group; QuesTek Innovations LLC; Sandvik Group; Umicore N.V.; WOLFRAM Company JSC; Xiamen Tungsten Co., Ltd. and Others. Coverage: All major geographies and key segments Segments: Application (Hardmetals / Cement Carbides; Steels, Superalloys, & Wear-Resistant Alloys; Mill Products; Other Applications); End-Use (Drilling, Boring & Cutting Equipment; Automotive Parts; Aerospace Components; Logging Equipment; Electrical & Electronics Appliances; Other End-Uses) Geographies: World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Russia; Rest of Europe; Asia-Pacific; Latin America; Rest of World. Complimentary Project Preview - This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass™ Platform which offers thousands of data bytes without an obligation to purchase our report. Preview Registry ABSTRACT- Amid the COVID-19 crisis, the global market for Tungsten estimated at 119.1 Thousand Metric Tons in the year 2022, is projected to reach a revised size of 141.4 Thousand Metric Tons by 2026, growing at a CAGR of 4% over the analysis period. Hardmetals/Cement Carbides, one of the segments analyzed in the report, is projected to grow at a 4.2%, while growth in the Steels, SupeRalloys, & Wear-resistant Alloys segment is readjusted to a revised 3.6% CAGR. The global market for tungsten is anticipated to deliver a subdued performance over the long term, and has experienced notable turbulence in the recent years owing to China's dominance. China has been the leading refined and mine producer of the metal for the past several decades, claiming more than 80% of global mine output in the year 2020. The country commands the major share regarding production of tungsten intermediates tungsten oxide and ammonium paratungstate (APT) along with tungsten carbide and tungsten metal powder. In addition to satiating considerable demand from the domestic cemented carbide tool sector, China exports finished and refined tungsten products to other countries. Considering high influence of China, tungsten prices have witnessed notable turbulence in the recent years. The announcement of a widespread environmental reform program by China that impacted tungsten smelter sites and mining activity significantly interrupted refined and upstream tungsten supply over 2017-2018. The performance of global tungsten market in 2020 was heavily impacted by the COVID-19 crisis. European APT quotation that peaked in February and maintained the level until April felt the heat following nationwide lockdowns and other stringent restrictions enforced by several governments globally. The COVID-19 pandemic disrupted supply chains and made numerous end-use sectors to suffer heavily, with aerospace and automotive sectors reporting considerable losses. The COVID-19 pandemic made the aerospace sector to face an extremely tough phase, with global deliveries of commercial aircraft declining by 40% over 2019-2020. Despite continuously increasing confirmed cases of COVID-19 across countries due to second and third waves, tungsten prices started recovering during the latter half of 2020. Though the scenario has coerced various governments to re-impose COVID-19 restrictions, global demand for the metal remains uninterrupted owing to consistent manufacturing output and announcement of vaccination programs. The market is anticipated to face some uncertainty over the coming years as various end-use industries are struggling to attain pre-pandemic levels. Vehicle production remains below the pre-COVID-19 level as well as significantly less than the production peak experienced in 2017. Tungsten demand from the automotive industry is unlikely to touch earlier levels owing to increasing adoption of electric vehicles on the expense of internal combustion engines. The tungsten market is also affected by continuing US-China trade dispute. As the trade deal in January 2020 failed to remove majority of US tariffs imposed on Chinese goods, the situation is affecting various tungsten-based products. Though the new administration in the US is expected to assume a low-tariff approach, it is unlikely to effectively mitigate trade tensions between China and the US. Tungsten producers in China have continued to face rising production costs and depleted high-grade ores owing to the safety guarantee costs, labor costs, and environmental laws. Thus, the price of ammonium paratungstate (APT) has remained firm in recent months. China's government policy, ore grades, and production levels always provide wider signals about the market price as the country is the largest exporter of tungsten. Additionally, the consumer reference prices for tenders and domestic demand in China support the global tungsten market as the country is one of the largest consumers of tungsten in the world. Global tungsten trade can witness a complete and sudden halt in exports and imports as China's government adopted a zero-tolerance stance concerning the spread of COVID-19, which can be accompanied by the closure of ports. Such a scenario can tighten the spot supply of tungsten and increase the prices. The policy followed by the Chinese government is mainly responsible for the higher prices of tungsten in the US and Europe markets. APT prices in Europe have witnessed a substantial rise in recent years. In China, reducing demand from downstream users, lower bid prices from major tungsten consumers, and a decline in ingredient costs are the major factors influencing the tungsten market in the last few months. APT prices have declined significantly in recent months after reaching record levels in the latter half of 2021 due to subdued consumption of tungsten by major end-use industries such as aerospace, construction, and automotive sectors. The price rise in the latter half of 2021 has been attributed to the substantial increase in ingredient costs for ammonium sulfide, sulfuric acid, and caustic soda and curbs on power supply in the main tungsten production hub of Ganzhou City. On the other side, there are certain breathers for the tungsten market such as promising outlook for majority of first-use sectors. While the robust demand for super-alloys and other alloys is anticipated to push overall consumption of alloys and steel, the market is likely to receive a notable impetus from healthy performance of the chemicals industry along with rising demand for semiconductors and consumer electronic products. In addition, decent performance of various segments in the cemented carbides industry is likely to counterbalance dismal demand from the automotive tooling category. The market is anticipated to gain further from commencement of operations at new mining projects. As numerous large-scale mines in Russia and China are nearing their end of useful life, they are indicating the requirement of new mines for ensuring uninterrupted supplies. More MarketGlass™ Platform Our MarketGlass™ Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide. Our platform is free for qualified executives and is accessible from our website www.StrategyR.com or via our just released mobile application on iOS or Android About Global Industry Analysts, Inc. & StrategyR™ Global Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years. CONTACTS: Zak Ali Director, Corporate Communications Global Industry Analysts, Inc. Phone: 1-408-528-9966 www.StrategyR.com Email: [email protected] LINKS Join Our Expert Panel https://www.strategyr.com/Panelist.asp Connect With Us on LinkedIn https://www.linkedin.com/company/global-industry-analysts-inc./ Follow Us on Twitter https://twitter.com/marketbytes Journalists & Media [email protected] SOURCE Global Industry Analysts, Inc.	https://www.prnewswire.com/news-releases/global-industry-analysts-predicts-the-world-tungsten-market-to-reach-141-4-thousand-metric-tons-by-2026--301557153.html	2022-05-31T12:44:35	en	0.908705
WIXOM, Mich., May 31, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that it has entered into securities purchase agreements with Armistice Capital Master Fund Ltd., a leading healthcare investor, to purchase $15 million of common stock (or common stock equivalents in lieu thereof) and warrants. The combined purchase price for one share of common stock (or common stock equivalent) and a warrant to purchase one share of common stock is $1.515. The warrants have an exercise price of $1.39 per share and have a term of 5.5 years. The Company is offering $12 million of securities in a registered transaction under the Company's shelf registration statement on Form S-3. The remaining $3 million of securities are being sold in a private placement transaction that is exempt from registration under Section 4(a)(2) of the Securities Act of 1933. The receipt of the $15 million in proceeds is expected to trigger a subsequent $7.5 million investment from DaVita, Inc. on terms previously disclosed. The Company intends to use the net proceeds to restructure its dialysis business and, pending FDA clearance, to advance the development of ferric pyrophosphate citrate (FPC) for patients with iron deficiency anemia who are receiving home infusion therapy. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Rockwell Medical is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate (FPC), which has the potential to lead transformative treatments for iron deficiency in multiple disease states, reduce healthcare costs and improve patients' lives. The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform. Rockwell Medical is also advancing its FPC platform by developing FPC for the treatment of iron deficiency anemia in patients outside of dialysis, who are receiving intravenous medications in the home infusion setting. In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States. For more information, visit www.RockwellMed.com. Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend," "look forward to," "remain confident" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to those risks more fully discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2021, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law. View original content to download multimedia: SOURCE Rockwell Medical Technologies, Inc.	https://www.wlbt.com/prnewswire/2022/05/31/rockwell-medical-announces-15-million-at-market-offering/	2022-05-31T12:44:37	en	0.956444
THE HAGUE, Netherlands — Representatives of a group of nations working together to investigate war crimes in Russia's invasion of Ukraine are meeting in The Hague amid ongoing calls for those responsible for atrocities to be brought to justice. Tuesday's coordination meeting at the European Union's judicial cooperation agency, Eurojust, of members of a Joint Investigation Team and International Criminal Court Prosecutor Karim Khan comes as Russian forces continue to pound Ukrainian towns. Moscow’s invasion of Ukraine has been widely condemned as an illegal act of aggression. Russian forces have been accused of killing civilians in the Kyiv suburb of Bucha and of repeated attacks on civilian infrastructure including hospitals and a theater in the besieged city of Mariupol that was being used as a shelter by hundreds of civilians. An investigation by The Associated Press found evidence that the March 16 bombing killed close to 600 people inside and outside the building. Since Russia invaded Ukraine on Feb. 24, the AP and PBS series Frontline have verified 273 potential war crimes. Ukrainian President Volodymyr Zelenskyy has denounced killings of civilians as “genocide” and “war crimes,” while U.S. President Joe Biden has called Russian President Vladimir Putin “a war criminal” who should be brought to trial. The joint investigation team, made up of Ukraine, Lithuania and Poland, that is meeting Tuesday in The Hague was established in late March, a few weeks after the ICC opened an investigation in Ukraine, after dozens of the court's member states threw their weight behind an inquiry. Khan has visited Ukraine, including Bucha, and has a team of investigators in the country gathering evidence. Ukraine's prosecutor general, Iryna Venediktova, will be among those at the meeting. Her office has already opened more than 8,000 criminal investigations related to the war and identified over 500 suspects, including Russian ministers, military commanders and propagandists. Last week, in the first case of its kind linked to the war, a Ukrainian court sentenced a captured Russian soldier to the maximum penalty of life in prison for killing a civilian. Russia staunchly denies its troops are responsible for atrocities. The Defense Ministry said earlier this month that “not a single civilian has faced any violent action by the Russian military.” Analysts warn that the process of meting out justice will be long and complex as investigators piece together forensic and other evidence and seek to establish who ordered or knew about atrocities and failed to act to prevent or punish them. The meeting in The Hague isn't the only place accountability is being sought. Prosecutors in Poland, Germany, Lithuania, Latvia, Estonia, France, Slovakia, Sweden, Norway and Switzerland have opened investigations of their own. And there have been growing calls to set up a special tribunal to try Russia for the crime of aggression in Ukraine. The ICC can't prosecute the crime of aggression because neither Russia nor Ukraine are members of the court.	https://www.12newsnow.com/article/news/nation-world/war-crimes-ukraine/507-b8b24f00-73e0-4e1f-93e0-9d1e0b726ce0	2022-05-31T12:44:40	en	0.966008
This is a carousel. Use Next and Previous buttons to navigate KATHMANDU, Nepal (AP) — Rescuers have recovered all 22 bodies from the site where a plane crashed on a mountainside in Nepal, the airline said Tuesday. All the bodies were flown to Kathmandu and taken to the Tribhuvan University Teaching Hospital where doctors are performing autopsies, Tara Air said in a statement. The bodies will be handed over to relatives once autopsy is done, it said. While 10 bodies were flown to Kathmandu on Monday, the remaining were brought by army helicopter on Tuesday. Relatives of the crash victims waited outside the hospital building for authorities to release the bodies. The Tara Air turboprop Twin Otter aircraft lost contact with the airport tower Sunday while flying on a scheduled 20-minute flight in an area of deep river gorges and mountaintops. Four Indians and two Germans were on the plane, Tara Air said. The three crew members and other passengers were Nepali nationals, it said. Local news reports said the passengers included two Nepali families, one with four members and the other with seven. The plane crashed Sunday in Sanosware in Mustang district close to the mountain town of Jomsom, where it was heading after taking off from the resort town of Pokhara, 200 kilometers (125 miles) west of the capital Kathmandu. The plane’s destination is popular with foreign hikers who trek on its mountain trails, and with Indian and Nepalese pilgrims who visit the revered Muktinath temple. The Twin Otter, a rugged plane originally built by Canadian aircraft manufacturer De Havilland, has been in service in Nepal for about 50 years, during which it has been involved in about 21 accidents, according to aviationnepal.com. The plane, with its top-mounted wing and fixed landing gear, is prized for its durability and its ability to take off and land on short runways.	https://www.theheraldreview.com/news/article/All-bodies-recovered-from-Nepal-plane-crash-17209010.php	2022-05-31T12:44:41	en	0.972392
KnowBe4 releases The Economic Impact of Cyber Attacks on Municipalities report to reflect changing cyber threat landscape TAMPA BAY, Fla., May 31, 2022 /PRNewswire/ -- KnowBe4, the provider of the world's largest security awareness training and simulated phishing platform, today announced the release of an updated version of The Economic Impact of Cyber Attacks on Municipalities report. KnowBe4 updated the research on financial costs, reputational effects, level of public trust and other impacts that cyber attacks have had on municipalities in recent years. The report breaks down the impact of ransomware attacks against state and local governments into five target areas: the average financial loss from state and local governments, the denial of service to citizens due to financial loss, the frequency/types of attacks and the risk of recurring attacks, the challenge of allocating capital to prevent attacks and the decline of economic investment in municipalities. Additionally, the new report revealed that ransomware is still the preferred method of cyber attacks against municipalities and continues to be a leading consequence of social engineering. However, the results of such attacks prove to be even more catastrophic as many state and local governments work through the variety of challenges presented by the COVID-19 pandemic and the shift in the workforce that followed as the majority of employees began working remotely. Key findings from the report include: - Many organizations' cybersecurity budgets are underfunded or do not exist at all. According to a study conducted by the National Association of State Information Officers (NASCIO), only 18 states have a cybersecurity budget. Additionally, only 16% of state's cybersecurity budgets increased by 10% or greater since 2018. - Only 40% of CISOs said they felt only somewhat confident that their state information assets are adequately protected from cyberattacks targeting local government and public higher education entities, according to a Deloitte-NASCIO study. - The average ransomware payment in the first half of 2021 was $570,000, while the average ransom amount demanded by cybercriminals for that time period was $5.3 million. - According to Accenture, from January to August of 2021, these five ransomware variants made up 75% of observed attacks: Hades, DoppelPaymer, Ryuk, Egregor and REvil/Sodinokibi topping the list. - In addition to the direct monetary impact, the downtime caused by ransomware can be extremely disruptive. In Q3 of 2021, Coveware reported that on average, organizations faced 22 days of business interruption. "Ransomware attacks continue to plague state and local governments on an all too regular basis," said Stu Sjouwerman, CEO, KnowBe4. "Without proper security awareness training and education along with necessary funding to combat such social engineering threats, municipalities are left defenseless against cyber attacks that could be prevented. In recent years, many healthcare, law enforcement, higher education institutions and other critical services have had to literally pay the price, sometimes in the millions, to overcome ransomware attacks. As the world continues to change and work through the COVID-19 pandemic, the time to act and prepare for potential cyber attacks is now". To download The Economic Impact of Cyber Attacks on Municipalities report, visit https://info.knowbe4.com/economic-impact-of-cyber-attacks-municipalities. About KnowBe4 KnowBe4, the provider of the world's largest security awareness training and simulated phishing platform, is used by more than 50,000 organizations around the globe. Founded by IT and data security specialist Stu Sjouwerman, KnowBe4 helps organizations address the human element of security by raising awareness about ransomware, CEO fraud and other social engineering tactics through a new-school approach to awareness training on security. Kevin Mitnick, an internationally recognized cybersecurity specialist and KnowBe4's Chief Hacking Officer, helped design the KnowBe4 training based on his well-documented social engineering tactics. Tens of thousands of organizations rely on KnowBe4 to mobilize their end users as the last line of defense. Media Contact Amanda Tarantino Public Relations Officer KnowBe4 [email protected] SOURCE KnowBe4	https://www.prnewswire.com/news-releases/global-pandemic-spreads-already-limited-local-government-cyber-defense-capabilities-even-thinner-301556486.html	2022-05-31T12:44:41	en	0.951198
Rosetta Stone will continue providing its platform to IRAP for free to ease the resettlement process for displaced persons NEW YORK, May 31, 2022 /PRNewswire/ -- Rosetta Stone, the world's leading language learning brand, and the International Refugee Assistance Project (IRAP), announced an extension of their partnership to provide IRAP's global staff and refugee clients with free Rosetta Stone subscriptions. The donated subscriptions will provide lifetime access to all 25 languages on Rosetta Stone to help refugees better navigate the resettlement process, communicate with IRAP staff and acclimate to their new homes. Conflicts and natural disasters prevent many refugees from returning home, and they often rely on legal aid to help them relocate to a safe country. IRAP grew out of similar efforts supporting refugee families displaced by the Iraq War to navigate complex and lengthy resettlement processes. It later expanded to become a global human rights organization that mobilizes free legal aid, litigation and systemic advocacy initiatives to empower displaced people. Rosetta Stone has supported IRAP since 2018. The collaboration began by providing language learning subscriptions to IRAP's staff, enabling the organization to better communicate with displaced persons while providing legal assistance. In light of the worsening refugee crisis, the partnership was extended in 2022 to aid IRAP's efforts and help more refugees acquire language skills. IRAP and its clients now have access to immersive lessons in 25 languages that build fluency and confidence, including the most popularly requested languages: English, French, German, Spanish and Arabic. Many refugees use Rosetta Stone as a valuable tool to better communicate with IRAP throughout resettlement and adjust to the culture of their new home before relocating there. Since displacement has a significant impact on children's education, the language lessons can also serve as a high-quality instructional resource. Additionally, IRAP staff use the language lessons to grow professionally and navigate cultural differences as the organization expands internationally. "Rosetta Stone is an important professional development resource for our team and organization," said IRAP Policy Director, Sunil Varghese. "IRAP works with refugees and partner organizations from around the world, and language capacity is a key component to our success. As global advocates for refugee rights and students of various languages, we appreciate Rosetta Stone's generosity to our organization and our clients." "Refugees face arduous journeys through complex legal systems in unfamiliar languages. IRAP's mission to provide displaced persons with legal resources to navigate these systems is both vital and admirable," said Paul Mishkin, CEO of IXL Learning, Rosetta Stone's parent company. "The renewed partnership underscores our commitment toward using education as an instrument of empowerment and removing language barriers so that refugees can build new futures." Through Rosetta Stone, learners practice new languages in an immersive environment that helps them build the fluency and confidence to speak. Lessons are filled with real-world images and audio from native speakers that accelerate language acquisition. Additionally, the TruAccent speech engine compares the learner to native speakers and gives immediate feedback on pronunciation, helping refugees feel confident participating in real-world conversations. Rosetta Stone can be accessed online or through its mobile app, which provides learners with a robust collection of speaking-focused activities that are available anytime, anywhere on iPhone, iPad and Android devices. Rosetta Stone also recently renewed its partnership with the Hebrew Immigrant Aid Society (HIAS) to continue providing its platform free of charge to assist the nonprofit's relief efforts. About IRAP The International Refugee Assistance Project (IRAP) develops and enforces a set of legal and human rights for refugees and displaced persons. Mobilizing direct legal aid, litigation, and systemic advocacy, IRAP serves the world's most persecuted individuals and empowers the next generation of human rights leaders. About Rosetta Stone Rosetta Stone is dedicated to changing people's lives through the power of language education. The company's innovative digital solutions drive positive learning outcomes for the inspired learner at home or in schools and workplaces around the world. Founded in 1992, Rosetta Stone uses advanced digital technology to help all types of learners read, write and speak 25 languages. Rosetta Stone joined the IXL Learning family of brands in 2021. Press Contacts Spencer Tilger International Refugee Assistance Project media@refugeerights.org 646.761.2556 Eric Bates IXL Learning press@ixl.com View original content to download multimedia: SOURCE IXL Learning	https://www.wlbt.com/prnewswire/2022/05/31/rosetta-stone-extends-partnership-with-irap-donating-language-learning-subscriptions-refugees/	2022-05-31T12:44:43	en	0.933987
UVALDE, Texas — Javier Cazares raced to his daughter’s school when he heard there was a shooting, leaving his truck running with the door open as he ran into the school yard. In his rush, he didn't bring his gun. He spent the next 35 to 45 agonizing minutes scanning the children fleeing Robb Elementary School for his 9-year-old “firecracker,” Jacklyn. All the while, he yearned to run in himself — and grew increasingly agitated, along with other parents, that the police weren't doing more to stop the gunman who holed up in a classroom, killing kids. “A lot of us were arguing with the police, ‘You all need to go in there. You all need to do your jobs,’” said Cazares, an Army veteran. “We were ready to go to work and rush in.” Nineteen children and two teachers were ultimately shot dead in the roughly 80 minutes the gunman spent inside the school in Uvalde, Texas, a small, predominantly Latino community that sits among vegetable fields halfway between San Antonio and the U.S.-Mexico border. The Justice Department has said it will review the law enforcement response. This account of the deadliest school shooting since Sandy Hook is based on law enforcement’s timeline, records and numerous interviews with Uvalde residents in the hours and days after the massacre. ___ Salvador Ramos was up early on May 24, sending ominous messages. The man authorities have identified as the gunman turned 18 the week before and promptly bought two AR-15-style rifles along with hundreds of rounds of ammunition. In the pre-dawn hours in his grandparents' shaded neighborhood just a half-mile from the site he would turn into a killing ground, Ramos wrote "I’m about to” to a woman over Instagram and sent someone a private Facebook message saying he was going to shoot his grandmother. Within hours, he’d done it. Sometime after 11 a.m., a neighbor who was in his yard heard a shot and looked up to see Ramos run out the front door of his grandparents' home to a pickup truck parked along the narrow street. The 18-year-old seemed panicked and struggled to get the Ford out of park, Gilbert Gallegos, 82, said. Ramos finally drove off, kicking a spray of gravel in the air. Moments later, his grandmother emerged from the single-story home covered in blood. “This is what he did,” Gallegos recalled her yelling. “He shot me.” Gallegos’ wife called 911 while he took the wounded woman into their backyard. As they hid and waited for the police, more gunshots rang out. ___ By 11:28 a.m., Ramos had sped to Robb Elementary and crashed the pickup in a drainage ditch, authorities said. At that moment, video shows a teacher entering the school through a door that the teacher had emerged from and propped open a minute earlier, according to Steven McCraw, the head of the Texas Department of Public Safety. That door was usually closed, and locked, per security protocol. But it stayed ajar. Witnesses said Ramos jumped from the passenger side of the truck with a rifle and a backpack full of ammunition. After shooting at two men who emerged from a nearby funeral home, Ramos hopped a chain-link fence and headed toward the school — still shooting — as panicked people nearby called the police. Authorities initially said Ramos exchanged fire with a school police officer before entering the building, but they later said the officer was not actually on campus and “sped” back upon hearing of the shooter. But the officer initially headed for the wrong man, confronting someone who turned out to be a teacher — after passing within feet of Ramos, who was crouched behind a vehicle parked outside the school. ___ From his hiding place, Ramos went for the propped-open door, slipped through it and into adjoining fourth-grade classrooms at 11:33 a.m., authorities said. He rapidly fired off more than 100 rounds. In one of those rooms, Miah Cerrillo, 11, covered herself with a friend’s blood to look dead, she told CNN. After the shooter moved into the adjacent room, she could hear screams, more gunfire and music being blared by the gunman. Two minutes after Ramos entered the school, three police officers followed him through the same door and were quickly joined by four more. Authorities said Ramos exchanged fire from the classroom with the officers in the hallway and two of them suffered “grazing wounds.” The first police on the scene were outgunned by Ramos' powerful, high-end rifle, according to a man who watched from a nearby home. “After he started firing at the cops, the cops stopped shooting,” said Juan Carranza, 24. “You could tell the firepower that he had was more powerful than the cops’ weapons.” After shots started ringing out, a cafeteria worker who had just finished serving chicken tacos to 75 third-graders said a woman shouted into the lunchroom: “Code black. This is not a drill!” The employees didn’t know what “code black” meant but closed blinds, locked the doors and escorted students behind a stage, said the worker, who spoke on condition of anonymity to avoid publicity. Some staff then took refuge in the kitchen. In the nearly half-hour after the first officers followed Ramos inside, as many as 19 piled into the hallway, authorities said. In the meantime, students and teachers elsewhere in the building were trying to get out, some climbing out of windows with the help of police. Cazares isn't sure exactly when he arrived on the scene, but when he did, he saw about five officers helping people escape. He kept a close watch to see if Jacklyn, who he later said loved gymnastics, singing and dancing, was among them. About 15 to 20 minutes after he got to the school, he said he spotted officers arriving with heavy shields for the first time. In the chaos, he felt that time was both “going so fast and it was was going so slow." But he added: “From what I saw, things could have been a lot different." Other parents felt the same. One onlooker recalled a woman yelling at officers, "Go in there! Go in there!” ___ At 12:03, a student called 911 and whispered that she was inside the classroom with the gunman. Minutes later, the Uvalde school district posted on Facebook that all campuses were going into lockdown but that “the students and staff are safe in the buildings. The buildings are secure.” The student called 911 again, minutes after her first call, to say there were multiple dead, and then called back soon after that, saying eight or nine students were still alive. Thirty-four minutes passed from the time of that last call to the moment a U.S. Border Patrol tactical team used a school employee's key to unlock the classroom door and kill the gunman. An open door had let him in. A locked door kept him in, and law enforcement out. ___ Police didn't breach the classroom faster because the commander inside the building — the school district’s police chief, Pete Arredondo — believed the situation had morphed from an active shooting to a hostage situation, said McCraw, of the Texas Department of Public Safety. Officers from other agencies urged the school police chief to let them move in because children were in danger, according to two law enforcement officials who spoke on condition of anonymity because they had not been authorized to discuss the investigation publicly. McCraw said gunfire was “sporadic” for much of the time that officers waited in the hallway and that investigators do not know if children died during that time. “It was the wrong decision,” McCraw said. Reporters from The Associated Press tried to speak to Arredondo at his home several times; on one visit, someone answered the door and said the police chief wouldn’t talk. He also did not reply to a phone message left at the district’s police headquarters. ___ The loss of so many young lives and the admission of errors by police have cast doubt, even for some Second Amendment-supporters in the Texas community, on a refrain the state’s Republican leaders have used after this and other mass shootings: “What stops armed bad guys is armed good guys.” Cazares, a gun owner and supporter of the Second Amendment, said he shies away from politics — but added that he thinks there should be stricter gun laws, including better background checks. He called selling the type of gun the assailant used to an 18-year-old “kind of ridiculous.” ___ Cazares left school before officers killed Ramos at 12:50 p.m. He rushed to the hospital because his niece said she'd seen Jacklyn in an ambulance. The entire family soon gathered there, pressing hospital staff for information for nearly three hours. Finally, a pastor, police officer and a doctor met with them. “My wife asked the question, ‘Is she alive or is she passed?’” Cazares said. “They were like, ‘No, she’s gone.’” When he was finally able to see his daughter's body, Cazares vowed that her death would not be in vain. Later, he fought back tears as he pondered his daughter's last moments. “She could be feisty,” he said. “It kind of comforts our hearts that she would be one of the ones that was brave and tried to help as much as she could.” ___ Bleiberg reported from Dallas. Associated Press journalists Jim Vertuno and Robert Bumsted in Uvalde, Mike Balsamo in Washington and Stephen Groves in Sioux Falls, South Dakota, contributed to this report.	https://www.12newsnow.com/article/news/special-reports/uvalde-school-shooting/a-dads-anguish-outside-texas-school-during-shooting/507-1e9b60ba-d13b-452b-ba21-7f3a165201b2	2022-05-31T12:44:46	en	0.986772
BERLIN (AP) — Authorities in Germany raided the offices of Deutsche Bank and its subsidiary DWS on Tuesday following claims that it was exaggerating the sustainable credentials of some of the products it sold. German news agency dpa quoted Frankfurt prosecutors saying the probe focused on allegations of investment fraud, but no specific suspects had been identified yet. A former manager in charge of sustainability at DWS has claimed that the asset management firm exaggerated the environmental and climate credentials of certain funds — referred to as “greenwashing.” “The measures of the Public Prosecutors are directed against unknown people in connection with greenwashing allegations against DWS,” Deutsche Bank said in a statement. “DWS said that they have continuously cooperated fully with all relevant regulators and authorities on this matter and will continue to do so.”	https://www.theheraldreview.com/news/article/Deutsche-Bank-subsidiary-raided-over-17209034.php	2022-05-31T12:44:47	en	0.980292
Golden State Wealth Management Welcomes Justin Peek of PEEK WEALTH, Exiting Edward Jones SOUTH COAST METRO, Calif., May 31, 2022 /PRNewswire/ -- Golden State Wealth Management is excited to announce the addition of Justin Peek, who operates under the DBA, PEEK WEALTHTM, and is the seventh advisor coming from Edward Jones. Justin serves as President of PEEK WEALTH and is a Certified Financial Planner®. The office is located in Carlsbad, CA and Justin has been providing the financial planning and investment needs of client families for nearly 20 years. He began his career in 2004 with Edward Jones. Over that time, he learned that the most impactful partnerships—where real 'magic' happens between client and advisor—is when there is alignment on values and philosophy. "Having a strong desire to serve clients more thoroughly and individually with an independent firm environment allows me to provide clients with a wider range of resources, investments, and financial planning technology. This, coupled with the autonomy and nimbleness of a boutique office, I can provide a next-level experience for my clients aiming to accomplish what is most important to them," says Justin. "We are more than pleased to add Justin and PEEK WEALTH to the Golden State Wealth Management team. I have personally known Justin for over 20 years. Understanding his business acumen, approach to financial planning and the care he takes with each and every client is exemplary, says Daniel R. Catone, Founder and CEO of Golden State Wealth Management, "I am excited to see how far he takes PEEK WEALTH," he continues. PEEK WEALTH is backed by the resources and technology of LPL Financial, the nation's largest independent broker-dealer1 and by Golden State Wealth Management, an investment adviser with over $1.5 billion in assets under management2 that provides personalized support systems such as compliance oversight, technology, marketing and operations. As a partner to Golden State Wealth Management, PEEK WEALTH is afforded multi-custodial flexibility through Charles Schwab and TD Ameritrade. Justin operates under a fiduciary standard and his firm serves a limited number of families to ensure they provide the highest level of comprehensive advice. Learn more about PEEK WEALTH at www.peekwealth.com. About Golden State Wealth Management Golden State Wealth Management is a Registered Investment Adviser that is dedicated to financial professionals and their clients. The firm's initial company was founded in 2013 by a group of executives who collectively contribute over 50 years of industry experience and has partnered with advisors serving over $1.5 billion in assets under management2. Golden State Wealth Management's infrastructure provides an extensive support network through succession planning, compliance oversight, dedicated transition support, and a Turnkey Asset Management Program. Golden State Wealth Management maintains business alignments with LPL Financial, the nation's largest independent broker/dealer1, TD Ameritrade Institutional and Charles Schwab, some of the nation's largest independent custodians, who provide comprehensive tools and research necessary in today's complex markets. Recognized as one of Orange County's largest RIAs3, Golden State Wealth Management's flagship office is located in South Coast Metro, California. With offices across the country, the firm is committed to creating an atmosphere that benefits both advisors and their investors. 1 As reported in Financial Planning magazine, June 1996-2021, based on total revenue. 2Source: SEC filing as of April 30, 2022; Golden State Wealth Management 3As reported in Orange County Business Journal, June 1, 2021, based on assets under management. Justin Peek and Daniel R. Catone are registered representatives with and securities offered through LPL Financial, Member FINRA/SIPC. Investment advice offered through Peek Wealth, an investment adviser registered with the SEC. Peek Wealth, Golden State Wealth Management and LPL Financial are separate entities. Registration as an investment adviser does not imply a certain level of skill or training. For information pertaining to the registration status of our firm, you may refer to the Investment Adviser Public Disclosure website (www.adviserinfo.sec.gov). Media Inquiries: Jennifer Nahas CMO, Golden State [email protected] SOURCE Golden State Wealth Management	https://www.prnewswire.com/news-releases/golden-state-wealth-management-welcomes-justin-peek-of-peek-wealth-exiting-edward-jones-301557039.html	2022-05-31T12:44:47	en	0.95274
Fight between 2 women leads to juvenile shooting, killing one of them, Orlando police say ORLANDO, Fla. - A woman is dead and two people, including a juvenile, are in custody after a shooting in Orlando, police said Tuesday. The shooting happened along Mercy Drive just before midnight. Police say two adult women were fighting and a juvenile female shot one of them. The woman was taken to Orlando Regional Medical Center where she was pronounced dead. MORE NEWS: Group calls for Orlando FreeFall ride to be taken down The juvenile and adult who survived have been arrested. Advertisement FOX 35 is working to learn more about the shooting and the names and ages of those involved.	https://www.fox35orlando.com/news/fight-between-2-women-leads-to-juvenile-shooting-killing-one-of-them-orlando-police-say	2022-05-31T12:44:50	en	0.981117
These two New Jersey wealth management professionals consistently show commitment to clients and maintain appropriate industry credentials WESTFIELD, N.J., May 31, 2022 /PRNewswire/ -- Once again this year, two advisory team members of Round Table Wealth Management (RTWM), an SEC Registered Investment Advisory firm, have received the Five Star Wealth Manager Award based on 10 objective eligibility and evaluation criteria including client retention and a regulatory review. This marks Mariella Foley's seventh year of winning the award, and Michael Fischer's third year. "The significant contributions that Mariella and Mike have made to our clients and firm over the past several years are outstanding," said Rich Policastro, President of RTWM. "Having them both achieve this award and accomplishment for multiple years is a testament to the quality of the relationships they've built and the professional, comprehensive services that we offer to our clients." Five Star Professional conducts market-specific research to recognize wealth management professionals who consistently show a commitment to clients, demonstrate strong industry credentials and are evaluated on the quality of their current practice. Founded in 2003, the Five Star Award Program is the largest and most widely published award program in North America, covering more than 45 major markets. Michael Fischer, honoree, believes that the team approach at RTWM is one of the reasons he is so successful. "I am grateful to work for a firm that continually seeks to provide first-class service to all clients. This attitude pushes me to always give my best, and it is an honor to see my hard work recognized with this award." In order to earn the award, a wealth manager must satisfy eligibility and evaluation criteria that are associated with wealth managers who provide quality services to their clients. Among the factors considered are assets under management and client retention rate as well as a thorough regulatory review. Mariella Foley, a seven-time award winner, shares her thoughts on the honor: "It means a lot to me to have received this award for consecutive years. As part of our fundamental principles, my goal is to provide the highest standard of service, a collaborative partnership, and a long-term commitment." Mariella Foley, CFP®, ADPA®, CDFA®, is a Partner and Wealth Advisor with Round Table Wealth Management. She has been with the firm since 2000 and has over 25 years of experience in the financial services industry. Heading the Women of ClarityTM program, Foley focuses her practice on working with women, advising them on their investments and finances and empowering them to take control of their financial lives whether they are experiencing a life transition due to divorce, death of a spouse or any other life changing event. Chosen to be a Featured Speaker for the InvestmentNews 2022 Women Adviser Summit, her areas of expertise include women in transition, female empowerment, multi-generational families, retirees and those going through divorce. Michael Fischer, CFP®, MST, Director and Wealth Advisor, has been a valued member of Round Table Wealth Management since 2011. Developing customized asset allocations, orchestrating comprehensive financial planning for each individual client and coordinating day-to-day client needs are just a small part of what makes him an outstanding member of the financial planning profession. Fischer focuses on solving the complex income and estate tax issues of his small business owner clients. Round Table Wealth Management (RTWM), an independent financial advisory firm established in 1999, is managed by four partners with over 100 years of industry experience. They, along with other members of the firm, form a dedicated team of highly-credentialed wealth advisors, financial planners, and investment management professionals. Global in their investing and personalized in their service, the firm provides objective strategies designed to meet the far-reaching goals of each client in a personal and comprehensive manner. Those clients are comprised of high-net-worth individuals, families (national and global), business owners, professionals, and women investors seeking thoughtful financial advice and guidance to grow and preserve their wealth. Assisting cross-border clients and expats with multi-national interests and a high degree of tax complexity is a key area of focus. In addition, the firm specializes in working with families and individuals who have multi-generational wealth concerns. With approximately $1.6B in assets under management (AUM) for its clients, RTWM offers personalized advisory services supported by institutional knowledge, deep experience, and skilled expertise. Their fiduciary approach involves a suite of holistic planning services including investment, philanthropy, retirement, insurance, cash flow and tax and estate counsel. Learn more at www.RoundTableWealth.com. Media Contact: Grace Vogelzang Impact Communications, Inc. 913-649-5009 GraceVogelzang@ImpactCommunications.org View original content to download multimedia: SOURCE Round Table Wealth Management	https://www.wlbt.com/prnewswire/2022/05/31/round-table-wealth-advisors-mariella-foley-michael-fischer-earn-five-star-wealth-manager-awards/	2022-05-31T12:44:50	en	0.959261
DUBAI, United Arab Emirates (AP) — Iran disrupted internet access to the outside world as angry demonstrators rallied over the collapse of a tower in southwestern Iran that has killed at least 34 people, experts said Tuesday as outrage and grief continued to grow in the country. The disruption has plunged the southwestern province into digital isolation, making it difficult for journalists to authenticate events on the ground and for activists to share footage and organize protests. It's a tactic the Iranian government has repeatedly employed during times of unrest, rights activists say, in a country where radio and television stations already are state-controlled and journalists face the threat of arrest. The internet interference in the oil-rich Khuzestan province started in early May, weeks before the fatal collapse, said Amir Rashidi, a researcher at Miaan Group, which focuses on digital security in the Middle East. The province, home to an ethnic Arab population that long has alleged discrimination, was a flashpoint in protests over the sinking economy and skyrocketing prices of food staples. Disruptions then intensified in the area after the Metropol Building collapse last week, according to data shared by the Miaan Group. The disaster ignited widespread anger in Abadan, where residents alleging government negligence gathered nightly at the site of the collapse to shout slogans against the Islamic Republic. Videos of the protests have circulated widely online, with some showing officers clubbing and firing tear gas at demonstrators. The footage analyzed by The Associated Press corresponded to known features of Abadan, some 660 kilometers (410 miles) southwest of the capital, Tehran. The number of casualties and arrests remains unclear. In response to the protests, Iranian authorities at times completely shut down the internet and other times allowed only tightly controlled use of a domestic Intranet, reported the Miaan Group. During the day, authorities also appear to have restricted bandwidths to make it very difficult for people to share large files, such as video, without leaving Abadan altogether, said Mahsa Alimardani, a senior researcher at Article 19, an international organization that fights censorship. Last Friday, as massive crowds took to the streets to chant against top officials, a digital barricade of sorts went up between Iran and the world, data showed. Only certain government-approved national websites could stream content but not websites based abroad. “There has been a pattern that we’ve seen when it gets dark where Google isn’t working but the website of the Supreme Leader is working well,” Rashidi said. The Iranian mission at the United Nations did not immediately respond to request for comment. Meanwhile, rescue workers pulled another body from the rubble on Tuesday, bringing the death toll to 34 amid fears more people could be trapped in the ruins. Five of the victims were school-age children, the official IRNA news agency reported. Another 37 people were injured in the collapse, with two still hospitalized. Officials have blamed the building’s structural failure on shoddy construction practices, lax regulation and entrenched corruption, raising questions about the safety of similar towers in the earthquake-prone country. Authorities reported they evacuated residents from buildings near the disaster site, fearing structural damages. The rising political and economic pressures come as talks to restore Tehran's tattered nuclear deal with world powers have hit a deadlock. Hostilities have simmered as Iran accelerates its nuclear program far beyond the limits of the nuclear deal and last week seized two Greek tankers on a key oil route through the Persian Gulf. In a sign of those rising tensions, Iran's Foreign Ministry sharply criticized the International Atomic Energy Agency on Tuesday over its quarterly report released the day before on Iran's nuclear program. Foreign Ministry spokesman Saeed Khatibzadeh rebuked the report's findings that Iran's highly enriched uranium stockpile had increased by 18 times since the 2015 nuclear deal as “not fair and balanced.” The U.N. nuclear watchdog also said that Iran has still failed to explain traces of uranium particles that IAEA inspectors found at former undeclared sites in the country — long a sore point between Iran and the agency despite a recent push for a resolution by June. Khatibzadeh said the agency's statements “did not reflect the reality of talks between Iran and the agency." “The agency should be watchful and not to destroy the path we walked down, with difficulty," he told reporters in Tehran.	https://www.theheraldreview.com/news/article/Experts-Iran-disrupts-internet-tower-collapse-17209048.php	2022-05-31T12:44:53	en	0.961937
Great Panther Announces Drill Results from the Urucum North Underground Project at the Tucano Gold Mine Drilling to be incorporated into an updated resource model for mine planning of the high-grade underground zones This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated October 15, 2021, to its short form base shelf prospectus dated September 10, 2021. TSX: GPR \| NYSE American: GPL VANCOUVER, BC, May 31, 2022 /PRNewswire/ - Great Panther Mining Limited (TSX: GPR) (NYSE-A: GPL) ("Great Panther" or the "Company"), a growth-oriented precious metals producer focused on the Americas, reports drill results for an additional 29 holes at the Urucum North ("URN") underground project at the Company's wholly owned Tucano Gold Mine ("Tucano") in Brazil. URN is the most northern of a series of open pits distributed along the 7-kilometre-long belt that hosts Tucano. Surface diamond drilling focused on a zone of multiple plunging high-grade lodes beneath the URN open pit where underground mine development studies are advancing. The resource conversion drill program, which commenced in 2021, was completed in April 2022 and totalled 18,948 metres ("m") in 48 drill holes. Drill results from the first 19 holes were announced in a news release dated July 22, 2021. Highlights from the remainder of the drill program are presented below and significant intercepts are presented in Table 1. Highlights (all intervals are estimated true mineralization widths) - 21URNDD028 2.5 m @ 5.80 g/t Au from 342 m - 21URNDD028 3.8 m @ 4.71 g/t Au from 409 m - 21URNDD049 3.9 m @ 7.65 g/t Au from 114 m - 21URNDD051 3.0 m @ 4.65 g/t Au from 139 m - 21URNDD053 3.7 m @ 6.20 g/t Au from 432.2 m Great Panther Chair and Interim CEO, Alan Hair, commented: "The zones of deeper, higher-grade mineralization being delineated at Urucum North demonstrate the potential for additional production from these underground resources in parallel with open pit operations at Tucano. In addition to the Urucum North underground zone, exploration has identified several similar potential high-grade zones associated with other pits along the seven-kilometre belt, which may also support underground production and warrant additional drilling. Drill results from the Urucum North underground will be incorporated into an updated underground resource estimate." Table 1: Significant intersections from drilling program (post-July 22, 2021) Notes: - Significant results are intersections that gave greater than 6 g/t Au*m (est. true width) - URNDD = URN diamond drilling - Grades over 2 g/t cut-off, max 2 m internal dilution - True widths are estimates based on current geologic knowledge but may vary after resource modelling. Drill hole inclinations vary between 55° and 75° and mineralization is sub-vertical. Intersection azimuths may be slightly oblique to the mineralized zones as a result of access constraints due to topography and pit development - Assays are first carried out by the Tucano Laboratory and all resource model assays are re-analyzed by the Certified SGS Laboratory in Belo Horizonte, Brazil. On receipt, following QA/QC approval, the SGS assays replace the Tucano assays in the resource database Diamond drilling was primarily focused on the URN high-grade zone (HGZ1), which lies less than 100 m below the planned URN final pit shell. In addition to the HGZ1 lode, drilling also identified an additional four high-grade lodes, which are being incorporated into the mine plan for Tucano. These lodes are expected to allow access to ore during early stages of ramp development prior to reaching the HGZ1 zone. The URN gold resource comprises five parallel, tabular bodies with grades ranging from 2 to 121 g/t gold and true thicknesses that range from a minimum true mining width of 2 m to 7 m (Figure 1). The gold mineralization is associated with pyrrhotite and hosted in banded iron formation and calc-silicate units. High-grade ore shoots plunge 20-30 degrees to the north. Drill samples are analyzed for gold by fire assay at Great Panther's onsite laboratory, with all samples to be included in the resource model re-analyzed at the certified SGS Laboratory in Belo Horizonte, where multi-element ICP analyses are also undertaken. The data is being modelled with updated mineralization and lithology wireframes being prepared for an updated resource model to support underground mine development planning. Engineering studies for underground development at URN are currently in progress. The drilling plan and mine planning focus is on near-term development and production largely above the -200 masl level (Figure 1) and will result in access to the top of the main high-grade zone (HGZ1) as well as provide access for reserve drilling along deeper parts of the HGZ1 and sub-parallel lodes and further infill drilling on the deeper, sub-parallel, plunging high-grade zone, shown in Figure 1. QUALIFIED PERSONS On behalf of Great Panther, Nicholas Winer, Fellow AusIMM supervised the preparation of data for inclusion in, and approved, this news release. Mr. Winer is a non-independent Qualified Person as defined by National Instrument 43-101 - Standards of Disclosure for Mineral Projects. The Qualified Person has reviewed the Tucano QA/QC program. The QA/QC program for drill core includes the regular insertion of blanks, standards, and duplicates into sample batches, diligent monitoring of assay results, and necessary remedial actions. Resource drilling samples are first assayed at the Tucano onsite laboratory. All intervals with anomalous gold are submitted and re-analyzed by the Certified, SGS Geosol laboratory in Belo Horizonte by 50 g fire-assay. All SGS Geosol assays, after diligent monitoring of QA/QC and necessary remedial actions, supersede the Tucano assay results in the database for MRMR grade estimation. In addition to the data verification methodology described above, personal inspections of the Tucano property have also been completed. ABOUT GREAT PANTHER Great Panther is a growth-oriented precious metals producer focused on the Americas. The Company owns a portfolio of assets in Brazil, Mexico and Peru that includes three gold and silver mines, an advanced development project and a large land package with district-scale potential. Great Panther is focused on creating long-term stakeholder value through safe and sustainable production, reinvesting into exploration and pursuing acquisition opportunities to complement its existing portfolio. Great Panther trades on the Toronto Stock Exchange trading under the symbol GPR and on the NYSE American under the symbol GPL. CAUTIONARY STATEMENT ON FORWARD-LOOKING INFORMATION This news release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward-looking information within the meaning of Canadian securities laws (together, "forward-looking statements"). Such forward-looking statements may include, but are not limited to, statements regarding (i) the potential for additional gold production resulting from exploration activities at URN, (ii) the Company's ability to commence production from underground resources in parallel with open pit operations, (iii) the Company's ability to extend Tucano's mine life, (iv) the potential for additional high-grade zones associated with other surface mines to support underground production, (v) the expectations that drilling and mine planning will result in access to the top of HGZ1 and provide access for reserve and infill drilling further below, (vi) the success of future mine and operational planning and the Company's ability to unlock the larger potential of the region at Tucano, and (vii) the Company's ability to grow as a result of exploration or from accretive acquisition opportunities in South America. These forward-looking statements and information reflect the Company's current views with respect to future events and are necessarily based upon a number of assumptions that, while considered reasonable by the Company, are inherently subject to significant operational, business, economic and regulatory uncertainties and contingencies. These assumptions include: continued operations and exploration work, including plans to complete infill drilling at Tucano in 2022 without significant interruption due to COVID-19 or any other reason; the accuracy of the Company's geological modeling at Tucano and the assumptions upon which they are based, ore grades and recoveries; prices for gold, silver, and base metals remaining as estimated; currency exchange rates remaining as estimated; prices and inflation rates for energy inputs, labour, materials, supplies and services (including transportation); all necessary permits, licenses and regulatory approvals for the Company's operations and exploration work are received in a timely manner on favourable terms, including permitting for tailings dam construction in Tucano; Tucano will be able to continue to use cyanide in its operations; the Company will not be required to impair Tucano as the current open pit mineral reserves are depleted through mining; the ability to procure equipment and operating supplies without interruption including the Company's ability to work with its current mining contractor in Tucano, U&M, to resolve equipment availability issues and restore contracted volume deficits without escalating to a formal dispute; the ability to fully mobilize the Company's new mine contractor, MINAX, in Q2; that there are no material unanticipated variations in the cost of energy or supplies; operations not being disrupted by issues such as pit-wall failures or instability, mechanical failures, labour disturbances and workforce shortages, illegal occupations or mining, seismic events, and adverse weather conditions; the Company's ability to comply with environmental, health and safety laws; the Company's ability to comply with Brazil's new tailings dam criteria and review processes and to secure the required permits for new tailings storage capacity beyond mid-2024 at competitive costs; and the Company's ability to maintain its stock exchange listings. The foregoing list of assumptions is not exhaustive. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements expressed or implied by such forward-looking statements to be materially different. Such factors include, among others, risks and uncertainties relating to: the impact of COVID-19 on the Company's ability to operate and conduct exploration work, including drilling plans, as anticipated, and the risk of an unplanned partial or full shutdown of the Company's mines and processing plants, whether voluntary or imposed, which would adversely impact the Company's revenues, financial condition and ability to meet its production and cost guidance and fund its capital programs and repay its indebtedness; the inherent risk that estimates of Mineral Reserves and Resources may not be accurate and accordingly that mine production will not be as estimated or predicted; planned exploration activities, including plans for further exploration drilling and infill drilling may not result in the discovery of new Mineral Resources/definition of Mineral Resources and readers are cautioned that Mineral Resources that are not Mineral Reserves have no defined economic viability; there is no certainty that the Company will be able to define a mineral resource with infill drilling and the Company is undertaking new mineral resource studies at URN and is not treating the AMC historical estimate as a current mineral resource estimate; open pit mining operations at Tucano have a limited established mine life and the Company may not be able to extend the mine life for Tucano open pit operations beyond 2025 as anticipated; gold, silver and base metal prices may decline or may be less than forecasted; fluctuations in currency exchange rates (including the U.S. dollar to Brazilian real exchange rate) may increase costs of operations; operational and physical risks inherent in mining operations (including pit wall collapses, tailings storage facility failures, environmental accidents and hazards, industrial accidents, equipment breakdown, unusual or unexpected geological or structural formations, cave-ins, flooding and severe weather) may result in unforeseen costs, shut downs, delays in production and drilling and exposure to liability; potential political and social risks involving Great Panther's operations in a foreign jurisdiction; the potential for unexpected costs and expenses or overruns; shortages in the ability to procure equipment and operating supplies without interruption including the inability of the Company to resolve concerns over lost production and equipment availability issues with contractor U&M and avoid any escalation to a formal dispute; employee and contractor relations; relationships with, and claims by, local communities; the Company's inability to obtain all necessary permits, licenses and regulatory approvals in a timely manner on favourable terms; changes in laws, regulations and government practices in the jurisdictions in which the Company operates; legal restrictions related to mining; diminishing quantities or grades of mineral reserves as properties are mined; operating or technical difficulties in mineral exploration; changes in project parameters as plans continue to be refined; the Company's inability to meet its production forecasts or to generate the anticipated cash flows from operations could result in the Company's inability to meet its scheduled debt payments when due or to meet financial covenants to which the Company is subject or to fund its exploration programs as planned; the Company's ability to raise additional financing to fund its operations, capital requirements or maturing debt obligations as required; the ability to maintain and renew agreements with local communities to support continued operations; ability to identify or complete acquisition opportunities or to complete acquisitions that are accretive to the Company; the potential for incremental closure bond requirements with respect to the Company's Coricancha mine and whether such requirements would have a material and adverse effect on the Company's liquidity and could require additional financing to be raised; the risk that the Company does not maintain its listing on the exchanges where it trades and that any delisting may have a material impact on the liquidity of its stock and its ability to raise capital; the potential for tailings storage facility permitting regulations in Brazil to negatively impact the Company's ability to maintain its existing tailings facilities without any modifications and to secure new tailings capacity at competitive costs or at all; and other risks and uncertainties, including those described in respect of Great Panther in its most recent annual information form and material change reports filed with the Canadian Securities Administrators available at www.sedar.com and reports on Form 40-F and Form 6-K filed with the Securities and Exchange Commission and available at www.sec.gov. There is no assurance that these forward-looking statements will prove accurate or that actual results will not vary materially from these forward-looking statements. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated, described, or intended. Accordingly, readers are cautioned not to place undue reliance on forward looking statements. Forward-looking statements and information are designed to help readers understand management's current views of our near- and longer-term prospects and may not be appropriate for other purposes. The Company does not intend, nor does it assume any obligation to update or revise forward-looking statements or information, whether as a result of new information, changes in assumptions, future events or otherwise, except to the extent required by applicable law. SOURCE Great Panther Mining Limited	https://www.prnewswire.com/news-releases/great-panther-announces-drill-results-from-the-urucum-north-underground-project-at-the-tucano-gold-mine-301557484.html	2022-05-31T12:44:54	en	0.931226
First all-female honor flight out of Florida heads to Washington D.C. SANFORD, Fla. - Florida’s first all-women honor flight left for Washington D.C. early Tuesday morning. "It’s always cool when you get with other vets. But these are all female vets. And you’ve got some that they came in when women weren’t exactly welcomed with open arms," said retired U.S. Army Lt. Col. Heath Davenport. She spent 25 years in the Army, working her way up to lieutenant colonel. But as a woman, she had to overcome a lot to prove herself. "So many people, you go and they say ‘oh was your husband in the military?’ No, it was me," said Davenport. That’s why she’s so touched to fly to Washington D.C. on an honor flight this week. It’s the first all-female honor flight out of Florida. One hundred and nine female veterans and their provided guardians will go on a grand tour of D.C., including monuments, war memorials, and banquets. MORE NEWS: 'Taps Across America' echoes through Central Florida community The oldest woman is board is 97-years-old. Heath Davenport Heath is familiar with the city. She’s served two tours at the Pentagon, but for some others, "For some of these gals, it’s going to be fun to look around and see because some of them have never been to the Tomb of the Unknown. So to see them experience is going to be cool." We asked if serving at the Pentagon was what she was most proud of. But she told us "I’d say probably the thing I’m most proud of is being Airborne. When I went, there were no women there, so it was really unusual, so I’m going to be wearing my Airborne hat." Advertisement The women took off for D.C. at 6 a.m. Tuesday. Usually, these honor flights are done in one day, but these female veterans raised the funds and will be spending the night in the Capitol before returning Wednesday night.	https://www.fox35orlando.com/news/first-all-female-honor-flight-out-of-florida-heads-to-washington-d-c	2022-05-31T12:44:56	en	0.975387
The #SayGay campaign features gender-neutral fragrances and a bold fashion assortment supporting the most diverse customer base in retail WARRENDALE, Pa., May 31, 2022 /PRNewswire/ -- rue21, a leading American specialty retailer, announced today its #SayGay Pride 2022 campaign partnering with The Trevor Project, the world's largest suicide prevention and mental health organization for lesbian, gay, bisexual, transgender, queer & questioning (LGBTQ) young people. In addition to launching a new gender-neutral clothing assortment and two returning fragrances, rue21 will make a donation to The Trevor Project, which will help expand their free, 24/7 crisis services to serve the more than 1.8 million LGBTQ young people who seriously consider suicide each year in the U.S. rue21 proudly serves the most vibrant, fastest-growing and historically underserved segment of Gen Z shoppers, who are considered the most socially aware generation. According to a study by global analytics and advice firm Gallup, one in five Gen Z adults identify as LGBTQ. This year's Pride Month campaign and collection further demonstrates the brand's commitment to celebrating inclusivity and community as part of its core values, empowering young people of all identities to express their authentic selves every day. "Our customer is the heart of our brand, and we proudly stand alongside our community with our #SAYGAY Campaign," said rue21's CEO, Bill Brand. "Our customer base is a kaleidoscope of races, ethnicities, genders and orientations, and we want everyone to feel and look good, simply because they feel and look like themselves. rue21 is committed to empowering people of all identities as part of our core values and ensuring affordable fashion for all to express themselves through style, and we are honored to partner with The Trevor Project once again to bring awareness to the issues facing the LGBTQ community." The Pride 2022 Collection further empowers the youth and accelerates acceptance by providing them with the freedom of expression through fashion. The collection features a gender-neutral clothing assortment, including accessories, shorts, screen tees, and underwear in sizes XS-4X, and "Unity Love" and "Unity Strong" fragrances. Pricing ranges from $3.99 to $32.99. Select products feature statements such as "Stay Proud," "Let Me Be Perfectly Queer" and "LGBT Rights Are Human Rights." "Every product we offer allows our customer to express their individuality through their own personal style while celebrating our differences," said Cat Morisano, Chief Merchandising Officer. "At rue21, integrity matters and we own our words and actions, and our Pride collection is our continued commitment to show that all are accepted, respected and welcomed." According to research conducted by The Trevor Project, more than 1.8 million LGBTQ young people in the U.S. seriously consider suicide –and at least one LGBTQ young person attempts suicide every 45 seconds. Those are staggering numbers, but Trevor's research also indicates that LGBTQ youth who reported having at least one LGBTQ-affirming space had 35% reduced odds of attempting suicide in the past year. All products in the collection are available at rue21.com and in rue21 stores nationwide. The campaign goes until the end of June. Resources courtesy of The Trevor Project can be found here. For media requests, please contact Najah Hooks at Najah@skaibluemedia.com. About rue21 rue21 is a fashion destination that promises to give customers quality styles at accessible prices. They offer the largest selection of products, sizes, and trends that fit every personality and budget. Headquartered just north of Pittsburgh, Pennsylvania, in Warrendale, they currently operate over 650 US stores in 45 states and online at www.rue21.com. About The Trevor Project The Trevor Project is the world's largest suicide prevention and mental health organization for lesbian, gay, bisexual, transgender, queer & questioning (LGBTQ) young people. The Trevor Project offers a suite of 24/7 crisis intervention and suicide prevention programs, including TrevorLifeline, TrevorText, and TrevorChat as well as the world's largest safe space social networking site for LGBTQ youth, TrevorSpace. Trevor also operates an education program with resources for youth-serving adults and organizations, an advocacy department fighting for pro-LGBTQ legislation and against anti-LGBTQ rhetoric/policy positions, and a research team to discover the most effective means to help young LGBTQ people in crisis and end suicide. If you or someone you know is feeling hopeless or suicidal, our trained crisis counselors are available 24/7 at 1-866-488-7386, via chat TheTrevorProject.org/Help, or by texting 678678. PRESS CONTACT Najah Hooks Skai Blue Media Najah@skaibluemedia.com View original content to download multimedia: SOURCE rue21	https://www.wlbt.com/prnewswire/2022/05/31/rue21-launches-saygay-pride-2022-campaign-partnering-with-lgbtq-nonprofit-trevor-project/	2022-05-31T12:44:57	en	0.940261
BERLIN (AP) — Police raided homes and offices in northern and western Germany on Tuesday as part of an investigation into a case involving five men accused of fraudulently applying for 26 million ($28 million) worth of pandemic-linked aid. The German government drew up a series of aid packages to help businesses withstand the impact of lockdowns and other restrictions at the height of the coronavirus pandemic. The suspects in this investigation — men aged 26 to 62 — are suspected of making at least 363 aid applications under false pretenses “for their own purposes and for companies that commissioned them,” according to a police statement. It's believed to have resulted in a loss of several million euros, it added. The investigation was launched in April 2020 after a development bank in the northern state of Lower Saxony reported suspicious activity. Twenty-five properties were raided on Tuesday, including the five suspects' homes, but police said there were no arrests. They froze assets totaling 3.5 million euros, seizing cash and expensive watches. In a separate case, a 20-year-old man was on Monday convicted of fraud in the southwestern city of Freiburg for taking 5.7 million euros from a doctors' association last year for a test center he never opened, German news agenc dpa reported. A bank later returned the money. The court will decide after a year's probation whether to impose a sentence under juvenile law. He was ordered to pay 1,500 euros to charity and cover the costs of the proceedings, dpa reported. ___ Follow all of AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic	https://www.theheraldreview.com/news/article/German-police-mount-raids-in-COVID-19-aid-fraud-17209025.php	2022-05-31T12:44:59	en	0.968141
Hexaware is a proud Snow Row Partner at the Snowflake Summit 2022 ISELIN, N.J., May 31, 2022 /PRNewswire/ -- Hexaware Technologies, one of the fastest-growing next-generation digital transformation providers, is proud to sponsor the Snowflake Summit 2022 in Las Vegas. Starting June 13, the four-day Summit is Snowflake's biggest event of the year, with more than 12,000 attendees. Snowflake customers, partners, and industry peers will gather to collaborate around data, with the goal of developing new data products, apps, and cutting-edge solutions that will help drive businesses forward. At the event, Hexaware will be launching Crystal, its proprietary accelerator for Snowflake modernization. Crystal will help businesses accelerate, optimize, innovate and speed time to value on their data cloud journey. The IP is a game-changer for end-to-end enterprise transformation powered by Amaze® for Data and AI, Hexaware's enterprise data management platform for seamless migration of data warehouse and analytics ecosystems to the cloud. Crystal enables an optimized data cloud experience, with its automation-led approach offering substantial TCO and implementation cost savings. As a Snow Row Partner, Hexaware helps future-ready businesses connect data silos to Snowflake storage solutions for integrated access anytime, anywhere. Their data cloud experts will be in person at the event to answer all questions about making the most of Snowflake data with their connectivity solutions. During the four-day conference, Hexaware will be showcasing its thought leadership expertise at exhibit booth #1109c. To know more about how Hexaware can help enterprises rapidly migrate their data to Snowflake's Data Cloud in an accelerated and cost-efficient way, check out their Snowflake services spectrum. About Hexaware Hexaware is a global IT, BPS and consulting services company empowering businesses worldwide to realize digital transformation at scale and speed. Learn more about Hexaware at https://www.hexaware.com. SOURCE Hexaware Technologies Ltd.	https://www.prnewswire.com/news-releases/hexaware-is-a-proud-snow-row-partner-at-the-snowflake-summit-2022-301557693.html	2022-05-31T12:45:00	en	0.90257
Fisherman spots whale shark feeding on plankton off coast of Sarasota SARASOTA, Fla. - First, a fisherman spotted a line of plankton near Sarasota, then, to his surprise, a whale shark breached the surface. "That's wild!" said Brad Ward, who was offshore fishing about 26 miles from New Pass. He quickly started capturing video of the encounter. "He's soaking in this line of plankton here," Ward said in the video. "He's soaking it up." It's not unusual for whale sharks to make their presence known near Tampa Bay. They are usually seen between March and June – and have been spotted for several years. READ: Yearly tradition of whale shark sightings off Anna Maria Island continues In early June 2018, there were two sightings of a whale shark off Anna Maria Island. A few days later, vacationers spotted a large whale shark in the same area. Five days later, boaters got an underwater look at a whale shark off St. Pete Beach. One year and three days later, a FOX 13 viewer captured underwater video of a whale shark in the same spot. And in June 2019, a fisherman saw a whale shark off Clearwater Beach. Advertisement It’s unclear whether the whale shark might be the same one, year after year, but the sightings are a sign whale sharks are able to thrive in the waters off Tampa Bay.	https://www.fox35orlando.com/news/fisherman-spots-whale-shark-feeding-on-plankton-off-coast-of-sarasota	2022-05-31T12:45:02	en	0.971304
Funding from Peach State Health Plan helps local health providers with purchasing medical equipment ATLANTA, May 31, 2022 /PRNewswire/ -- Today, Peach State Health Plan announced it awarded $35,000 in financial grants to seven providers in Georgia for ranking among the top 100 providers with the highest increase in COVID-19 vaccination rates. Last year, Centene, the parent company of Peach State Health Plan, formed an initiative to encourage Peach State Health Plan providers to educate members about the COVID-19 vaccine. The top 100 providers with the highest increase in vaccination rates after the initiative would receive a $5,000 grant for medical equipment. Seven local providers were recognized for their top rankings: - Buford Norcross Primary Care, Southbridge Pkwy, Alpharetta - Better Health Medical Group, Steve Reynolds Blvd, Norcross - Gwinnett Hospital System, East Crogan St, Lawrenceville - SY Med, LLC, Philip Blvd, Lawrenceville - QCPI-VillageMD, PC, Old Norcross Rd, Lawrenceville - Sumter Pediatrics, LLC, GA Hwy 27 E, Americus - Stone Mountain Family Medicine, Hairston Rd, Stone Mountain "Medical equipment can be expensive, especially as providers deal with the ongoing repercussions of the pandemic and its impact on their resources," said Wade Rakes, CEO and President of Peach State Health Plan. "By pairing vaccination efforts with medical equipment grants, we're not only helping our network of trusted providers protect their communities and loved ones from COVID-19; we're helping them invest in efficiency and new equipment for their facilities to continue providing quality healthcare to every individual who walks through their doors." As the world continues to face outbreaks caused by COVID-19 variants, it is important as ever to receive the COVID-19 vaccine. Through this initiative, Centene and Peach State Health Plan worked with local providers to conduct engagement campaigns that educated their patients about the importance of getting vaccinated. The additional incentive helped motivate providers to engage their communities as much as possible and increase vaccination rates. "We take it seriously in protecting our community, especially the vulnerable population during this pandemic," said Dr. Nelson Madrazo of Sumter Pediatrics, LLC. "We believe vaccination is our best tool in combating COVID-19. Get vaccinated!" For more information about Peach State Health Plan and its activities, visit https://www.pshpgeorgia.com/www.pshp.com. Peach State Health Plan is a Care Management Organization that serves the needs of Georgians through a range of health insurance solutions. Peach State Health Plan serves the Medicaid and PeachCare for Kids® population in partnership with Georgia Families. The organization also focuses on under-insured and uninsured individuals through its federal insurance marketplace plan, Ambetter, and its Medicare Advantage Special Needs Plan. Peach State Health Plan is a wholly-owned subsidiary of Centene Corporation, a leading multi-line healthcare enterprise. For more information visit www.pshp.com. View original content: SOURCE Peach State Health Plan	https://www.wlbt.com/prnewswire/2022/05/31/seven-georgia-healthcare-providers-receive-grants-covid-vaccination-efforts/	2022-05-31T12:45:03	en	0.93912
CAIRO (AP) — Human Rights Watch on Tuesday called for the International Criminal Court to investigate allegations of the use of landmines in 2019 by Russian paramilitaries fighting in Libya. According to the New York-based watchdog, new data has emerged from Libyan demining groups linking mercenaries from Russia’s Wagner Group to the use of “banned booby traps” in Libya during an offensive by east-based Libyan forces trying to capture the capital of Tripoli from rival militias. The Wagner Group backed the offensive of the east-based forces led by commander Khalifa Hifter, who was also supported at the time by the United Arab Emirates, Egypt and Russia. Hifter’s offensive collapsed in the spring of 2020, when Turkey and Qatar stepped up their military support to his rivals in western Libya. Libya plunged into turmoil after a NATO-backed uprising in 2011 toppled dictator Moammar Gadhafi, who was later killed. It has for years been split between rival administrations, each backed by different militias and foreign powers. Lama Fakih, HRW’s director for Mideast and North Africa, said a “transparent and international” inquiry is needed to look into the use of land mines around Tripoli. The group said that a demining group with the Tripoli-based Defense Ministry reported that mines and other explosive ordnance killed at least 130 people and wounded 196, mostly civilians, between May 2020 and March 2022 in Tripoli’s southern suburbs. HRW cited a tablet left on a Libyan battlefield by a Wagner mercenary that contained maps of the locations of 35 unmarked anti-personnel mines. The tablet was obtained by the BBC in early 2021. A U.N. panel of experts said earlier this week it considers the device to be authentic.	https://www.theheraldreview.com/news/article/Group-urges-ICC-to-probe-alleged-use-of-mines-in-17209002.php	2022-05-31T12:45:05	en	0.960911
AUSTIN, Minn., May 31, 2022 /PRNewswire/ -- Hormel Foods Corporation (NYSE: HRL), a global branded food company, will be participating at the 2022 Deutsche Bank dbAccess Global Consumer Conference in Paris, France. Jim Snee, chairman of the board, president and chief executive officer, and Swen Neufeldt, group vice president and president of Hormel Foods International Corporation, will represent the company. Hormel Foods Corporation, based in Austin, Minn., is a global branded food company with over $11 billion in annual revenue across more than 80 countries worldwide. Its brands include Planters®, SKIPPY®, SPAM®, Hormel® Natural Choice®, Applegate®, Justin's®, Wholly®, Hormel® Black Label®, Columbus®, Jennie-O® and more than 30 other beloved brands. The company is a member of the S&P 500 Index and the S&P 500 Dividend Aristocrats, was named on the "Global 2000 World's Best Employers" list by Forbes magazine for three years, is one of Fortune magazine's most admired companies, has appeared on the "100 Best Corporate Citizens" list by 3BL Media 13 times, and has received numerous other awards and accolades for its corporate responsibility and community service efforts. The company lives by its purpose statement — Inspired People. Inspired Food.™ — to bring some of the world's most trusted and iconic brands to tables across the globe. For more information, visit www.hormelfoods.com. SOURCE Hormel Foods Corporation	https://www.prnewswire.com/news-releases/hormel-foods-corporation-to-participate-in-the-deutsche-bank-dbaccess-global-consumer-conference-301557550.html	2022-05-31T12:45:06	en	0.951145
Hurricane Agatha's remnants could bring rain to Florida this weekend PUERTO ESCONDIDO, Mexico - Hurricane Agatha made history as the strongest hurricane ever recorded to come ashore in May during the eastern Pacific hurricane center, making landfall on a sparsely populated stretch of small beach towns and fishing villages in southern Mexico. The storm came ashore in Oaxaca state Monday afternoon as a strong Category 2 hurricane, with maximum sustained winds of 105 mph (165kph), then it quickly lost power as it moved inland over the mountainous interior. Agatha was downgraded to a tropical storm late Monday, its sustained winds down to 70 mph (110 kph). The U.S. National Hurricane Center said the storm should dissipate overnight, but warned that the system’s heavy rains still posed a threat of dangerous flash floods for Mexico’s southern states. According to the National Hurricane Center (NHC), there is now a 60-percent chance for the remnants to redevelop. "A large and complex area of low pressure is expected to develop near the Yucatan Peninsula and the northwestern Caribbean Sea in a couple of days, partially related to the remnants of Agatha from the eastern Pacific," the NHC said Tuesday. "Despite strong upper-level winds over the area, this system could become a tropical depression while it moves northeastward over the northwestern Caribbean Sea and southeastern Gulf of Mexico late this week." Regardless of development, the NHC says locally heavy rainfall is likely across portions of southeastern Mexico, the Yucatan Peninsula, Guatemala, and Belize during the next few days, spreading across western Cuba, southern Florida, and the Florida Keys by the end of the week. Torrential rains and howling winds whipped palm trees and drove tourists and residents in Mexico into shelters. Oaxaca state’s civil defense agency showed families hustling into a shelter in Pochutla and a rock and mud slide that blocked a highway. RELATED: Tracking the Tropics: FOX 35 presents 2022 hurricane season preview Tuesday night Heavy rain and big waves lashed the beach town of Zipolite, long known for its clothing-optional beach and bohemian vibe. "There is a lot of rain and sudden gusts of strong wind," said Silvia Ranfagni, manager of the Casa Kalmar hotel in Zipolite. Ranfagni, who decided to ride out Agatha at the property, said, "You can hear the wind howling." DOWNLOAD: FOX 35 NEWS APP \| FOX 35 STORM TEAM WEATHER APP Heavy rain and big waves lashed the beach town of Zipolite, long known for its clothing-optional beach and bohemian vibe. Advertisement "There is a lot of rain and sudden gusts of strong wind," said Silvia Ranfagni, manager of the Casa Kalmar hotel in Zipolite. Ranfagni, who decided to ride out Agatha at the property, said, "You can hear the wind howling."	https://www.fox35orlando.com/news/hurricane-agathas-remnants-could-bring-rain-to-florida-this-weekend	2022-05-31T12:45:08	en	0.943736
BOCA RATON, Fla., May 31, 2022 /PRNewswire/ -- springbig, a leading provider of SaaS-based marketing solutions, consumer mobile app experiences, and omnichannel loyalty programs to the cannabis industry, today announced that it will participate in the Jefferies Cannabis Summit being held on Thursday, June 2, 2022 in New York. Jeffrey Harris, Chief Executive Officer and Co-Founder, is scheduled to participate in the cannabis technology panel taking place at 9:45 a.m. ET. Additionally, Mr. Harris and Paul Sykes, Chief Financial Officer, will attend one-on-one meetings with investors throughout the day. To schedule a meeting with springbig's management, please contact your Jefferies representative. About springbig springbig is a market-leading software platform providing customer loyalty and marketing automation solutions to cannabis retailers and brands in the U.S. and Canada. springbig's platform connects consumers with retailers and brands, primarily through SMS marketing, as well as emails, customer feedback system, and loyalty programs, to support retailers' and brands' customer engagement and retention. springbig offers marketing automation solutions that provide for consistency of customer communication, thereby driving customer retention and retail foot traffic. Additionally, springbig's reporting and analytics offerings deliver valuable insights that clients utilize to better understand their customer base, purchasing habits and trends. On November 9, 2021, springbig announced that it entered into a definitive agreement for a business combination with Tuatara Capital Acquisition Corporation (NASDAQ: TCAC), subject to closing conditions and shareholder and regulatory approvals. The closing of the business combination is expected to take place approximately mid-June 2022 and in connection with the completion of the transaction, TCAC intends to change its name to SpringBig Holdings, Inc. Following closing, SpringBig Holdings, Inc. common stock and warrants are expected to remain listed on the Nasdaq Global Select stock market under the new ticker symbols "SBIG" and "SBIGW". For more information about springbig, visit https://springbig.com/. Investor Relations Contact Courtney Van Alstyne MATTIO Communications ir@mattio.com Media Contact Phoebe Wilson MATTIO Communications springbig@mattio.com View original content to download multimedia: SOURCE springbig	https://www.wlbt.com/prnewswire/2022/05/31/springbig-announces-participation-jefferies-cannabis-summit-june-2-2022/	2022-05-31T12:45:10	en	0.923248
This is a carousel. Use Next and Previous buttons to navigate BUDAPEST, Hungary (AP) — Hungary's divisive leader has once again got his own way with the European Union — this time in tough negotiations on Russian oil at a summit in Brussels. And nationalist Prime Minister Viktor Orban wasn't shy about trumpeting his success in leveraging the bloc to win significant concessions, allowing his country to continue purchasing Russian crude even as war rages on in neighboring Ukraine. The European Commission’s "proposal to ban the use of Russian oil in Hungary was defeated,” Orban said in a video statement on Facebook. “Families can sleep well tonight as the most outrageous idea has been averted.” EU leaders concluded four weeks of negotiations on Monday to impose a partial embargo on Russian oil imports. The package of sanctions, the sixth imposed by the EU since the start of the war in February, had been delayed by vigorous opposition from Orban — widely seen as the Kremlin’s closest EU ally — who threatened to derail the block’s efforts to punish Moscow for its war if they affected energy imports to Hungary. While the agreement bans all Russian oil from being brought into the EU by sea, it allowed a temporary exemption for imports delivered by the Russian Druzhba pipeline to certain landlocked countries in Central Europe — something Orban touted as a victory for Hungarian interests over what he portrayed as potentially disastrous recommendations by the EU. EU officials say the agreement will succeed in cutting off 90% of Russian oil imports by year's end. But it was the latest instance of Orban breaking ranks with his European partners, dividing the bloc’s united response to crises and ensuring that Russian President Vladimir Putin still has an economic foothold in the EU. Hungary — which gets around 65% of its oil and 85% of its gas from Russia — was alone among Ukraine's EU neighbors to refuse to supply it with military aid. It also banned the shipment of lethal weapons into Ukraine across its borders, a policy that drew the ire of many EU leaders and of Ukrainian President Volodymyr Zelenskyy. Orban has also blocked other EU decisions which require unanimity among member states, including attempts last year to issue a joint statement on China's crackdown on a pro-democracy movement in Hong Kong and a joint call for a cease-fire in the Israeli-Palestinian conflict — also in 2021 . In 2020, Hungary joined its ally Poland in vetoing the EU's seven-year budget and a massive coronavirus recovery plan, stymying efforts to jumpstart European economies during the COVID-19 pandemic and plunging the 27-nation bloc into a political crisis. Yet despite Hungary's refusal to adopt the oil embargo as proposed, EU leaders hailed Monday's agreement as a success. European Council President Charles Michel tweeted that it covers more than two-thirds of EU oil imports from Russia, “cutting a huge source of financing for its war machine.” Along with Hungary, both the Czech Republic and Slovakia sought exemptions from the EU embargo, arguing their dependence on Russian oil made an immediate cutoff unrealistic. Slovakia gets around 97% of its oil from Russia through the Druzhba pipeline, and has argued that the country’s key refiner, Slovnaft, needs to be reoutfitted to be able to process any oil type other than Russian crude, a process that could take several years. But Orban's opponents see the pipeline concession as another instance of the autocratic leader dividing the EU to serve his own purposes. In a tweet on Tuesday, Hungarian member of the European Parliament Katalin Cseh said that Orban had “navigated Hungary into a desperate dependency on Russian energy.” “He then declares ‘victory’ over the EU, whose solidarity and protection is our only chance,” Cseh wrote. At home, Orban has depicted the debate over the oil embargo as a fight to defend Hungarians' pocketbooks, especially as it concerns household utility costs which have been subsidized by the government since 2013 as a flagship policy of Orban's government. “The most important news is that we defended the utility cost reduction,” Orban said following the end of the EU summit on Tuesday. ___ Karel Janicek contributed to this report from Prague. ___ Follow the AP’s coverage of the war at https://apnews.com/hub/russia-ukraine	https://www.theheraldreview.com/news/article/Hungary-s-Orban-wins-exemption-in-EU-Russian-oil-17209039.php	2022-05-31T12:45:11	en	0.9719
Johnny Depp-Amber Heard trial: Jury to continue deliberations in defamation case FALLS CHURCH, Va. - A Virginia jury will continue deliberations on Tuesday in Johnny Depp’s $50 million libel trial against his ex-wife Amber Heard, a closely-watched case that has drawn millions of viewers online and much public debate surrounding the claims. Testimony throughout the six-week trial provided an ugly glimpse into the couple's seemingly toxic relationship and captivated the public, with some fans even camping out and spending tens of thousands of dollars for a chance to witness the court proceedings in person. Both sides gave their closing arguments on Friday and the civil case went into the hands of the seven-person jury. Depp sued Heard for libel in Fairfax County Circuit Court over a December 2018 op-ed she wrote in The Washington Post describing herself as "a public figure representing domestic abuse." The article never even mentions Depp by name, but his lawyers say he was defamed nonetheless. Most of the article discusses public policy as it relates to domestic violence, and Heard's lawyers say she has a First Amendment right to weigh in. (L) Actor Amber Heard testifies in the courtroom at the Fairfax County Circuit Courthouse in Fairfax, Virginia, on May 16, 2022. (R) Actor Johnny Depp returns to the courtroom after a lunch break at the Fairfax County Circuit Court during his defamat In the first passage, Heard wrote that "two years ago, I became a public figure representing domestic abuse, and I felt the full force of our culture’s wrath." Depp’s lawyers called it a clear reference to Depp, given that Heard publicly accused Depp of domestic violence in 2016 — two years before she wrote the article. In a second passage, she stated, "I had the rare vantage point of seeing, in real-time, how institutions protect men accused of abuse." Depp's lawyers are also seeking damages over a headline that appeared above the online version of the article, even though Heard didn't write it. Heard also filed a $100 million counterclaim against the former "Pirates of the Caribbean" star after his lawyer called her allegations a hoax. During the trial, Heard testified about more than a dozen episodes of physical and sexual assault that she said Depp inflicted on her. Depp says he never struck Heard and that she concocted the abuse allegations. He has said he was the one physically attacked by Heard multiple times. What does the Johnny Depp-Amber Heard trial jury have to decide? The jury is now tasked with deciding whether those passages in the Washington Post are defamatory. And the verdict form gives them step-by-step instructions on how to determine that. They also must come to a unanimous decision for a verdict. Because both Heard and Depp are Hollywood actors, they're considered public figures under the law — meaning there's a higher bar to clear to prove defamation. Depp has to prove that Heard acted with actual malice, meaning she knew she was lying when she made her claims or she acted with reckless disregard for the truth. And though the counterclaim has received less attention at the trial, Heard's lawyer Elaine Bredehoft said it provides an avenue for the jury to compensate Heard for the abuse Depp inflicted on her even after they split by orchestrating a smear campaign. If the jury finds that either party defamed the other, they have to calculate how much that defamation damaged the hurt party financially. The jury also has to consider the value of reputation loss. When is the verdict for the Depp-Heard trial? The seven-person civil jury began its deliberations at 3 p.m. Friday and finished for the day about two hours later. They will resume Tuesday, looking at all the testimony, pictures and videos submitted into evidence. The judge said the jury will deliberate into the evening each day that they do their work, but not over weekends or holidays. Johnny Depp and Amber Heard’s relationship timeline The two met in 2009 while filming "The Rum Diary." Despite their 22-year age difference, Heard testified there was an instant connection when Depp met with her as he considered her for a role in the film. "I was a no-name actor. I was 22. He was twice my age. He’s this world-famous actor and here we are getting along about obscure books, old blues" music, testified Heard, who’s now 36. While they had chemistry during the filming of the movie, she said they didn’t begin dating until doing a press tour for the film’s release in 2011. At the outset, they kept their relationship a secret. Heard testified that the first act of physical abuse against her by Depp happened in 2013. The two married in February 2015 reportedly at their Los Angeles home, but the nuptials didn’t last long. In May 2016, Heard filed for divorce and obtained a temporary restraining order against Depp. Their divorce was finalized in early 2017, with Heard saying she was going to donate her $7 million settlement to charity. Heard’s op-ed was published in The Washington Post in 2018. In 2019, Depp filed a $50-million defamation lawsuit against her. Heard countersued Depp for $100 million. The defamation trial began on April 12, 2022. Johnny Depp-Amber Heard abuse claims In order to rule on Depp’s libel claim, the jury must decide whether the facts in the case prove Depp, in fact, abused Heard. Depp said he never physically abused her, while Heard said she was assaulted on more than a dozen occasions. Depp also alleged he was the victim of abuse inflicted by her. Heard testified the first act of physical violence against her happened in 2013. She said it happened when the two were talking about one of Depp’s tattoos, and she said she made the mistake of laughing at it. She said Depp responded by slapping her. Thinking the slap must be a joke, she laughed more. Depp responded by slapping her twice more, with the third slap knocking Heard off balance. Depp, while he was on the stand, flatly denied it occurred. The tattoo in question was one that used to say "Winona Forever," which Depp got when he was dating actor Winona Ryder. He had it altered to "Wino Forever" when they broke up. Depp and Heard both agreed the worst violence occurred in March 2015 in Australia while Depp was shooting the fifth "Pirates of the Caribbean" movie, but that’s where their agreement of the account ends. Heard said Depp sexually assaulted her with a bottle of Maker’s Mark bourbon as part of an alcohol-fueled rage that included accusing her of infidelity with a co-star. Depp said he was the victim of violence because Heard was irate over a pending post-nuptial agreement and his struggles with sobriety. Depp testified Heard threw a liquor bottle at him twice, and that one smashed against his hand while it rested on a counter and severed the tip of his middle finger. Photos of the aftermath showed Depp wrote vulgar messages to his wife in blood on the walls of the house. Jurors also saw contemporaneous text messages Depp sent to others in which he said he cut off his own finger. Depp said he made up that story to protect Heard and avoid police involvement. A hand surgeon later testified that Depp could not have lost the tip of his middle finger the way he told jurors it happened. Why is Depp-Heard trial happening in Virginia? The trial is taking place in Fairfax County Circuit Court in Fairfax, Virginia. Heard’s lawyers had sought to have the case tried in California, where the actors reside. But a judge ruled that Depp was within his rights to bring the case in Virginia because The Washington Post’s computer servers for its online edition are located in the county. Depp’s lawyers have said they brought the case in Virginia in part because the laws there are more favorable to their case. Advertisement This story was reported from Cincinnati. The Associated Press, Megan Ziegler and FOX 5 DC contributed.	https://www.fox35orlando.com/news/johnny-depp-amber-heard-trial-jury-deliberations-verdict-update	2022-05-31T12:45:14	en	0.980906
You need to enable JavaScript to run this app.	https://sportspyder.com/nhl/florida-panthers/articles/39657996	2022-05-31T12:45:15	en	0.738227
Highlights the Company's Troubling Corporate Governance Practices and the Board's Lack of Relevant Experience and Ineffective Oversight Views the Company's Decision to Delay the Annual Meeting in Order to Make Reactionary Changes as a Transparent Effort to Defend the Status Quo and Entrench the Board Remains Open to Engaging in Constructive Settlement Discussions Which Would Include Providing Access to Its Nominees for Interviews Following an Understanding on an Appropriate Level of Board Change Believes a Reconstituted Board with Starboard's Highly-Qualified Nominees Would Bring Much Needed Industry and Public Company Board Expertise and Improved Diversity to the Board NEW YORK, May 31, 2022 /PRNewswire/ -- Starboard Value LP (together with its affiliates, "Starboard"), one of the largest stockholders of LivePerson, Inc. ("LivePerson" or the "Company") (NASDAQ: LPSN), with an ownership interest of approximately 9.4% of the Company's outstanding shares, today announced that it has delivered an open letter to LivePerson stockholders. The full text of the letter to the Company's stockholders can be viewed at the following link: About Starboard Value LP Starboard Value LP is a New York-based investment adviser with a focused and differentiated fundamental approach to investing primarily in publicly traded U.S. companies. Starboard invests in deeply undervalued companies and actively engages with management teams and boards of directors to identify and execute on opportunities to unlock value for the benefit of all shareholders. CERTAIN INFORMATION CONCERNING THE PARTICIPANTS Starboard Value LP, together with the other participants named herein (collectively, "Starboard"), has filed a preliminary proxy statement and accompanying WHITE proxy card with the Securities and Exchange Commission ("SEC") to be used to solicit votes for the election of its slate of highly-qualified director nominees at the 2022 annual meeting of stockholders of LivePerson, Inc., a Delaware corporation (the "Company"). STARBOARD STRONGLY ADVISES ALL STOCKHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS' PROXY SOLICITOR. The participants in the proxy solicitation are anticipated to be Starboard Value and Opportunity Master Fund Ltd ("Starboard V&O Fund"), Starboard Value and Opportunity S LLC ("Starboard S LLC"), Starboard Value and Opportunity C LP ("Starboard C LP"), Starboard R Value R LP ("Starboard R LP") , Starboard Value and Opportunity Master Fund L LP ("Starboard L Master"), Starboard Value L LP ("Starboard L GP"), Starboard Value R GP LLC ("Starboard R GP"), Starboard X Master Fund Ltd ("Starboard X Master"), Starboard Value LP, Starboard Value GP LLC ("Starboard Value GP"), Starboard Principal Co LP ("Principal Co"), Starboard Principal Co GP LLC ("Principal GP"), Jeffrey C. Smith, Peter A. Feld, John R. McCormack, Vanessa Pegueros and Yael Zheng. As of the close of business on May 27, 2022, Starboard V&O Fund beneficially owned directly 4,098,775 shares of Common Stock, par value $0.001 per share, of the Company (the "Common Stock"). As of the close of business on May 27, 2022, Starboard S LLC directly owned 589,370 shares of Common Stock. As of the close of business on May 27, 2022, Starboard C LP directly owned 364,260 shares of Common Stock. Starboard R LP, as the general partner of Starboard C LP may be deemed the beneficial owner of an aggregate of 364,260 shares of Common Stock owned by Starboard C LP. As of the close of business on May 27, 2022, Starboard L Master directly owned 253,094 shares of Common Stock. Starboard L GP, as the general partner of Starboard L Master, may be deemed the beneficial owner of the 253,094 shares of Common Stock owned by Starboard L Master. Starboard R GP, as the general partner of Starboard R LP and Starboard L GP, may be deemed the beneficial owner of an aggregate of 617,354 shares of Common Stock owned by Starboard C LP and Starboard L Master. As of the close of business on May 27, 2022, Starboard X Master directly owned 945,388 shares of Common Stock. As of the close of business on May 27, 2022, 754,113 of Common Stock were held in an account managed by Starboard Value LP (the "Starboard Value LP Account"). Starboard Value LP, as the investment manager of each of Starboard V&O Fund, Starboard C LP, Starboard L Master, Starboard X Master and the Starboard Value LP Account and the manager of Starboard S LLC, may be deemed the beneficial owner of an aggregate of 7,005,000 shares of Common Stock directly owned by Starboard V&O Fund, Starboard S LLC, Starboard C LP, Starboard L Master, Starboard X Master and held in the Starboard Value LP Account. Each of Starboard Value GP, as the general partner of Starboard Value LP, Principal Co, as a member of Starboard Value GP, Principal GP, as the general partner of Principal Co, and Messrs. Smith and Feld, as members of Principal GP and as members of each of the Management Committee of Starboard Value GP and the Management Committee of Principal GP, may be deemed the beneficial owner of 7,005,000 shares of Common Stock directly owned by Starboard V&O Fund, Starboard S LLC, Starboard C LP, Starboard L Master, Starboard X Master and held in the Starboard Value LP Account. As of the close of business on May 27, 2022, Mr. McCormack directly beneficially owned 950 shares of Common Stock. As of the close of business on May 27, 2022, Ms. Pegueros directly beneficially owned 1,349 shares of Common Stock. As of the close of business on May 27, 2022, Ms. Zheng directly beneficially owned 3,000 shares of Common Stock held in a revocable trust she serves as co-trustee for with her husband. Investor contacts: Peter Feld, (212) 201-4878 Prithvi Reddy, (212) 201-6231 www.starboardvalue.com View original content: SOURCE Starboard Value LP	https://www.wlbt.com/prnewswire/2022/05/31/starboard-delivers-open-letter-liveperson-stockholders/	2022-05-31T12:45:17	en	0.891218
BERLIN (AP) — A court in Germany on Tuesday convicted five men for membership in a local cell of the Islamic State group that received orders from a leading IS figure in Afghanistan. The Duesseldorf regional court sentenced the Tajik nationals, aged 25 to 34, to lengthy prison terms. The longest sentence of nine years and six months was handed to Sunatullokh K., whose surname wasn’t released due to German privacy rules. He was also convicted of planning to kill a man who had made critical comments about Islam. The attack was foiled by authorities. The other men, identified as Muhammadali G., Azizjon B., Farhodshoh K. and Komron B., received prison sentences of between 44 months and 8.5 years for membership to a terrorist organization, with some also convicted of involvement in plans to carry out a contract killing in Albania that was later abandoned. Another man, Ravsan B., was convicted by the same court last year of membership in IS for co-founding the German cell and supporting two planned attacks. He was sentenced to seven years in prison. Prosecutors said the men honed their military skills in paintball games, and that participants in those included “other people from the Islamist scene” who were in contact with the gunman who killed four people in an attack in Vienna in November 2020. They also allegedly acquired components for an “unconventional” bomb. Federal prosecutors had sought prison terms of between four and 12 years for the men. Their lawyers had asked the court to acquit them.	https://www.theheraldreview.com/news/article/Islamic-extremists-convicted-of-membership-in-17209083.php	2022-05-31T12:45:18	en	0.987397
Lynyrd Skynyrd legend Ronnie Van Zant's childhood home put up for sale The house in Jacksonville, Florida where Lynyrd Skynyrd rock legend Ronnie Van Zant and his brothers Donnie and Johnny grew up is now up for sale. The home is on the market for $629,000 and comes with eight lots, a fourplex home and a manufactured home. The property also includes a historical marker that was placed in the front yard in 2018. The sign reads, "The Van Zants’ legacy, memorialized in this house, commemorates their prodigious contribution to the world of rock music." "That house was our life, that neighborhood was our neighborhood," Johnny Van Zant said in 2018. "We all learned how to play drums in that house, we all learned how to swing on the swing-set out there — that’s where we learned to sing. We didn’t have 700 channels like today. We didn’t have nothing but four channels. We weren’t super rich." According to property records, Blue Horizon Property Solutions purchased the home in 2015 for $67,500. Ronnie Van Zant and friends from the west Jacksonville neighborhood formed Lynyrd Skynyrd in the 1960s, and the band became Southern Rock superstars in the 1970s. He and several others died in a plane crash in 1977. His brother Johnny Van Zant has been the lead singer for Lynyrd Skynyrd since 1987. FILE - Rickey Medlocke, Johny Van Zant and Gary Rossington of Lynyrd Skynyrd perform on stage at Resorts World Arena on June 30, 2019, in Birmingham, England. (Photo by Steve Thorne/Redferns) And brother Donnie Van Zant founded another 1970s rock band, .38 Special, but hearing problems forced him to retire in 2013. INFLATION CAUSING INCREASED ‘CONCERN’ FOR HOMEBUILDERS: NAHB CEO Johnny and Donnie both still live in northeast Florida. Advertisement	https://www.fox35orlando.com/news/lynyrd-skynyrd-legend-ronnie-van-zants-childhood-home-put-up-for-sale	2022-05-31T12:45:20	en	0.962401
BENTON HARBOR, Mich. (AP) — A 19-year-old man has been killed and six other people were wounded during a shooting at a club and liquor store in southwestern Michigan's Benton Harbor. Benton Harbor public safety officers responding to reports of multiple gunshots saw a large number of people in the area about 2:30 a.m. Monday, the police department said in a release. Marlon Bowman was shot multiple times in his chest and died, police said. The wounded were treated at an area hospital. Officers found multiple shell casings of various calibers, but none of the people at the scene of the shooting have come forward to give statements to police, the department said. A $2,000 reward was being offered for information that leads to the identification and arrest of anyone involved in the shooting, police said.	https://www.theheraldreview.com/news/article/Man-slain-6-people-wounded-during-shooting-in-17209068.php	2022-05-31T12:45:24	en	0.989246
- Designation provides fast track reviews and a 30% fungible tax credit for all future clinical development expenses - Company on track to submit IND in 2023 DOYLESTOWN, Pa., May 31, 2022 /PRNewswire/ -- SteroTherapeutics LLC, a clinical-stage company targeting metabolic and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for ST-003, a novel galanin receptor inhibitor, for the treatment of primary sclerosing cholangitis (PSC). PSC is a rare, heterogeneous, idiopathic, inflammatory disorder of the bile ducts resulting in strictures and scarring of the ducts that can gradually cause serious liver damage. ST-003 is designed to halt the impact of excessive galanin concentrations that increase cholangiocyte proliferation and fibrogenesis, as demonstrated in humans and in specific mouse models. "This important designation is a milestone in the development of ST-003 and highlights the need for potential new treatment options for patients with PSC," said Manohar Katakam, Ph.D., Chief Executive Officer of SteroTherapeutics. "Orphan designation for ST-003 is a critical step toward clinical development as we now have fast track reviews and a 30% fungible tax credit for all future clinical development expenses. ST-003 has the potential to be an important treatment by addressing a host of disease factors found in the PSC disease state. We are especially pleased that this is the second program in our pipeline to receive this designation, as it validates and adds value to our programs." SteroTherapeutics expects to submit an Investigational New Drug (IND) application to the FDA for ST-003 in 2023 and marks the second program, following ST-002 for the treatment of Cushing's syndrome, to receive Orphan Drug Designation by the FDA. FDA Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the United States. Orphan drug status provides benefits to drug developers, including assistance in the drug development process, tax credits for clinical costs, exemptions from certain FDA fees and seven years of post-approval marketing exclusivity. About Primary Sclerosing Cholangitis: Primary sclerosing cholangitis (PSC) is a chronic liver disease in which the bile ducts inside and outside the liver become inflamed and scarred, and eventually narrowed or blocked. When this happens, bile builds up in the liver and causes further liver damage. About SteroTherapeutics: SteroTherapeutics, a clinical stage company is focused on developing novel orphan disease therapeutics with significant unmet needs as well as potentially larger indications affecting large patient populations. SteroTherapeutics' lead programs, ST-002 to treat Cushing's syndrome, ST-003 to treat primary sclerosing cholangitis and ST-004 to treat multiple myeloma, have been proven in previous animal and human studies to possess a strong safety profile and established mechanisms of action. Both ST-002 and ST-003 have received Orphan Drug Designation from the U.S. FDA. The company's strategic intent is to focus on platform technologies and corresponding disease pathways in disease states with significant unmet or underserved medical needs. In each individual disease target SteroTherapeutics embraces the opportunity to provide safe, effective treatments and restore an optimal quality of life. Learn more at sterotx.com Investor/Media Contact: Lisa Sher lsher@sterotx.com Tel: 970-987-2654 View original content: SOURCE Sterotherapeutics LLC	https://www.wlbt.com/prnewswire/2022/05/31/sterotherapeutics-granted-orphan-drug-designation-st-003-novel-drug-candidate-treatment-primary-sclerosing-cholangitis/	2022-05-31T12:45:23	en	0.927524
Buying your first car is already an intimidating experience; in the midst of historic supply shortages, it’s easy to feel overwhelmed. In March of this year, the average price of a used car was $27,246, according to Cox Automotive — an automotive marketplace and data company — or 28% higher than it was a year ago. With those price increases, monthly payments have also swelled. Average payments for used cars reached $488 in the last quarter of 2021, according to Experian. On top of that, the average loan term for used vehicles was just over 67 months, or more than five years. For many, cars are a necessity. If you have little or no credit, no co-signer or just a limited budget, it can be easy to accept a loan that pushes your budget or binds you to a car for six, even seven years. Not being ready before stepping onto a car lot can open the door to making a purchase you’ll later regret. Set your limits before you ever stop at a dealership; with the right preparation, you can keep your purchase from becoming a burden. SECURE A LOAN Your first step is calculating what loan payments you can afford and the total loan amount that’s within your budget. Aim to keep your monthly loan payment below 10% of your take-home pay, and if you’re buying a used car, keep your loan term under 36 months. If you’re looking for a new vehicle, keep the term under 60 months. Limiting your loan term will save you money on interest and will lower the risk of your loan becoming upside-down — owing more than the car is worth. Numbers in hand, start looking for a lender that will give you a loan. Getting preapproved for a loan before visiting dealer lots can give you a better negotiating position, keep you from going over budget and reduce what you pay in interest. With little or no credit history — especially since you have not had a car loan before — your best shot at being approved for a loan at the lowest interest rate possible is to apply with a co-signer. But if that’s not a possibility for you, there are still financing alternatives available: — One of the first places to look are banks and credit unions, particularly institutions that you have an established relationship with. — Search your area for lenders with first-time buyer programs, which put conditions on the amount you can borrow and the vehicles you can buy but dispense with some of the credit requirements. — You can also look for loans from online lenders that offer bad-credit auto loans, since they will often have low or no minimum credit scores. These loans can carry interest rates of over 25%, so a year after taking one on, you can try to refinance for lower rates. PICK THE RIGHT CAR Finding a cheap car used to be easy — or at least easier than it is now. If you have a $10,000 budget, your options are limited, but that doesn’t mean there aren’t options. With a limited budget, most choices will be older, used cars, and that increases the annual cost to maintain your car. A 2021 Consumer Reports study found that 2016 model year vehicles cost $205 to maintain over the previous 12 months, while 2011 model year vehicles cost $430. In addition to maintenance costs, there’s also fuel, insurance, registration and taxes that all add to the cost of owning a vehicle. As you search for a car, look into the cost of ownership, since it will differ from car to car. The total cost of owning your vehicle, including your loan payment, shouldn’t exceed 20% of your take-home pay. Although some costs can’t be significantly reduced, you can minimize others — such as future maintenance, repairs and fuel — with the right car. “The most important thing to look for is a car with good maintenance history,” Joey Capparella, a senior editor at Car and Driver, said in an email. “If the previous owner has taken good care of the car and can provide service receipts, that trumps other attributes such as the number of miles or the brand. One-owner cars are desirable for this same reason.” Service and ownership history can sometimes be found through a service such as Carfax. Use this information, along with total mileage and the car’s age, to narrow down your search. When looking at vehicles for less than $10,000, the car with fewer miles will often be the better choice, if all else is equal. Once you’ve settled on a car, take it for an extensive test drive, Capparella added, and pay attention to “the seating position, the visibility out of the windows, and the sound of the engine.” If something about the car isn’t right for you, a different vehicle is likely a better choice, and don’t be afraid to be picky. You may not be buying the car of your dreams, but you could be living with your choice — and making payments on it — for years to come. _______________________________ This column was provided to The Associated Press by the personal finance website NerdWallet. Colin Beresford is a writer at NerdWallet. Email: cberesford@nerdwallet.com. Twitter: @Colin_beresford. RELATED LINK:	https://www.theheraldreview.com/news/article/Millennial-Money-Don-t-let-your-first-car-be-a-17208999.php	2022-05-31T12:45:24	en	0.963993
'No place for a horse': Animal control rescues horse found abandoned on streets of Philadelphia PHILADELPHIA - A horse that was abandoned in the streets of Philadelphia is now in need of a new home. The horse was found wandering down Darien Street in Hunting Park after allegedly being left by a man who brought him. Concerned residents notified authorities and staff from Philadelphia's Animal Care & Control Team responded. The horse, which has since been named Darien, is now in ACCT custody for treatment and care. The agency says the horse is underweight and in need of some extra care. It is not illegal to own a horse in Philadelphia, but the ACCT says there are better places to keep horses for adequate care and safety. Advertisement	https://www.fox35orlando.com/news/no-place-for-a-horse-animal-control-rescues-horse-found-abandoned-in-streets-of-philadelphia	2022-05-31T12:45:26	en	0.973065
MANILA, Philippines (AP) — Philippine police killed four suspected Chinese kidnappers in a gunbattle and rescued a Chinese man they had allegedly abducted in a central city, officials said Tuesday. Backed by a SWAT team and intelligence agents, police raided a hideout in Lapu Lapu city on Monday night after tracking down the suspects, who had received a partial ransom payment through the Chinese smartphone app WeChat, police said. “Our men were met with gunfire from the suspects, prompting them to retaliate,” said police Brig. Gen. Rudolph Dimas, who heads the national police’s anti-kidnapping force. The Chinese victim, identified by police as Lyu Xingou from China’s southeastern province of Fujian, was seized from his house by Chinese-speaking gunmen last Wednesday as he prepared to leave for work in Lapu Lapu city, police said. The kidnappers called the victim’s son in China and demanded a ransom, which the family partially paid through WeChat in an arrangement that allowed the police to track down the suspects, police said, without elaborating. Police recovered four pistols, a laptop computer, cellphones and handcuffs from the slain suspects, who may have been involved in past kidnappings of Chinese working for lucrative online casinos in the Philippines that cater to Chinese clients in China, Dimas said.	https://www.theheraldreview.com/news/article/Philippine-police-say-they-killed-4-Chinese-17209082.php	2022-05-31T12:45:30	en	0.971825
Storms with lightning, hail possible for parts of Central Florida on Tuesday ORLANDO, Fla. - WHAT IS THE WEATHER FORECAST FOR TODAY AROUND ORLANDO? Tonight’s forecast high: 91 degrees Tomorrow's forecast low: 71 degrees MAIN WEATHER CONCERNS: Hot, humid conditions continue today with lower 90s likely inland, 80s along the coast. Showers and storm chances look rather limited from around Orlando and along the beaches, coverage remains in the 30% range there. Higher (50%) from around the theme parks over to the Gulf beaches. Could be a few strong or locally severe storms west of Orlando. RELATED: Tracking the Tropics: FOX 35 presents 2022 hurricane season preview Tuesday night Heavy rain, lightning, gusty winds and hail could all accompany the stronger storms. WHAT IS THE WEATHER FORECAST FOR WALT DISNEY WORLD, UNIVERSAL, AND SEAWORLD? On this Tuesday, park visitors can expect hot and humid conditions with low-90s common during the afternoon. Rain chances will phase in mainly after 2pm. Coverage stands at 50%. Heavy rain, lightning, gusty winds and small hail could all accompany the stronger storms. WHAT IS THE WEATHER FORECAST FOR THE BEACHES IN CENTRAL FLORIDA? Tuesday beach side: the day will start with mixed skies with mainly late morning-early PM showers and storms, coverage is quite low at 20%. Temperatures at the beaches will be in the mid 80s. Surf will be around 2ft or less with a moderate rip current risk. Winds will be out of the East at 5-15 mph. LOOKING AHEAD: Advertisement Hot-humid and down right tropical weather conditions will dominate the extended forecast. Highs near 90 and super high humidity. Rain chances will move up and down through the week as daily waves of moisture are guided through the region. Watching the tropics longer term as well so stay tuned for details as we head through the coming week. If some models are correct, the area could see quite a bit of rain this weekend.	https://www.fox35orlando.com/news/storms-with-lightning-hail-possible-for-parts-of-central-florida-on-tuesday	2022-05-31T12:45:33	en	0.912794
Industry veterans roll out end-to-end incident response services and innovative tech-enabled platform, following successful incubation PHILADELPHIA, May 31, 2022 /PRNewswire/ -- Surefire Cyber today launched as a new incident response company to help cyber insurers, brokers, law firms, and the organizations they support to better manage cyber events such as ransomware, email compromise, and other cybercrimes. The company also announced $10 million in Series A funding, led by Forgepoint Capital. "Surefire Cyber's goal is to work with our clients and partners to swiftly manage a cyber incident and then bring forward capabilities to help them become more cyber resilient. Our delivery of end-to-end digital forensics and incident response capabilities is built on a tech-enabled framework and delivered through a platform that aligns and connects an organization's executives, technical team, insurance carrier, and legal counsel." said Billy Gouveia, the CEO and Founder of Surefire Cyber. Mark Greisiger, President and Founder of NetDiligence®, comments that "Surefire Cyber is committed to being great partners to carriers, brokers, Breach Coaches®, and the clients they work together to support. We are pleased to welcome them as new contributors to the cyber insurance ecosystem who offer deep experience and a valuable perspective." Given two long-term trends, the rising cost of cyber incidents and the growing adoption of cyber insurance, industry veterans created Surefire Cyber as a purpose-built response firm that leverages a proven team and a tech-enabled platform to improve transparency, accelerate decision making, reduce business interruption, and guide organizations from recovery through to long term resilience. Surefire Cyber is backed by Forgepoint Capital, the world's most active early-stage venture capital firm focused on cybersecurity. Prior to launching Surefire Cyber, Gouveia joined Forgepoint as an Entrepreneur-in-Residence to incubate and develop the company's strategy, model, technology, and team while establishing valuable partnerships with companies across the firm's portfolio. "Our support from Forgepoint Capital enabled us to bring aboard a highly-experienced team of skilled responders, to develop a tech-enabled solution for collaboration with clients and partners during a response, and to leverage the leading cyber venture firm's unmatched capabilities of over 30 portfolio companies so that our clients can better protect their data and defend their organizations," continued Gouveia. "Surefire Cyber has brought together leading responders with hands-on experience in preparing for all aspects of a cyber incident, expertise to collaboratively guide clients and partners through high-stakes response events, and skill in helping organizations emerge stronger," said Don Dixon, Managing Director of Forgepoint Capital. "What Billy and team are building is truly unprecedented and serves a critical gap in the market." To learn more, please visit www.surefirecyber.com. Surefire Cyber delivers swift, strong response to cyber incidents such as ransomware, email compromise, malware, data theft, and other threats with end-to-end response capabilities. Surefire Cyber was founded to provide clients confidence by helping them prepare, respond, and recover from cyber incidents—and to fortify their cyber resilience after an incident. To learn more, please visit: www.surefirecyber.com or follow us on LinkedIn. Breach Coach is a registered trademark of NetDiligence®. Forgepoint Capital is the most active cybersecurity venture capital firm in the world, with 36 active portfolio companies and the largest and most diverse team dedicated to investing in the sector. The firm brings over 100 years of proven company-building experience and its Advisory Council of more than 75 senior executives across industries to support entrepreneurs advancing innovation as they protect the digital future. Founded in 2015, Forgepoint has raised $770 million, deployed over $500 million, and empowered industry leaders such as 1Kosmos, Area 1 Security (Cloudflare), Attivo Networks (SentinelOne), BehavioSec (RELX), Bishop Fox, Cysiv, Huntress, IronNet Cybersecurity (NYSE: IRNT), Noname Security, NowSecure, ReversingLabs, Uptycs and more to reach their market potential. Learn more about Forgepoint at https://forgepointcap.com or follow us on LinkedIn. Media Contact Billy Gouveia for Surefire Cyber View original content to download multimedia: SOURCE Surefire Cyber	https://www.wlbt.com/prnewswire/2022/05/31/surefire-cyber-launches-help-cyber-insurance-ecosystem-response-resilience-with-10-million-funding-by-forgepoint-capital/	2022-05-31T12:45:30	en	0.940725
This is a carousel. Use Next and Previous buttons to navigate BELGRADE, Serbia (AP) — Aleksandar Vucic was sworn in for his second term as Serbia’s president Tuesday, pledging to keep the Balkan country on its European Union membership path and hinting that a new government might consider joining Western sanctions against Russia over the war in Ukraine. Despite voting in favor of three U.N. resolutions condemning Russia's invasion of Ukraine, Serbia remains the only European state that has not joined sanctions against its ally Moscow. In his inaugural speech in parliament, Vucic said Serbia’s priority will be its EU membership path and that the new government -- which should be formed in July -- will have to work harder on gaining entry into the 27-member bloc and consider sanctions against Moscow, although he didn't specifically refer to Russia. “Forming a new government is of utmost importance because of the situation we are in, difficult situation,” he said. “We will have to deal with new sanctions and stuff, which could damage us so we will ask our European partners to help us,” he said. Vucic, who convincingly won the presidential election mostly on his pro-Russian agenda, said that he wants to take Serbia into the EU during his new term. But he has spent recent years cementing ties with Russian President Vladimir Putin, a long-time ally. Opposition groups and foreign observers said the April vote was far from being free and fair and that Vucic's autocratic rule sidelines the government and parliament. Vucic announced on Sunday that he has secured an “extremely favorable” three-year natural gas deal with Russia during a telephone conversation with Putin -- something widely seen as his determination not to join EU sanctions despite pressure from the West. But the Serb president on Tuesday appeared to soften his pro-Russia stance, saying “we must be firm on the European path." He said Serbia will not seek NATO membership and would maintain its military neutrality. “We are not politically neutral because we want membership in the European Union,” said Vucic.	https://www.theheraldreview.com/news/article/Serb-president-pledges-EU-course-hints-Russia-17209019.php	2022-05-31T12:45:36	en	0.985647
Tammy Sytch arrest: WWE star returns to Florida court after bond is revoked DAYTONA BEACH, Fla. - WWE Hall of Famer Tammy Sytch will be back in Volusia County court on Tuesday afternoon after a judge revoked her bond earlier this month. Sytch was arrested on several felony DUI charges after allegedly striking another vehicle that killed a man in March in Daytona Beach. According to officers, Sytch was believed to be under the influence when she crashed into Julian Lasseter on US-1 on March 25. Lasseter was taken to the hospital, where he died. The 49-year-old was arrested at the Hard Rock Hotel in Daytona Beach. Police said her blood alcohol level was more than three times the legal limit at the time of the crash. In its court motion, the state alleged Sytch had previously been convicted of a crime, including two DUI charges in 2015 in Pennsylvania, and years later violated probation. The state also alleged that Sytch's license was suspended. The 49-year-old Stych, known to WWE fans as "Sunny," made her professional wrestling debut the mid-1990s and was inducted into the WWE Hall of Fame in 2011. Advertisement FOX 35 will update this story after Sytch's appearance in court. Check back for updates.	https://www.fox35orlando.com/news/tammy-sytch-arrest-wwe-star-returns-to-florida-court-after-bond-is-revoked	2022-05-31T12:45:39	en	0.980383
NETANIA, Israel, May 31, 2022 /PRNewswire/ -- TAT Technologies Ltd. (NASDAQ: TATT) ("TAT" or the "Company"), a leading provider of products and services to the commercial and military aerospace and ground defense industries, reported today its unaudited results for the three-month period ended March 31, 2022. Financial highlights for the first quarter of 2022: - Revenues for Q1 2022 increased by 8.1% to $19.9 million compared to $18.4 million in Q1 2021. - Gross profit for Q1 2022 was $3 million (15.2% of revenues) compared to $3.4 million in Q1 2021 (18.5% of revenues). - Adjusted EBITDA for Q1 2022 decreased to $0.5 million compared to $1.6 million in Q1 2021. - Net loss for Q1 2022 was $1.6 million compared to a net income of $0.6 million in Q1 2021. - Q1 2021 Gross Profit, EBITDA and Net Income included government rants in the amount of $1.4 million ($1 million recorded in the COGS and an additional $0.4 million recorded in G&A) Mr. Igal Zamir, TAT's CEO and President commented on the results: "As air travel begins to recoup and more and more plains resume flights, we see a growing demand for our services and products and an increase in order intake. We are working relentlessly to meet this demand despite strong headwinds resulting from supply chain issues and shortages in raw materials, which are hampering our ability to fully ramp up our production. During Q1 of 2022 we continued making significant steps in improving our manufacturing efficiencies as we successfully completed merging our 2 facilities in Israel to a single manufacturing site. We believe the cost savings expected from this unification will begin to impact us toward the second half of 2022. In addition we continue to invest in building additional MRO and production capabilities, following the strategic contacts recently signed with Honeywell and hope to have these new capabilities available by the end of this year." "Given our growing backlog, the continued recovery of commercial airline traffic and the strategic agreements we signed with Honeywell, coupled with the actions we have taken and to improve our manufacturing efficiencies, I am optimistic about our ability to continue our topline and bottom line growth." concluded Mr. Zamir Mr Zamir added: "Mr. Ron Ben-Haim has informed our Board of Directors of his retirement from his directorship position effective, May 30, 2022. I wish to thank Ron for his service on behalf of the Company, its board of directors, its management and its employees" Non-GAAP Financial Measures To supplement the consolidated financial statements presented in accordance with GAAP, the Company also presents Adjusted EBITDA. The adjustments to the Company's GAAP results are made with the intent of providing both management and investors a more complete understanding of the Company's underlying operational results, trends and performance. Adjusted EBITDA is calculated as net income excluding the impact of: the Company's share in results of affiliated companies, share-based compensation, taxes on income, financial (expenses) income, net, and depreciation and amortization. Adjusted EBITDA, however, should not be considered as alternative to net income and operating income for the period and may not be indicative of the historic operating results of the Company; nor it is meant to be predictive of potential future results. Adjusted EBITDA is not measure of financial performance under generally accepted accounting principles and may not be comparable to other similarly titled measures for other companies. See reconciliation of Adjusted EBITDA in pages 13 below. About TAT Technologies LTD TAT Technologies Ltd. is a leading provider of services and products to the commercial and military aerospace and ground defense industries. TAT operates under four segments: (i) Original equipment manufacturing ("OEM") of heat transfer solutions and aviation accessories through its Gedera facility; (ii) MRO services for heat transfer components and OEM of heat transfer solutions through its Limco subsidiary; (iii) MRO services for aviation components through its Piedmont subsidiary; and (iv) Overhaul and coating of jet engine components through its Turbochrome subsidiary. TAT controlling shareholders is the FIMI Private Equity Fund. TAT's activities in the area of OEM of heat transfer solutions and aviation accessories primarily include the design, development and manufacture of (i) broad range of heat transfer solutions, such as pre-coolers heat exchangers and oil/fuel hydraulic heat exchangers, used in mechanical and electronic systems on board commercial, military and business aircraft; (ii) environmental control and power electronics cooling systems installed on board aircraft in and ground applications; and (iii) a variety of other mechanical aircraft accessories and systems such as pumps, valves, and turbine power units. TAT's activities in the area of MRO Services for heat transfer components and OEM of heat transfer solutions primarily include the MRO of heat transfer components and to a lesser extent, the manufacturing of certain heat transfer solutions. TAT's Limco subsidiary operates an FAA-certified repair station, which provides heat transfer MRO services for airlines, air cargo carriers, maintenance service centers and the military. TAT's activities in the area of MRO services for aviation components include the MRO of APUs, landing gears and other aircraft components. TAT's Piedmont subsidiary operates an FAA-certified repair station, which provides aircraft component MRO services for airlines, air cargo carriers, maintenance service centers and the military. TAT's activities in the area of overhaul and coating of jet engine components includes the overhaul and coating of jet engine components, including turbine vanes and blades, fan blades, variable inlet guide vanes and afterburner flaps. For more information of TAT Technologies Ltd., please visit our web-site: www.tat-technologies.com Contact: Mr. Ehud Ben-Yair Chief Financial Officer Tel: 972-8-862-8503 ehudb@tat-technologies.com Safe Harbor for Forward-Looking Statements This press release contains forward-looking statements which include, without limitation, statements regarding possible or assumed future operation results. These statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause our results to differ materially from management's current expectations. Actual results and performance can also be influenced by other risks that we face in running our operations including, but are not limited to, general business conditions in the airline industry, changes in demand for our services and products, the timing and amount or cancellation of orders, the price and continuity of supply of component parts used in our operations, the change of control that will occur on the sale by the receiver of the Company's shares held by our previously controlling stockholders, and other risks detailed from time to time in the Company's filings with the Securities Exchange Commission, including, its annual report on form 20-F and its periodic reports on form 6-K. These documents contain and identify other important factors that could cause actual results to differ materially from those contained in our projections or forward-looking statements. Stockholders and other readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. We undertake no obligation to update publicly or revise any forward-looking statement. View original content: SOURCE TAT Technologies Ltd.	https://www.wlbt.com/prnewswire/2022/05/31/tat-technologies-reports-first-quarter-2022-results/	2022-05-31T12:45:39	en	0.946528
IMAX Turns in Dominating Performance at Domestic Box Office, Earning 14% of Overall North American Gross with $21 Million NEW YORK, May 31, 2022 /PRNewswire/ -- IMAX Corporation (NYSE: IMAX) soared to its best global four-day Memorial Day Weekend opening ever with the $32.5 million debut of Paramount Pictures' "Top Gun: Maverick", starring cinema icon Tom Cruise. Crushing industry expectations, the aerial actioner also scored the biggest domestic four-day Memorial Day Weekend opening ever in IMAX with $21 million, good for a stunning 14% of the overall North American box office. "Top Gun: Maverick" now stands as Tom Cruise's biggest opening weekend ever in IMAX — global, domestic, and in 50 individual countries and territories worldwide — topping a run of eight Cruise-led blockbuster releases dating back to 2011. "If you thought movies were dead, go see 'Top Gun: Maverick' and then let me know what you think. This film heralds the return of the summer blockbuster and is a catalyst that will accelerate demand for moviegoing like an F-18 breaking the sound barrier," said Rich Gelfond, CEO of IMAX. "There's no way you sit in a theatre, with a huge screen and chest-pounding speakers, and come away thinking there's any other way you want to experience 'Top Gun: Maverick', and our hats are off to Tom Cruise, Joe Kosinski and their fearless creative team for what they've accomplished." "Top Gun: Maverick" is a Filmed For IMAX release shot with IMAX-certified Sony Venice cameras and includes nearly an hour of scenes in IMAX-exclusive 1:90:1 expanded aspect ratio. This includes all the film's stunning flight sequences and as well as additional scenes that are available with up to 26% more picture only available in IMAX. Six of the specialized IMAX cameras were strapped to the inside of the cockpit of an F-18A Super Hornet to enable the film's groundbreaking aerial photography, and IMAX image quality enhancements in post-production and higher dynamic range sound systems allowed the filmmakers to design the movie to be experienced in IMAX. Internationally, "Top Gun: Maverick" delivered a top ten all-time IMAX opening weekend in eighteen diverse markets, including the UK, France, Germany, Italy, Saudi Arabia, Belgium, Japan, Singapore, Argentina, Sweden, and Norway. About IMAX Corporation IMAX, an innovator in entertainment technology, combines proprietary software, architecture, and equipment to create experiences that take you beyond the edge of your seat to a world you've never imagined. Top filmmakers and studios are utilizing IMAX theaters to connect with audiences in extraordinary ways, and, as such, IMAX's network is among the most important and successful theatrical distribution platforms for major event films around the globe. IMAX is headquartered in New York, Toronto, and Los Angeles, with additional offices in London, Dublin, Tokyo, and Shanghai. As of December 31, 2021, there were 1,683 IMAX theater systems (1,599 commercial multiplexes, 12 commercial destinations, 72 institutional) operating in 87 countries and territories. Shares of IMAX China Holding, Inc., a subsidiary of IMAX Corporation, trade on the Hong Kong Stock Exchange under the stock code "1970." IMAX®, IMAX® Dome, IMAX® 3D, IMAX® 3D Dome, Experience It In IMAX®, The IMAX Experience®, An IMAX Experience®, An IMAX 3D Experience®, IMAX DMR®, DMR®, IMAX nXos® and Films to the Fullest®, are trademarks and trade names of the Company or its subsidiaries that are registered or otherwise protected under laws of various jurisdictions. More information about the Company can be found at www.imax.com. You may also connect with IMAX on Instagram (https://www.instagram.com/imax), Facebook (www.facebook.com/imax), Twitter (www.twitter.com/imax) and YouTube (www.youtube.com/imaxmovies). For additional information please contact: Investors: Heather Anthony [email protected] 212.821.0121 Media: Mark Jafar [email protected] 212.821.0102 SOURCE IMAX Corporation	https://www.prnewswire.com/news-releases/imax-fires-up-best-memorial-day-weekend-opening-ever-with-32-5-global-million-debut-of-top-gun-maverick-301557551.html	2022-05-31T12:45:42	en	0.915545
WFO EUREKA Warnings, Watches and Advisories for Tuesday, May 31, 2022 _____ FROST ADVISORY URGENT - WEATHER MESSAGE National Weather Service Eureka CA 417 AM PDT Tue May 31 2022 ...FROST ADVISORY REMAINS IN EFFECT UNTIL 8 AM PDT THIS MORNING... * WHAT...Temperatures as low as 35 will result in frost formation. * WHERE...Southern Trinity and Northern Trinity Counties. * WHEN...Until 8 AM PDT this morning. * IMPACTS...Frost could kill sensitive outdoor vegetation if left uncovered. PRECAUTIONARY/PREPAREDNESS ACTIONS... Take steps now to protect tender plants from the cold. Frost Advisories and Freeze Warnings are issued during the local growing season as defined by climatology and local agriculture experts. Once the growing season has ended these statements will no longer be issued until the spring. _____ Copyright 2022 AccuWeather	https://www.theheraldreview.com/weather/article/CA-WFO-EUREKA-Warnings-Watches-and-Advisories-17209018.php	2022-05-31T12:45:44	en	0.901869
Tracking the Tropics: FOX 35 presents 2022 hurricane season preview Tuesday night ORLANDO, Fla. - FOX 35 is helping you get prepared for what is predicted to be an above-average hurricane season. Be sure to tune in Tuesday night at 7 p.m. for our 2022 hurricane season preview special. The FOX 35 Storm Team is showing you how to inspect your home, the dangers of cleaning up debris, and we've got an exclusive look inside the hurricane hunters base in Central Florida. You can watch in the live player above or in the FOX 35 News App. The National Oceanic and Atmospheric Administration (NOAA) predicts another above-average Atlantic hurricane season for the 2022 season, marking the seventh consecutive above-average hurricane season. NOAA anticipates between 14 and 21 named storms, and between 6-10 of those becoming hurricanes. Of those 10, NOAA said three to six could become major hurricanes (category 3, 4, or 5). Advertisement Hurricane season officially begins Wednesday, June 1.	https://www.fox35orlando.com/news/tracking-the-tropics-fox-35-presents-2022-hurricane-season-preview-tuesday-night	2022-05-31T12:45:45	en	0.920163
THE WOODLANDS, Texas, May 31, 2022 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE:TTI) announced that its senior management will be presenting at the Louisiana Energy Conference ("LEC 2022"). The conference is being held at the Ritz-Carlton in New Orleans, Louisiana on June 1-3, 2022. Tim Moeller, Senior Vice President of Chemicals and Supply Chain, and Jacek Mucha, Vice President of Finance for TETRA's Energy Services Group and Corporate Treasurer, will be participating on a panel titled "U.S. Onshore Oil Field Services - How are Companies Reacting to Increased Demand for Services" on June 3, 2022 and hosting one-on-one meetings on June 2-3, 2022. Interested parties who would like to listen to the panel discussion or participate in a one-on-one with TETRA's management, please register on the following link (https://louisianaenergyconference.com/). LEC 2022 is an in-person Energy Conference in New Orleans directed to investment professionals including buy-side and sell-side analysts and portfolio managers, private equity and wealth management executives and trust officers, as well as energy industry participants. LEC 2022 will feature a series of approximately 21 presentations, panels and discussions that will address key domestic and international oil, natural gas, renewables and clean energy developments and topics. Confirmed investment professional attendees will also be given the opportunity to participate in one-on-one sessions during the conference. TETRA Technologies, Inc. is an industrial and oil & gas products and services company operating on six continents focused on bromine-based completion fluids, calcium chloride, water management solutions, frac flowback and production well testing services. Calcium chloride is used in the oil and gas, industrial, agricultural, road, food and beverage markets. TETRA is evolving its business model by expanding into the low carbon energy markets with its chemistry expertise, key mineral acreage and global infrastructure. Recently announced initiatives include commercialization of TETRA PureFlow® an ultra-pure zinc bromide for stationary batteries and energy storage; advancing an innovative carbon capture utilization and storage technology with CarbonFree to capture CO2 and mineralize emissions to make commercial, carbon-negative chemicals; and development of TETRA's lithium and bromine mineral acreage to meet the growing demand for oil and gas products and energy storage. Visit the Company's website at www.tetratec.com. View original content to download multimedia: SOURCE TETRA Technologies, Inc.	https://www.wlbt.com/prnewswire/2022/05/31/tetra-technologies-inc-participate-louisiana-energy-conference/	2022-05-31T12:45:46	en	0.933025

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.